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Abstract 
Previous work in this laboratory has shown that topical application of a protein kinase C (PKC) 
activator (the ingenol ester PEP005) cured subcutaneous tumors in mice with a favourable cosmetic 
outcome. Efficacy involved a neutrophil-dependent host inflammatory response; characteristic of 
diterpene esters that activate PKC. The aim of this study was to explore the antitumor efficacy and 
mechanism of action of EBC-46, a novel diterpene ester of the tigliane (phorbol) class, isolated by 
QBiotics Pty Ltd from a native rainforest plant in North Queensland, Australia, when given by 
intratumoral injection rather than by topical application. 
Preliminary work with EBC-46 in vivo resulted in successful treatment of tumors via intratumoral 
injection, showing outcomes similar to topical application of PEP005. Intralesional therapy 
bypasses the barrier zone and establishes a sub-epidermal depot, and, depending on the mode of 
action, may minimize the circulating level of the drug. 
EBC-46 activated protein kinase C (PKC), as shown by the translocation of PKC isoforms to the 
plasma membrane of HeLa. Here, PKC can phosphorylate other proteins involved in signal 
transduction of cellular activities such as growth, differentiation, migration, proliferation and 
inflammatory responses. TPA, a prototype PKC activator, was used for in vitro and in vivo 
experiments as a positive control. A single intratumoral injection of EBC-46 resulted in a local 
inflammatory response and ablation of tumors in human xenograft (melanoma, HNSCC) and mouse 
tumors (B16-F0, MC38) in immunocompromised (BALB/c Foxn1nu) and immunocompetent 
(C57BL6/J) mice respectively.  The cure rate was > 75% and there were no recurrences over a 
period of up to 12 months. Compared with the sub-microgram per ml IC50 levels of current 
anticancer drugs, the cytotoxic effect of EBC-46 was minimal in most tumor lines in vitro, requiring 
doses of 100-300 µg/ml to stop growth. IC50 levels in the region of 100 ng/ml however could be 
achieved in the same cell lines by over-expression of PKC-α and -δ. EBC-46 had minimal effect on 
the cell cycle, but caused phosphorylation of ERK 1/2. 
It was inferred that the mechanism of action was co-dependent on the host response to the drug, 
thus further studies focused on the host.  
Tumors exhibited an inflamed appearance within 1-2 hr of injection, changing to greenish black 
color by 24 hr, typical of a severe bruise. Indurations were formed at the now-flattened site, and 
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resolved over the next 2 weeks with sloughing of the scab, resulting in cure and excellent healing of 
the skin. A key finding in this project, emerging from the novel approach of ex vivo culture of 
treated tumor sites, was that no clonogenic tumor cells remained by 4 hr after injection of EBC-46; 
and significant loss of such cells even within 1 hr.  This established a short time window for drug 
action and cell kill, and focused subsequent studies of mechanism. 
Immunohistochemical analysis confirmed the clinical observations, revealing loss of capillaries and 
the endothelial cell marker PECAM, tumor cell necrosis, and presence of neutrophils. EBC-46 
induced the production of the pro-inflammatory cytokines IL-1β, TNF-α and IL-8 in tumor cells, 
dependent on activation of PKC isoforms. Global gene expression of treated tumor sites showed 
rapidly changing profiles but no dominant cell signaling pathway, with no RNA recoverable after 8 
hr. The target tumor cells, analyzed with human-specific chips, showed .>10-fold elevation of 3 
SNORD RNA sequences at the early time points, non-coding RNA sequences involved in regulation 
of gene expression. The antitumor role of this striking finding, if any, is yet to be determined but 
may reflect a novel, possibly EBC-46-specific cellular response to hemorrhagic necrosis. Such 
changes were not found using TPA, and numerous other differences in gene expression caused by 
the two drugs in vivo were observed.  The host response at tumor sites, analyzed with murine-
specific chips, also showed no single significant signaling pathway but induction of some 
proinflammatory markers was found. A more controlled in vitro expression profiling of human 
lymphocytes also revealed induction of proinflammatory markers by EBC-46, some but not all of 
which were paralleled by release of cytokine proteins. 
EBC-46 was therefore distinguished from most current anticancer agents by triggering a rapid and 
tumor-destructive host response at and around the tumor site, with no discernible adverse effects. 
Tumor ablation was associated with local inflammation, hemorrhagic necrosis, and cellular effects 
consistent with PKC activation in both tumor and host cells.  
Intratumoral injection of EBC-46 has been successfully trialed by QBiotics in a range of cutaneous 
and subcutaneous tumors in more than 250 companion animals (dogs, cats and horses). The 
macroscopic changes at the tumor site were similar to those found in mouse tumors in this study. 
The evidence overall suggests that EBC-46 may find use as a palliative treatment, local disease 
control or adjuvant therapy preceding surgery or radiation. Ongoing advances in drug delivery and 
imaging technologies may facilitate intratumoral administration to less accessible sites.
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1.1  PREFACE 
Cancer is described as a class of diseases, where an abnormal growth of cells caused by multiple 
changes in gene expression or mutations lead to a dysregulated balance in cell proliferation and 
death. Such cells can ultimately invade locally and metastasize to distant sites in the body.  
From a clinical point of view, cancer is a large group of complex diseases that vary in their age of 
onset, state of cellular differentiation, rate of growth, invasiveness, metastatic potential, diagnostic 
detectability, prognosis and treatment response. From a molecular and cell biological point of view, 
however, cancer may be a relatively small number of diseases caused by similar molecular defects 
in cell function resulting from common types of alterations to specific genes. Ultimately, cancer is a 
disease of abnormal gene expression. There are a number of mechanisms associated with alteration 
of gene expression; which may occur via a direct insult to DNA, such as gene mutation, 
translocation, amplification, deletion, loss of heterozygosity, or via a mechanism resulting from 
abnormal gene transcription or translation. The overall result is an imbalance in cell replication and 
cell death in tumor cell population that leads to an expansion of tumor tissue. In normal tissues, cell 
proliferation and cell loss are in a state of equilibrium.  
In addition to mutations, epigenetic events such as abnormal DNA methylation can also lead to 
silencing of tumor suppressor genes or result in the activation of oncogenes, thus compromising the 
genetic balance and leading to malignant transformation. 
Cancer is a leading cause of death in Australia with 1 in 3 Australians being affected in their 
lifetime. It is estimated that an approximate 120,710 new cases of cancer were diagnosed in 2012 
with more than 43,000 cases resulting in mortality in spite of a 30% improvement in survival over 
the last two decades (AIHW, 2012). The National Health Priority Area cancers include prostate, 
lung, and colorectal cancers in males and breast, lung and colorectal in women; accounting for 59% 
of all cancers. The age group below 15 years is commonly affected by lymphoid, brain and central 
nervous system neoplasms, while melanoma and breast cancers are predominant in the 15 – 44 age 
groups. 
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1.1.1  Skin Cancer 
The three most common forms of skin cancer are basal cell carcinoma (BCC), squamous cell 
carcinoma (SCC) and melanoma, each of which is named after the type of cell from which it 
originates. Melanoma is less common than basal and squamous cell carcinomas, however it is the 
most serious, being responsible for ~75% of all skin cancer – related deaths. The primary cause of 
skin cancers is over-exposure to UV-radiation via direct or indirect DNA damage. Smoking tobacco 
and related products (Morita, 2007, Tanaka et al., 2007), genetic predisposition (Halpern and 
Altman, 1999) and human papilloma virus (HPV) (Pfister, 2003) are some of the factors that can 
increase the risk of skin cancer.  
Basal cell carcinomas originate in the basal cell layer of the epidermis, where they begin as a papule 
and develop into a crater that erodes and bleeds. Metastasis is rare, but BCC cells can locally invade 
into adjacent tissues (Hauben et al., 1982). A mutant of the human homologue of the Drosophila 
gene, PTCH (PATCHED), has been identified in the development of basal cell carcinoma (Gailani 
et al., 1996, Unden et al., 1996). 
Squamous cell carcinomas are the second most common form of non-melanoma skin cancer. They 
originate in the epidermis, squamous mucosa or areas of squamous metaplasia. Their clinical 
appearance is highly variable, where the tumor is often elevated, or may be ulcerated with irregular 
borders. Squamous cell carcinomas spread faster than BCCs, but are still relatively slow. Rarely, 
they can metastasize to other locations including internal organs (Alam and Ratner, 2001). Actinic 
keratosis is a precancerous lesion that can develop into a squamous cell carcinoma (Leffell, 2000). 
UV-induced mutations in p53 have been observed in basal cell carcinomas, as well as squamous 
cell carcinomas (Brash et al., 1991, Quinn et al., 1994, Rady et al., 1992). In addition, EGFR-1 and 
HER2 mutations have been detected in squamous cell carcinomas of the head and neck (Lee et al., 
2005, Willmore-Payne et al., 2006).   
Melanoma results from the uncontrolled proliferation of melanocytes giving rise to the formation of 
malignant melanoma. Melanoma may arise de novo or from a precursor lesion. Melanoma is less 
common than the other forms of skin cancer; however it is more often fatal, resulting in 75 – 80% 
mortality if it has progressed to stage II. The strongest risk factors for melanoma are exposure to 
UV-radiation, multiple nevi, a previous incidence of melanoma and a family history of the cancer 
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(Elder, 2006, Miller and Mihm, 2006). A number of genes have been identified in the development 
of the various types of melanoma, some of which are BRAF, NRAS, c-kit, PTEN, CDKN2A and 
CDK4 (Herlyn, 2009, Miller and Mihm, 2006, Willmore-Payne et al., 2005). 
1.1.2  Breast Cancer 
Breast cancers originate from breast tissue, most commonly from the inner lining of milk ducts or 
the lobules that supply the ducts with milk. Depending on their origin, breast cancer can be broadly 
classified into ductal carcinomas (originating from the ducts) and lobular carcinomas (originating 
from the lobules) (Perry and Phillips, 2002). Many breast cancers develop from a progression 
sequence that begins with an increase in the number of breast cancer precursor cells (known as 
hyperplasia) followed by the emergence of atypical breast cells (called atypical hyperplasia). This 
stage is followed by carcinoma in situ, a non-invasive cancer which may finally develop into an 
invasive cancer. 
Mutations in either of two major susceptibility genes BRCA1 (breast cancer susceptibility gene 1) 
and BRCA2 (breast cancer susceptibility gene 2), confer a lifetime risk for breast cancer and ovarian 
cancer, respectively (Thompson et al., 2002, The Breast Cancer Linkage Consortium, 1999).  
1.1.3  Colon Cancer 
Colon cancer, also called colorectal cancer, includes cancerous growths in the colon, rectum and 
appendix. It is the third most common cause of cancer – related deaths in the Western world. Colon 
cancers arise from epithelial cells lining the colon and rectum, which grow into an adenoma with 
high-grade dysplasia and then progress to invasive cancer (Kinzler and Vogelstein, 2002).  
Colon cancer is associated with genetic alterations, environmental exposures including diet and 
inflammatory conditions of the digestive tract. At the cellular and molecular level, colorectal cancer 
begins with a mutation in the Wnt signaling pathway. When Wnt binds to a receptor, it activates a 
chain of molecular events that ends with β-catenin entering the nucleus and interacting with 
TCF/LEF family of transcription factors that are bound to DNA via a high mobility group domain. 
The early event of colon cancer is the result of a mutation of APC (adenomatous polyposis gene). 
The protein encoded by APC is important in the activation of an oncogene c-myc and cyclin D1 
which initiates a malignant progression (Cancer Council NSW, 2007). Other changes featuring in 
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colon carcinogenesis include KRAS mutation, chromosomal abnormalities such as in chromosome 
18 (loss of heterozygosity – LOH), chromosome 17p deletion and mutations in the p53 tumor 
suppressor gene (Lea et al., 2009, Vogelstein et al., 1988). 
1.1.4  Treatment Modalities  
Treatment of cancer is dependent on the type, location of the cancer, age of the patient, and whether 
the cancer is a primary tumor or a recurrence. Surgery and radiation have been the most common 
modes for treatment of cancers, with the choice of technique being dictated by the size and location 
of the disease. Immunotherapy, or biological therapy, is a relatively new addition to the group of 
cancer treatments. Topical therapy might also be indicated for accessible tumors for a good 
cosmetic outcome. 
Radiation is an adjuvant treatment, usually administered in association with other forms of cancer 
therapies. It is also used as a palliative treatment aiming for local disease control. Radiotherapy 
works by damaging DNA in cells which is triggered by radioisotopes. Unlike their healthy 
differentiated counterparts, cancer cells are generally undifferentiated and have diminished ability 
to repair damaged DNA (Camphausen and Lawrence, 2008). Oxygen acts as a potent 
radiosensitizer. One of the limitations of radiotherapy is that solid tumor cells become deficient in 
oxygen, and thus create a hypoxic environment. This makes solid tumor cells resistant to radiation 
damage compared to those in a normal oxygen environment. 
Chemotherapy involves the use of toxic drugs to kill cancer cells. In a broad sense, 
chemotherapeutic drugs effectively target fast-dividing cells by impairing mitosis or other events 
associated with proliferation. Tumors with higher growth rates therefore tend to be more sensitive 
as a larger proportion of cells are undergoing cell division. On the other hand, tumors with a slower 
growth rate respond moderately (Skeel, 2003). Depending on the medications used, a range of side 
effects is observed such as depression of the immune system, fatigue, tendency to bleed easily, hair 
loss, erythema, and dry skin. More recently, targeted therapies such as B-raf inhibitors have induced 
spectacular remission in some melanoma patients (Flaherty et al., 2010, Sosman et al., 2012)but 
resistance eventually emerges. 
Immunotherapy uses the body’s immune system to fight cancer or to minimize the adverse effects 
that may be caused by chemotherapy or radiation. Biological response modifiers such as cytokines, 
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antibodies, growth factors, peptides, nucleic acids and dendritic cells are being used in the 
development of vaccines (Agarwala, 2010, Dunn et al., 2004).  
Although there have been vast improvements in the currently available techniques, there still are 
limitations with respect to safety, side effects and long-term efficacy. This suggests the need for 
new and improved treatments. 
 
1.2  PROTEIN KINASE C 
First identified in the late 1970s (Takai et al., 1977), protein kinase C enzymes were described to be 
a product of limited proteolysis by a calcium-dependent protease (Inoue et al., 1977). However 
shortly after, it was reported that PKC was activated by Ca2+ and phospholipids with no proteolysis 
(Takai et al., 1979); and the significant activation of PKC by  diacylglycerol was also independent 
of proteolysis (Kishimoto et al., 1980). Protein Kinase C consists of a family of serine/threonine 
protein kinases that are physiologically activated by 1,2-diacylglycerol (DAG) and other lipids. 
When an external stimulus activates a G-protein coupled receptor (GPCR), it in turn stimulates a G-
protein. The G-protein activates phospholipase C (PLC), which cleaves phosphoinositol-4,5-
biphosphate (PIP2) into 1,2-diacylglycerol and inositol-1,4,5-triphosphate (IP3). The IP3 interacts 
with a calcium-ion channel in the endoplasmic reticulum (ER), releasing Ca2+ into the cytoplasm. 
Increase of Ca2+ activates PKC by binding to the C2 domain of the PKC complex and translocates 
to the membrane, anchoring the PKC to DAG and phosphatidylserine (Newton, 1995, Newton, 
1997). Importantly, phorbol esters were found to activate PKC directly in a manner analogous to 
diacylglycerol (Castagna et al., 1982). From molecular cloning studies,  a family of 12 distinct 
members of mammalian PKCs have been identified, not all of which are activated by DAG or 
phorbol esters (Nishizuka, 1995). They are subdivided based on their sequence similarities and their 
modes of activation. The ‘conventional’ PKCs (cPKC) which include α; β1 and β2 (alternative splice 
variants from the same gene); and γ, are activated by phosphatidylserine, diacylglycerol or phorbol 
esters and Ca2+ (Table 1.1). Members of the ‘novel’ PKC subfamily (nPKC), δ, ε, η, and θ, rely on 
DAG/phorbol esters for activation but are independent of calcium. Though structurally similar to 
conventional PKCs, the activation requirement of this subfamily may be explained by the 
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Table 1.1 Basic structures of members of the PKC family.  
PKC subfamily Isoforms Domains present Mode of activation 
 
Conventional PKC 
α PseudoS – C1A-C1B – C2 – C3 – C4 
 
DAG/phorbol esters + Ca2+ +  PS 
β1 PseudoS – C1A-C1B – C2 – C3 – C4 
β2 PseudoS – C1A-C1B – C2 – C3 – C4 
γ PseudoS – C1A-C1B – C2 – C3 – C4 
 
Novel PKC 
δ C2 – PseudoS – C1A-C1B – C3 – C4 
 
DAG/Phorbol esters 
ε C2 – PseudoS – C1A-C1B – C3 – C4 
η C2 – PseudoS – C1A-C1B – C3 – C4 
θ C2 – PseudoS – C1A-C1B – C3 – C4 
 
Atypical PKC 
ι PseudoS – C1 – C3 – C4  
phospholipids ζ PseudoS – C1 – C3 – C4 
μ PTD – PseudoS – C1 – PH – C3 – C4 
DAG/Phorbol esters + phospholipids 
ν PseudoS – C1 – PH – C3 – C4 
Abbreviations: PseudoS – pseudosubstrate; PH – pleckstrin homology, PTD – putative transmembrane domain. 
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difference in the peptide sequence (Sutton et al., 1995). A third subfamily, termed ‘atypical’ PKC 
 (aPKC) and including ι (which is a homolog of the murine isotype λ) and ζ, are independent of 
activation by DAG/phorbol esters and calcium, but have been found to be activated by cis-
unsaturated fatty acids. The distant relatives of this subfamily include PKCµ/PKD (the mouse 
homolog) and PKC- ν, and are found to be activated by diacylglycerol or phorbol esters and L-α-
phosphatidyl-D-myo-inositol-4,5-bisphosphate (Hayashi et al., 1999, Johannes et al., 1994, 
Valverde et al., 1994). These kinases have common structural features which suggests that they 
belong to the same family (Hofmann, 2001). 
1.2.1  Structure 
The members of the PKC family are monomeric enzymes, with an N-terminal regulatory region (20 
– 70 kDa) and a C-terminal catalytic region (~45 kDa); where each isozyme is a product of a 
separate gene, except for β1 and β2 which are splice variants of the same gene. Four conserved 
domains have been revealed by molecular cloning: C1 – C4 (Figure 1.1); with alternating variable 
regions V1 – V4. The regulatory region of PKCs comprises an autoinhibitory pseudosubstrate 
domain and a membrane-targeting motif, the C1 domain, which is present in duplicate in 
conventional and novel PKCs, and singly in the atypical PKCs. These are cysteine-rich motifs and 
are specific for the diacylglycerol/phorbol ester binding. The C2 domain, also grouped within the 
regulatory region, is present in conventional and novel protein kinase Cs; provides the binding site 
for the Ca2+, and in some isozymes, for acidic lipids. In the catalytic region, the C3 and C4 domains 
(present in all PKC isoforms) form the ATP- and substrate-binding regions. The regulatory and 
catalytic regions are separated by a hinge region that becomes proteolytically unstable when the 
enzyme is bound to a membrane (Gomperts et al., 2003, Newton, 1995). 
 
The atypical protein kinase Cs differ considerably from the other classes, in that, the C1 domain 
contains only a single Cys-rich sequence and also the key residues that maintain the C2 fold, appear 
to be absent. More importantly, these isozymes cannot respond to phorbol esters either in vivo or in 
vitro (Nishizuka, 1995). Between the distant members of this subfamily – PKC-µ and PKC-ν, there 
exists ~80% structural homology. A single Cys-rich sequence (C1 domain), catalytic region with 
the C3 and C4 domains and a pleckstrin homology between the C1 domain and catalytic region 
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Figure 1.1 Schematic diagram of the primary structure of Protein Kinase C isozymes. 
 
Protein kinase Cs comprise of four conserved domains have been revealed by molecular cloning: 
C1 – C4 with alternating variable regions V1 – V4. The regulatory region of PKCs consist of an 
autoinhibitory pseudosubstrate domain and a membrane-targeting motif, the C1 domain, which 
is present in duplicate in conventional and novel PKCs, and singly in the atypical PKCs. cPKC; 
conventional PKCs include α, β  and γ. nPKC; novel PKCs include δ, ε, η and θ. aPKC; atypical 
PKCs include ι, ζ, μ and ν.(Gomperts et al., 2003, Hayashi et al., 1999, Johannes et al., 1994, 
Newton, 1995). 
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are found to be conserved among the two enzymes (Hayashi et al., 1999, Johannes et al., 1994). 
PKC-µ was also reported to harbour a putative transmembrane domain in the regulatory region 
which is absent in PKC-ν (Johannes et al., 1994). 
1.2.2  Regulation 
Newly synthesized PKC is present in an inactive state in the cytosol, with the autoinhibitory 
pseudosubstrate domain bound to the catalytic domain (C4 domain). This conformation restricts the 
ability of the PKC to bind to substrates. The main regulatory inputs that control PKC activity are: 1) 
phosphorylation signals, 2) cofactor binding and 3) protein – protein interactions. 
1.2.2.1  Regulation by Phosphorylation 
Phosphorylation of Serine/Threonine and Tyrosine residues is essential for the maturation and 
activation of PKC. In the initial phosphorylation step, all PKC isozymes are trans-phosphorylated 
by phosphoinositol-dependent protein kinase – 1 (PDK-1) on the Ser/Thr and Tyr residues in the 
activation segment of the catalytic domain (Chou et al., 1998, Dutil et al., 1998, Krauss, 2003d, Le 
Good et al., 1998). As a consequence of PDK-catalyzed phosphorylation, auto-phosphorylation on 
two sites near the C-terminus is triggered (Figure 1.2). Overall, the trans- and auto-phosphorylation 
events are important for regulating the catalytic activity of PKCs and their subcellular distribution. 
The two auto-phosphorylation events have been observed both in vivo  and in vitro (Keranen et al., 
1995). The first phosphorylation is essential for membrane translocation of PKC to the plasma 
membrane. The second phosphorylation increases the thermal and proteolytic stability of PKC, 
thereby, increasing the enzymatic affinity towards cofactor binding, such as ATP, peptide substrate 
and Ca2+ (Edwards et al., 1999, Edwards and Newton, 1997, Keranen et al., 1995) (Table 1.2). 
1.2.2.2   Regulation by Membrane Association   
The first steps of signal transduction often take place in close association with the plasma 
membrane, before the signal is directed towards the cell interior. The cell mainly uses two 
mechanisms for transmission of signals at the cytosolic site of the membrane and the cell interior.  
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Figure 1.2 Regulation of Protein Kinase C 
Regulation of protein kinase C involves three main regulatory steps 1) phosphorylation signals, 2) cofactor binding and 3) protein – protein 
interactions (Keranen et al., 1995). 
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Table 1.2 Alignment of phosphorylation sites on members of the PKC family 
Isoform In activation loop  In C-terminus 1  In C-terminus 2  
hPKC-α GVTTRTFCGTPDYIAPE T497 RGQPVLTPPDQLVI T638   QSDFEFGSYVNPQ S657 
hPKC-β1 GVTTKTFCGTPDYIAPE T500  RQPVELTPTDKLFI T642  QNEFAGFSYTNPE S661 
hPKC-β2 GVTTKTPCGTPDYIAPE T500  RHPPVLTPPDQEVI T641   QSEFEGFSFVNSE S660 
hPKC-γ  GTTTRTFCGTPDYIAPE T514 RAAPAVTPPDRLVL T655  QADFQGFTYVNPD T674 
hPKC-δ  ESRASTFCGTPDYIAPE T507 NEKARLSYSDKNLI S645  QSAFAGFSFVNPK S664 
hPKC-ι  GVTTTTFCGTPDYIAPE T566  REEPVLTLVDEAIV T710  QEEFKGFSYFGED S729 
hPKC-η GVTTATFCGTPDYIAPE T510  KEEPVLTPIDEGHL T650  QDEFRNFSYVSPE S672 
hPKC-θ DAKTNTFCGTPDYIAPE T538  NEKPRLSPADRALI S676 QNMFRNFSFMNPG S695 
hPKC-ζ  GDTTSTFCGTPNYIAPE T410  SEPVQLTPDDEDAI T552   QSEFEGFEYINPL E579 
hPKC-λ  GDTTSTFCGTPNYIAPE T411  NEPVQLTPDDDDIV T563   QSEFEGFEYINPL E582 
hPKC-µ KSFRRSVVGTPAYLAPE S742 Absent  Absent  
The first phosphorylation occurs in the activation loop near the APE sequence (targets indicated in red). This is brought about by 
phosphoinositide-dependent protein kinase-1 (PDK-1). The subsequent autophosphorylations targets at the C-terminus of the catalytic domain 
are indicated in yellow and green respectively. Adapted from Toker, A. (Toker, 1998). 
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Signals may be transmitted with the help of low-molecular-weight messenger substances known as 
“second messengers” (Newton, 1993). The intracellular messenger substances are products of 
specific enzyme reactions. They are diffusible signal molecules and reach their target mostly by 
diffusion.  
The second messengers can be differentiated into: 
Hydrophilic messengers with good aqueous solubility and are localized in the cytosol, such as 
inositol phosphates and Ca2+. 
Hydrophobic messengers such as diacylglycerol and the phosphatidyl inositol derivatives which are 
membrane localized. They reach their targets by diffusing through the plasma membrane and 
regulate their activity. 
These cofactors are products of enzyme reactions, namely, G-protein-dependent pathways and 
Receptor Tyrosine Kinase pathways. Upon binding with Ca2+, there is an increase in membrane 
association and activation by the release of the autoinhibitory pseudosubstrate from the catalytic 
domain of the protein kinase C. Further activation takes place by the binding of DAG to the C1 
domain, which directly favors membrane association and enhances binding of PS to the C2 domain 
(Griner and Kazanietz, 2007, Newton, 1995, Newton, 1997). 
Multiple Sources of DAG 
Considering the requirement for DAG, the regulation of PKC is linked to PLC (Berridge and Irvine, 
1984). The hydrophobicity and small size of DAG, enables it to diffuse laterally in membranes. It is 
also short-lived as it is either broken down by DAG lipase or converted to phosphatidate by the 
action of DAG kinase. Virtually all ligands, growth factors, hormones or neurotransmitters promote 
the production of DAG (and IP3), which means PKC is implicated in a large number of cellular 
responses. 
Several other lipid second messengers and mediators either potentiate the effect of DAG and Ca2+ 
or directly activate PKC. 3-phosphorylated inositol lipids PI(3,4)P2, and products of the 
phosphoinositide-3-kinases PI(3,4,5)P3; activate both the novel (δ, ε and θ) and atypical (ζ) PKCs in 
a phosphatidylserine environment (Toker et al., 1994). Unsaturated fatty acids, particularly 
arachidonic acid, lysophosphatidic acid (LPA) and lyso-phosphatidylcholine (lysoPC), can enhance 
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the activity of PKC (Sando and Chertihin, 1996). Breakdown products of sphingolipids, such a 
sphingosine and lysosphingolipids, inhibit the conventional PKCs most likely by masking their 
interaction with phosphatidylserine (Hannun and Bell, 1989). 
1.2.2.3   Regulation by Localization and Protein-Protein Interaction 
A major regulatory aspect of protein kinase C is the localization of the enzymes to distinct 
subcellular compartments mediated by protein-protein interactions (Jaken, 1996). PKC enzymes 
have been found to interact with a range of proteins of diverse functions such as scaffolding, 
adaptor or membrane-targeting, inhibitory functions and also substrate proteins. Examples of 
membrane-targeting proteins are the receptors for activated C kinase, the RACK proteins; a group 
of proteins that bind to the active conformation of PKC and anchor them to the membrane, 
providing access to membrane-localized substrates (Mochly-Rosen, 1995). Members of the A 
kinase-anchoring protein, AKAPs, have also been identified as binding partners of PKC enzymes 
that assemble PKC into protein signaling complexes, keeping it in an inactive state. Upon receipt of 
Ca2+/DAG signals, PKC is released from this inhibitory state (Klauck et al., 1996).  
The regulation of PKC by phorbols and DAG occur by the same mechanism; with some differences 
is the strength of the reaction. Upon activation, PKC isoforms translocate to the particulate fraction 
where they interact with the substrates, such as the mitogen activated protein kinase (MAP kinase); 
after which they are proteolytically degraded. TPA can both activate PKC and after longer 
incubation, down-regulate the enzyme (Silinsky and Searl, 2003), via the ubiquitin – proteosome 
pathway (Hofmann, 2001, Lu et al., 1998). Diacylglycerol, the physiological activator of PKC, also 
demonstrated the degradation of PKC, thus suggesting that ubiquitination is a physiological 
response to PKC activation (Lu et al., 1998). 
 
1.3  PROTEIN KINASE C ACTIVATION BY PHORBOL ESTERS 
The protein kinase C family of phospholipid-dependent protein kinases plays a key role in signal 
transduction. The PKC isozymes are activated by diacylglycerol, one of the products of the 
receptor-mediated hydrolysis of inositol phospholipids, and also by certain drugs, such as phorbol 
esters. PKC activators have been previously studied as chemotherapeutic agents (Section 1.3.1). 
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It has been suggested that the cysteine-rich regions in PKC are essential for phorbol ester binding 
(Ono et al., 1989). The PKC activators form hydrogen-bonds with main-chain groups forming a 
hydrophobic surface over one-third of the C1 domain, thereby stabilizing the membrane-inserted 
state of the PKC (Zhang et al., 1995). 
1.3.1  Phorbol Esters 
Phorbol esters are naturally occurring compounds and are found to mimic the action of 
diacylglycerol in the activation of PKC, which regulates different signal transduction pathways and 
other cellular metabolic activities. Their structure is dependent on the tetracyclic diterpene carbon 
skeleton known as tigliane (Figure 1.3). A tigliane contains four rings; A, B, C and D. 
Hydroxylation of this basic structure at different positions followed by ester bonding to various acid 
moieties results in the formation of a number of different phorbol ester compounds. The widely 
active phorbol 12-O-tetradecanoylphorbol-13-acetate (TPA) is accepted as the prototype of phorbol 
ester (Figure 1.3). It is obtained from the latex of Croton tiglium, a leafy shrub member of the 
Euphorbia family that is native to Southeastern Asia (Goel et al., 2007). 
 
 
 
 
 
 
 
 
 
 
     
 
Figure 1.3  Structure of Phorbol Ester 12-O-tetradecanoyl-13-acetate (TPA) (Evans, 
1986, Goel et al., 2007, Zucker et al., 1974) 
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Phorbol esters are amphiphillic molecules and tend to bind to phospholipid membrane receptors. 
The phorbol acts as an analogue for DAG (Castagna et al., 1982); though, unlike DAG, phorbol 
esters are not readily metabolized (Asaoka et al., 1992, Nishizuka, 1992, Nishizuka, 1995).  
Though graded as a tumor-promoter in carcinogenic experiments performed on normal mouse skin 
and xenograft human foreskins (Yuspa et al., 1979), TPA has also been established to induce 
cytostatic, cytotoxic and differentiation end points in cancer cells (Hofmann, 2001).  
Studies of TPA as a therapeutic agent indicated an effect upon systemic administration in 
myelocytic leukaemia patients; though there was a decrease in myeloblasts in bone marrow and 
peripheral blood as well as temporary remissions (Han et al., 1998 (i)). It was also observed that 
TPA induced an increase in depressed white blood cell counts and neutrophils towards the normal 
range, when administered to patients treated with cytotoxic cancer chemotherapeutic drugs (Han et 
al., 1998 (ii)). These findings broaden the therapeutic potential of phorbol esters towards treatment 
of solid tumors.  
The compound PEP005 (ingenol-3-angelate) is a novel anticancer drug (Kedei et al., 2004) that is 
an activator of protein kinase C. Topical application of a high-dose of the diterpene ester, has been 
shown to cure ~80% of subcutaneous tumors in mice. In vitro, PEP005 was found to be highly toxic 
to cells when treated with high concentrations (Ogbourne et al., 2004). Treatment of melanoma cell 
lines with TPA or PEP005 indicated irreversible growth arrest, with no adverse effects observed in 
normal melanocytes and normal fibroblasts (Cozzi et al., 2006). Phase IIa trials of topically applied 
PEP005, indicated that it was safe and efficient in treating basal cell carcinomas and the squamous 
cell carcinoma precursor, actinic keratosis (AK) (Siller et al., 2009, Siller et al., 2010). Phase III 
trials of PEP005 in a gel formulation successfully reached a primary clinical endpoint of complete 
clearance of actinic keratosis in non-head locations (www.leo-pharma.com, 2010). 
 
1.4  PROTEIN KINASE C AND SIGNAL TRANSDUCTION 
Protein kinase C is an enzyme activated by diacylglycerol or phorbol esters and relays information 
via a variety of extracellular signals across the cell membrane to regulate many intracellular 
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processes. PKCs have been largely implicated in the regulation of gene expression with its ability to 
translocate and enter the cell nucleus (Nishizuka, 1992, Nishizuka, 1989, Nishizuka, 1984).  
Phosphorylation by protein kinases to side chains of either serine or threonine specific protein 
substrates inside cells, can control their interaction with other proteins and molecules, their 
enzymatic activity and their predisposition to degradation by proteases. The family of mitogen-
activated protein kinases is an example of such protein kinases. Phosphorylation of substrate 
proteins by mitogens functions as a switch to turn on or off the activity of the protein. Substrate 
proteins include other protein kinases, phospholipases, transcription factors and cytoskeletal 
proteins (Johnson and Lapadat, 2002). Protein Kinase C is known to phosphorylate members of the 
mitogen – activated protein kinase pathways (MAPK) (Section 1.4.1). 
1.4.1  MAPK Pathways: 
In general, an intracellular signaling pathway involves an extracellular signal that activates a 
transmembrane receptor. This activation transmits signals to downstream effector molecules via a 
sequential cascade. Among such pathways are the highly conserved mitogen-activated protein 
kinase (MAPK) modules and are found in all eukaryotic organisms. The mitogenic activated protein 
kinase pathways are organized in modules containing a core of three protein kinases. A multitude of 
signals have been found to activate MAPK modules. Initially, the activation of Raf kinase the by 
Ras family were discovered as the entry point into the MAPK signaling cascade. Later on it was 
established that the signal – transducing function of a MAPK pathway is determined by the nature 
of the MAPK module involved, this in turn depends on the properties of the protein kinases it 
contains, which differ in regulation and substrate specificity. Furthermore, the modules can share a 
common protein kinase but regulate different biological processes. The signal is passed on by the 
terminal member in the phosphorylation cascade in the form of phosphorylated substrate proteins. 
In many cases, this process is linked to translocation of the protein kinase into the nucleus, where 
nuclear localized substrates, particularly transcription factors, are phosphorylated. The various 
modules are not strictly independent; rather they mutually influence each other (Krauss, 2003a).  
 One of the first and best characterized MAPK pathways consists of Raf isoforms that activate two 
MEKs; MEK1 and MEK2, which in turn activate protein kinases known as ERK1 and ERK2. This 
pathway is known as the ERK pathway and is linked to cell proliferation and survival. Two other 
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mammalian pathways that stand out are the c-Jun amino-terminal kinase/stress-activated protein 
kinase (JNK/SAPK) and p38 pathways, which mediate responses to cellular stress, such as cell-cell 
interaction, U.V. radiation and heat-stress and are associated with apoptosis (Figure 1.4). 
Components of the MAPK pathways: 
MAPK pathways comprise of a core module of three protein kinases that are organized as 
functional units with the aid of scaffolding proteins. The MAPK proteins are at the lower end of the 
signal transduction within a MAPK module and are generally preceded by two other protein 
kinases; MAPK kinase (MAP2K or MAPKK) and MAPK kinase kinase (MAP3K or MAPKKK). 
Generally, the ERK pathway starting from Ras protein activation is used to represent other MAPK 
pathways with similar structure.  
1.4.1.1  Small molecular weight GTPases:  
Small molecular weight GTP binding proteins (GTPases) comprise a superfamily of regulatory 
proteins that control a diverse array of intracellular signaling pathways. Diverse external stimuli 
activate the MAPK pathways via interactions with small molecular weight GTPases such as the Rho 
family proteins, Ras, ARF. Rac and CDC42 are members of the Rho family and are found to couple 
different stimuli and receptors to intracellular signaling pathways, such as the JNK/SAPK pathway 
(Price and Collard, 2001, Takai et al., 2001). They have been known to regulate the organization of 
the actin cytoskeleton where Rac regulates lamellipodia and CDC42 regulates the filopodia in cells. 
Activation of the signaling pathway involves a guanine nucleotide exchange in Rac or CDC42 
where the GTPases function as molecular switches that cycle between a GDP bound inactive state 
and a GTP bound active state. This cycle is controlled by GTPase Activating Proteins (GAPs) 
(Scheffzek et al., 1997), which stimulate the slow intrinsic rate of GTP hydrolysis and Guanine 
Nucleotide Exchange Factors (GEFs), which promote dissociation of GDP and loading of GTP. The 
GTP-bound Rac or CDC42 bind and stimulate p21 – activated kinases (PAKs) which are the 
mammalian homologs of Ste20p (Price and Collard, 2001, Reuther and Der, 2000). 
1.4.1.2` MAP3Ks, MEKKs (MAPK/ERK kinase kinase):  
MAP3Ks (MEKKs) are Ser/Thr-specific protein kinases and are the entry point for signal 
transduction in a MAPK module. The best characterized representative is the Raf-1 kinase which is 
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activated by the Ras protein in its GTP-bound form. Other representatives include the Mos kinase 
and the MEKK1 protein. Signaling proteins that deliver signals to the MAP3Ks comprise mostly 
small GTPases like members of the Ras and Rho/Rac family. Raf proteins and Mos are perhaps the 
only MEKKs, which phosphorylate MEKs in a single cascading event. Four mammalian MEKKs 
have been identified: MEKK1 (Lange-Carter et al., 1993, Xu et al., 1996), MEKK2 and 3 (Blank et 
al., 1996) and the two splice variants of MEKK4, namely MEKK4α and MEKK4β (Gerwins et al., 
1997). MEKK2 and 3 are closely related, sharing a 94% homology in the catalytic region and 65% 
homology in their N-terminal regions. MEKK1 and 4 both contain a proline-rich sequence that is 
involved in binding of proteins containing Src-homology 3 (SH3) domains, suggesting a specific 
regulatory function of these sequences (Gerwins et al., 1997, Xu et al., 1996). The presence of a PH 
(pleckstrin homology) domain in MEKK1 may partly account for its interaction with membranes of 
the cell (Xu et al., 1996) and in MEKK4 it may be responsible for the co-localization with Golgi-
associated vesicles (Gerwins et al., 1997). Pleckstrin homology domains have been shown to 
mediate localization of proteins to the plasma membrane (Pawson, 1995). MEKK1 contains a Ras-
binding site close to the catalytic region (Russell et al., 1995) while MEKK4 has a cdc42/Rac 
binding site at a similar position (Gerwins et al., 1997). MEKK2 and 3 have been shown to lack 
definable domains and are found in the cytoplasm (Hagemann and Blank, 2001). The differential 
subcellular localization of the MEKK family members, with their potentially divergent interaction 
motifs, suggests that MEKKs are regulated by distinct extracellular stimuli and intracellular 
pathways and also implies that they have different functions. MEKK1 preferentially activates 
JNK/SAPK pathway in transfected cells (Minden et al., 1994, Thorburn et al., 1997, Xu et al., 
1996), however, in reconstituted cells, it activates both ERK and JNK/SAPK pathways 
(Khokhlatchev et al., 1997). MEKK2 and 3 are also both able to activate JNK/SAPK and ERK 
pathways; however, MEKK2 preferentially activates JNK/SAPK while MEKK3 shows an 
inclination towards the ERK pathway (Blank et al., 1996). In the ERK pathway, MEKKs appear to 
phosphorylate only two MEKs; MEK1 and MEK2, thereby placing them exclusively in the 
MAP/ERK pathway. Activation of MAP3Ks is a complex process requiring the steps of membrane 
translocation, phosphorylation, oligomerization, and binding to scaffold proteins (Robinson and 
Cobb, 1997). 
Raf proteins:  The Raf family of protein kinases was the first known MEKKs and is composed of 
A-Raf, B-Raf and Raf-1 (or C-Raf). Raf-1 is ubiquitous, while highest expression of A-Raf occurs 
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in urogenital tissue. B-Raf appears to function primarily in neuronal tissue and testis. Regulation of 
Raf-1 is complex, involving protein-protein interactions, phosphorylation of serine, threonine and 
tyrosine residues, and cellular localization (Hagemann and Rapp, 1999, Morrison and Cutler, 1997). 
There are significant differences in the regulation of Raf isoforms. One notable difference between 
Raf-1 and B-Raf is the differential regulation by small G-proteins Ras and Rap1a (Erhardt et al., 
1995, Seidel et al., 1999, Vossler et al., 1997, Zwartkruis et al., 1998). Raf-1 is activated by H-, K- 
and N-Ras proteins while B-Raf is activated both by Ras and Rap (Vossler et al., 1997, Zwartkruis 
et al., 1998). Phosphorylation of Raf-1 is influenced by a number of factors including Src (tyrosine 
protein kinases), p21-activated protein kinase (PAK), Akt (also called protein kinase B) and most 
importantly for the current study protein kinase C (PKC) family members (Diaz et al., 1997, Fabian 
et al., 1993, Morrison et al., 1993). 
1.4.1.3  MAP2Ks: 
The MAP2K proteins are a special class of proteins as they have a dual specificity characteristic 
with respect to the nature of the amino acid at the phosphorylation site on the target substrate 
protein. The dual specificity kinase (DSK) that phosphorylates ERK is known as MEK. Thus, 
MEK1/2 phosphorylates ERK1/2 respectively (Ahn et al., 1991, Crews et al., 1992, Zheng and 
Guan, 1993). In addition to MEK1/2, there are five other dual specific kinases involved in MAPK 
modules. MEK3 and 6 phosphorylate and activate the p38/MAPK pathway (Derijard et al., 1995, 
Han et al., 1996, Moriguchi et al., 1996, Raingeaud et al., 1996). MEK4 and 7 are involved in the 
phosphorylation of the JNK protein kinases (Derijard et al., 1995, Moriguchi et al., 1997, Tournier 
et al., 1997, Yao et al., 1997). A less well – characterized MAPK pathway; the ERK5 pathway is 
activated by MEK5 protein kinase (Zhou et al., 1995).  The structural and functional relationships 
of these kinases have been studied and explained using MEK1/2 as prototypic kinases. MEKs 
activate the MAPK/ERK proteins by phosphorylation at a Tyr and a Ser/Thr residue in the T-X-Y 
sequence where ‘X’ can be Glu, Pro or Gly (Marshall, 1995). Due to this property, the MEKs differ 
significantly from other protein kinases which are either Tyr or Ser/Thr – specific (Lindberg et al., 
1992).  
MEK1/2:  MEK1 and 2 are 43 – 46 kDa proteins that contain proline – rich sequences in their 
carboxy – and amino – terminal domains. A deletion of this insert impairs its activation by Raf – 1 
(Catling et al., 1995) which is one of the principal upstream kinases that is involved in the 
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activation of MEKs (Howe et al., 1992, Kyriakis et al., 1992). However, it is worth noting that 
MEK1/2 can be activated independent of the Ras – Raf pathway where phosphorylation can be 
achieved by other dual specificity kinases such as cMos (Nebreda et al., 1993, Shibuya and 
Ruderman, 1993).  
MEK3:  MEK3 activates p38MAPK through phosphorylation of Thr-180 and Tyr-182 in the 
TXY motif (Derijard et al., 1995, Raingeaud et al., 1996). Activation of the p38MAPK pathway, 
leads to the activation of different kinases such as MAPKAP-2 (Rouse et al., 1994, Stokoe et al., 
1992) and MAPKAP-3 (Ludwig et al., 1996). Phosphorylated p38MAPK translocates to the 
nucleus and phosphorylates transcription factors such as ATF2 (Raingeaud et al., 1995), MEF2C 
(Han et al., 1997) and CREB (Tan et al., 1996).  
MEK4:  JNK1 (Jun N-terminal kinase-1) was identified as the kinase that phosphorylates 
transcription factors such as c-Jun at Ser-63 and Ser-73 residues (Derijard et al., 1994), ATF2 
(Gupta et al., 1995) and Elk1 (Whitmarsh et al., 1995). Activation of this kinase requires a dual 
phosphorylation at Thr-183 and Tyr-185 by a dual specificity kinase MEK4 (Derijard et al., 1995).  
MEK5:  MEK5, the last of the dual specificity kinases to be characterized, is found to 
regulate a novel downstream enzyme termed as ERK5 (Zhou et al., 1995). Structural analysis of 
MEK5 suggests a critical role in cytoskeletal organization of the cell. It shares an overall structural 
similarity with MEKs-1, 2, 3 and 4, with a Raf-1 phosphorylation site similar to MEK1 and the 
absence of a proline-rich sequence resembling MEK3 and MEK4 (Zhou et al., 1995). There are two 
distinct alternatively spliced isoforms of MEK5 – MEK5α and MEK5β (English et al., 1995). 
Activation of the ERK5 pathway by MEK5 leads to phosphorylation of MEF2C transcription 
factor, belonging to the myocyte enhancer factor – 2 (MEF2) family that have been indicated the 
expression of several immediate early genes including c-Jun (Kato et al., 1997). 
MEK6:  MEK6 is a dual specificity kinase that shares close structural similarity to MEK3 and 
is strongly activated by stress – inducing factors such as U.V. radiation or osmotic shock 
(Moriguchi et al., 1996, Raingeaud et al., 1996). Expression of MEK6 activates p38MAPK which 
includes all the four isoforms - p38MAPKα, p38MAPKβ, p38MAPKδ and p38MAPKγ (Raingeaud 
et al., 1996, Wang et al., 1997). MEK 3 or MEK6 regulates p38MAPK activity and the resultant 
gene expression mediated by ATF2 and Elk1 (Raingeaud et al., 1996).  
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MEK7:  MEK7 is the mammalian homolog of the Drosophila Hep gene product. It is 
expressed in all adult and embryonic tissue (Moriguchi et al., 1997, Tournier et al., 1997, Yao et 
al., 1997). MEK7 is activated in response to cellular stress including proinflammatory cytokines, 
osmotic stress and Fas – induced apoptosis (Finch et al., 1997, Toyoshima et al., 1997). Analysis of 
mammalian MEK7 has indicated that it is highly specific to JNK regulation (Wu et al., 1997) as is 
MEK4. However, they appear to be differentially regulated. MEK7 is preferentially activated by 
TNFα, a proinflammatory cytokine (Moriguchi et al., 1997), whereas MEK4 is not; though other 
diverse stress stimuli activate both MEK4 and MEK7. MEK7 is specific to JNK, whereas MEK4 
can activate both JNK and p38 pathways (Lin et al., 1995, Tournier et al., 1997, Yao et al., 1997).  
1.4.1.4  MAPKs: 
MAPKs are divided into different subgroups based on their sequence homology, nature of the 
preceding MEK and the input stimulus. Within these subgroups, further diversification is possible 
by alternative splicing. Most of the known MAPKs contain a T-X-Y sequence, phosphorylation of 
which is essential for conduction of signaling of downstream substrate proteins. The T-X-Y motif is 
found as part of the activation loop. Location of the substrates of the MAPKs can be nuclear or 
cytoplasmic. Recognition and selection of substrate proteins occurs via specific docking sites on the 
substrates, which are bound by complementary binding domains on the MAPK (Barsyte-Lovejoy et 
al., 2002). Till date many MAPKs have been discovered, with ERKs 1/2, p38MAPKs α/β/γ/δ, 
JNK/SAPK being the well-characterized.  
ERK1 and ERK2:  These protein kinases, also known as MAPK3 and MAPK1 respectively, are 
nearly 85% identical with greater identity in the core regions which are involved in binding 
substrates. Based on their molecular weight they are sometimes referred to as p44ERK1 and p42ERK2. 
They were initially isolated and cloned as kinases activated in response to insulin and NGF 
(Boulton et al., 1991, Boulton et al., 1990). ERK1 and ERK2 are expressed in most, if not all, 
mammalian tissues. Alternatively spliced isoforms have been reported for ERK1 (ERK1b and 
ERK1c) (Shaul and Seger, 2006, Yung et al., 2000) and ERK2 (ERK2b) (Gonzalez et al., 1992). 
Many different stimuli including, cytokines, viral infection, growth factors and activation of G-
protein coupled receptors activate the ERKs. 
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p38MAPKs:  There are four p38 kinases: α, β, γ and δ among which p38α enzyme is the best 
characterized and is expressed in most cell types. The p38MAPKs regulate the expression of many 
cytokines. They are activated in immune cells by inflammatory cytokines and play an important 
role in the activation of the immune response (Wang et al., 1997, Jiang et al., 1997, Jiang et al., 
1996, Li et al., 1996). The four p38 isoforms are strongly activated by various environmental 
stimuli such as oxidative stress, UV radiation, hypoxia, and inflammatory cytokines such as 
interleukins, tumor – necrosis factor alpha (TNFα). P38 isoforms are also activated by G-protein 
coupled receptors and the Rho family GTPases CDC42 and Rac. 
JNKs:   Like the p38MAPKs, JNK also responds to stress stimuli, hence the synonym, stress 
– activated protein kinase (SAPK). There are three known JNK isoforms, JNK-1 (SAPKγ), JNK-2 
(SAPKα) and JNK-3 (SAPKβ) (Derijard et al., 1994, Kyriakis et al., 1994). The isoforms are 
strongly activated by oxidative stress, radiation and cytokines by dual phosphorylation on the 
Ser/Thr and Tyr residues (Bogoyevitch et al., 2010, Kyriakis and Avruch, 1996, Kyriakis et al., 
1991). The JNKs were in turn found to bind and phosphorylates the DNA binding protein c-Jun and 
increase its transcriptional activity (Kyriakis et al., 1994). Other transcriptional factors regulated by 
JNKs are ATF2, p53, Elk1, HSF1 and c-Myc (Bogoyevitch et al., 2010, Cargnello and Roux, 2011, 
Gupta et al., 1995, Raman et al., 2007, Whitmarsh et al., 1995). JNK1 and JNK2 are ubiquitously 
expressed, whereas JNK3 appears to be localized to neuronal tissues, cardiac myocytes and testis 
(Bode and Dong, 2007). The isoforms have been indicated in controlling programmed cell death or 
apoptosis (Tournier et al., 2000). Besides this, they have also been shown to have distinct roles in 
controlling cell proliferation. Activation of c-Jun by JNKs, promotes the AP-1 complex formation 
and the transcription of genes containing the AP-1 binding sites, including genes involved in cell 
cycle such as cyclin D1  (Sabapathy et al., 2004). 
Previous studies have shown that activation of PKC with drugs such as PEP005 leads to stimulation 
of the MAPK signaling pathway particularly the Ras/Raf/MEK/ERK arm (Cozzi et al., 2006) where 
terminal growth arrest of cancer cells was achieved at doses of TPA which stimulated an increased 
level of phosphorylation of ERK1/2 of the MAPK pathway.  
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Figure 1. 4 Schematic diagram of the mitogen-activated protein kinase pathways 
Activated PKC is considered to bind to Ras/Raf/MEK/ERK arm of the MAPK pathway and 
increase the level of phosphorylation of ERK1/2 (Cozzi et al., 2006, Technology). 
Abbreviations: ERK – Extracellular signal-regulated kinase; JNK/SAPK – c-Jun N-terminal 
kinase/stress-activated protein kinase  
 
 Chapter One 
________________________________________________________________________________ 
 
 
 
________________________________________________________________________________ 
 
Page | 26  
 
1.5  CELL CYCLE REGULATION 
1.5.1  Overview of the Cell Cycle 
Eukaryotic cells complete their reproduction in a cyclical process, in which at least two phases, S 
phase and M phase, can be differentiated on the basis of biochemical and morphological features. 
The biochemical characteristic of the S (synthesis) phase is the replication of nuclear DNA and thus 
doubling of the genetic information. In the M (mitosis) phase, division of the chromosomes 
between the daughter cells occurs. 
In most cell types, two further phases can be distinguished, G1 and G2 phase. G1 phase covers the 
period between M phase and S phase while G2 phase covers the period between S phase and M 
phase. From G1 phase, the cell may transfer into a quiescent state known as G0 phase. Appropriate 
signals (e.g. addition of growth factors) can induce the cell to return from G0 into G1 phase and 
proceed with the cell cycle. The cyclic sequence of G1, S, G2 and M phases describes a standard cell 
cycle (Figure 1.5) (Krauss, 2003c). 
1.5.2  Principles of Cell Cycle Control 
The different phases of the cell cycle include a number of highly ordered processes that ultimately 
lead to duplication of the cell. The various cell cycle events are highly coordinated to occur in a 
defined order and with an exact timing, requiring precise control mechanisms. 
The ordered sequence of cell cycle events is ensured by different control loops that have an 
inhibitory or promoting effect on the progress of the cell cycle. These are monitoring mechanisms 
that register the completion of important cell cycle events (e.g. complete DNA synthesis) and allow 
transition to the next event (e.g. entry into mitosis) to occur. The control systems of the cell cycle 
ensure that the various phases are executed completely and in the correct sequence. Entry into a 
new phase can only take place when the preceding phase has been completed.  
Many of the control mechanisms of the cell cycle are of an intrinsic nature and are constitutive, i.e., 
they are operational in every cell cycle and ensure the ordering of the individual steps. However, 
other control mechanisms exist that are not active in every cell cycle; these are only induced when 
defects are detected in central cell cycle events. These control mechanisms are known as 
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checkpoints. An example is the DNA damage checkpoint, a biochemical pathway that detects DNA 
damage and creates a signal that slows cells cycle progression or arrests cells in the G1, S, or G2 
phase. A biochemical pathway is at the centre of the cell cycle, of which the most important players 
are Ser/Thr-specific protein kinases and regulatory proteins associated with these. In addition to the 
built-in protection and control mechanisms, the cell is also subject to a number of external controls 
such as growth conditions and mitogenic (e.g. growth factors) and antimitogenic (e.g. TGF-β, cell 
damage) signals during cell-cell communication. 
These ensure that cell division occurs in balance with the overall development of the organism and 
with external growth conditions. This is a kind of social control of cell division that regulates the 
progress of the cell cycle, with the help of circulating signal molecules or via cell – cell interactions. 
The cell cycle contains critical events where the cell switches from one state of biochemical activity 
to another, in an irreversible manner. These events are called cell cycle transitions. Often, activating 
and inhibitory signals are received and transmitted at these cell cycle transitions. Key elements of 
the cell cycle regulation have been identified.  
Two processes are central to the cell cycle regulation: 
Oscillating changes in the activity of the cell cycle machinery, with protein kinases as the 
most important component. 
Specific proteolysis of the cell cycle regulators 
The activity of the cell cycle machinery is controlled by the following proteins: 
Cyclin-dependent kinases (CDKs) 
Cyclins 
Inhibitors of cyclin-dependent kinases (CKIs). 
An oscillating system is formed by the interplay of the three protein classes. The activity of the 
cyclin-dependent kinases (CDKs) is central to the oscillating system. These create a signal that 
initiates downstream biochemical processes and thus determines the individual phases of the cycle 
(Krauss, 2003c, Weinberg, 2007a). 
 Chapter One 
________________________________________________________________________________ 
 
 
 
________________________________________________________________________________ 
 
Page | 28  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 5 Four Phases of the Cell Cycle in Eukaryotes 
The four phases of a typical cycle of a eukaryotic cell. G1, S and G2 phases form the 
interphase, while the cell grows continuously. Cell division occurs in M phase. New synthesis 
of DNA is limited to S phase. G1 phase includes the period between M phase and S phase; G2 
phase lies between S phase and M phase (Krauss, 2003c, Weinberg, 2007a). 
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1.5.3  Mechanisms of Cell Cycle Regulation 
Mammalian cell cycle progression is regulated by the activation and inactivation of a conserved 
family of protein kinases known as cyclin – dependent kinases (CDKs). The CDKs are proteins of 
34-40 kDa with Ser/Thr-specific protein kinase activity. The CDKs must associate with the 
corresponding cyclin (or cyclin-like proteins) to be active. Active cyclin – dependent protein 
kinases are thus heterodimers in which the CDK subunit carries the catalytic activity and the other 
subunit, the cyclin, performs an activating and specificity – determining function. In addition to 
association of the cyclin, most CDKs require phosphorylation in the activation segment for full 
activation. In mammals, there are at least ten different CDKs, numbered CDK1 to CDK10 (Table 
1.3). 
Progress of the cell cycle appears to be mainly controlled by CDK1 (also known as CDC2) and 
CDKs 2, 4 and 6. CDKs 5 and 7-10, are not directly involved in cell cycle control and perform other 
tasks such as transcription regulation. Particular CDK/cyclin complexes act at different stages of the 
cell cycle controlling the two key checkpoints, G1  S and G2  M transitions. Progression 
through early G1 depends on CDKs 4 and 6 which are activated by the D-type cyclins (D1, D2, D3). 
The cyclin D-CDK4/6 complexes to perform a dual task in G1 phase regulation; one task is to 
integrate external signals into the cell cycle and the other function is to activate metabolism and 
promote cell growth. Progression through G1 and into S phase requires activation of CDK2, which 
is sequentially regulated by cyclin E and A. CDK2 associates with cyclin E in late G1 phase and 
once it enters the S phase, cyclin E is degraded and CDK2 combines with cyclin A. Degradation of 
cyclin A occurs in early M phase. Transition of the cell cycle from G2 to M is regulated by CDC2 
(CDK1) in association with cyclin A and cyclin B (Figure 1.5). 
Activity of the CDK/cyclin complexes is controlled by several mechanisms including the positive 
and negative phosphorylation events and their interaction with CDK inhibitory proteins. 
Phosphorylation at Thr161 of CDC2 (CDK1) kinase or the equivalent positions Thr160 of CDK2 
and Thr172 of CDK4/6 activates the CDK complexes, while phosphorylation at Thr14 and Tyr15 
has an inhibitory effect. Positive phosphorylation of CDKs is mediated by cyclin H-CDK7 
complex, also known as CDK-activating kinase (CAK), which is achieved by the phosphorylation 
of CDK1 (Fisher and Morgan, 1994, Kaldis, 1999). Negative control of CDK activity in cell cycle 
is achieved by cyclin-dependent kinase inhibitors (CKIs) (Chellappan et al., 1998, Sherr and 
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Roberts, 1995). They are a heterogenous family of proteins that associate with a CDK or a cyclin-
CDK complex and are divided into two groups:  CIP/KIP family (p21Waf1/Cip1, p27Kip1, p57Kip2), and 
INK4 family (p15INK4b, p16INK4a, p18INK4c, p19INK4d) (Lee and Yang, 2001). The Cip/Kip family 
mainly acts on CDK2 complexes, while the inhibitors of the INK family interact with CDK4 and 
CDK6 complexes.  
Important targets of CDK4 and CDK6 include members of the retinoblastoma family which 
comprise pRb (retinoblastoma protein), p107 and p130. The pRb protein is a nuclear 
phosphoprotein of 105kDa and belongs to a class of proteins called pocket proteins (Grana et al., 
1998). These pocket proteins are growth suppressor proteins and are involved in the control of cell 
cycle progression and differentiation, cell cycle entry and exit, and apoptosis (Grana et al., 1998, 
Yee et al., 1998). With the characteristics of a tumor suppressor protein, loss of pRb functions can 
result in deregulation of cell division and tumor formation. The pRb protein can be divided into at 
least three functional regions: an N-terminal region, a central pocket and a C-terminal region. The 
N-terminal region appears to be required for oligomerization; the pocket region contains binding 
sites for the transcription factor E2F, for viral oncoproteins TAg, E1A and E7, and for a large 
number of other cellular proteins. A nonspecific DNA – binding domain is found on the C-terminal 
region. Numerous Ser/Thr phosphorylation sites have been identified on pRb (Stiegler and 
Giordano, 2001, Weinberg, 1995).  
 
1.6  PROTEIN KINASE C IN CELL CYCLE REGULATION 
Protein Kinase C (PKC) is a family of Ser/Thr kinases which play a central role in cellular 
processes, including proliferation, and cell cycle progression, differentiation, cytoskeletal 
remodeling and apoptosis (Dekker et al., 1995, Nishizuka, 1984, Olson et al., 1993). Studies using 
in vitro and in vivo systems demonstrate PKC as a key regulator of critical cell cycle regulations. 
PKC-mediated control of these cell cycle transitions can be either positive or negative; depending 
on the specific PKC isozymes involved and on the timing of PKC activation during cell cycle. In a 
vascular endothelial system, short-term application of PKC agonists in the early G1 phase, 
potentiated progression of the cell from G1  S phase, while PKC activation in mid-to-late G1 
phase, prevented entry into S phase (Zhou et al., 1993, Zhou et al., 1994). The major target of PKC- 
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Table 1. 3 Functions of the different CDK/Cyclin associations 
CDK CYCLIN CKI FUNCTION 
CDC2, 
CDK2 
A1  
p21, p27, p57 
Meiosis 
 A2 S, G1  S, M phases (Russo et al., 1996) 
CDC2 
B1, B2, 
B3 
 M phase (Krauss, 2003b) 
CDK8 C  
Transcription repression of RNA polymerase II; phosphorylates cyclin-H thereby inactivating CTD 
kinase activity of CDK7 (Sano and Schneider, 2003) 
CDK2, 4, 5, 
6 
D1, D2, 
D3 
p15, p16, p18, p19, 
p21, p27 
G1, Restriction point (Dhavan and Tsai, 2001, Krauss, 2003b) 
CDK2 E p21, p27, p57 G1/S 
 F  G2, binding to cyclin B 
CDK7 H  
Phosphorylation of CDC2; phosphorylation of CTD of RNA polymerase II (Masai and Arai, 2002, 
Kaldis, 1999) 
CDK9 T  Phosphorylation of CTD of RNA polymerase II (Simone and Giordano, 2001) 
CDK5 p35, p39  Phosphorylation of structural proteins (Dhavan and Tsai, 2001) 
CDK10   Phosphorylation of transcriptional factors (Kasten and Giordano, 2001) 
CDK: Cyclin dependent kinase; S phase: Synthesis phase; G1 phase: growth phase. 
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mediated cell cycle regulation is a Cip/Kip cyclin-dependent kinase inhibitor, p21waf1/cip1. An 
increase in the expression of p21waf1/cip1 blocks the activity of cdk2 in G1 phase. This leads to 
hypophosphorylation of the retinoblastoma protein and ultimately results in the inhibition of the cell 
cycle progression into S phase. Increased expression of p21waf1/cip1 during G2 phase, blocks 
CDC2/cyclin B activity and prevents progression into M phase (Weinberg, 1995, Weinberg, 
2007b). Sustained activation of PKC is a requirement for long-term cellular responses such as 
differentiation and proliferation. A major step toward understanding the basis for the physiological 
responses attributed to PKC would involve the recognition of the specific functions of the 
individual PKC isozymes and their molecular pathways. 
Most of the available information relates to the involvement of PKC isozymes in negative control of 
cell cycle transitions, although limited data is also available regarding positive regulation of PKC-
mediated G2  M progression. PKC became the subject of intense investigation when it was 
discovered that it is a key cellular receptor for phorbol esters, which can substitute for 
diacylglycerol (DAG) in activating the enzyme. Though, unlike DAG, phorbol esters are not rapidly 
metabolized, hence resulting in a more prolonged activation of PKC by treatment with these agents. 
Studies with melanoma cells (Coppock et al., 1995) and myelocytic leukemia cells (Millard et al., 
1997), treated with DAG analogues or phorbol esters, has been shown to result in accumulation of 
cells in the G1 and G2 phases. This indicates that PKC induces a biphasic block in cell cycle 
progression in these systems. Cells that are in G1 when the stimulus is added, are blocked in G1 
(Coppock et al., 1995), while cells which have progressed through G1  S transition, complete the 
S phase and are blocked in G2 (Kosaka et al., 1996). Notably, inhibition of cell cycle transitions has 
also been observed as a result of over-expression of PKC isozymes alpha, delta and eta (Black, 
2000, Gavrielides et al., 2004, Serova et al., 2008). On the contrary, PKC-β2 has been shown to be 
essential in cell proliferation (Duprez et al., 2009).  
 
1.7  PKC FAMILY IN CARCINOGENESIS  
Twelve different isozymes have been identified where each isozyme has been implicated in many 
cellular responses including permeability, contraction, migration, hypertrophy, proliferation, 
apoptosis and secretion. PKC isozymes are ubiquitously expressed with PKC-α, β and δ found 
abundantly in various tissue types (Wetsel et al., 1992). Furthermore, opposing effects of PKC 
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activation on cell growth have been demonstrated within the same cell type, either by stable over-
expression of individual PKC isozymes or by the use of PKC agonists that differently activate 
individual isozymes (Table 1.4) 
The role of PKC in carcinogenesis has been recognized for decades. Two-stage mouse 
carcinogenesis models have demonstrated that application an initiating agent which may be 
mutagenic to proto-oncogenes such as Ras, followed by the prolonged exposure to a non-mutagenic 
promoting agent are both needed for cancer development. Variable expression profiles of PKC 
isozymes have been displayed during cancer progression, depending on a particular cancer type 
(Table 1.4).  
The role of PKC in cancers arises not from mutations in PKC genes but rather the result of their 
action as receptors for tumor promoting agents and the downstream targets of mitogenic signals. 
TPA is the strongest known inducer of PKC activation. However, exposure to TPA or closely 
related genes does not pose a problem in humans, thus it is not considered as an important factor in 
the contribution towards the development of human tumors. Tobacco smoke contains a number of 
substances such as catechols, hydroquine and nitrosamines, which are considered as tumor 
promoters that activate PKC. Particularly, nitrosamines have been shown to increase the expression 
and activation of PKC-α and β while expression of PKC-δ is lowered (Gopalakrishna et al., 1994, 
La Porta et al., 1997). High consumption of dietary lipids is carcinogenic as they increase 
production of bile acids which activate PKC directly (Pickering et al., 1995). Introduction of 
oncogenic Ras has been shown to up-regulate PKC-α in keratinocytes and colon cancer cells, while 
it down-regulates PKC-δ in keratinocytes. c-myc and p53 are also linked to regulation of PKC 
expression (Denning et al., 1993); while c-myc oncogene induces an increase in PKC-α expression, 
p53 mediated signaling displays an up-regulation of PKC-β (Barr et al., 1991). The overall response 
to PKC activation appears to be dependent on presence or activity of different isozymes in a 
particular cell. Several cancer initiating factors lead to an increase in activity of PKC-α/β compared 
to PKC-δ, which in turn is associated with the development of a malignant phenotype. 
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Table 1. 4 Protein Kinase C expression in Cancers 
PKC 
isoezymes 
Expression 
profile 
Cancer types 
PKC-α 
Overexpression 
High grade urinary bladder 
Endometrial 
Prostate 
(Fournier et al., 2001, Kamimura et al., 2004, Langzam et al., 
2001) 
Down-regulation 
Colon 
Hepatocellular 
Breast 
Basal cell cancers 
(Gokmen-Polar et al., 2001, Kerfoot et al., 2004, Neill et al., 2003, 
Tsai et al., 2000) 
PKC-β 
Up-regulation 
Colon 
Prostate 
(Gokmen-Polar et al., 2001, Kamimura et al., 2004) 
Down-regulation 
Bladder cancer 
Melanoma 
(Gokmen-Polar et al., 2001, Martinez-Gimeno et al., 1995, Neill et 
al., 2003) 
PKC-δ 
Up-regulation 
Hepatocellular cancer 
(Tsai et al., 2000) 
Down-regulation 
Urinary bladder cancer 
(Langzam et al., 2001) 
PKC-ι, ε, λ Down-regulation 
Pancreatic cancers 
(Evans et al., 2003, Martinez-Gimeno et al., 1995) 
PKC-η Up-regulated 
Renal cancers 
(Brenner et al., 2003) 
PKC-λ Up-regulated 
Ovarian cancers 
(Fournier et al., 2001, Weichert et al., 2003) 
PKC-ι Down-regulation 
Ovarian cancers 
(Fournier et al., 2001, Weichert et al., 2003) 
PKC-γ Up-regulated 
B-cell lymphoma 
(Kamimura et al., 2004) 
The table summarizes cancer indications where PKC is up or down-regulated.  
(Brenner et al., 2003, Evans et al., 2003, Fournier et al., 2001, Gokmen-Polar et al., 2001, 
Kamimura et al., 2004, Kerfoot et al., 2004, Langzam et al., 2001, Martinez-Gimeno et al., 
1995, Neill et al., 2003, Tsai et al., 2000, Weichert et al., 2003). 
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1.8  PROTEIN KINASE C AS A TARGET IN CANCER THERAPY 
A better understanding of the role of individual PKC isozymes in the pathogenesis of a disease can 
aid in developing a setting where these isozymes will emerge as viable therapeutic targets. The 
absence of mutations in genes encoding PKCs makes the enzyme a suitable target for cancer 
therapies with no expected failure of therapy due to mutations in the genes. 
Both PKC inhibitors and activators have been extensively studied as potential agents for 
chemotherapy. Both broad spectrum and isozyme-specific inhibitors have anticancer properties, in 
vivo and in vitro; but unfortunately their clinical efficacy has been low.  
1.8.1  PKC Inhibitors 
Some common inhibitors used in cancer therapy are PKC412 (a broad spectrum inhibitor), Go6976 
(a PKCα/β inhibitor), LY317615 (a PKCβ inhibitor), UCN-01/02 (selective inhibitors of the 
conventional PKCs). These compounds have shown either a decrease in invasion, inhibition of 
angiogenesis or reduced growth of cancerous cells which demonstrate anti-neoplastic effects. 
Go6976 and PKC412 have proven to be anti-invasive agents (Koivunen et al., 2004, Masur et al., 
2001, Nakamura et al., 2003). A reduction in growth of cancerous cells has been shown to be 
induced by UCN-01, Go6976 and PKC412 (Biswas et al., 2001, Fabbro et al., 2000, Seynaeve et 
al., 1993b). The retardation in growth is suggested to be a result of cell cycle arrest i.e. senescence 
(Mack et al., 1999, Seynaeve et al., 1993b). To some extent this mechanism is also governed by an 
increase in apoptosis, as demonstrated by Go6976 and UCN-01 in breast and colon cancers 
respectively (Bhonde et al., 2005, Biswas et al., 2001, Biswas et al., 2003). LY317615, a PKCβ 
inhibitor, has been shown to inhibit angiogenesis and plasma VEGF-levels in human tumor 
xenograft-bearing mice (Keyes et al., 2004).  
PKC inhibitors PKC412 and UCN-01 have been tested in phases I-III studies of human clinical 
trials in combination with classical chemotherapeutic drugs. However, due to their strong binding to 
human plasma proteins, there is limited bioavailability resulting in poor clinical effects. Clinical 
trials of LY317615 as a single agent in the treatment of gliomas and lymphomas have shown to 
have minimal effects (www.cancer.gov/clinicaltrials).  
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1.8.2  PKC Activators 
Protein Kinase C rocketed to the forefront of cancer research when it was identified as a target for 
phorbol esters. Phorbol esters compete with DAG for the binding site in the C1 domain of the 
regulatory region. A widely accepted phorbol ester is 12-O-tetradecanoylphorbol-13-acetate (TPA). 
It is obtained from the latex of Croton tiglium L., a leafy shrub of the Euphorbia family native to 
Southeastern Asia (Hecker, 1968). Short term exposure of cells to TPA has been shown to bind 
with greater affinity to PKC compared to diacylglycerol (DAG), leading to a more potent activation 
of PKC isozymes. Following a long-term exposure of cells to TPA, many PKC isozymes have been 
found to be down-regulated via the ubiquitin – proteosome pathway (Hofmann, 2001). In 
experimental studies, TPA is the strongest known inducer of PKC activation. However, exposure to 
TPA or closely related agents is not a problem for humans and thus, TPA is not considered as an 
important factor in the development of human cancers (Koivunen et al., 2006). Although graded as 
a tumor-promoter in carcinogenic experiments performed on normal mouse skin and xenograft 
human foreskins by Yuspa et al. in 1979, TPA has also been established to induce cytostatic, 
cytotoxic and differentiation end points in cancer cells (Hofmann, 2001). TPA has been indicated as 
a therapeutic agent in two studies. Systemically administered TPA was used alone or in 
combination with vitamin D3 and cytosine arabinoside (Ara C) in myelocytic leukaemia patients. In 
most of the cases, the treatment with TPA resulted in complete or partial remission with improved 
hematological parameters. Fever, chills and dyspnea were the common side effects of the treatment, 
although these were shown to be temporary (Han et al., 1998 (i)). In the second study, it was 
observed that TPA induced an increase in depressed white blood cell counts and neutrophils 
towards the normal range, when administered to patients treated with cytotoxic cancer 
chemotherapeutic drugs (Han et al., 1998 (ii)).  
Bryostatin-1 is the first of 20 members of a class of naturally occurring macrolides isolated from a 
marine byrozoan Bugula neritina found in the Gulf of Mexico (Mutter and Wills, 2000, Pettit et al., 
1982). Bryostatin-1 is a novel antineoplastic agent that binds and activates PKC. It is more potent 
than TPA for translocating PKC-δ and –ε. Similarly to phorbol esters, short-term exposures of cell 
to Bryostatin-1 leads to PKC activation while long-term exposure results in protein degradation 
(Kraft et al., 1988, Kraft et al., 1986). However, the ability of Bryostatin-1 to cause degradation of 
PKC is influenced by concentration. Low doses have been shown to cause down-regulation of PKC, 
while high doses have not (Szallasi et al., 1994). Bryostatin-1 has shown the ability to induce only a 
 Chapter One 
________________________________________________________________________________ 
 
 
 
________________________________________________________________________________ 
 
Page | 37  
 
subset of the biological functions of TPA. This suggests that it may act as either a PKC agonist or 
antagonist (Hocevar and Fields, 1991, Kraft et al., 1988, Kraft et al., 1986). In animal models, 
Bryostatin-1 has shown antineoplastic activity against leukemia (Jones et al., 1990), melanoma 
(Schuchter et al., 1991) and ovarian cancer (Hornung et al., 1992).  
Initial phase I studies of Bryostatin-1 in a broad spectrum of tumors, including malignant 
melanoma, ovarian cancer and low grade non-Hodgkin’s lymphoma produced objective response. 
This spawned a number of single – agent and combination studies in various tumor types 
(Varterasian et al., 1998). The first published phase II study of Bryostatin-1 as a single agent failed 
to demonstrate activity in previously treated patients with metastatic malignant melanoma (Propper 
et al., 1998). Results from a phase I study of a sequential therapy with Bryostatin-1 and vincristine 
showed that this combination was feasible and well tolerated. This warranted a phase II study of 
Bryostatin-1 in combination with other cytotoxic agents (Varterasian et al., 2000). A correlative 
study of a combination of Bryostatin-1 and vincristine showed significant antitumor activity in 
relapsed B-cell malignancies (Dowlati et al., 2003). Combinations of bryostatin-1 with 
chlorodeoxyadenosine and auristatin PE have also resulted in successful treatment of human 
chronic lymphocytic leukemia (Mohammad et al., 1998a, Mohammad et al., 1998b).  
The compound ingenol-3-angelate (PEP005) is a novel anticancer drug (Kedei et al., 2004) that is 
an activator of protein kinase C. Topical application of a high-dose of PEP005, has been shown to 
cure ~80% of subcutaneous tumors in mice. Similarly it has been found to be toxic to cells in vitro 
(Ogbourne et al., 2004). Treatment of melanoma cell lines with PEP005 indicated irreversible 
growth arrest, with no adverse effects observed in normal melanocytes and normal fibroblasts 
(Cozzi et al., 2006). Three daily topical application of PEP005 cured a series of s.c. mouse and 
human tumor xenografts in mice. The treatment resulted in a mild short-term erythema (Ogbourne 
et al., 2004). PEP005 has been shown to be a potent activator of PKC isozymes (Kedei et al., 2004) 
which are important modulators of a range of biological processes (Nishizuka and Nakamura, 
1995). PKC family members have been investigated as important anti-cancer targets, and have been 
shown to activate or facilitate activation of the innate immune response (Fernandez et al., 2000, 
Kontny et al., 1999). Topical treatment of PEP005 has been shown to be associated with an acute T 
cell-independent inflammatory response distinguished by a pronounced neutrophil infiltration 
(Challacombe et al., 2006). Phase II trials of a topical application indicated PEP005to be safe and 
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efficient in treating basal cell carcinomas and the squamous cell carcinoma precursor, Actinic 
Keratosis (AK) (Siller et al., 2009, Siller et al., 2010).  
A novel diterpene ester named EBC-46 (formal name 12-tigloyl/angeloyl-13-(2-methylbutanoyl)-
6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one) has been isolated from the seed of the 
Blushwood tree in Queensland, Australia. It belongs to the tigliane class of naturally occurring 
products and is structurally similar to TPA (Figure 1.6). Veterinary trials of intratumoral treatments 
of EBC-46 in animals have been highly successful with a cure rate at more than 80% (data not 
provided). It is a potential PKC activator and is considered a candidate agent for intralesional 
therapy (discussed later). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1.6  Structure of EBC46 (12-tigloyl/angeloyl-13-(2-methylbutanoyl)-6,7-
epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one) 
(Structure of EBC-46 obtained from Dr. Paul Reddell and Prof. Peter Parsons; 
unpublished data). 
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1.9  PKC AND CELL DEATH 
1.9.1  Cell Death: 
In general, cell death is a vital process in the development, homeostasis and immune regulation of 
multicellular organisms. It is often induced upon pathogen infection as part of the defense 
mechanism. There are two major types of cell death, namely apoptosis and necrosis, defined by 
their morphological criteria (Duprez et al., 2009). 
Until 1971, the term necrosis was used for all types of cell death. Kerr et al. in 1971 first observed a 
form of non-pathologic cell death in certain tissues which they termed shrinkage necrosis (Kerr, 
1971). Later shrinkage necrosis became implicated in organ homeostasis and the term “apoptosis” 
was coined in 1972 by Kerr and colleagues (Kerr et al., 1972) which described a form of cell-
intrinsic programmed suicide mechanism associated with cell shrinkage membrane blebbing and 
chromatin condensation. 
Morphologically, apoptosis can be morphologically by pyknosis which is a deep staining of the 
nuclear mass, nuclear fragmentation, and formation of condensed cell bodies or apoptotic bodies. 
This is a systematic process which is energy-dependent. On the other hand, necrosis can be defined 
by electron-lucent cytoplasm, swelling of cellular organelles, and loss of plasma membrane 
integrity which can be brought about by loss of ATP production. (Zong and Thompson, 2006). 
1.9.2  Drug-induced Cell Death: 
Many insults induce apoptosis at lower doses and necrosis at higher doses. Even in response to a 
certain dose of death-inducing agent, features of apoptosis and necrosis may co-exist in the same 
cell. In addition, if not engulfed by neighbouring phagocytic cells or in cell culture in vitro where 
phagocytosis usually does not occur, dead cells in the late stages of apoptosis may present necrotic 
features due to loss of cellular energy and plasma membrane integrity. This is known as apoptotic 
necrosis or secondary necrosis (Majno and Joris, 1995). 
Doxorubicin, etoposide, bleomycin and paclitaxel are widely used anticancer drugs in various 
clinical trials. They induce apoptosis of tumor cells directly linked to their anti-proliferative effects 
(Fisher, 1994, Skladanowski and Konopa, 1993, Tu et al., 1996). Mailloux and colleagues in 2001 
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confirmed these findings and showed that doxorubicin and bleomycin resulted in similar cytotoxic 
effects with cell lysis and detachment which were time-dependent while etoposide and paclitaxel 
were less cytotoxic (Mailloux et al., 2001). However, the disadvantage of these anticancer agents 
such as doxorubicin and etoposide was found to be the induction of apoptosis of non cancerous cells 
such as epithelial cells and thymocytes (Lock and Stribinskiene, 1996, Walker et al., 1991) which 
could probably be attributed to their toxicities. Similarly, protein kinase C activator Bryostatin 1 
was shown to interact in a synergistic manner with cyclin dependent kinase inhibitor flavopiridol 
(FP) to trigger apoptosis in human leukemia cells. This interaction resulted from enhanced TNF-α 
production and engagement of the extrinsic apoptotic pathway (Cartee et al., 2003).  
1.9.3  Protein Kinase C in Cell Death: 
Protein kinase Cs are a family of serine-threonine/tyrosine kinases which are important regulators 
of cell proliferation and malignant transformation. PKCs are not only able to promote pro-survival 
responses in cells but are also able to mediate cell growth arrest or lead to cell death through 
apoptotic mechanisms. Activated PKC isozymes can inhibit the cell cycle both at G1/S and G2/M 
transitions (Black, 2000, Gavrielides et al., 2004). Nakagawa et al. in 2005 determined that TPA-
induced PKC activation in lung adenocarcinoma H358 lead to p21 up-regulation, Rb 
hypophosphorylation and G1 arrest.  
Of the twelve isozymes, PKC-δ is known to play a key role in the apoptotic response via activation 
of the p38 MAPK pathway (Emoto et al., 1995). The majority of studies to date indicate this novel 
PKC isoform to play a major role in apoptosis in different cellular models. TPA-induced apoptosis 
was shown to be induced in LNCaP cells via over-expression of the PKC-δ isoform (Fujii et al., 
2000).  
 
1.10  PKC AND INFLAMMATION   
1.10.1  Phorbol ester and activation of leukocytes and endothelial cells 
Phorbol ester TPA is a skin irritant and inflammatory agent. It induces prompt remodelling of the 
vasculature, resulting in edema formation (Janoff et al., 1970) and this response is enhanced by the 
induced secretion of histamine from mast cells and blood-borne basophils (Katakami et al., 1984, 
Schleimer et al., 1981). It activates adhesion molecules present on the surface of the leukocytes 
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causing them to bind and then to migrate through the vascular endothelial layer into the tissues 
underlying the skin (Kavanaugh et al., 1991). In the tissues, TPA potentiates antigen-mediated 
stimulation of T-lymphocytes, enhancing the production of the cytokine interleukin-2 (IL-2) 
(Rosenstreich and Mizel, 1979). TPA also causes degranulation of neutrophils, releasing pro-
inflammatory cytokines and matrix proteases, and activation of oxidative burst (Repine et al., 
1974). 
Neutrophils are dedicated phagocytic cells and they constitute the first line of defense against 
invading micro-organisms. Their action can be dissected into 3 distinct processes: 
direct migration towards micro-organisms (chemotaxis), 
engulfment of the micro-organism (phagocytosis), and 
it’s killing. 
The intracellular killing mechanism is based on two independent but mutually supportive 
mechanisms, the generation of toxic oxygen metabolites and the release of microbicidal proteins 
from the storage granules into phagosome (Dale et al., 2008, Segal, 2005). The generation of toxic 
oxygen metabolites, superoxide anion (O2
-) and hydrogen peroxide (H2O2), is accompanied by a 20 
– 30-fold increase in oxygen consumption, called the respiratory burst (Dahlgren and Karlsson, 
1999, Quinn and Gauss, 2004). The enzyme responsible for oxidative burst is NADPH oxidase 
(nicotinamide adenine dinucleotide phosphate); it transfers electrons from NADPH to O2, resulting 
in the formation of superoxide anion. During oxidase activation, cytosolic oxidase proteins 
translocate to the plasma membrane, where they assemble around a membrane-bound component 
known as flavocytochrome b. This is a highly regulated process involving phosphorylation, 
translocation and multiple conformational changes (Quinn and Gauss, 2004). The core of the 
NADPH oxidase enzyme is composed of four oxidase-specific proteins (p22phox, p47phox, p67phox, 
gp91phox) and GTPase (Rac1/2).  
1.10.2  Role of PKC in the regulation of the respiratory burst 
Infection elicits activation of the serum complement cascade and the binding of specific antibodies 
(IgG, immunoglobulin G) by microbial antigens. This results in the occupation of neutrophil Mac-1 
and Fcγ-receptors which activate phagocytosis and respiratory burst. The binding of Mac-1 and 
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Fcγ-receptors activates PLCβ, resulting in the generation of DAG and IP3. A number of kinases 
have been proposed to participate in p47phox phosphorylation, including protein kinase C (el Benna 
et al., 1994), p38-mitogen activated protein kinases (MAPK) (El Benna et al., 1996) and 
extracellular signal-regulated kinases (ERK1/2) (Dewas et al., 2000). PKC plays a vital role in the 
phosphorylation of p47phox which has been demonstrated by PKCs – α, β2, δ and ζ (Dang et al., 
2001, Fontayne et al., 2002, Reeves et al., 1999). The respiratory burst activity can be induced 
directly by phorbol ester and in this case the level of phosphorylation of p47phox matches the level of 
respiratory burst activity. Conversely, compounds that inhibit PKC prevent the respiratory burst 
(Dekker et al., 2000, Kramer et al., 1989). It is also reduced by 50% in neutrophils obtained from 
mice that fail to express PKC-β(1+2) and PKC-δ (Dekker et al., 2000). 
 
1.11 PROTEIN TARGETS FOR DITERPENE ESTERS OTHER THAN PKC 
The traditional view that diterpene esters bind solely to protein kinase C (Section 1.8.2) has been 
challenged in recent years with the discovery of nonkinase proteins that bind diterpene esters with 
equal affinity. These receptors include Unc13/Munc13 (mammalian) isoforms (scaffolding proteins 
involved in exocytosis), chimaerins (a family of RacGTPase activating proteins) and RasGRPs 
(exchange factors of Ras/Rap1) (Kazanietz, 2002). All of these proteins contain a C1 binding 
domain similar to protein kinase C and bind to diterpene esters in the presences of phospholipids. It 
has been shown that PEP005 binds to the C1 domain in a similar manner to phorbol esters and 
DAG (Pak et al., 2001). Song et al, in 2013 reported that the C1 domains of RasGRP1 and 
RasGRP3 bound PEP005 with higher affinities than they bound to phorbol ester PDBu and similar 
affinity to PKC-α binding to PEP005.  
The RasGRPs are positive regulators of the small GTPase Ras while chimaerins are negative 
regulators. Increased expression of RasGRP1 ad RasGRP3 show restricted distribution in tissue 
with prominent expression in lymphocytes with evidence that these proteins play an important role 
in the function of immune receptors of B- and T-cells (Aiba et al., 2004, Stone, 2011). Stimulation 
of the immune receptors leads to phospholipase C activation and DAG accumulation in membranes. 
The C1 domains of RasGRP1 and RasGRP3 bind DAG and phorbol ester (Lorenzo et al., 2000, 
Lorenzo et al., 2001) leading to their translocation to cellular membranes where they interact with 
their substrate. Additionally, RasGRPs undergo an activating phosphorylation by PKC which is 
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itself activated by DAG (Brodie et al., 2004, Ebinu et al., 1998, Roose et al., 2005). Ras activation 
by RasGRPs is important for thymocyte differentiation, T-cell effector function and lymphocyte 
homeostatis (Song et al., 2013, Stone, 2011). This raises the possibility of RasGRPs being viable 
drug targets. 
 
1.12  AIMS and HYPOTHESIS of this THESIS 
Topical application of the protein kinase C activator PEP005 was shown to cure subcutaneous 
tumors in mice (Ogbourne et al., 2004), primarily involving a neutrophil-dependent host 
inflammatory response. This is an expected reaction considering that one of the biological 
properties of PKC activators is to cause inflammation at the site of application. This also resulted in 
cure and a restoration of normal skin (Challacombe et al., 2006, Ogbourne et al., 2004).  
The concept of intralesional therapy is to bypass the barrier zone and establish a sub-epidermal 
depot, thus allowing a higher concentration of the drug to act on the tumor. It eliminates the need 
for long-term topical treatment, coupled with the fact that it reaches deeply into the tumor tissue 
where topical medications may not penetrate. Pilot experiments of intralesional injections of PKC 
activators demonstrated the potential of treating larger tumors with similar outcomes as topical 
applications. 
EBC-46 (formal name 12-tigloyl/angeloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-
hexahydroxy-1-tigliaen-3-one) is a short-chain diterpene ester of the tigliane class, isolated from a 
rainforest plant Fontainea picrosperma in North Queensland, discovered and purified by EcoBiotics 
Ltd. It is structurally similar to 12-O-13-tetradecanoylphorbol-acetate (TPA/PMA), and is thought 
to share similar bioactivity.  
Hypothesis:  intratumoral injections of PKC activating diterpene esters, notably EBC-46, can 
locally cure tumors by inducing an inflammatory response. 
Aim 1. To determine the antitumor efficacy of EBC-46. The initial aim was to compare the 
antitumor efficacy of EBC46 with other potent PKC activators (e.g., TPA) in vitro and in vivo. This 
was achieved by inducing tumor cell arrest in vitro in a selection of sensitive and resistant tumor 
cell lines, and intratumoral injection in mouse tumor models.  
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Aim 2. To determine the role of the inflammatory response in EBC-46 efficacy. The pro-
inflammatory response to the diterpene esters was determined by assessing the respiratory burst in 
human neutrophils and the tumoricidal activity of treated neutrophils towards tumor cells.  
Aim 3. To investigate the role of neutrophils in the antitumor efficacy of EBC-46.  
Aim 4. To determine the cellular and molecular responses of tumor and host cells after treatment 
with EBC-46. Capillary damage, neutrophil density, mode of cell death were inferred from 
immunohistochemistry and histopathology of tissue sections taken at various time-points. Whole 
genome arrays were used to follow changes in gene expression in host and tumor cells following 
treatment with EBC-46. 
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2.1 Materials 
2.1.1 Biologicals & Chemicals: 
12-O-tetradecanoylphorbol-13-acetate (TPA)   Sigma Chemicals 
Acetic acid        Merck 
Agarose        Invitrogen 
Ammonium persulfate      Sigma Chemicals 
Bisindolylmaleimide-1 (BIS-1)     Sigma Chemicals 
Bromophenol blue       Mallinckrodt 
CellTitre 96 Aqueous One Solution Assay    Promega 
Collagenase A        Roche Applied Science 
Deionized formamide       Amresco 
Dihydroethidium bromide (DHE)     Sigma Chemicals 
Dimethyl sulfoxide (DMSO)      Sigma Life Sciences 
Ethanol        BDH Chemicals 
Ethidium bromide       Sigma Chemicals 
Fetal Calf Serum (FCS)      Gibco Life Technologies 
Glycerol        Sigma Chemicals 
Glycine        BDH Chemicals 
Hank’s balanced salt solution      Gibco Life Technologies 
Hydrochloric acid (32% (v/v) HCl)     APS 
Isopropanol        BDH Chemicals 
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Methanol        Merck 
Methylated spirits       KCB 
MilliQ water        Millipore 
Penicillin/Streptomycin      Gibco Life Technologies 
Phosphate Buffered Saline      prepared at QIMR Berghofer 
Polyacrylamide 30% (mono:bis 29:1)    Bio-Rad Laboratories 
Propidium Iodide       Sigma Chemicals 
Propylene Glycol (PG)      Sigma Life Sciences 
Protease Inhibitor Cocktail (PIC)     Roche Applied Science 
RNase         Sigma Chemicals 
RPMI-1640         prepared at QIMR Berghofer 
Skim Milk powder       Diploma 
Sodium chloride (NaCl)      Ajax Finechem 
Sodium hydroxide (NaOH)      BDH Chemicals 
Sulforhodamine B dye (SRB)      Sigma Life Sciences 
TEMED        APS 
Tris         Sigma Chemicals 
Triton X-100        Sigma Chemicals 
Trypsin        Invitrogen 
Tween 20        Sigma Chemicals 
β-Mercaptoethanol       Sigma Chemicals 
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2.1.2 Solutions: 
1x SDS Running Buffer: 25 mM Tris (unbuffered), 250 mM glycine, 0.1% SDS. Buffer was made 
up to 1 litre with MilliQ water. 
5% (w/v) Blotto: Dissolved 5 g of non-fat dry milk powder in 100 ml 1x PBS-Tween20 solution. 
For detection of phosphorylated proteins 1x PBS-Tween20 was substituted with 1x TBS-Tween20. 
5% SDS-PAGE stacking gel: For 5 ml of stacking gel mix, added 3.4 ml MilliQ water, 830 µl of 
30% acrylamide mix, 630 µl of 1.0 mM Tris (pH 6.8), 50 µl 10% SDS, 50 µl 10% ammonium 
persulfate (AMPS) and 5 µl TEMED. 
1× Propidium Iodide Solution: Propidium iodide (50 mg/ml), RNase A (1 mg/ml), 0.01% (v/v) 
Triton X-100 freshly made-up in PBS just before use. 
10x PBS-0.5% Tween20 Wash Buffer: Added 5 ml Tween20 to 1 litre 10x PBS solution. 
10% SDS-PAGE resolving gel: For 10 ml of resolving gel mix added 4 ml MilliQ water, 3.3 ml of 
30% acrylamide mix, 2.5 ml of 1.5 mM Tris (pH 8.8), 100 µl of 10% SDS, 100 µl of 10% 
ammonium persulfate (AMPS) and 4 µl TEMED. 
10x TBS-1% Tween20 Wash Buffer: Dissolved 80 g NaCl, 24.4 g Ultra-Pure Tris, 10 ml Tween20 
in MilliQ water. Adjusted pH to 7.5 with 32% HCl. The buffer was made up to 1 litre with MilliQ 
water. The TBS-Tween20 wash buffer was used when probing for phosphorylated proteins.  
Collagenase A: A working solution of 1 mg/ml of Collagenase A (Roche) was prepared in 1X 
Hank’s solution (Gibco) and sterilized using a 0.20 µm filter unit (Sartorius Stedim Biotech). The 
sterile Collagenase A solution was diluted to 1:10 in RPMI-1640 and used in ex vivo cultures of 
tumors.  
Cell Lysis Buffer: A stock of 20 ml of cell lysis buffer was prepared with 4 ml of 100% glycerol, 2 
ml of 10% SDS, 1 ml of 200 mM stock Tris pH 7.4. The solution was made up to desired volume 
by adding 12.8 ml MilliQ H2O. 
Diterpene Ester Stocks: 10 mg of EBc-46 or TPA was weighed into a 2 ml glass vial and labeled. A 
stock solution of 10 mg/ml was made up by dissolving the powder in 1 ml of 20% propylene glycol 
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(PG) (100% PG + Saline) or 1 ml of 100% Ethanol (EtOH). The 10 mg/ml stocks were stored at -
20˚C. 
Electroblot Buffer: 250 mM glycine, 25 mM Tris (unbuffered), 20% methanol, MilliQ water. Buffer 
was stored at 4˚C until ready to use for protein transfer.  
Formamide Loading Buffer: 50% Glycerol, 40% deionised formamide, 1 mM EDTA, 0.4% 
Bromophenol Blue. 
Sulforhodamine B solution: Dissolved 4.0 g SRB (Sigma) in 1 litre 1% acetic acid (Merck; prepared 
in MilliQ H2O and stored at room temperature). The prepared solution was transferred to 4 x 250 ml 
Schott bottles and stored at 4˚C. The working bottle was stored at RTemp. 
 
2.2 Methods 
2.2.1 Cell Lines 
The cell lines used in this project were of mouse and human origin and included those described in 
Table 2.1.  
2.2.2 Cell Culture 
Cells were cultured at 37 degrees Celsius in a humidified 5% CO2 incubator in RPMI-1640 culture 
medium supplemented with 10% v/v fetal calf serum (heat-inactivated at 55˚C for 30 min after 
thawing in a 37˚C water bath), 50 µg/ml penicillin, 50 µg/ml streptomycin and 3 mM HEPES. 
2.2.3 Cryopreservation 
Cells were stored at -70˚C when in log phase growth as a source of viable cells for future 
experiments. Cells were harvested when ~80% confluent, pelleted at 1,500 rpm, 5 min, resuspended 
in a final concentration of 10% DMSO in RPMI-1640 culture medium and cooled to -80˚C in a 
Cryo Freezing Container before transferring to liquid nitrogen (-196˚C). 
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2.2.4 Resuscitation and Maintenance of Cells  
Cells stored in liquid nitrogen were transferred to -70˚C, and then thawed to room temperature 
before culturing. The cells were diluted 1:10 with RPMI-1640 culture medium, centrifuged at 1,500 
rpm for 5 min at RTemp, then resuspended in 5 ml of fresh RPMI-1640 medium. The cell 
suspension was transferred to 25 cm2 flasks (T25) and incubated at 37˚C. To maintain cells in log 
phase, cultures were passaged biweekly. 
 
2.3 In Vitro Growth Inhibition 
2.3.1 Sulforhodamine B proliferation Assay 
The Sulforhodamine B (SRB) assay was developed in 1990 by Skehan et al., to measure drug–
induced cytotoxicity with a clonogenic-type assay, whereby cell proliferation was allowed to 
proceed for an extended period after drug treatment, followed by comparison of cell numbers 
relative to controls using a quantitative protein stain. Its principle is based on the ability of the pink 
acidic SRB dye to bind electrostatically to basic cell proteins that had been fixed to tissue–culture 
plates by trichloroacetic acid.  
In the present method, cells sparsely seeded in microtitre plates (3000 cells/well) were treated for 5-
6 days. The medium was then tipped off and cells washed with PBS to remove excess FCS protein. 
Cells were then fixed with 95% ethanol (methylated spirits) for a minimum of 5 min. The fixative 
was tipped off; cells washed once with tap water and stained with 50 µl/well of 2% SRB solution in 
1% acetic acid for 15 min. The SRB stain was tipped off and wells washed twice, rapidly but gently 
with 1% acetic acid. 100 µl/well of 10 mM Tris base (unbuffered, pH > 9) was added. The 
absorbance of the wells was read at 564 nm on the ELISA reader (VERSA max microplate reader; 
Molecular Devices) with 3 second prior shaking to ensure that the released dye was evenly 
distributed throughout the well. Cell survival was plotted as % control absorbance vs. dose. 
2.3.2 MTS Cell Proliferation Assay 
The CellTitre 96 Aqueous One Solution Assay from Promega is a colorimetric method for 
comparing the number of viable cells in proliferation. The solution contains a thiazolium compound 
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which is bioreduced by cells to a coloured formazan product, and an electron coupling reagent PES. 
The quantity of formazan product solubilised in the culture medium is measured as absorbance at 
490 nm and is directly proportional to the number of viable cells in culture. 
10 µl of the MTS reagent was added to each well of a 96–well plate containing 100 µl of cell 
suspension and the plate incubated at 37˚C for ~2 hr until a dark brown colour developed in wells. 
10 µl/well of 10% SDS was added and the plate centrifuged at 2,000 rpm for 15 min. The 
absorbance was recorded at 490 nm using the ELISA plate reader with 10 second prior shaking.  
Cell survival was plotted as % control absorbance vs. dose. 
 
2.4  Inoculation of tumor cells into mice 
Mice were housed, and all animal work carried out in the QIMR Animal facility. Experiments were 
approved by the QIMR Animal Ethics Committee (P345). The mice used for in vivo 
experimentation were male immunocompetent C57BL/6J mice and male immunocompromised 
BALB/c Foxn1nu mice. Procedures were carried out in a pathogen-free environment in a laminar 
flow hood. B16-F0, Sk-Mel-28, MC38 tumor cells were inoculated into mice in different 
experiments. The tumor cells from serial passaging were trypsinized using trypsin/versene in 
Dulbecco’s solution and suspended in RPMI-1640 media with 10% FCS. A cell count was 
performed using a haemocytometer and the number of cells required for injection calculated. Listed 
below are the different cell lines experimented upon, along with the cell densities injected per 50 µl 
and the respective mice (Table 2.2). The cell suspension was centrifuged at 1,500 rpm for 5 min and 
the cell pellet resuspended in the required volume of culture media. This cell suspension was taken 
to the animal house on ice. When C57BL/6J mice were used, their hindquarters were shaved with 
battery-operated clippers prior to inoculation. Using a Terumo® U-100 Insulin 29G x ½” needle 
with the bevel facing upwards, 50 µl of the cells were injected subcutaneously into 2 sites on the 
hindquarter of the mouse. Mice were tagged using an ear punch. Mice were then placed back in 
their cage and monitored for clinical signs and tumor growth. Tumor volume was determined from 
the formula length x length x breadth / 2 according to the chart in Appendix Table 1, “Monitoring 
of Tumor Bearing Mice”. 
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2.5 Intratumoral injections of tumors 
Tumor sites were observed until they were at the desired volume range of approximately 100 mm3 
at the start of the treatment. Due to the heterogeneity of the tumor population, occasionally smaller 
and larger tumors were included in the study. EBC-46 or TPA was dissolved in propylene glycol 
(PG) solution in varying concentrations, warmed in a 37˚C water bath for 1–2 hr, vortexed for 10 
seconds and spun for 5 seconds. The baseline dose of EBC-46 used was 30 µg in 20% PG in a final 
volume of 50 µl. As a control, 50 µl of 20% PG was injected into tumors. Injections were carried 
out using a 0.3 ml Terumo® U-100 Insulin syringe with a 29G x ½” needle.  The mice were placed 
back in the cage and monitored daily.  
 
2.6 Monitoring of mice and tumors 
Mice were monitored by measuring tumor volume and tissue reaction which was determined by the 
purplish discolouration and the eventual eschar formation within 5 days after treatment with the 
diterpene esters EBC-46 or TPA. The tumor sites were measured prior to the first treatment and 
then underwent regular monitoring 2 – 3 times per week. 
Tumor volume: The tumor length (l), width (w) ad height (h) were measured using digital Vernier 
callipers (Kinachrome) and the tumor volume calculated using the formula (l x w x h) in mm3. 
The raw data for the above measurements was recorded in the Microsoft Excel program and the 
average calculated and plotted against time with the standard error (SE). A Kaplan-Meier survival 
curve was prepared in GraphPad Prism 6 with percent survival as a function of time. Mice were 
monitored for up to 3 months after treatment of tumor. When the tumor load per mouse became too 
large (approximately 1000 mm3) the mice were euthanized with carbon dioxide (CO2) inhalation. 
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Table 2.1 Cell Lines used in this study 
Cell Line Name Species Disease Source 
B16-F0 Mouse Melanoma ATCC № CRL-6322 
MC38 Mouse Colon Carcinoma QIMR Berghofer 
Sk-Mel-28 Human Metastatic Melanoma ATCC № HTB-72 
D04 Human Metastatic Melanoma QIMR  Berghofer 
MM649 Human Metastatic Melanoma QIMR  Berghofer 
A549 Human Lung Carcinoma ATCC № CCL-185 
HOP-62 Human Non-small Cell Lung 
Carcinoma 
QIMR  Berghofer 
K562 Human Leukaemia QIMR  Berghofer 
 
Table 2.2 Table detailing the densities of the tumor cell lines inoculated into mouse 
models. 
Cell Line Cell Density per site  Mice strain used № of sites per mouse 
B16-F0 5 x 105 cells / 50 µl C57BL/6J 2 tumor sites 
MC38 106 cells / 50 µl C57BL/6J 2 tumor sites 
Sk-Mel-28 2 x 106 cells / 50 µl BALB/c Foxn1nu 2 tumor sites 
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2.7 Ex Vivo Cell Survival Assessment 
An ex vivo cell survival was performed to assess the time course for clonogenic survival of tumor 
cells after treatment with EBC-46. Sk-Mel-28 tumors grown in male BALB/c Foxn1nu nude mice 
were treated with 30 µg of EBC-46 parallel with 20% propylene glycol (PG) injection of controls.  
Control and treated tumors were harvested from euthanized mice using sterile disposable surgical 
instruments. Tumors were briefly washed in 70% ethanol, teased out in 1 ml sterile PBS and 
pelleted at 1,500 rpm for, 5 min at RT. Cells were resuspended in complete RPMI-1640 with 
collagenase A (recipe in Section 2.1.2) and incubated at 37˚C for 30 min. Collagenase A was used 
in ex vivo cell cultures for disaggregation of the tissues and preparation of single cell suspensions. 
The Collagenase A-treated cells were then centrifuged at 1,500 rpm for 5 min, resuspended in 
complete RPMI-1640 and plated into 24–well plates at 3-fold serial dilutions to achieve varying 
densities (Figure 2.1). Cells were incubated at 37˚C in a humidified 5% CO2 incubator and were 
monitored daily. The dilution that allowed controls to become confluent within 3-5 days was 
subjected to SRB assay (Section 2.3.1) as a measure of clonogenic survival of cells from the treated 
tumor. 
 
2.8 Gene Expression Analysis using Microarrays 
2.8.1 Total RNA extraction and purification 
2.8.1.1  In vivo tumor treatments  
Sk-Mel-28 tumors were grown subcutaneously in BALB/c Foxn1nu mice with two tumors per 
mouse. Three individual experimental groups of mice were divided into three treatment groups: 
vehicle, TPA or EBC-46. Mice in the control vehicle treatment group received a single intratumoral 
injection (Terumo® U-100 Insulin 29G x ½” syringe) of 50 µl of 20% PG per tumor. The mice in 
the TPA – and EBC-46 – treatment groups received a single intratumoral injection of 30 µg per 
tumor of TPA or EBC-46 respectively in 50 µl of 20% PG. To determine/analyze the gene 
expression profile of tumor and host in response to EBC-46 treatment over a time-frame, tumors 
were excised at different times, 30 min, 1 hr, 2 hr, 4 hr and 8 hr after treatment and stored at -80˚C. 
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Figure 2.1:  Plate format for ex vivo cell survival of tumor cells treated with EBC-46 in vivo. 
 
2.8.1.2  In vitro cell treatments 
Whole blood from a human donor was processed and peripheral blood mononuclear cells (PBMCs) 
were isolated by Dr. Viviana Lutzky. The PBMCs were cultured in RPMI-1640 10% FCS and 
treated 4 hr after seeding with the diterpene ester compounds EBC-46 or TPA at 30 ng/ml 
concentration. Untreated PBMCs were used as the control in this experiment. Cells were harvested 
at different times following treatment with the compounds, at 4 hr, 24 hr and 96 hr. The cell 
monolayer was washed once with phosphate buffered saline (PBS) and cells were harvested using 
sterile cell scrapers. The harvested cells were centrifuged (Eppendorf Centrifuge 5810 R) at 1,500 
rpm for 5 min at RTemp. Cell pellets were stored at -80˚ C. 
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2.8.1.3  Total RNA extraction and purification  
Approximately 30 mg of frozen tumor sample was weighed or 1 x 107 cells were counted and total 
RNA extracted using the Qiagen RNeasy Plus Mini Kit, according to manufacturer’s instructions. 
The samples were homogenized using a rotor-stator homogenizer (Polytron) in Buffer RLT Plus 
containing 10 µl/ml β-mercaptoethanol (β-MeOH). Supernatant was collected after centrifugation 
(Eppendorf Centrifuge 5415 D) at maximum speed for 3 min and passed through a gDNA 
Eliminator spin column with a further centrifugation for 1 min at 10,000 rpm. An equal volume of 
70 % ethanol was added to the flow-through and mixed well by pipetting.  This was immediately 
passed through an RNeasy spin column in aliquots and centrifuged for 30 sec (10,000 rpm; 
RTemp). Columns were washed with 700 µl Buffer RW1 and centrifuged at RTemp for 30 sec 
(10,000 rpm), followed by two washes with 500 µl Buffer RPE and centrifuged at 10,000 rpm for 
30 sec – 2 min. Total RNA was eluted with 50 µl RNase-free water by centrifugation for 1 min at 
maximum speed. 
2.8.1.4  Total RNA quantity and quality determination 
The concentration of total RNA extracted was measured on a NanoDrop (NanoDrop® ND-1000 
UV-Vis Spectrophotometer) using 1 µl of the RNA sample. RNA integrity was determined by 
denaturing agarose gel electrophoresis and staining with ethidium bromide (EtBr). An aliquot of 2 
µl of the RNA sample was diluted 1:5 in water, and a formamide-based loading buffer was added to 
denature the RNA.  The RNA was heated to 65˚C for 5 min before loading into the gel. The agarose 
gel was run at 80 V for 45 min to separate the bands for visualization on a UV gel doc. An 
molecular weight size marker (1 kb Marker, Life Technologies) included in the gel run was not only 
a good control to ensure the gel was run properly but also facilitated the determination of the size of 
the bands. Distinct 28S rRNA and 18S rRNA bands indicated intact ribosomal RNA where the ratio 
should be approximately 2:1. A smear towards the smaller sized RNAs indicated partial degradation 
of RNA while completely degraded RNA appeared as a low molecular weight smear.  
2.8.2 Whole Genome Gene Expression Direct Hybridization Assay 
Total RNA extracted from tissues or cells was amplified using the Ambion Illumina® TotalPrep 
RNA Amplification Kit to produce an amplified amount of biotin-labeled cRNA. The RNA 
Amplification Kit consists of a first- and second-strand reverse transcription step to produce cDNA 
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with a T7 site overhang, followed by an in vitro transcription amplification step that incorporates 
biotin-labelled nucleotides. The subsequent steps include array hybridization, washing, blocking 
and Cy3-Streptavidin staining. The Direct Hybridization gene expression assays were imaged using 
the iScan System. 
2.8.2.1   RNA amplification and labeling 
Approximately 500 ng of total unlabelled RNA was adjusted to a final volume of 11 µl with 
nuclease-free water.  The RNA was incubated with 9 µl of the reverse transcriptase master mix (1 
µl of T7 Oligo (dT) Primer, 2 µl of 10X first strand buffer, 4 µl of dNTP mix, 1 µl of RNase 
inhibitor and 1 µl of ArrayScript) at 42 ˚C for 2 hr. This was followed by the second strand cDNA 
synthesis step which involved a further incubation at 16 ˚C for 2 hr with 80 µl of the second strand 
master mix (63 µl nuclease-free water, 10 µl 10X second strand buffer, 4 µl dNTP mix, 2 µl DNA 
polymerase and 1 µl RNase H). The cDNA was purified by filtering through a cDNA Filter 
Cartridge with 250 µl of cDNA binding buffer and washing with 500 µl of the wash buffer provided 
in the kit. Purified cDNA was eluted with 20 µl of 55 ˚C nuclease-free water. The next stage 
involved the synthesis of cRNA by in vitro transcription to generate multiple copies of biotinylated 
cRNA from the double-stranded cDNA templates where each cDNA sample was incubated with 7.5 
µl of the IVT master mix (2.5 µl of T7 10X reaction buffer, 2.5 µl of T7 enzyme mix and 2.5 µl 
biotin-NTP mix) at 37 ˚C for 16 hr. The reaction was stopped with the addition of 75 µl of 
nuclease-free water to each cRNA sample. The biotinylated, amplified RNA was purified by 
filtering the cRNA samples through cRNA Filter Cartridges with 350 µl of cRNA binding buffer 
and 250 µl of 100 % ethanol mixed together  prior to loading onto the filters. The cRNA filter 
cartridges with attached RNA were then washed with 650 µl of wash buffer before eluting purified 
cRNA with 200 µl of 55 ˚C nuclease-free water. 
2.8.2.2  Illumina Expression BeadChip Hybridization 
The biotinylated cRNA was quantified on the NanoDrop® ND-1000 UV-Vis Spectrophotometer 
before hybridization to the Illumina Expression BeadChips. The cRNA samples were heated at 65 
˚C for 5 min and collected by pulse centrifugation. Approximately 750 ng of each biotin-labelled 
cRNA sample was aliquoted into separate tubes to which were added ~ 5 µl of RNase-free water 
and 10 µl of Hyb Mix. Approximately 15 µl of the prepared cRNA mix was loaded onto the 
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Illumina Expression BeadChips. The HumanHT-12 v4 Expression BeadChips provide coverage for 
more than 47,000 transcripts and known splice variants across the human transcriptome while 
examination of 12 samples in parallel. The MouseRef-8 v2.0 Expression BeadChips present 
updated content for the mouse genome targeting approximately 25,600 well-annotated RefSeq 
(Reference Sequence) transcripts over 19,000 unique genes.  
According to the Whole-Genome Gene Expression Direct Hybridization Assay Guide provided by 
Illumina, the loaded BeadChips with the cRNA samples were inserted into the Hyb Chamber and 
allowed to hybridize overnight for 16 hr at 58 ˚C. The seals of the BeadChips were removed while 
submerged in E1BC wash buffer and then washed with 1X High-Temp Wash Buffer in a Hybex 
waterbath at 55 ˚C for 10 min. The high temperature wash was followed by a room-temp wash in 
250 ml of Wash E1BC Buffer on an orbital shaker for 5 min. The rack with the BeadChips was then 
transferred to a staining dish for another wash with 250 ml 100 % ethanol for 10 min followed by a 
second room-temp wash in 250 ml of fresh Wash E1BC Buffer for 2 min. The BeadChips were then 
transferred to wash trays with 4 ml of Block E1 Buffer and placed on a rocker for 10 min. Cy3-
Streptavidin (Cy3-SA) fluorescent dye was used to stain the probes. Two ml of Block E1 Buffer 
with 1:1000 dilution of Cy3-SA was prepared for each BeadChip which was added to new wash 
trays with the BeadChip. The wash trays were covered from light with a lid and rocked for 10 min 
at room-temp. Excess stain was washed off the BeadChips with a third room-temp wash in 250 ml 
of fresh Wash E1BC Buffer for 5 min on the orbital shaker and dried by centrifugation (Eppendorf 
Centrifuge 5810 R) at 1,400 rpm for 4 min at room temperature.  
2.8.2.3  Data Normalization and Analysis 
Raw microarray data generated by the iScan System were extracted in GenomeStudio using default 
settings and were then exported into GeneSpring GX v12.5 (Agilent Technologies, Santa Clara, 
CA, USA) for processing where the expression values were normalized using quantile 
normalization with default settings. The entities were filtered based on the detection score 
calculated by GenomeStudio where p ≤ 0.05 was considered significant. 
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2.9 Protein Analysis 
2.9.1 Preparation of Protein Samples 
Cells were grown in 25 cm2 or 75 cm2 flasks and grown to 70% confluence. B16-F0 cells were 
grown in T25 flasks due to their proliferative growth and Sk-Mel-28 cells were grown in T75 
flasks.  
The culture medium from the flasks was removed by aspiration. The cell monolayer was washed 
once with ice-cold PBS and cells were harvested using sterile disposable cell scrappers. Cells were 
collected by centrifugation at 1,500 rpm for 5 min. The pellets were resuspended in 1 ml ice-cold 
PBS and transferred to 1.5 ml eppendorf tubes. Cells were collected by spinning at full speed 
(~13,200 rpm) for 1 min in an Eppendorf Centrifuge 5415 D. The supernatant was discarded and 
the pellets stored at -20˚C.  
The frozen pellets were thawed on ice, and resuspended in cell lysis buffer about 3-4 times the 
volume of the pellet. The cells were lysed in 200 µl cell lysis buffer (recipe in Section 2.1.2) and 
were sonicated using a Branson Sonifier 250) for 30-40 pulses at 4˚C with a duty cycle of 30% and 
output control of 3. The cell lysates were centrifuged at 4˚C for 10 min at 13,200 rpm to isolate the 
soluble fraction, which was then transferred to a fresh 1.5 ml eppendorf tube for determination of 
protein quantity. The extracted protein was stored at -70˚C. 
2.9.2 Determination of Protein Concentration 
Bovine Serum Albumin (BSA) protein standards (Pierce Chemical Corporation) were used to 
quantify the amount of protein in each sample. This method is based on the well-known reduction 
of copper Cu2+ to cuprous cation Cu1+ by protein in an alkaline medium (the biuret reaction) with 
the highly sensitive and selective colorimetric detection of Cu1+ using a unique reagent containing 
bicinchoninic acid. The purple-coloured end-point of this assay is formed by the chelation of two 
molecules of BCA with one cuprous ion and exhibits a strong absorbance at 562 nm which is nearly 
linear with increasing protein concentrations over a broad working range (20-2000 µg/ml) (as 
explained in the manufacturer’s instructions provided in the kit). 
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Protein samples were diluted 1:10 (v/v) in MilliQ H2O and 10 µl was plated out in duplicate in a 
flat-bottom 96-well plate (Costar).  A final volume of 100 µl of BSA working reagent (50 parts 
reagent A: 1 part reagent B) from the BSA protein assay kit was added to each well. The solutions 
were mixed well by pipetting and the plate was incubated at 37˚C for 30 min before reading at 564 
nm using an ELISA plate reader (VERSA max microplate reader; Molecular Devices). The 
concentration of the protein in the samples was determined by interpolations on the standard curve. 
2.9.3 SDS Polyacrylamide Gel Electrophoresis 
Depending upon the amount of protein extracted, approximately 15-30 µg of the protein sample was 
loaded onto SDS-PAGE gel alongside 10 µl of BenchMark™ Prestained Protein Ladder (Gibco 
Life Technologies).  Prior to loading, protein samples were prepared with 2x SDS loading buffer 
with β-mercaptoethanol and made up to a final concentration (w/v) of 2 µg/µl with cell lysis buffer. 
Samples were denatured at 65˚C for 5 min. The SDS-PAGE gel was prepared using the minigel 
system (Bio-Rad Laboratories). A 10% resolving gel was prepared (Section 2.1.2) and allowed to 
set for 30-40 min at RTemp while overlayed wit water-saturated butanol. Before pouring the 5% 
stacking gel, the water-saturated butanol was tipped off, the stacking gel poured on top of the 
resolving gel with a 10-well comb (Bio-Rad Laboratories) and allowed to set for 15 min. 
Electrophoresis was performed for approximately 45 min or until the dye had run off the bottom of 
the gel in 1x SDS running buffer (200 V, RTemp). 
2.9.4 Western Blotting 
Following SDS-PAGE electrophoresis, the gel plates were carefully separated, and the stacking gel 
transferred to a transblot apparatus. The transfer sandwich was assembled as follows: a porous 
sponge pre-wet in cold electroblot buffer, a sheet of blotting (Whatmann) paper, Hybond-C 
nitrocellulose membrane (Amersham Pharmacia), the gel, another sheet of blotting paper, lastly 
followed by another porous sponge soaked in cold electroblot buffer. This was then inserted into the 
transfer apparatus with the nitrocellulose membrane closer to the anionic side. Care was taken to 
prevent any air bubbles during assembly as it would result in inconsistent transfer of proteins. The 
proteins were transferred at 100 V for 1 hr in ice-cold transfer buffer at 4˚C with an ice-pack and 
magnetic stirrer added to maintain temperature during transfer. 
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2.9.5 Immunodetection of Proteins 
Once transferred, the nitrocellulose membrane was incubated in 5% (w/v) Blotto at room 
temperature for 1 hr with gentle orbital shaking (Bioline) to block non-specific binding sites. The 
primary antibody was diluted as recommended by the manufacturer in 5% (w/v) Blotto to a final 
volume of 2 ml. A plastic envelope containing the membrane and antibody was prepared and heal-
sealed, removing any air bubbles present. The membrane was rotated at 4˚C overnight 
(approximately 16 hr) on a custom made rotor. A list of antibodies used in this study has been 
compiled in Table 2.3. 
Following the incubation period, the membrane was removed from the bag, placed in a plastic tray 
with 1x PBS-0.05% Tween20 or 1x TBS-0.1% Tween20 and washed (3 x 2 min; 2 x 5 min) on an 
orbital shaker and incubated with the appropriate secondary antibody made up in 2 ml 5% Blotto for 
1½ hr at RTemp on the rotator. Blots were washed as previously with 0.05% Tween20 in 1x PBS. 
Antibody detection was performed using the Enhanced Chemilluminescence (ECL) detection kit 
(Perkin Elmer). Following 1 min of incubation in the chemilluminescence solution (equal volumes 
of Enhanced Luminol Reagent and Oxidizing Reagent) the blots were dried using blotting paper and 
imaged using the X-OMAT autoradiography film (Kodak; Rochester, NY). 
 
2.10 Histology 
Mice were euthanized by cervical dislocation at various times following a single intratumoral 
injection of EBC-46 or vehicle to the pre-established tumor. The treated sites were excised using 
sterile disposable surgical instruments. One tumor each of vehicle – treated and EBC-46 – treated 
were fixed in 10% phosphate buffered formalin for histological processing. Tumors were processed 
and stained for H&E, neutrophils, macrophages, mast cells and endothelial cells by Clay 
Winterford, Rita Collins and Glynn Rees of QIMR Berghofer Histology Facility. Tissue – section 
slides were scanned at 20x magnification using the Aperio XT Scanscope. 
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2.11 Cytokine Expression Analysis 
2.11.1  Preparation of samples 
 a.  From animal tumors 
Mice were treated with 30 µg of EBC-46 per tumor site (maximum of 4 sites per mouse) over a 
time – course with duplicates at each time. Control and treated tumors were harvested using sterile 
disposable surgical instruments. Tumors were briefly washed in 70% ethanol, and cells were teased 
out into 1 ml PBS with a final 1x concentration of protease inhibitor cocktail from Roche. The cell 
suspension was centrifuged at 1,500 rpm for 5 min at RTemp. The supernatant was stored at -80˚C 
until ready to assay for cytokines using either the mouse or human inflammation kits depending on 
the origin of the cell lines. Whole blood from these mice was collected and the serum was assessed 
for soluble cytokines using the mouse inflammation kit. 
 b.  From cultured cells 
Tumor cells of both human and mouse origin were grown in 24 – well cell culture plates (Corning) 
and treated with varying doses of EBC-46 in the presence of human peripheral blood mononuclear 
cells (PBMC) at various times. Cells were incubated with RPMI-1640 culture media prepared with 
10% v/v FCS and antibiotics. At the different time – points, the medium was transferred to labelled 
1.5 ml eppendorf tubes and centrifuged at 10,000 rpm for 2 min. The supernatants were collected in 
fresh eppendorf tubes and stored at -80˚C until ready to assay for cytokines using either the mouse 
or human inflammation kits depending on the origin of the cell lines.  
2.11.2  Cytokine Expression Analysis 
The BD (Becton Dickinson) Cytometric Bead Array assays provide a method for capturing a 
soluble analyte or set of analytes using beads of known sizes and fluorescence, thus making it 
possible to detect analytes by flow cytometry. Each supernatant was assayed in duplicate for the 
presence of soluble cytokines in the host and in the tumor microenvironment using the BD (Becton 
Dickinson) Inflammation Kits for mice and humans respectively (Table 2.4) and a FACSArray plate 
reader (BD Biosciences) according to manufacturer’s instructions.  
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Table 2.3: Antibodies Used in this Study 
Antibody Origin Dilution Supplier 
Anti-PKC α Mouse 1:1000 Pharmingen, Becton and Dickinson Biosciences 
Anti-PKC β Mouse 1:250 Pharmingen, Becton and Dickinson Biosciences 
Anti-PKC δ Mouse 1:500 Pharmingen, Becton and Dickinson Biosciences 
Anti-Phospho-p44/42 MAPK (Thr202/Tyr204) Rabbit 1:1000 Cell Signaling 
Anti-p44/42 MAPK Rabbit 1:1000 Cell Signaling 
Anti-Phospho-MEK1/2 Rabbit 1:1000 Cell Signaling 
Anti- MEK1/2 Rabbit 1:1000 Cell Signaling 
Anti-Phospho-PKC (pan) Rabbit 1:1000 Cell Signaling 
Anti-GAPDH Rabbit 1:10,000 R & D Systems 
Anti-Mouse Ig HRP-conjugate Sheep 1:1000 Chemicon 
Anti-Rabbit Ig HRP-conjugate Sheep 1:1000 Chemicon 
Anti-Rabbit Ig HRP-conjugate Sheep 1:1000 Cell Signaling 
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Table 2.4:  Cytokine Bead Assay kits used in this study 
BD CBA Inflammation Kit Target proteins 
Mouse Inflammation Kit IL-6, IL-10, MCP-1, IFN-γ, TNF, IL-12p70 
Human Inflammation Kit IL-8, IL-1β, IL-6, IL-10, TNF, IL-12p70 
 
2.12 Neutrophil Recruitment 
B16-F0 and Sk-Mel-28 cells were injected into male C57BL/6 and BALB/c Foxn1nu mice, 
respectively. Tumors were allowed to grow to approximately 100 mm3, following which mice were 
segregated into cages and experimental groups labelled as per table below Table 2.5 Mice were 
administered with the neutrophil neutralizing anti-Ly-6G antibody or the isotype control IgG2 
antibody via intraperitoneal (IP) injection on days -2, 0 and 2 relative to treatment with EBC-46 (50 
µl of 600 µg/ml) or the 50 µl of the control vehicle 20% PG. The neutrophil counts in blood were 
determined for each of the groups by preparation of blood smears immediately after treatment on 
SuperFrost® Plus slides from Menzel-Glaser. Mice were regularly monitored until tumors were 
ablated or mice were culled as a result of tumor burden.  
Dried blood smears were fixed with methanol and air dried. Slides were placed in staining racks and 
submerged in a container with Quick Dip stain I (Fronine/Thermo Fisher Scientific for leukocytes) 
1 for 30 sec. The slides were rinsed by dipping into a container with water and were then transferred 
to a second container with Quick Dip solution II (Fronine/Thermo Fisher Scientific) for 30 sec. The 
stained slides were placed under gentle running water to wash off excess Quick Dip solution II and 
were left to dry overnight. Once dried, cover slips were applied onto the slides using 20 – 40 µl of 
the fixative Kaiser’s glycerol gelatine, depending on the area of smear. Slides were allowed to set 
and dry before observing under 40X magnification.  
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2.13 Respiratory Burst 
Human neutrophils were isolated from fresh blood by lysis of the red blood cell pellet obtained by 
sedimentation using Ficoll-Plaque. Isolation of the human neutrophils was carried out by Dr. 
Viviana Lutzky. The neutrophils (~ 4 x 106 cells/ml) were incubated with 10 µg/ml 
dihydroethidium (DHE) (Sigma-Aldrich) in complete culture medium at 37˚C for 15 min alongside 
an aliquot of unstained cells to be tested as unstained control. This was followed by treatment with 
EBC-46 or TPA at 0, 1 ng/ml, 10 ng/ml, 100 ng/ml, 1 µg/ml, 10 µg/ml, 100 µg/ml for 15 min. 
Neutrophils were also treated with BIS-1 (pan-PKC inhibitor) to determine the PKC activating 
characteristic of EBC-46. For this, neutrophils were treated with a final concentration of 2 µM of 
BIS-1 for 1 hr prior to diterpene ester treatment with EBC-46 or TPA. Reactive oxygen species 
generated in the oxidative burst resulted in an increase in fluorescence (emission at 610 nm), 
measurable immediately on a FACS Canto flow cytometer. The experiment was completed in 
triplicate. 
 
Table 2.5:  Mouse Treatment Groups for Neutrophil Recruitment Study 
 
Day -2 
 
Day 0 
 
Day 2 
IgG2 
or 
anti-Ly-6G 
 
IgG2 
or 
anti-Ly-6G 
IgG2 
or 
anti-Ly-6G 
+ 
30 µg EBC-46 
or 
20% PG 
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2.14 Live uptake of Propidium Iodide 
Approximately 3-5 x 104 cells/well were seeded in a 96-well microtitre plate. Cells were treated 
with either EBC-46 or TPA (100 µg/ml, 200 µg/ml and 300 µg/ml) for 30 min and 4 hr, alongside 
controls which included untreated cells and cells treated with 10 µl of 1% Triton X-100. Propidium 
iodide solution was added to give a 5 µg/ml final concentration for the last 30 min of treatment. The 
temperature of the cells was then decreased to zero by placing the plate on ice for about 5 min 
before imaging using the AMG EvosFl inverted fluorescence microscope at 20x magnification, to 
stop any further cytotoxic activity of EBC-46  
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3.1 Introduction 
PKC activators such as diterpene esters have been extensively studied as potential agents for 
chemotherapy. Previous research in this laboratory has established that the diterpene ester PEP005 
(ingenol-3-angelate) is a PKC activator (Kedei et al., 2004) and is toxic to cancer cells.  
Bioactivity-guided fractionation carried out by QBiotics together with the Drug Discovery Group at 
QIMR Berghofer Medical Research Institute revealed a potential PKC-activating compound in the 
extracts from the kernel of the Blushwood seed. The extracts were rich in diterpene esters. 
Preliminary experiments conducted in this laboratory on compounds from the Blushwood kernels 
established that intralesional injection of a purified compound cured mice bearing tumors of either 
the human metastatic melanoma MM96L or the murine B16-F0 melanoma cell line, suggesting a 
role for the compound in the treatment of melanoma. 
The purified compound was found to be a novel short chain diterpene ester named EBC-46 (formal 
name 12-tigloyl/angeloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-
3-one).  Elucidation of the chemical structure of EBC-46 revealed a polycyclic carbon skeleton 
similar to TPA (Figure 3.1). Hence it was proposed to share similar biological/functional properties 
with those of TPA. 
Diterpene esters such as the phorbol ester TPA are known to target PKC by binding to the C1 
domain and inducing the translocation of classical and novel PKC isoforms from the cytoplasm to 
the membranous fractions (Section 3.2.1). Given the structural similarity between TPA and EBC-
46, a potential role of PKC as a target for this compound was explored. 
The aim of the following studies was to characterize the PKC activity profile of EBC-46 and to 
compare it to that of the phorbol ester TPA. The studies focused on: (1) determining the ability of 
EBC-46 to selectively induce translocation of PKC isoforms possessing a C1 DAG-binding domain 
to the plasma membrane; (2) comparing the effects of EBC-46 to TPA on activation of MAPK 
signaling, a process known to be modulated by PKC activity; (3) establishing the potency of the 
diterpene esters in inducing human leukocytes into respiratory burst, a process reported to the 
dependent on PKC activity; and (4) testing the effect of EBC-46 on the cell cycle. 
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EBC-46 
Figure 3.1:  Structures of diterpene esters TPA and EBC-46 used in this study  
(Evans, 1986, Goel et al., 2007, Zucker et al., 1974). 
(Structure of EBC-46 obtained from Dr. Paul Reddell and Prof.Peter Parsons; unpublished 
data). 
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3.2 Results 
3.2.1 Translocation of PKC Isoforms by EBC-46 and TPA 
To determine whether EBC-46 was an activator of PKC, initial experiments aimed to establish the 
ability of EBC-46 to cause translocation of classical and novel PKC isoforms in HeLa cells 
transiently transfected with EGFP-tagged PKC vectors. The isoforms examined were α, β1, β2 and γ, 
and θ, and ζ of the classical, novel and atypical subfamilies respectively. Cells were treated with 
either 10 ng/ml, 30 ng/ml or 100 ng/ml of EBC-46 or TPA for 1 hour, a day following transient 
transfection of the tagged PKC isoforms. Control cells treated with the vehicle alone showed PKC 
isoforms to be localized in the cytosol, while cells treated with EBC-46 or TPA demonstrated 
differences in subcellular localization of the activated PKC isoforms. TPA resulted in efficient 
translocation of PKC-α, -β1, -β2, γ and θ. As expected, neither compound led to translocation of 
atypical PKC-ζ which lacks the C1 domain required for binding of phorbol esters (Figure 3.2). 
EBC-46 resulted in complete translocation of PKC isoforms -β1 and -β2 and less translocation of –α 
and –γ isoforms (Figure 3.2). Fluorescence microscopy showed PKC-β to be translocated to the 
plasma membrane following treatment with EBC-46 similar to that of TPA in comparison to control 
PKC β1 localized in the cytosol of tested HeLa cells (Figure 3.3). TPA translocated PKC-θ from the 
cytoplasm to the plasma membrane and other organelles such as the Golgi, and nucleus. In contrast, 
treatment of HeLa cells transiently transfected with EGFP tagged PKC-θ with EBC-46 led to no 
translocation of this isoform to the plasma membrane (Figure 3.2). Fluorescence microscopy images 
of HeLa cells showing translocation of PKC isoforms α, γ, θ and ζ after treatment with the diterpene 
esters, correlated with the data plotted in Figure 3.2. Among the isoforms tested, PKC-α, -γ and -θ 
demonstrated differential translocation patterns when stimulated with TPA or EBC-46. Photographs 
of the critical findings are shown in Figure 3.3. No work was done with inhibitors using this 
technique. 
3.2.2 Comparison of EBC-46 and TPA in activating the MAPK pathway 
PKC isoforms are present in varying combinations and concentrations in different cell types. In 
addition, PKC isoforms play an important role as tumor suppressors in cancer development.  The 
spatial regulation of PKC isoforms may be dependent on the phosphorylation of substrates which 
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Figure 3.2: EGFP-tagged PKC isoform translocation in transiently-transfected HeLa cells following 1 hr treatment with 100 ng/ml 
of TPA or EBC-46.  
EGFP-tagged PKC- isoform translocation in transiently transfected HeLa cells following 1 hr of treatment with either 100 ng/ml of EBC-46 
or TPA. Data is from assessment of at least 50 cells per well from each of triplicate transient-transfection experiments. The error bars indicate 
standard deviation. 
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Figure 3.3:  Translocation of PKC-β1 in HeLa cells achieved through treatment with 
EBC-46 or TPA and visualized by fluorescence microscopy 
Representative fluorescence images of translocation of PKC-β1 transiently-transfected HeLa 
cells treated with 10 ng/ml or 100 ng/ml of EBC-46 or TPA for 1 hour.  
A. Control PKC β1 in vehicle-treated HeLa cells. 
B. PKC β1 translocated to the plasma membrane in HeLa cells treated with 10 ng/ml of 
EBC-46 or TPA. 
C. PKC β1 translocated to the plasma membrane in HeLa cells treated with 100 ng/ml of 
EBC-46 or TPA. 
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facilitate intracellular localization. For instance, PKC-δ was shown to translocate differently to the 
Golgi or mitochondrion, the nucleus, or membrane based on the regulatory molecule(s) it bound to, 
namely ceramide, DAG or RACKs (Steinberg, 2005). Activated PKC participates in different 
cellular signaling pathways. Studies have shown phorbol ester TPA to be involved in the regulation 
of the MAPK pathways (Joppich et al., 1967). Activated/phosphorylated PKC is translocated to 
membranous fractions with the aid of the cytosolic receptor for activated C kinases (RACK) 
(Buensuceso et al., 2001) where they participate in down-stream signal transduction pathways.  
As outlined in the Introductory Chapter of this thesis, prolonged exposure of cells to PKC 
activators such as TPA resulted in activation of PKC isoforms followed by proteolytic degradation 
of the isoforms via the ubiquitin-proteosome pathway (Lu et al., 1998). Western blot analysis was 
conducted to confirm the ability of EBC-46: (1) to activate PKC and its specificity for certain 
isoforms, and (2) to modulate the MAPK pathway where phospho-specific antibodies were used 
against ERK1/2 which is the target substrate of the Ras/Raf/MEK/ERK signaling pathway.  
B16-F0 and Sk-Mel-28 cells were grown in 25 cm2 and 75 cm2 flasks respectively at an appropriate 
sub-cultivation ratio to ensure ~ 70% confluence in growth by the end of treatment duration which 
extended to a maximum of 48 hr. Cells were pre-treated with the PKC inhibitor at a final 
concentration of 5 µM BIS-1 for 1 hr prior to treatment with 1 µg/ml of EBC-46 or TPA for 6 hr, 24 
hr, and 24 hr recovery in fresh media after 24 hr of treatment. At the end of the treatment duration, 
cells were washed with ice-cold PBS and harvested for extraction of proteins for western blotting 
analysis. Western blots of B16-F0 and Sk-Mel-28 cell lysates were probed for PKC-α, -β, -γ, -δ, -ε, 
-θ and -ι which represent the classical, novel and atypical isoforms, and the house-keeping gene 
GAPDH which was probed to ensure equal loading of protein samples into wells of the gel (Figure 
3.4). 
The protein levels of the classical isoform PKC-α appeared to be similar in both melanoma cell 
lines, B16-F0 and Sk-Mel-28. Further, protein levels of PKC-α following 6-24 hr of either EBC-46 
or TPA treatment were also similar. However there was a difference observed in the protein 
expression levels, when comparing the two diterpene esters EBC-46 and TPA compared to the 
controls. 
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There was a slight decrease in expression noted between 6 hr to 24 hr after treatment of B16-F0 
cells with TPA but not with EBC-46 which indicated a more sustained expression efficiency with 
the latter (Figure 3.4; Panel A). Expression of PKC-α after 24 hr of treatment with either diterpene 
ester followed by 24 hr of recovery in fresh media does not change when treated with either 1 µg/ml 
of EBC-46 or TPA indicating sustained depletion of the PKC isoform up to 24 hr (Figure 3.4; Panel 
A). PKC-β and –γ were absent in both cell types (data not shown). Among the other PKC isoforms 
probed for, the western blot analysis showed no expression of PKC-δ, -ε, -θ, and –ι in B16-F0 cells 
(data not shown). 
In Sk-Mel-28 cells, PKC-δ showed a similar expression profile upon treatment with TPA and EBC-
46 as seen with PKC-α (Figure 3.4; Panel B). No striking changes were noticed in the expression 
levels among the other isoforms tested, namely PKC-ε, -θ, -ι. Immunodetection with PKC-ε 
antibody showed low expression of the isoform through all of the protein samples extracted from 
Sk-Mel-28 cells indicating a slight decreased in expression by 24 hr after treatment. The expression 
of this isoform following recovery in fresh media showed a further decline in intensity. The overall 
expression of PKC-θ was low and as with PKC-ι, the expression of both isoforms appeared 
unaffected by exposure to EBC-46 or TPA (Figure 3.4; Panel B). 
Activation of the MAPK pathway by phorbol ester TPA has been reported in several studies 
(Krumhaar and Hecker, 1967, Joppich et al., 1967, Wen-Sheng, 2003). MAPKs are the final 
components of a three-tier protein kinase cascade (as explained in Chapter One; Section 1.4.1). 
Considerable evidence shows that PKC activates the MAPK pathway (Sugden and Clerk, 1998) 
with direct activation of the classical and novel PKC isoforms by phorbol esters TPA and phorbol 
12,13-dibutyrate (PDBu) which stimulated the ERKs in cardiac myocytes. Hence, the ability of 
diterpene ester EBC-46 to stimulate the MAPK pathway was examined in comparison to TPA. 
Controls included in the assay were cells grown in untreated culture media and cells treated with the 
vehicle EtOH. Tumor cells treated with TPA or EBC-46 for 6 hr or 24 hr were included in the assay 
as positive controls. Western blot analysis was performed on protein samples extracted from B16-
F0 and Sk-Mel-28 cells which were treated with a final concentration of 5 µM BIS-1, a pan-PKC 
inhibitor 1 hr prior to treatment with PKC activators TPA or EBC-46. 
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Figure 3.4:  PKC isoform activation by TPA or EBC-46 in melanoma cells in vitro 
Panel A: PKC isoforms expressed in B16-F0 cells upon treatment with TPA or EBC-46 
Panel B: PKC isoforms expressed in Sk-Mel-28 cells upon treatment with TPA or EBC-46 
 
Melanoma cells B16-F0 and Sk-Mel-28 of mouse and human origin respectively were treated 
with 1 µg/ml of TPA or EBC-46 for 6 hr, 24 hr and 24 hr recovery in fresh media following 24 hr 
treatment. The diterpene esters were dissolved in EtOH and added to cultures at a final 
concentration of 1% (v/v) EtOH. Controls used in the assay included untreated cells grown in 
media, a vehicle control in which cells were exposed to 1% (v/v) EtOH for 24 hr and a vehicle 
control recovery in which cells treated for 24 hr with 1% (v/v) EtOH were then exposed to 24 hr 
recovery in fresh media. Samples corresponding to 30 µg of total protein were electrophoretically 
separated on 10% (w/v) SDS-PAGE gels and transferred to nitrocellulose membrane (Chapter 2; 
Section 2.9.3 – 5) following which proteins of interest were blotted using the appropriate 
antibodies. 
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There was increased expression of phospho-proteins observed when treated with the PKC activators 
TPA or EBC-46. Pre-treatment of B16-F0 cells with BIS-1 greatly lowered MEK1/2 and ERK1/2 
activation (phospho-MEK1/2 and phospho-ERK1/2) by TPA and EBC-46 when compared to the 
positive controls (Figure 3.5, Panel A), confirming that diterpene ester-induced PKC activation is 
responsible for activating the MAPK pathway. 
However, a similar effect is not reflected in Sk-Mel-28 cells, where BIS-1 treatment resulted in only 
a minor decrease in levels of activated MEK1/2 and ERK1/2 compared with the phosphorylated 
protein controls (Figure 3.5, Panel B). A comparison of p-MEK1/2 and p-ERK1/2 between the two 
cell lines shows a somewhat higher expression in Sk-Mel-28 than B16-F0 by TPA or EBC-46. 
In addition, a time-course analysis of the activation of the PKC isoforms (Figure 3.4) demonstrated 
a time-dependent expression where the expression levels of these MAPK components decreased 
between 6 hr to 24 hr after treatment with the diterpene esters, although not very significant. A 
comparison of the effect of TPA and EBC-46 on the activation of MEK1/2 and ERK1/2 (Figure 
3.5) demonstrated a similar profile. This is consistent with the concept that activation of PKC 
isoforms leads to their depletion via the ubiquitin-proteosome pathway (Hofmann, 2001). These 
results support the hypothesis of EBC-46 as an activator of PKC isoforms, as evidenced by the 
lowered expression levels of the MAPK components upon treatment with a specific PKC inhibitor, 
BIS-1. 
3.2.3 The Induction of Respiratory Burst in Neutrophils by TPA and EBC-46 via PKC 
activation 
Another characteristic of PKC activation which has been reported in literature is its ability to induce 
oxidative burst of neutrophils (Hafeman et al., 1982). Neutrophils are dedicated phagocytic cells 
that constitute the first line of defense against invading micro-organisms. The intracellular killing 
mechanism is based on two independent but mutually supportive mechanisms; the generation of 
toxic oxygen metabolites and the release of microbicidal proteins from the storage granules into 
phagosome (Dale et al., 2008, Segal, 2005). 
The aim of this study was to compare the efficacy of EBC-46 with that of TPA in producing 
reactive oxygen species by neutrophils and determine the requirement of PKC in this process. 
Human blood was processed by Dr. Viviana Lutzky and neutrophils were isolated. Cells were 
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stained with 10 µg/ml dihydroethidium bromide (DHE) for 15 min at 37˚C. Cells were pre-treated 
with 5 µM BIS-1 (pan-PKC inhibitor) for 1 hr following which cells were treated with a range of 
concentrations of EBC-46 or TPA (Chapter Two; Section 2.13) for 15 min at 37˚C. The generation 
of reactive oxygen species was measured using FACS Canto flow cytometer. 
The results showed that both TPA and EBC-46 induced the production of reactive oxygen species 
(ROS) in a dose-dependent manner. Both compounds were found to be equally potent in the 
induction of oxidative burst of human neutrophils. To confirm that the activation of PKC by TPA 
and EBC-46 is essential for the induction of neutrophil oxidative burst, cells were pre-treated with a 
pan-PKC inhibitor, BIS-1. Pre-treating neutrophils with BIS-1 followed by treatment with TPA or 
EBC-46 resulted in nearly complete inhibition of the production of ROS (Figure 3.6) thus 
confirming the role of PKC activation by the diterpene esters, TPA and EBC-46 in this process.  
3.2.3 Cytotoxicity Profiles of Diterpene Esters TPA and EBC-46 
In vitro cytotoxicity studies were performed to compare the cytotoxicity profile of TPA and EBC-
46 on the tumor cell lines B16-F0 (mouse melanoma), Sk-Mel-28 (human melanoma), A549 and 
HOP-62 (human lung cancers) and K562 (human leukemia). Given the similarities it shares with 
TPA, it was hypothesized that EBC-46 would affect tumor cells in a similar manner as TPA. 
The aim of these experiments was to study the cytotoxic effect of varying concentrations of TPA or 
EBC-46 on different tumor cell lines. Based on cell growth rates, flat-bottomed 96 well plates were 
seeded with B16-F0, Sk-Mel-28, A549 or HOP-62 cells at densities ranging between 3000 – 5000 
cells in 100 µl culture media, per well. 
K562 cells were seeded into a U-bottom plate as it is a suspension cell line. The cells were treated 
with varying concentrations of TPA or EBC-46 in media alongside control treatments using the 
vehicle EtOH, across the plate so that each concentration in each treatment group was tested in 
quadruplicate (Chapter Two; Section 2.1.2). Growth inhibition of cells was assayed by the 
Sulforhodamine B (SRB) assay on the B16-F0, Sk-Mel-28, HOP-62 and A549 cells while an MTS 
assay was performed on the K562 cell line. 
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Figure 3.5:  Activation of ERK1/2 and MEK1/2 in melanoma cells treated with 
Diterpene Esters 
Panel A:  MAPK activity shown by expression of ERK1/2 and MEK1/2 in B16-F0 mouse 
melanoma cells treated with 1 µg/ml of TPA or EBC-46. 
Panel B:  MAPK activity shown by expression of ERK1/2 and MEK1/2 in Sk-Mel-28 
human metastatic melanoma cells treated with 1 µg/ml of TPA or EBC-46. 
 
Melanoma cells Sk-Mel-28 and B16-F0 cells of human and mouse origin respectively were pre-
treated for 1 hr with 5 µM BIS-1 (pan-PKC inhibitor) following which the cells were treated 
with 1 µg/ml of either TPA or EBC-46 for 6 hr, 24 hr and 24 hr recovery in fresh media 
following 24 hr treatement. The diterpene esters were dissolved in EtOH and added to cultures 
at a final concentration of 1% (v/v) EtOH. Controls used in the assay included untreated cells 
grown in culture media, cells treated with the vehicle control EtOH for 24 hr and vehicle-treated 
control recovery where cells were treated for 24 hr with 1% (v/v) EtOH then exposed to 24 hr 
recovery I fresh culture media., Protein was extracted, ~30 µg of total protein was separated on 
a 10% SDS-PAGE gel and transferred to nitrocellulose membranes (Chapter 2; Section 2.9.3 – 
5) following which the proteins of interest were blotted using appropriate antibodies. 
 Chapter Three 
________________________________________________________________________________ 
 
________________________________________________________________________________ 
 
Page | 84  
 
 
 
Figure 3.6 Induction of Oxidative Burst in Neutrophils by Diterpene Esters via PKC  
Activation 
Production of reactive oxygen species following treatment of PMN cells.  PMN cells were 
pre-loaded with dihydroethidium bromide and pre-treated where indicated with 1 µM 
bisindolylmaleimide-l for 15 min, then stimulated with 100 ng/ml of either PMA (top) or 
EBC-46 (bottom) for 15 min at 37˚C. Untreated PMN cells – red, PMN cells pre-loaded – 
blue, loaded PMN cells treated with either 100 ng/ml PMA or EBC-46 – green, loaded PMN 
cells treated with either 100 ng/ml PMA or EBC-46 in presence of bisindolylmaleimide-l – 
yellow.   
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The results demonstrated that an IC50 of 30 µg/ml and greater of EBC-46 was required to induce a 
cytotoxic effect on some tumor cell lines, namely B16-F0 and Sk-Mel-28 in vitro. The same was 
seen to be true for TPA (Figure 3.7; Panel A). The cytotoxic effect of EBC-46 on some other cell 
lines was demonstrated at doses as low as 10 ng/ml, and lower again TPA (Figure 3.7; Panels B and 
C). 
Similarly melanoma cells Sk-Mel-28 and B16-F0, were treated in vitro at high drug concentrations 
and for a shorter treatment time. Where the previously described cell survival assays were 
monitored over a period of 5-6 days incubation time at concentrations below 100 µg/ml; in the 
following assay (Figure 3.8, Panels A, B, C) cells were treated with EBC-46 or TPA at 
concentrations above 100 µg/ml for 30 min. Cells were viewed and imaged using an AMG EvosFL 
inverted fluorescence microscope to assess cell morphology upon treatment with the diterpene 
esters. From the images in Figure 3.8, Panels B and C at 30 min after treatment, EBC-46 appears to 
be more potent than TPA on both Sk-Mel-28 and B16-F0 cells where 100 µg/ml of EBC-46 leads to 
cell shrinkage which is a characteristic of apoptosis, with a few viable cells. While there are a 
number of cells which appear shrunken and dead indicating necrosis, on the other hand there are 
still many viable cells after treatment with 100 µg/ml of TPA. Higher concentration of EBC-46 or 
TPA (i.e. 200 µg/ml) on Sk-Mel-28 and B16-F0 cells resulted in a necrotic outcome within 30 min 
after treatment where cells had lost adherence and appeared like debri (Figure 3.8, Panel B and C). 
Examples of necrotic cells in Sk-Mel-28 and B16-F0 upon treatment with EBC-46 or TPA are 
indicated with red arrows in Figure 3.8, Panel B and C. 
3.2.4 Ectopic expression of PKC isoforms and the effect of EBC-46  
To determine if the level of PKC expression influenced the sensitivity of cells to cytotoxic killing 
by diterpene esters, we engineered cell lines to over-express isoforms by lentiviral transduction. Sk-
Mel-28 and D04 melanoma cell lines over-expressing PKC isozymes, specifically, α, δ, and cells 
expressing lacZ as a control, were obtained from Dr. Glen Boyle. Cell lines were treated with TPA 
or EBC-46 at varying concentrations. Two human melanoma cell lines, one naturally resistant to 
death/cell cycle arrest induced by PKC activators (Sk-Mel-28) and the other sensitive (D04), were 
selected. Following the same procedure as the parent lines, cells were seeded into flat-bottom 96-
well plate at 4,000 – 5,000 cells in 100 µl culture media per well. The plates were treated with  
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Figure 3.7  Dose-Response for Growth Inhibition of Tumor Cell Lines by Diterpene 
Esters TPA or EBC-46  
Panel A: Melanoma cell lines Sk-Mel-28 (human origin) and B16-F0 (mouse origin) 
Panel B: Lung cancer cell lines A549 and HOP-62 (human origin) 
Panel C: Leukemic cell line K562 (human origin) 
Cells were plated at varying densities 3000-5000 cells/well in 96-well plates depending on 
growth rate determined from routine cell culture passaging. Cells were allowed to attach 
overnight and treated with varying concentrations of the diterpene esters TPA or EBC-46 the 
following day. Cell survival was monitored daily and growth inhibition was determined by 
performing an SRB (Sulforhodamine B) or an MTS assay when control cells reached 80% 
confluency approximately 5-6 days after diterpene ester treatments. Absorbance was read at 
564 nm (for SRB assay) and 490 nm (for MTS assay) using ELISA plate reader (VERSA max 
microplate reader; Molecular Devices). Cell survival was plotted as % control absorbance 
versus dose. 
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Figure 3.8. Panel A   Bright-field images of control melanoma cells of human and mouse 
origin (Sk-Mel-28 and B16-F0 respectively). 
Sk-Mel-28 and B16-F0 cells were used to study the growth inhibitory effect of diterpene esters 
EBC-46 and TPA. The above bright-field images are of control cells i.e. untreated cells grown 
in culture media RPMI-1640 and cells treated with 0.1% Triton-X as a positive control. 
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Figure 3.8. Panel B   Bright-field images of melanoma cells of human and mouse origin 
(Sk-Mel-28 and B16-F0 respectively) treated with varying concentrations of EBC-46. 
Sk-Mel-28 and B16-F0 cells were used to study the growth inhibitory effect of high 
concentrations of EBC-46 (100 µg/ml and 200 µg/ml) over 30 min of incubation time. Arrows 
show examples of necrotic cells. 
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Figure 3.8. Panel C   Bright-field images of melanoma cells of human and mouse origin 
(Sk-Mel-28 and B16-F0 respectively) treated with varying concentrations of TPA. 
Sk-Mel-28 and B16-F0 cells were used to study the growth inhibitory effect of high 
concentrations of TPA (100 µg/ml and 200 µg/ml) over 30 min of incubation time. Arrows 
show examples of necrotic cells. 
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different concentrations of TPA or EBC-46 in media, across the plate so that each concentration in 
each treatment group was tested in quadruplicate. The drug concentrations ranged between 0.01 –10 
ng/ml. The cells were allowed to incubate for 4-5 days and were visually examined under a 
microscope daily for morphological changes. When control cells reached approximately 80% 
confluency, an SRB cell survival assay was performed. The results in Figure 3.9 on page 90 
confirmed that the cell lines over-expressing PKC were highly sensitive to TPA or EBC-46 
compared to the wild type cell line, the latter being cells expressing lacZ as a control. At doses 
greater than 0.1 ng/ml both Sk-Mel-28 and D04 were approximately 10-fold more sensitive to 
treatment, compared to the control cells expressing lacZ. At doses below 0.1 ng/ml, growth of D04 
cells was arrested, but no cell death was observed. 
 
3.3 Discussion 
Protein Kinase C rocketed to the forefront of cancer research, when it was identified as a target for 
phorbol esters. A widely researched phorbol ester is 12-O-tetradecanoyl-13-acetate (TPA) which 
has been obtained from latex of Croton tiglium L., a leafy shrub of the Euphorbia family native to 
Southeastern Asia (Zong and Thompson, 2006). A prototype PKC activator, TPA is known for its 
tumor promoting activity albeit in the presence of carcinogens (Blumberg, 1988, Mailloux et al., 
2001, Yuspa et al., 1979). In vitro studies of the biological effects of TPA on cells demonstrated a 
range of effects on tumor cells from the induction of bipolar morphology of MM96L melanoma 
cells to the induction of reactive oxygen species (Fisher and Morgan, 1994, Johnson et al., 2001, 
Hawkes et al., 2001) which are found to be characteristics of PKC activation. Another diterpene 
ester identified in this laboratory is the compound ingenol-3-angelate (PEP005), with similar 
biological properties as TPA and it is also an activator of PKC isozymes (Kedei et al., 2004). Not 
only has PEP005 been found to be toxic to cells in vitro but a high dose of the compound has 
resulted in ~ 80 % cure of subcutaneous tumors in mice via topical applications (Mailloux, 2001, 
Ogbourne et al., 2004).  
A novel short chain diterpene ester named EBC-46, has recently been extracted and purified from 
the kernels of the Blushwood plant. Elucidation of the chemical structure of EBC-46 revealed that it  
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Figure 3.9 Growth Inhibition Assays of Human Melanoma Cell Lines Over-Expressing PKC isoforms and Treated with Diterpene 
Esters TPA and EBC-46. 
Panel A: Melanoma cell line Sk-Mel-28 (human origin) over-expressing PKC-α and -δ 
Panel B: Melanoma cell lines D04 (human origin) over-expressing PKC-α and -δ 
Cells over-expressing PKC isoforms α and δ were plated at varying densities 3000-5000 cells/well in 96-well plates depending on growth rate 
determined from routine cell culture passaging. Cells were allowed to attach overnight and treated with varying concentrations of the diterpene 
esters TPA or EBC-46 the following day. Cell survival was monitored daily and growth inhibition was determined by performing an SRB 
(Sulforhodamine B) assay when control cells reached 80% confluency approximately 5-6 days after diterpene ester treatments. Absorbance 
was read at 564 nm using ELISA plate reader (VERSA max microplate reader; Molecular Devices). Cell survival was plotted as % control 
absorbance versus dose. 
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shared a similar backbone as TPA (see Introduction of Chapter Three) and hence it was 
hypothesized to share similar functional properties as TPA. 
The initial aim of this project was to determine the activity profile of EBC-46 in comparison to the 
well-researched PKC activator TPA, by comparing the ability and specificity of the diterpene esters 
to bind to and activate PKC isozymes and also compare the ability to induce oxidative burst which 
is a measurable consequence of PKC activation (Hafeman et al., 1982). 
3.3.1 Translocation of activated PKC isoforms by EBC-46 
PKCs are serine/threonine protein kinases which are present in an inactive state in the cytosol. To 
date there have been twelve isoforms identified which are categorized into four groups classical (α, 
β1, β2, and γ), novel (δ, ε, η, and θ), atypical (ι/λ, ζ) and distant PKCs (μ, ν), based on their sequence 
similarities and modes of activation (Chapter One: Section 1.2.1). Although the distant PKCs, 
PKC-µ and –ν, contain some similar certain common structural features that suggest they are 
members of the PKC family, they remain controversial. Activation of PKCs is brought about by the 
binding of DAG or phorbol esters in conjunction with Ca2+ facilitated by phosphorylations of the 
serine/threonine or tyrosine residues. These phosphorylations are essential for the priming and 
stabilization of the PKC isoforms. Once activated, the PKCs translocate to the plasma membrane or 
other membranous fractions (Newton, 1995, Newton, 1997). Similarly, diterpene esters such as 
TPA activate the conventional and novel PKC isoforms by forming hydrogen bonds with main-
chain groups thereby stabilizing the membrane-inserted state of PKC (Zhang et al., 1995). The 
conventional and novel PKCs with a C1 domain in their regulatory region are activated by DAG or 
phorbol esters and are known to subsequently translocate from the cytosol to membranous fractions 
(Castagna et al., 1982, Cartee et al., 2003). Hence, translocation of PKCs is a good marker of the 
enzyme activation. To visualize/measure this translocation, GFP-PKC fusion proteins were used 
which were described by Sakai and colleagues in 1997 (Karasavvas et al., 1996).  
The aim of this study was to confirm that EBC-46 is an activator of PKC by analyzing the 
translocation of the PKC isoforms upon treatment with EBC-46 and TPA. EGFP-tagged PKC 
isoforms were transiently transfected into HeLa cells and were subsequently treated with EBC-46 or 
TPA for 01 hr with doses ranging between 10 ng/ml – 100 ng/ml. The translocation of the PKC 
isoforms was determined by visual examination using the AMG EvosFL inverted fluorescence. 
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microscope. A hallmark of PKC activation is the translocation to membranous fractions (Oancea 
and Meyer, 1998, Karasavvas et al., 1996). The results in (Figure 3.3) demonstrated that EBC-46 
induced translocation of the conventional PKC isoforms that were tested, but not of novel PKC-θ. 
On the other hand, TPA induced translocation of both classical and novel PKC isoforms tested. As 
expected, both diterpene esters TPA and EBC-46 failed to induce translocation of the atypical PKC-
ζ which lacks the C1 DAG/phorbol ester binding domain. There were also differences noted in 
terms of potency of translocation and subcellular localization of the PKC isoforms. Classical PKC–
α and –γ were translocated from cytoplasm to plasma membrane by TPA, but not EBC-46 which led 
to translocation to nuclear or perinuclear regions. However, both TPA and EBC-46 resulted in very 
efficient translocation of classical PKCs -β1 and-β2 from the cytoplasm to the plasma membrane 
thus confirming the role of EBC-46 as a PKC activator and indicating its specificity for the β 
isoform. The differences in the subcellular localization of PKC isoforms may result in differences in 
substrate specificity thereby determining the downstream biological responses.  
3.3.2 Role of EBC-46 in activation of the MAPK pathway 
The hypothesis that EBC-46 is a PKC activator was further strengthened by immunodetection of 
proteins influenced by the activation of PKC. Once translocated to the membrane, the activated 
PKC phosphorylates substrates such as members of the mitogen-activated protein kinase family 
(MAPK) which play a vital role in growth inhibition (Aeschlimann and Hecker, 1967, Mason et al., 
2010). Activation of the MAPK pathway by TPA has been reported in several studies (Krumhaar 
and Hecker, 1967, Joppich et al., 1967). Hence the effects of EBC-46 in modulating the MAPK 
pathway were examined in comparison to TPA.  
As previously described, both classical and novel PKC isoforms share a common ligand for 
activation at the C1 domain in the form of 1,2-diacylglycerol (DAG). Phorbol esters with their 
unique configuration as tetracyclic diterpenes have a close structural relationship with DAG which 
gives them a high affinity for the PKC regulatory site. As seen in Figures 3.4 and 3.5 of the results, 
EBC-46 is specific for the PKC isoforms with a C1 domain which include the classical and novel 
PKC isoforms. The results show a vast reduction in the expression of total PKC levels within cancer 
cells as a direct result of diterpene ester exposure. 
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There have been several studies indicating the relationship between PKC isoforms and members of 
the MAPK pathway. PKC-β has been shown to activate ERKs in cardiac myocytes (Sugden and 
Clerk, 1998), PKC-δ has been shown to activate Ras in different cell lines (Kim et al., 2003, 
Krumhaar and Hecker, 1967, Shanmugam et al., 1998) and PKC-α and PKC-ε have been shown to 
directly phosphorylate Raf-1 (Cacace et al., 1996, Cai et al., 1997, Kolch et al., 1993). These results 
indicated that PKC activity is important in regulating the cell signaling through MAPK pathways. 
The pre-treatment of B16-F0 cells with BIS-1 greatly lowered the activation of MEK1/2 and 
ERK1/2 by EBC-46 and TPA (Figure 3.5) confirming that diterpene ester-induced PKC activation 
is responsible for activating the MAPK pathway. However, Sk-Mel-28 human melanoma cells 
appeared more resistant to the activity of BIS-1 suggesting the involvement of a different signaling 
pathway. To further explore this hypothesis, regulation of the other MAPK pathways such as 
JNK/p38 and PTEN need to be assessed. Studies with PEP005 have resulted in the activation of a 
variety of signaling pathways demonstrated by increased phosphorylation of PKC-δ, Raf1, MAPK 
molecules ERK1/2 and p38, c-Jun (NH)-2 terminal kinase and PTEN (Serova et al 2008). 
The western blot analysis identified that PKC isoforms also MEK1/2 and ERK1/2 were activated by 
6 hr of treatment with TPA or EBC-46. A time-course analysis of B16-F0 and Sk-Mel-28 cells 
revealed that the activation of ERK1/2 was short-lived with expression levels reducing steadily with 
time between 6 hr – 24 hr leading eventually loss of intracellular PKC.  
3.3.3 Induction of oxidative burst of neutrophils by EBC-46 
Neutrophils and macrophages are professional phagocytic cells that play an important role in 
defending the host against microorganisms by producing reactive oxygen species (ROS) via the 
NADPH oxidase enzyme complex. This process known as respiratory or oxidative burst involves 
generation of superoxide anion (O2
-) and hydrogen peroxide (H2O2) (Dahlgren and Karlsson, 1999, 
Dahlgren et al., 2007). The NADPH oxidase enzyme which is the primary catalyst for this process 
is a multicomponent enzyme comprising of four oxidase-specific proteins (p22 phox, p47 phox, p67 
phox, gp91phox) and GTPase (Rac1/2). Respiratory burst is a highly regulated process involving 
phosphorylation, translocation and multiple conformational changes (Quinn and Gauss, 2004). A 
number of soluble and particulate factors such as opsonized bacteria, platelet activating factor 
(PAF), complement component 5a, diacylglycerol (DAG) and PKC activators such as TPA can 
stimulate NADPH oxidase in phagocytes. Protein phosphorylation and subsequent translocation of 
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cytosolic components to the plasma membrane are required to facilitate the phosphorylation of key 
components of the NADPH oxidase complex (Walker et al., 1991). 
The NADPH oxidase system has been mainly studied in neutrophils (el Benna et al., 1994, Uhlinger 
et al., 1993). The results in Figure 3.6 showed that both TPA and EBC-46 induced the production of 
reactive oxygen species in neutrophils in a dose-dependent manner. Both compounds were found to 
be equally potent in the induction of oxidative burst of human neutrophils. Pre-treating neutrophils 
with the PKC inhibitor BIS-1 followed by co-treatment with TPA or EBC-46 resulted in a complete 
reduction in the diterpene ester-induced production of ROS by neutrophils (Figure 3.6) thereby 
confirming the role of PKC activation in the process. The results are in accordance with several 
studies on the effect of PKC isoforms in inducing respiratory burst that have demonstrated the PKC 
isoforms to play a vital role in the phosphorylation of p47 phox (Dang et al., 2001, Fontayne et al., 
2002, Zoellner et al., 1996, Reeves et al., 1999). Conversely, compounds that inhibit PKC were 
shown to prevent the respiratory burst (Dekker et al., 2000, Kramer et al., 1989).  
3.3.4 EBC-46 Inhibits Growth in Melanoma cells in a manner similar to TPA 
EBC-46 shares not only structural similarities with this prototypic PKC activator, it has also been 
found to induce respiratory burst in neutrophils via a PKC-dependent process with equal potency as 
TPA. On the other hand, translocation of individual isoforms in response to treatment with TPA or 
EBC-46 resulted in differences with respect to isoform-specific potency as well as 
compartmentalization of the activated isoforms. As a result, it was thought that this unique PKC 
activity in response to diterpene ester stimulation could account for differences in potency in a 
biological setting.  
TPA has the ability to induce permanent senescence in a subset of melanoma cell lines (Cozzi et al., 
2006). In vitro cytotoxicity studies were performed to compare the cytotoxicity profile of TPA and 
EBC-46 on different tumor cell lines. With the similarities it shares with TPA, it was hypothesized 
that EBC-46 would affect tumor cells in a similar manner as TPA. The cells were treated with either 
diterpene ester, TPA or EBC-46 at varying concentrations alongside control untreated cells. An 
initial visual examination followed by protein estimation assay revealed that the different cell lines 
responded differently to treatment with TPA or EBC-46. This could be due to the differences in cell 
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type i.e. origin of tumor cells, growth rates of the different lines and sensitivity or resistance of the 
cells to the drug.  
As seen in the results of the growth inhibition assays an IC50 of 30 µg/ml and greater of EBC46 was 
required to induce a cytotoxic effect on tumor cells B16-F0 and Sk-Mel-28 in vitro. The cytotoxic 
effect of EBC-46 on the sensitive cell lines was demonstrated at doses as low as 10 ng/ml which 
was about 10-fold lower than TPA (Figure 3.7). The different cell lines responded differently to 
treatment with TPA or EBC-46. This could be due to the differences in cell type i.e. origin of tumor 
cells, growth rates of the different lines and sensitivity or resistance of the cells to the drug. For 
instance, A549 is a lung cancer cell line while K562 is a leukemic cell line, both of human origin. 
Compared to K562 which are a non-adherent, suspension cell line and hence grown in U-bottom 
well plates, A549 though sensitive to diterpene ester treatments (as seen in preliminary experiments; 
data not shown), are a more resistant cell line than K562. Also TPA in vitro is seen to be more toxic 
than EBC-46.  
Differences were also observed between the two compounds EBC-46 and TPA with respect to 
concentration and time of treatment. Growth inhibition potential of EBC-46 and TPA was assessed 
using SRB or MTS stains for cell survival or proliferation where the drug concentrations were 
maintained lower than 100 µg/ml and cells at densities ranging between 3,000 – 5,000 cells/well 
were treated for 5-6 days. In contrast, images in Figure 3.8 show melanoma cell lines Sk-Mel-28 
and TPA plated at higher cell densities of 10,000 cells/well treated in vitro with high concentrations 
of either EBC-46 or TPA (100 µg/ml or 200 µg/ml; which were equivalent to doses administered in 
vivo) and were treated for 30 min. Over a short treatment time, lower concentrations of the 
diterpene esters led to apoptosis identified by blebbing and cell shrinkage while treatment with 
higher concentrations for the same time resulted in necrotic cells (red arrows in Figure 3.8). 
Propidium Iodide assays have been performed on these treated cells and images shown in Figure 
4.12 of Chapter Four. These results are in parallel with that observed in vitro on cells treated with 
the diterpene esters long-term for 5-6 days. However, where a long-term assay renders TPA more 
potent than EBC-46, treatment of tumor cells with the diterpene esters for 30 min shows EBC-46 to 
work faster to achieve cell death than TPA. The differences in the effects of EBC-46 and TPA on 
the different cell lines can be attributed to a number of factors including toxicity of the compounds, 
the cellular pathways they recruit and time of exposure to cancer cells. In addition, apart from the 
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potency of the compound in vivo, there is also a host response that supports the total ablation of 
tumors by EBC-46 (explained in Chapters Four and Five). 
3.3.5 Over-expression of PKC Isoforms increases sensitivity to diterpene ester treatment 
This Chapter has also examined the effects of over-expression of two PKC isoforms, PKC-α and 
PKC-δ, on the sensitivity of melanoma cells to growth inhibition by phorbol ester treatment in 
comparison to the control lacZ. These two isoforms were selected as they are widely recognized as 
key targets of this class of drug although future work will investigate other isoforms of PKC as 
well. In addition to the PKC-α and –δ over-expressed isoforms, the control lacZ in Figure 3.9 also 
demonstrated increased sensitivity compared to parent cell lines in Figure 3.7. This could probably 
be due to increased cell fragility as a result of the lentiviral transfection process. However, a 
comparison of over-expressed PKC-α and PKC-δ  to the control lacZ were shown to increase 
sensitivity of two resistant melanoma cell lines SK-Mel-28 and D04 to growth inhibition by TPA 
and EBC-46.  
While this work provides additional evidence that EBC-46 activates the classical and novel classes 
of PKC isoforms, the effect of pan-PKC inhibitor BIS-1 on cells over-expressing PKC isoforms 
needs to be investigated to substantiate the role of PKC on sensitivity of the diterpene esters. The 
involvement of PKC isoforms in the mechanism of action of EBC-46 could be studied by reducing 
the expression of individual isoforms to show decreased killing. However, the absence of critical 
isoforms such as PKC-α and –β in tumor cells implies that a knock down would not be useful to 
probe mechanism which is likely a result of the host response to the compound as shown in 
Chapters Four and Five.  
To reiterate other significant evidences of PKC activation by EBC-46 which have been presented in 
the course of this Chapter, the diterpene ester EBC-46 has been shown to translocate PKC isoforms 
to the plasma membrane with specificity for classical and novel isoforms of PKC when compared to 
the prototype PKC activator, TPA (shown in Figures 3.2 and 3.3). Activated PKC is known to 
participate in downstream signaling pathways such as the MAPK pathways including ERK1/2, p38, 
JNK signaling pathways which play a role in cellular growth, differentiation and apoptosis (Serova 
et al., 2008). Pre-treatment of melanoma cells B16-F0 and Sk-Mel-28 with the pan-PKC inhibitor 
BIS-1 resulted in lowered activation to almost complete inhibition of MAPK molecules MEK1/2 
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and ERK1/2 as shown in Figure 3.5. Another characteristic of PKC activation is the induction of 
oxidative stress as a result of increased production of reactive oxygen species (ROS) which was 
observed upon treatment of neutrophils with EBC-46 in comparison with TPA in Figure 3.6. TPA 
has been shown to stimulate neutrophils to produce ROS and consequently lead to accelerated 
apoptosis (Lundqvist-Gustafsson and Bengtsson, 1999). Over-expression of PKC isoforms α and δ 
in tumor cells resulted in increased sensitivity to growth inhibition with EBC-46 although less 
significantly as expected (Figure 3.9). 
The results presented in this Chapter support EBC-46 as being an activator of PKC isoforms and 
resulting in the phosphorylation of ERK1/2 in the MAPK pathway. Although structurally similar to 
TPA and sharing the same biological functions there were differences observed between EBC-46 
and TPA. Both EBC-46 and TPA have a cytotoxic effect on tumor cell growth in vitro, however, 
EBC-46 is not as potent as TPA. Differences were observed between the two diterpene esters on 
different cell lines in cell survival assays, specificity to and translocation of PKC isoforms and 
protein analysis via western blots. As mentioned earlier in the discussion, the reason for these 
differences in the effects of EBC-46 and TPA could be due to a number of factors including toxicity 
of the compounds, the cellular pathways they recruit and time of exposure to cancer cells. To 
further investigate the co-dependence of EBC-46 on host specific aspects, the following Chapter 
will address the potential anti-tumor activity and efficacy of EBC-46 in pre-clinical models of 
cancer. 
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4.1  Introduction 
From the previous Chapter it has been established that the novel diterpene ester EBC-46, is a potent 
PKC activator. Similar to the prototypic PKC activator, TPA, it was shown to induce translocation 
of PKC to the plasma membrane and other subcellular organelles facilitating its participation in 
downstream cellular signaling pathways. TPA, although labeled as a tumor-promoter in 
carcinogenic experiments performed on normal mouse skin and xenografts of human foreskins with 
carcinogens such as urethane (Yuspa et al., 1979), it has also been established to induce cytostatic 
and cytotoxic effects on cancer cells (Hofmann, 2001). 
Previous studies of PKC-activating compounds utilized as localized therapeutics in vivo have been 
limited primarily to topical application of PEP005 in gels to subcutaneous tumors in mice (Li et al., 
2010, Ogbourne et al., 2004). The anticancer activity of PEP005 in vivo has been demonstrated on 
B16-F0 melanoma, LK2 UV-induced SCC, Lewis lung carcinoma and D04 human melanoma 
grown subcutaneously in C57BL/6J or BALB/c Foxn1nu mice and treated with three daily topical 
applications (Gillespie et al., 2004, Ogbourne et al., 2004). In one study (Le et al., 2009), PEP005 
was reported to induce a systemic immunostimulatory response and regress metastasis. 
Surgery and radiation are the mainstays of local treatment of tumors but are limited with respect to 
efficiency, inaccessibility and intolerance for repeated courses of treatment. There is need for new 
and improved forms of local therapy. The concept of intralesional or intratumoral therapy is to let 
the drug pass the barrier zone and establish a sub-epidermal depot, thus, allowing a higher 
concentration of the drug to act on the tumor. This mode of treatment eliminates the need for long-
term topical medications, coupled with the fact that it works deep into the tissue where topical 
applications may not penetrate. 
Pilot experiments at QIMR Berghofer had shown that intratumoral injection of EBC-46, a novel 
diterpene ester dissolved in 90% PEG400, ablated B16-F0 tumors in C57BL/6 mice. However, with 
the realization that aqueous propylene glycol (PG) was a more suitable excipient for eventual 
clinical use it was desirable to confirm the initial findings from PEG400 and extend the scope of 
EBC-46 efficacy to other mouse tumor models. Optimization of drug delivery was important to be 
achieved not only for future use but also to improve reproducibility in studying the mechanism of 
action in vivo.  
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In this Chapter, the biological response and efficiency of EBC-46 in vivo on different tumor models 
was be investigated. From these studies we aimed to (i) optimize the intratumoral delivery and dose 
response of EBC-46 in 20% PG, (ii) compare the efficacy of EBC-46 with that of the prototype 
PKC activator, TPA, (iii) determine whether ectopic expression of PKC isoforms in tumor cells 
improved efficacy of EBC-46 and (iv) determine the efficacy of EBC-46 on different tumor models, 
melanomas and non-skin cancers. 
 
4.2  Results 
4.2.1  Comparison of the efficacies of EBC-46 and TPA for treatment of tumors in mice 
All mouse experiments were conducted with the approval of the QIMR Berghofer Animal Ethics 
Committee, in Project P345. TPA was compared to EBC-46 in vivo to test its efficacy in curing 
C57BL/6 mice of B16-F0 tumors. Preliminary work in this laboratory had determined a range of 
doses of EBC-46 that induced a positive response in ablation of tumors in mice which ranged from 
30 µg to 135 µg (personal communication Prof. Peter Parsons). Hence, an initial dose of 30 µg of 
TPA or EBC-46 was used in this study to compare the efficacies of the two compounds. A total of 
thirty mice were included in this study, which were divided into three groups of ten mice each 
group. B16-F0 tumor cells at 5 x 105 cells in a volume of 50 µl were injected in the bilateral flanks 
of all C57BL/6J mice. Upon growth of tumors to approximately 100 mm3, two tumors on each 
mouse were treated with either 50 µl of the vehicle control 20% PG, 50 μl of 600 μg/ml of TPA or 
EBC-46 for a final dose of 30 μg per tumor. The day of treatment of tumors was recorded as day 0. 
Mice were regularly monitored, tumor sizes measured and animals euthanized when the total tumor 
burden reached 1000 mm3. The mouse tumors were measured using digital calipers and following 
the calculation chart in Appendix Table 1 titled “Monitoring of Tumor Bearing Mice”. Data 
obtained from this experiment were used to compare the efficacies of EBC-46 with that of TPA at 
30 µg per tumor. 
The control mice treated with 20% PG were euthanized by day 4 due to the volume of the tumors 
(Figure. 4.1). Among the treatment groups, all of the tumors initially treated with 30 μg of TPA per 
tumor gradually relapsed after treatment as a result of which all the mice in the TPA treatment 
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group were culled by day 20 due to excessive tumor burden. Whereas tumors that received a dose of 
30 μg of EBC-46 per tumor resulted in a cure of 75 % of the tumors with 15 cures among the 20 
tumors which were treated (Figure. 4.1). Recurrences were observed at 5 of the treated sites while 
there were no recurrences recorded among the 15 cures over the remainder of a 62-day monitoring 
period. Some of the failures in the EBC-46 treatment group may have been due to deeper tumors 
below the skin, growing in the muscle. This may have resulted at the time of inoculation when the 
B16-F0 tumor cells were inadvertently injected deeper under the skin instead of intradermally, 
hence would have required a deeper penetration of the drug.  
Plots of individual tumor volume (Figure. 4.2) showed considerable variation, becoming more 
pronounced as some treated tumors recurred. This meant that having 2 tumors per mouse to 
minimize the number of animals required, led to some mice being euthanized with 1 recurrence and 
one potentially cured site, thus underestimating the Kaplan-Meier-based survival. 
4.2.2   Dose response for efficacy of EBC-46 on mouse tumors 
All mouse experiments were conducted with the approval of the QIMR Berghofer Animal Ethics 
Committee, in Project P345. Using preliminary in vivo results as reference, the previous study 
(Section 4.2.1) on the comparison of the efficacies of TPA and EBC-46 used 30 µg of either 
compounds to treat B16-F0 tumors in C57BL/6J mice.  
The dose response for efficacy of EBC-46 on B16-F0 tumors in C57BL/6J mice was further 
investigated to determine a baseline concentration for in vivo activity of EBC-46 in killing tumor 
cells. Thirty C57BL/6J mice were divided into groups of ten mice each and subcutaneously injected 
with B16-F0 tumor cells at 5 x 105 cells in a volume of 50 µl at 2 sites on the hind quarter of each 
mouse. Upon growth of tumors to approximately 100 mm3, two tumors on each mouse were treated 
with either 50 µl of the vehicle control 20% PG, 50 μl of 200 μg/ml of EBC-46 for a final dose of 
10 μg per tumor or 50 µl of 600 µg/ml of EBC-46 for 30 µg final doses per tumor. Mice were 
monitored regularly and tumor sizes measured. Mice were euthanized when the total tumor size per 
mouse reached 1000 mm3. Data recorded from the above treatments were organized to investigate 
the optimal dose response for the efficacy of EBC-46 in mice. 
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Figure 4.1  Kaplan-Meier plot comparing the differences in efficacy between TPA 
and EBC-46 on the survival of male C57BL/6J mice treated for B16-F0 tumors. 
B16-F0 mouse melanoma cells (5 x 105 cells/site) were inoculated subcutaneously into 
C57BL/6J mice in a volume of 50 µl per site with 10 mice per group and 2 sites per mouse. 
Upon growth to 100 mm3, the tumors were treated with a single intratumoral injection of 50 
µl of 600 µg/ml EBC-46 in 20% PG for a final concentration of 30 µg/tumor (green line) and 
50 µl of 600 µg/ml of TPA in 20% PG for a final of 30 µg/tumor (red line). These treatment 
groups were compared to mice treated with the vehicle control 20% PG (black line). Data 
was plotted in GraphPad Prism 6 and the p value was calculated to be less than 0.0001 for 
the two treatment groups (EBC-46 and TPA) compared to vehicle alone treatment (Log-rank 
(Mantel-Cox) test). TPA versus EBC-46 curves p=0.0004. 
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Figure 4.2  Tumor volume of B16-F0 tumors in C57BL/6J mice treated with diterpene 
esters TPA (■; red line) or EBC-46 (▼; green line) and compared to treatment with 20% 
PG (●; black line) vehicle control. 
B16-F0 cells were inoculated subcutaneously at two sites on the flanks of C57BL/6J mice at 5 
x 105 cells per site. Tumors were treated with 50 µl of 600 µg/ml of TPA or EBC-46 for a final 
dose of 30 µg per tumor. The controls included mice that had received an intratumoral 
injection of 50 µl of the vehicle control 20% PG. Tumor growth was measured in mm3 and 
plotted against time as day of euthanasia. Day 0 denotes the day of intratumoral delivery of the 
respective treatment and the subsequent numbers indicate the days post treatment. 
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The Kaplan-Meier plot for survival (number of days after treatment to euthanasia) in Figure 4.3 
shows that all of the 10 control mice (2 tumors per mouse), which had received injections of 50 µl 
of 20% propylene glycol (PG), were culled by day 4 due to tumor burden. Among the EBC-46 dose 
treatments, the 10 µg dose did not result in any cure as all mice had developed recurrences and were 
culled by day 25 due to tumor burden. In contrast, the 30 µg dosed mice fared much better, with 
cure of 75 – 80 % of tumors. Henceforth, treatments were carried out with 50 μl of 600 μg/ml EBC-
46 in 20% PG; a 30 μg dose per tumor. 
The initial major reaction of the mouse to intratumoral injection of EBC-46 or TPA was 
inflammation at the site, seen as an almost immediate reddening of the overlying skin, followed 
within 4-8 hr by flattening of the raised tumor and development of a bruised appearance. The 
inflamed region developed into a scab with the onset of necrosis at the site of inflammation. The PG 
vehicle alone on the other hand had little effect, except for a slight swelling of the tumor which 
subsided within 4 hr. Photographs of C57BL/6J mice with B16-F0 tumors (treated when about 100 
mm3 in size) taken over a 2-month observation period (Figure 4.4) showed indurations covering the 
area of inflammation by 5 days after treatment with EBC-46. This resolved over the next 14 days 
resulting in long-term healing with minimum scarring. No adverse clinical effects were observed in 
the treated mice and normal weight and activity were maintained. 
4.2.3  Effect of tumor cell inoculation volume on efficacy of EBC-46 
The success of local, intratumoral therapy may depend on a number of factors, the area of viable 
tumor in relation to the injection volume, being one. Varying volumes containing the same number 
of B16-F0 mouse melanoma cells were therefore injected subcutaneously into the hind quarter of 
C57BL/6 immunocompetent mice. This was done to assess the volume/concentration of the drug 
required to ablate tumors of varying inoculation densities. Three different tumor cell inoculation 
volumes were prepared; 25 µl, 50 µl and 100 µl, each containing a total of 5 x 105 B16-F0 tumor 
cells per site, injected subcutaneously into mice with 20 mice per group and 2 tumors per mouse. 
These 20 mice were further divided into 10 in the control group and the other 10 in the treatment 
group with EBC-46. 
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Figure 4.3  Kaplan-Meier plot for dose response of EBC-46 on survival of male 
C57BL/6J mice with B16-F0 tumors. P values <0.0001 showed significance compared with 
vehicle. 
B16-F0 mouse melanoma cells (5 x 105 cells/site) were inoculated subcutaneously into 
C57BL/6J mice in a volume of 50 µl per site with 10 mice per group and 2 sites per mouse. 
Upon growth of tumors to 100 mm3, were treated with single intratumoral injection of 50 µl of 
200 µg/ml EBC-46 in 20% PG for a final concentration of 10 µg/tumor (blue line) and 50 µl of 
600 µg/ml of EBC-46 in 20% PG for a final of 30 µg/tumor (red line). These treatment groups 
were compared to mice treated with the vehicle control 20% PG (black line). Data was plotted 
in GraphPad Prism 6 and p value was calculated to be less than 0.0001 for the two treatment 
groups (10 µg and 30 µg of EBC-46; Log-rank (Mantel-Cox) test). 
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Figure 4.4  Serial photographs of male C57BL/6J mice with B16-F0 mouse melanomas 
prior to and following treatment with a final of 30 µg/tumor of EBC-46.  
C57BL/6J immunocompetent mice were inoculated with B16-F0 mouse melanoma cells 
subcutaneously at 5 x 105 cells per site. Tumors were grown to approximately 100 mm3, then 
treated with a single intratumoral injection of 50 µl of 600 µg/ml of EBC-46 in 20% PG for a 
final concentration per tumor of 30 µg. Mice were monitored daily for the first week following 
treatment, thereafter periodically three times a week. Mice were weighed and tumor sizes 
measured regularly. 
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In the first group (Figure 4.5.A), all the 10 control mice treated with 20% PG per tumor, were culled 
by day 7 due to tumor burden whereas the treatment with 30 µg of EBC-46 resulted in a 30% cure 
among the 20 tumors treated with 3 mice surviving tumor-free. The second group included mice 
inoculated with 5 x 105 tumor cells inoculated in 50 µl volume (Figure 4.5.B). In this group, the 10 
mice treated with the vehicle (50 µl of 20% PG per tumor) were euthanized by day 4 as a result of 
tumor sizes. While treatment with 600 µg/ml of EBC-46 (50 µl for a final dose of 30 µg per tumor) 
fared much better with complete ablation of tumors in 5 mice of the 10 treated and no recurrence up 
to day 60 post-treatment. From the results, it was apparent that a 100 µl cell inoculation was too 
dilute to respond favorably to the optimal dose and volume of injection of EBC-46 as achieved in 
the first part of this experiment (see Section 4.2.2.) While the control mice were all culled by day 11 
post-treatment, mice that received an EBC-46 treatment had developed recurrences with all of the 
mice being culled by day 46 due to tumor burden (Figure 4.5.C). 
4.2.4 Efficacy of EBC-46 against B16-F0 tumors over-expressing PKC isoforms α and δ 
versus lacZ control 
Since over-expression of PKC isoforms made melanoma cells Sk-Mel-28 and D04 sensitive to 
killing by EBC-46 in culture compared to the parent cell lines (Chapter Three; Section 3.2.4), the 
efficacy of EBC-46 on tumors over-expressing these PKC isoforms (α and δ) was compared in B16-
F0 cells containing empty plasmid (lacZ). B16-F0 cells at 5 x 105 cells/site over-expressing PKC-α 
or PKC-δ or the control lacZ were inoculated into mice subcutaneously in 25 µl (Figure 4.6) or 100 
µl inoculation (Figure 4.7) in culture medium using 20 mice per cell type. Mice were further sub-
grouped into control and treated, with 10 mice in each group treated with 50 µl of either 20% PG or 
30 µg of EBC-46 at 2 tumor sites per mouse. 
In both experiments, all of the vehicle-treated mice (20% PG) were culled between days 4 – 7. In 
the EBC-46 treatment group from the 25 µl inoculum (Figure 4.6), mice carrying B16-F0 with lacZ 
control tumors gradually recurred and were all culled by day 25, while there was a 60% and 40% 
survival among the mice with B16-F0 tumors over-expressing PKC-α and -δ respectively. The p 
value was calculated at <0.01 for both the PKC isoforms in Prism. (Log-rank (Mantel-Cox) test). 
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Figure 4.5 Kaplan-Meier survival plots of male C57BL/6J mice with varying volumes 
of B16-F0 tumor cell inoculums treated with 50 µl of 600 µg/ml EBC-46 per tumor. Each 
experimental group consisted of 20 mice; 10 as controls and 10 as treatments. 
A. 5 x 105 B16-F0 tumor cells in a total of 25 µl volumes were inoculated into bilateral 
flanks of twenty C57BL/6J mice and treated with 50 µl of 600 µg/ml of EBC-46 or 
50 µl of 20% PG vehicle control. 
B. 5 x 105 B16-F0 tumor cells in a total of 50 µl volumes were inoculated into bilateral 
flanks of twenty C57BL/6J mice and treated with 50 µl of 600 µg/ml of EBC-46 or 
50 µl of 20% PG vehicle control. 
C. 5 x 105 B16-F0 tumor cells in a total of 100 µl volumes were inoculated into 
bilateral flanks of twenty C57BL/6J mice and treated with 50 µl of 600 µg/ml of 
EBC-46 or 50 µl of 20% PG vehicle control. 
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Figure 4.6  Efficacy of EBC-46 in B16-F0 tumors over-expressing a PKC isoform 
compared with an empty vector control cell line (cells inoculated in 25 µl volumes)  
A:  5 x 105 B16-F0 tumor cells expressing lacZ vector control in a total of 25 µl volume 
were inoculated into bilateral flanks of twenty C57BL/6J mice and treated with 50 µl of 600 
µg/ml of EBC-46 or 50 µl of 20% PG vehicle control. 
B:  5 x 105 B16-F0 tumor cells expressing PKC α in a total of 25 µl volume were inoculated 
into bilateral flanks of twenty C57BL/6J mice and treated with 50 µl of 600 µg/ml of EBC-46 
or 50 µl of 20% PG vehicle control. 
C: 5 x 105 B16-F0 tumor cells expressing PKC δ in a total of 25 µl volume, were 
inoculated into bilateral flanks of twenty C57BL/6J mice and treated with 50 µl of 600 µg/ml of 
EBC-46 or 50 µl of 20% PG vehicle control. 
B16-F0 tumors over-expressing PKC isoforms α or δ or the empty vector control lacZ were 
inoculated into the bilateral flanks of male C57BL/6J mice at 5 x 105 cells per 25 µl of cell 
suspension. 10 mice were used per experimental group. When tumors had grown to 
approximately 100 mm3 in volume, treatment with 50 µl of 600 µg/ml of EBC-46 (red line) or 
50 µl of 20% PG vehicle control (black line) was carried out. Tumors were regularly monitored 
and tumor volumes measured and recorded. When total tumor burden reached 1000 mm3, mice 
were euthanized. P values determined using a Log-rank (Mantel-Cox) test. 
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Figure 4.7  Efficacy of EBC-46 on B16-F0 tumors over-expressing a PKC isoform 
compared with an empty vector control cell line (cells inoculated in a volume of 100 µl) 
A:  5 x 105 B16-F0 tumor cells expressing lacZ vector control in a total of 100 µl volume 
were inoculated into bilateral flanks of twenty C57BL/6J mice and treated with 50 µl of 600 
µg/ml of EBC-46 or 50 µl of 20% PG vehicle control. 
B:  5 x 105 B16-F0 tumor cells expressing PKC-α in a total of 100 µl volume were 
inoculated into bilateral flanks of twenty C57BL/6J mice and treated with 50 µl of 600 µg/ml 
of EBC-46 or 50 µl of 20% PG vehicle control. 
C:  5 x 105 B16-F0 tumor cells expressing PKC-δ in a total of 100 µl volume were 
inoculated into bilateral flanks of twenty C57BL/6J mice and treated with 50 µl of 600 µg/ml 
of EBC-46 or 50 µl of 20% PG vehicle control. 
B16-F0 tumors over-expressing PKC isoforms -α or -δ or the empty vector control lacZ were 
inoculated into the bilateral flanks of C57BL/6J mice at 5 x 105 cells per 100 µl of cell 
suspension. 10 mice were used per experimental group. When tumors had grown to 
approximately 100 mm3 in volume, treatment with 50 µl of 600 µg/ml of EBC-46 (red line) or 
50 µl of 20% PG vehicle control (black line) was carried out. Tumors were regularly monitored 
and tumor volumes measured and recorded. When total tumor burden reached 1000 mm3, mice 
were euthanized. P values determined using a Log-rank (Mantel-Cox) test. 
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As seen in Figure 4.7, tumors grown from a larger inoculation volume of all three B16-F0 sub-lines 
responded positively to EBC-46 treatment but resulted in recurrences and no cures were obtained.  
These recurrences at previously treated tumor sites were most likely residual disease left untreated 
due to the larger volume of the inoculum. Similarly B16-F0 cells over-expressing PKC isoforms –α 
and -δ, injected in a volume of 100 µl of 5 x 105 tumor cells/ml did not respond well to treatment 
with 600 µg/ml of EBC-46. There were relapses recorded among the tumors over-expressing PKC-
α and -δ with mice culled by days 26 and 46 respectively. 
 
4.2.5  Efficacy of EBC-46 on Sk-Mel-28 human melanoma xenografts 
A human melanoma model Sk-Mel-28 was used to test the efficacy of EBC-46 in xenografts in 
BALB/c Foxn1nu mice. These are athymic mice which according to the name lack the thymus that 
produces T cells and thus test the efficacy of EBC-46 in immunocompromised animals. 
Sk-Mel-28 xenografts inoculated subcutaneously at 2 x 106 cells/site in the flanks of BALB/c 
Foxn1nu mice (6 mice in control group with 7 tumors total and 7 mice in the treatment group with 
17 tumors in total). In the control group, mice treated with 20% PG were all culled by day 25 as a 
result of tumor burden (Figure 4.8). The discrepancy in the number of tumors per mouse may be a 
result of the nature of the cell type. Sk-Mel-28 cells are not as proliferative as the B16-F0 cells and 
are slower growing. Of the 17 tumors in the group treated with 30 µg of EBC-46 per tumor there 
were 15 cures (Figure 4.8.A). These results were reflected in measurements of tumor size (Figure 
4.8.A). The total loss of tumor volume 24 hr after treatment can be seen in the plot for treated cells. 
The early effects at the injected tumor site were seen more clearly in this nude mouse model than in 
the C57BL/6 mice: immediate inflammation and a notable bruised appearance at 4 hr (Figure 4.9). 
By day 13 the inflammatory region encompassing the tumor site and the skin around the perimeter 
developed into an eschar that detached by day 20. The mice were monitored for a period of 40 days 
post treatment over which there were no recurrences recorded. 
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Figure 4.8  Efficacy of EBC-46 in treating Sk-Mel-28 human metastatic melanomas in 
male BALB/c Foxn1nu (nude) mice. 
A. Kaplan-Meier plot of survival of BALB/c Foxn1nu (nude) mice treated with 30 µg 
of EBC-46 (red line) for subcutaneous Sk-Mel-28 tumor growth (2 x 106 cells/site) 
and compared to the vehicle control 20% PG (black line). (Log-rank (Mantel-Cox) 
test). 
B. Tumor volumes of SK-Mel-28 human metastatic melanomas in BALB/c Foxn1nu 
(nude) mice following treatment with EBC-46 at a final dose of 30 µg per tumor 
(red line) in comparison to treatment with the vehicle control 20% PG (black line). 
A total of 6 mice with 7 tumors were included in the control group while there were 7 mice 
with 17 tumors in the treated in this experiment. The discrepancy in the number of tumors per 
mouse may be a result of the nature of the cell type. 
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Figure 4.9  Photographs of male BALB/c Foxn1nu (nude) mice with Sk-Mel-28 
tumors treated with EBC-46. 
BALB/c Foxn1nu (nude) mice were transplanted with Sk-Mel-28 tumor cells subcutaneously 
in their bilateral flanks. Tumors were treated with EBC-46 at a final concentration of 30 µg 
per tumor and compared to control mice treated with the vehicle control 20% PG. Digital 
photographs were taken starting on the day of intratumoral delivery of EBC-46 or vehicle 
control. 
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4.2.6 Effect of EBC-46 on non-melanoma tumors in vivo: 
The in vitro efficacy of EBC-46 had been tested beyond melanomas including lung cancers and 
leukemia cell lines (Chapter Three; Section 3.2.3) resulting in killing tumor cells. The results were 
extended to non-melanoma tumors in vivo where the efficacy of EBC-46 in ablating MC38 tumors 
in mice was tested.  
MC38 mouse colon tumors were grown in C57BL/6J mice by subcutaneous injection of MC38 cells 
(5 x 105 cells per site) and treated with a single intralesional injection of EBC-46. Treatment with 
30 µg of EBC-46 led a rapid ablation of tumors, compared to the control tumors treated with 
vehicle only (20% propylene glycol). The survival curve in Figure 4.10.A shows that all control 
mice (black line) treated with 20% PG had to be culled by day 12 due to overall tumor burden. In 
contrast, MC38 tumors treated with 30 µg per tumor EBC-46 resulted in total ablation of 8 out of 10 
tumors. Among the tumors treated with EBC-46 there were only 2 recurrences rising individually 
on 2 mice which had to eventually be euthanized by day 20 due to tumor burden. In the 49 day 
observation period following treatment there were no recurrences at the 8 cured sites (Figure 4.10).  
4.2.7 Ex Vivo clonogenic survival of tumor cells following treatment with EBC-46 
The rapid and dramatic changes in visual appearance of the tumor sites following injection of EBC-
46 prompted an investigation of how quickly viable, clonogenic tumor cells were being destroyed. 
This was conducted by removing tumors at early times after treatment, dispersal into culture and 
determination of clonogenic survival. 
Microscopic inspection of cultures from tumors harvested from mice and dispersed in culture 
showed many granular, non-adherent and presumably dead cells within 1 hr after the in vivo 
treatment. This was confirmed by a clonogenic-type survival assay, in which ex vivo cultures were 
allowed to grow for 5-6 days to assess growth of the surviving cells. All tumor cells were destroyed 
by 4 hr after treatment with EBC-46 (Figure 4.11). Cells began to lose their viability as early as 1 hr 
after treatment, indicated by long term growth of 40% compared to cells from control tumors 
treated with 20% PG. Vehicle injected in vivo had very little effect on ex vivo clonogenicity 
compared with tumors not treated at all (results not shown). 
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Figure 4.10  Efficacy of EBC-46 on MC38, mouse colon cancer 
MC38 mouse colon tumors were grown subcutaneously in C57BL/6J mice on their bilateral 
flanks. When tumors had grown to approximately 100 mm3, tumors were treated with 50 µl 
of 30 µg of EBC-46 per tumor or 50 µl of 20% PG vehicle control. Tumors were regularly 
monitored and volumes measured and recorded. P values determined using a Log-rank 
(Mantel-Cox) test. 
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Figure 4.11  Clonogenic survival of Sk-Mel-28 tumor cells destroyed by 4 hr after 
treatment with EBC-46 
Sk-Mel-28 tumors were treated in vivo in BALB/c Foxn1nu (nude) mice with either 50 µl of 
600 µg/ml of EBC-46 in 20% PG or 50 µl of 20% PG vehicle control. Tumors were excised at 
different times following treatment and the cells recovered back into culture media in vitro in 
serial dilutions. Plates were incubated at 37˚C and reviewed daily. After 4-5 days, when 
control cells reached a confluency of ~70%, a cell survival assay was performed using the SRB 
dye to stain and the plate was read at 564 nm using an ELISA plate reader. 
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4.2.8 Rapid killing of tumor cells in culture with high dose EBC-46: detection of necrosis by 
uptake of propidium iodide 
To determine whether the rapid, high-dose killing of tumor cells inferred from the above ex vivo 
scenario could be reproduced away from the host context in vitro, a growth inhibition assay using 
propidium iodide was carried out in vitro using a high EBC-46 concentration range, similar to the 
600 µg/ml injected concentration. Propidium iodide (PI) intercalates with DNA and causes nuclei 
and fragmented nuclei to become strongly fluorescent. PI is membrane impermeant and is excluded 
from viable cells. It can therefore be used to detect cell death associated with disruption of the 
plasma membrane, allowing ingress of charged molecules. This includes primary or secondary 
necrosis of cells, as well as apoptosis where fragmented nuclei will be seen. In this assay, cells were 
plated at a high density to mimic the in vivo scenario where tumor cells are present at high density 
within the tumor capsule. It was not possible to reproduce exactly the drug delivery method used in 
vivo because 20% PG alone was toxic in culture. Instead, a stock solution of 20 mg/ml EBC-46 in 
ethanol was diluted directly into the cultures. The final 2% level of ethanol was not toxic to cells, 
and the presence of 10% FCS enabled the EBC-46 to remain in solution, albeit bound reversibly to 
protein. Pilot studies had previously shown that EBC-46, a water-insoluble molecule, could be 
solubilized in 4% albumin and still retain its potency against cultured cells. 
Cells were treated with TPA or EBC-46 at varying doses (300 µg/ml, 100 µg/ml and 50 µg/ml) for 
different times (5, 10 and 30 min). The controls were untreated cells and EtOH-only (vehicle). 0.1% 
Triton-X100 was used as a positive control, to instantly lyse cells for propidium iodide uptake and 
allow the total cell number to be determined. Cells were photographed with the AMG EvosFL 
inverted fluorescence microscope at 4X, under bright-field or red fluorescence illumination. 
Micrographs of at least 3 different fields per well were captured. 
Bright field images showed numerous blebs forming on the plasma membranes of the Sk-Mel-28 
cells within several minutes of treatment. By 30 min the blebs had disappeared, and many cells 
could be seen with the faint outline of grossly swollen cytoplasm and shrunken nuclei. No nuclear 
fragments typical of apoptotic bodies were seen. Fluorescence examination of the cells (Figure 4.12 
on p.126-127) and counting of PI-stained cells showed 80 – 90% killing of cells treated with EBC-
46 at the highest dose (300 µg/ml) within 30 min of treatment. However, the cytotoxic effect of 
TPA detected by PI uptake was delayed, with maximum cell death reached 24 hr after treatment.  
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4.3  Discussion 
In order to establish a strong correlation between the outcomes of experimentation and the 
indications of EBC-46 in future treatment of patients with cancers, it is vital to investigate the 
action of EBC-46 within the host biological system. Bearing in mind the dose ranges tested in the 
cell based assays in Chapter Three and the optimal dose of TPA and EBC-46 at which an IC50 was 
obtained, a range of doses was tested on tumors in vivo, that would have a clinically relevant 
outcome in ablating the tumors in mice. The results in this Chapter showed that a single 
intratumoral injection of 600 µg/ml of EBC-46 rapidly ablates subcutaneous tumors in a range of 
mouse models, accompanied by an inflammatory response resulting in long term cures.  
Judging by the enhanced potency of TPA in vitro, compared with EBC-46 (refer Figure 3.7) it was 
hypothesized that TPA would be just as potent as EBC-46, if not more so, on tumor cells in vivo 
upon intratumoral injection. Hence, its efficacy was tested in parallel to EBC-46 on different tumor 
models. Surprisingly, TPA failed to demonstrate the expected outcome in curing tumors in mice 
given its cytotoxic action in vitro. Previous studies using a PKC activator to treat tumors in vivo 
involved the use of PEP005 (ingenol 3-angelate; Ing3A) via topical application. It was shown to be 
able to penetrate deeper into the dermis compared to TPA following application, as PEP005 is a 
substrate for P-glycoprotein 1 (also known as MDR1, ABCB1) which is an ABC transporter (Li et 
al., 2010). Studies have shown that TPA was restricted to the epidermis of the skin hence leading to 
a lack of anti-cancer activity. Our studies showed that intratumoral injection of TPA, bypassing the 
epidermis, failed to cure mice of the subcutaneously transplanted B16-F0 tumors. On the other. 
hand, a single intratumoral injection of EBC-46 led to a distinct anti-tumor effect over the long 
term. B16-F0 mouse melanoma is a well-established solid-tumor model and is regarded as highly 
invasive and metastatic in nature (Corbett et al., 2002). Hence, it is a difficult model to treat and 
positive results have more credibility than with some other models. B16-F0 first arose 
spontaneously in C57BL/6 mice in 1954 (Alvarez, 2002) which makes the mouse strain immuno-
competent for growth of transplanted syngeneic tumors. This compatibility therefore provides a 
more complete test system than growth of human tumor cells implanted into immuno-compromised 
mice. SK-Mel-28 is a human metastatic melanoma obtained from ATCC for research work in nude 
BALB/c Foxn1nu mice to complement the immune-competent locally aggressive murine counterpart 
B16-F0. 
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Figure 4.12. Photomicrographs of Sk-Mel-28 tumor cells treated with TPA or EBC-46 in vitro and stained with propidium iodide. 
Sk-Mel-28 melanoma cells were treated with either 300 µg/ml EBC-46 or 300 µg/ml TPA for 30 min and 24 hr prior to staining with 5 µg/ml 
(w/v) propidium iodide for 5 min. Cells were imaged using the AMG EvosFL inverted fluorescence microscope at 4x, under bright-field or red 
fluorescence illumination. 
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Nude BALB/c Foxn1nu mice have been utilized in this project to treat human xenografts of Sk-Mel-
28 metastatic melanomas. This is a well utilized athymic strain of laboratory mice with a 
spontaneous deletion in the FOXN1 gene lacking thymus thus, resulting in an inhibited adaptive 
immune system. The BALB/c Foxn1nu (Nude) mice allow for a more accurate inoculation of tumor 
cells subcutaneously due to their hairless skin and docile nature. In addition, the hairless phenotype 
makes it easier to monitor tissue reaction to the treatment with EBC-46, inflammation at the treated 
site and ulceration. The deficiency of a cell-mediated immune response in these mice helped to 
determine the role of an immune response in the mechanism of action of intratumoral EBC-46. The 
depletion of T-cells did not prevent the high cure rates obtained from this model which implies that 
either the innate immune system is activated or other direct pathways are responsible for the 
mechanism of action of intratumoral EBC-46, rather than the adaptive immune response mediated 
by T-cells. 
As a PKC activator, the effect of EBC-46 on PKC over-expression in the target tumor cells in vivo 
was investigated. In Chapter Three, Sk-Mel-28 cells over-expressing PKC isoforms were tested in 
the presence of diterpene esters to determine their sensitivity to killing. It was found that EBC-46 
had greatly enhanced potency in killing cell lines with over-expressed PKC isoforms, at doses as 
low as 0.1 ng/ml compared to the more resistant response of Sk-Mel-28 cells with lacZ controls. 
However from a comparison of the survival curves of these over-expressed PKC cell lines to the 
parent cell lines it can be extrapolated that the sensitivity of EBC-46 on cells over-expressing PKC 
isoforms is not as heightened as expected. A level of enhanced sensitivity was found in vivo when 
B16-F0 tumors over-expressing PKC isoforms -α or -δ were treated with 30 µg EBC-46 per tumor, 
where more cures were recorded compared to the lacZ controls. However, similar to the cell 
survival assay in Chapter Three, the increased sensitivity of B16-F0 tumors over-expressing PKC-α 
or –δ cannot be justified as mice carrying tumors over-expressing PKC-α were monitored for less 
than a month with 60% cure, while those mice with tumors over-expressing PKC-δ were monitored 
for about 45 days with 40% cure. The most important observation from this experiment was that the 
volume of EBC-46 injected was a crucial factor in treatment of tumors. Here the volume of the 
tumor inoculum in relation to the volume of the diterpene ester injected was investigated as a 
possible determinant of anti-tumor efficacy. Between the two experimental groups (Figure 4.5) 
tumors which arose from an initial inoculum of 25 µl responded positively to treatment with 30 µg 
per tumor of EBC-46 which has been established as an optimal dose for intratumoral treatment 
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(Figure 4.2). There were re-growths of tumors among the mice of the second experimental group 
which received an inoculum of 100 µl of B16-F0 cells with over-expressing PKC isoforms, which 
was most likely due to a more spread-out target area, allowing residual tumor to escape treatment 
from the single injection of 50 µl of the diterpene ester. In addition, pilot experiments using co-
injection with BIS-1 has shown some loss of efficacy (data not shown) but optimization of the BIS-
1 dose is needed. Overall, the results suggest that PKC levels in the tumor are not closely associated 
with efficacy in vivo. 
The in vivo efficacy studies have shown that EBC-46 caused a marked inhibition in growth of all 
tumor types tested, with similar clinical outcome of initial inflammation, followed by eschar 
development and eventual healing. Despite the differences in origin, growth rate and morphology of 
the tumor subtypes, there was a similar significant regression of tumor growth following treatment 
via a single intralesional injection of EBC-46. There was rapid enduring response to treatment with 
EBC-46 that began with a visible inflammatory reaction as soon as 2 hr post treatment, through to 
development of an eschar and clearance of tumors by 20 days.  
The early effects including development of a bruised appearance prompted the use of an ex vivo 
functional assay to determine how quickly and total tumor cell death occurred. An ex vivo 
clonogenic survival assay of treated Sk-Mel-28 cells was performed by harvesting tumors from the 
euthanized mouse and assessing the clonogenic potential of teased-out tumor cells in culture. It 
became evident that EBC-46 destroyed tumor cells by 4 hr post treatment, leaving no viable tumor 
cells. A parallel in vitro assay in which cultured cells were treated with comparable doses of EBC-
46 showed total ablation of viability within 30 min, considerably faster than in vivo, thus leaving 
open the question of whether direct lysis of tumor cells by EBC-46 could fully explain its potency 
in vivo. Though the propidium iodide assays did not show definitive nuclear fragmentation, bright 
field images of the treated cells showed irregular cell morphologies and shrinkage indicative of 
necrotic cells which have been identified by red arrows in Figure 3.8, Panel B and C of Chapter 
Three. 
Similar to previous studies of PEP005 and TPA on tumors in vivo, EBC-46 also resulted in a 
cutaneous inflammation and hemorrhaging. The inflammatory reaction observed upon treatment of 
tumors with EBC-46 suggested potential involvement of the innate immune system. Surgical 
examination of control and treated tumors at different times following treatment with EBC-46 or 
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TPA indicated a loss of blood supply to the tumor by possibly damaging the blood vessels in the 
tumor periphery, as early as 4 hr following treatment with the diterpene esters. The resulting 
vascular disruption caused by treatment with EBC-46 led to the subsequent development of tumor 
necrosis. This observation has been validated by histological and immunohistochemical analysis in 
Chapter Five of this thesis. To investigate this further, the following Chapter (Chapter Five) studied 
the effect of EBC-46 on the immune and other host cells and the involvement of pro-inflammatory 
cytokines. 
In conclusion, single intratumoral injection of EBC-46 ablates tumors in a range of mouse and 
human tumor xenografts models where the ration of tumor volume and spread to the volume of 
injected EBC-46 may affect efficacy. As demonstrated in Chapter Three, TPA was more potent as a 
PKC activator in vitro than EBC-46 where TPA can attain increased growth inhibition of tumor 
cells at doses about 10-fold more than EBC-46. However, EBC-46 has a strong negative effect on 
the tumor cell growth and survival in vivo compared to TPA which failed to cure tumors in mice 
with eventual recurrences. This increased efficiency of EBC-46 in ablating tumor cells in vivo may 
be due to a PKC-dependent intracellular pathway in addition to a host response triggered by the 
presence of the diterpene ester in the tumor microenvironment. Sustained PKC activation in 
cultured melanoma cells leads to hyper-activation of the MAPK pathway and can induce cell death 
(Arita et al., 1994, Deng et al., 2004). On the other hand, prolonged activation of PKC leads to its 
subsequent degradation making it difficult to ascertain if the growth inhibition is due to PKC 
activation or a result of its absence. Previous work in this laboratory with PKC activators indicated 
that overstimulation of the Ras/Raf/MEK/ERK pathway is associated with induction of senescence 
in human melanoma cells (Cozzi et al., 2006). Western blot analysis in Chapter Three has shown 
that loss of protein levels was a prolonged effect, where after 24 hr of recovery following 24 hr 
treatment with TPA or EBC-46, PKC isoform levels did not return to original levels. Over-
expression of the two PKC isoforms –α and –δ in the target tumor in mice did not greatly enhance 
the efficacy of EBC-46 unlike the sensitivity obtained in vitro. This may be due to the ratio of 
tumor volume to the volume of EBC-46 injected into the tumor (Figures 4.9 and 4.10). The rapid 
changes in visual appearance of the tumor sites following injection of EBC-46 prompted the use of 
an ex vivo assay to assess the cellular response which established a rapid disappearance of viable 
clonogenic tumor cells within 4 hr following treatment. Further, the inflammatory reaction and 
associated hemorrhage is hypothesized to lead to tumor disruption. To better understand the 
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mechanism of action, it would be useful to analyze the histology and immunohistochemistry of the 
tumors and surrounding skin, conduct multiplex bead arrays for cytokine/chemokine analysis and 
visual analysis of the mouse skin and tumor vasculature. 
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5.1  Introduction 
TPA is a skin irritant and induces an inflammatory response on contact with the skin. EBC-46 has a 
strong negative effect on tumor growth and survival as demonstrated in Chapter Four in C57BL/6J 
and BALB/c Foxn1nu mice. Previous work with PKC activators such as TPA and PEP005 suggested 
there was a host-mediated inflammatory response to treatment with these compounds, and in the 
case of PEP005 efficacy of the topical application was abrogated in neutrophil deficient mice 
(Challacombe et al., 2006).  
A similar inflammatory response was observed upon injection of EBC-46 into tumors in mice. A 
dose of 30 µg of EBC-46 delivered into each tumor via intratumoral injection resulted in a visible 
inflammatory reaction within 2 hr of treatment with a purplish bruising coloration on the skin of 
BALB/c Foxn1nu mice around the area of treatment. However in vitro TPA appeared to be more 
potent in killing tumor cells than EBC-46, which raised the possibility that the increased efficacy of 
EBC-46 witnessed in mice relies on a PKC-dependent pathway as well as a host immune response 
triggered by the presence of the diterpene ester within the tumor microenvironment. 
In addition, EBC-46 activates neutrophils to produce reactive oxygen species (Chapter Three; 
Section 3.2.3) which are known to have antitumor activity (Zivkovic et al., 2005, Zivkovic et al., 
2007). While the production of ROS has been shown to be PKC-dependent (Marks and Hecker, 
1967) as supported by results shown in Figure 3.6 (Chapter Three), it was hypothesized that EBC-
46 activated PKC which in turn led to the recruitment of neutrophils to the site of infection.  
It was therefore desirable to ascertain the pro-inflammatory profile of EBC-46 in the mouse and 
determine whether such effects formed part of the anticancer efficacy of the compound. 
Immunohistochemical analysis of the cellular response to the activity of EBC-46 was conducted 
wherein tissue sections of control and treated tumors in mice were stained for immune cells such as 
neutrophils and macrophages. To further develop this profile flow cytometry was used to 
investigate the expression of immune modulators such as inflammatory and chemotactic 
interleukins and interferons. 
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5.2  Results 
5.2.1  Histology and immunohistochemistry of SK-Mel-28 tumors treated with EBC-46 in 
vivo 
As shown in Chapter Four there was an inflammatory reaction within 2-4 hr of treatment with 30 
µg of EBC-46 at each tumor site. Hence, the histology of the cellular response was important 
information for piecing together the mode of action of EBC-46. The aim was to study the 
inflammatory response in the skin and tumor during the early stages following intratumoral 
injection with EBC-46. SK-Mel-28 metastatic melanoma cells were grown subcutaneously in 
BALB/c Foxn1nu nude mice and were treated with single intratumoral injections of 20% propylene 
glycol (PG) as control and 30 µg of EBC-46 which was determined to be the optimal dose to 
successfully cure tumors in mice (Chapter Four; Section 4.2.4). The tumors along with the skin 
within the inflammatory area were excised at different times (30 min, 1 hr, 2 hr, 4 hr, 8 hr, 24 hr, 48 
hr and 7 days). Tissue samples were processed and stained by Clay Winterford at QIMR Berghofer 
Histology Facility after which the slides were scanned using the Aperio Scanscope XT and analyzed 
in the lab.  
Myeloperoxidase (MPO) is a peroxidase enzyme expressed in neutrophil granulocytes, hence 
histological sections of the tumors were stained with anti-myeloperoxidase antibody to detect 
neutrophils infiltrating the tissue. This stain gets localized to the cytoplasm and lysosomes. 
Microscopic analysis of the stained tumor sections showed no neutrophils at 1 hr after treatment 
however they began to appear in small numbers along the periphery of the tumor in the early stages 
of treatment, between 2 – 4 hr. The neutrophils were identified by their multilobed nuclei and 
reddish-brown cytoplasm. Within the next 4 hr, neutrophils had penetrated into the tumor mass 
(Figure 5.1; A). Cell count of the neutrophils detected upon treatment with the control vehicle 20% 
PG or 30 µg EBC-46 at different times showed a gradual increase in the number migrating into the 
tumor by 8 hr (Figure 5.1; B). Figure 5.1; C shows presence of neutrophils within the tumor at 48 hr 
after treatment. An inflammatory reaction is known to result in hemorrhaging and tumor disruption. 
The onset of necrosis is at 48 hr is indicated with a green arrow in Figure 5.1; C. The 
immunohistochemical changes observed in tumors with respect to presence and activity of 
neutrophils are shown collectively in the Appendix (p.250-258) as photomicrographs, comparing 
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the treatment of EBC-46 to that of the control vehicle 20% PG. A similar outcome has been 
observed upon treatment of normal skin comparing EBC-46 with the vehicle (Appendix, Figure 2). 
Macrophages also called macrophagocytes, are phagocytes and are produced by the differentiation 
of monocytes in tissues. Their role is to phagocytose or engulf and then digest cellular debris and 
pathogens. They also stimulate lymphocytes and other immune cells to respond to pathogens. 
Macrophages are identified by the expression of a number of proteins such as CD14, CD40, CD64, 
F4/80 (mice)/ERM1 (human), and CD68 (Khazen et al., 2005). 
The F4/80 protein expression in mice was targeted to detect the presence of macrophages in the host 
upon treatment of tumors with EBC-46. Following treatment with a single intratumoral injection of 
30 µg of EBC-46, tumors were excised and processed for immunohistochemical analysis. The 
F4/80 antibody localizes to the cellular membrane staining cells with a brown colour. From the 
images of the stained tumor sections, tumors treated with the control vehicle 20% PG as well as 
those treated with 30 µg of EBC-46 showed the presence of macrophages along the periphery of the 
tumor as blood vessels surround the tumor (Figure 5.2; A). With increase in time of exposure of the 
tumor cells to EBC-46, there was a migration of macrophages into the tumor (Figure 5.2; B) 
followed by a gradual decline in macrophage numbers after 48 hr of  treatment with EBC-46 
(Figure 5.2; C). A detailed time-course graphic representation of the activity of macrophages is 
included in the Appendix (p.255-258) showing the comparison between treatment with EBC-46 and 
the control vehicle 20% PG. 
Examination of the H&E tissue sections revealed the loss of sheet-like arrangement of cells treated 
with 30 µg of EBC-46 compared to 20% PG vehicle control (Figure 5.3). The progression towards 
necrosis among tumors treated with 30 µg of EBC-46 each tumor was clearly evident from the first 
day of treatment to day 7. H&E staining showed lightly-stained pockets of cells within the tumor 
from as early as 4 hr after treatment (Figure 5.3). These pockets were of necrotic cells which lacked 
nuclei hence the light stain with hematoxylin.  The decrease in vascular pockets was observed by 24 
hr post- treatment with EBC-46 (Figure 5.4). CD-31 was used to evaluate the degree of tumor 
angiogenesis upon treatment with EBC-46. From the images of the treated and control cells it was 
demonstrated that EBC-46 has an anti effect on the vascular structure within and around the tumor. 
The gradual decrease in the number of endothelial cells (indicated by brown pigmentation) was 
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Figure 5.1.A. Photomicrographs of Sk-Mel-28 tumors stained for neutrophils (MPO) after single intratumoral injection of 30 µg 
EBC-46 per tumor  
Sk-Mel-28 tumor section stained with MPO, show neutrophils present along the periphery of the tumor at 4 hr after 
treatment with 30 µg of EBC-46, although in small numbers. The circle highlights neutrophils identified by the reddish-
brown cytoplasmic stain and their multilobed nuclei.  
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for 
immunohistological analysis and stained with MPO for detection of neutrophils. Stained tissue sections were scanned and imaged using the 
Aperio ScanScope XT at 20X magnification. Photographs of tumor sections treated with the control vehicle 20% PG are included in the 
Appendix (page.252-254). 
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Figure 5.1.B. Photomicrographs of Sk-Mel-28 tumors stained for neutrophils (MPO) after single intratumoral injection of 30 µg 
EBC-46 per tumor  
A gradual increase in the number of neutrophils recruited to the tumor site and their migration into the tumor is seen. Tumor 
section at 4 hr (same as Figure 5.1;A) shows neutrophils along the periphery of the tumor wile tumor section at 8 hr shows 
neutrophils within the tumor identified by the black arrows. 
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for 
immunohistological analysis and stained with MPO for detection of neutrophils. Stained tissue sections were scanned and imaged using the 
Aperio ScanScope XT at 20X magnification. Photographs of tumor sections treated with the control vehicle 20% PG are included in the 
Appendix (page.252-254). 
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Figure 5.1.C. Photomicrographs of Sk-Mel-28 tumors stained for neutrophils (MPO) after single intratumoral injection of 30 µg 
EBC-46 per tumor  
Scan of the tumor section shows neutrophils well within the tumor mass by 48 hr after treatment with 30 µg of EBC-46. 
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. The black circled area 
shows neutrophils within the tumor at 8 hr and the green arrow indicates an area of necrotic cells. Photographs of tumor 
sections treated with the control vehicle 20% PG are included in the Appendix (page.252-254).  
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for 
immunohistological analysis and stained with MPO for detection of neutrophils. Stained tissue sections were scanned and imaged using the 
Aperio ScanScope XT at 20X magnification. 
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Figure 5.2.A. Photomicrographs of Sk-Mel-28 tumors stained for macrophages (F4/80) after single intratumoral injection of 30 µg 
EBC-46 per tumor  
Sk-Mel-28 tumor section stained with F4/80, show macrophages present along the periphery of the tumor at 4 hr after 
treatment with 30 µg of EBC-46, although in small numbers. The black arrows indicate towards macrophages which are 
identified by the reddish-brown cytoplasmic stain and a blue nucleus. 
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for 
immunohistochemical analysis and probed with F4/80 which is specific for macrophages. Stained tissue sections were scanned and imaged 
using the Aperio ScanScope XT at 20X magnification.Photographs of tumor sections treated with the control vehicle 20% PG are included 
in the Appendix (page.255-256). 
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Figure 5.2.B. Photomicrographs of Sk-Mel-28 tumors stained for macrophages (F4/80) after single intratumoral injection of 30 µg 
EBC-46 per tumor  
Scan shows macrophages within the tumor following 8 hr of exposure to 30 µg of EBC-46. 
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for 
immunohistochemical analysis and probed with F4/80 which is specific for macrophages. Stained tissue sections were scanned and imaged 
using the Aperio ScanScope XT at 20X magnification.Photographs of tumor sections treated with the control vehicle 20% PG are included 
in the Appendix (page. 255-256). 
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Figure 5.2.C. Photomicrographs of Sk-Mel-28 tumors stained for macrophages (F4/80) after single intratumoral injection of 30 µg 
EBC-46 per tumor  
Macrophage numbers gradually begin to decline 48 hr after treatment. Tumor section at 48 hr shows macrophages within the 
tumor mass which decreased in number by day 7.  
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for 
immunohistochemical analysis and probed with F4/80 which is specific for macrophages. Stained tissue sections were scanned and imaged 
using the Aperio ScanScope XT at 20X magnification.Photographs of tumor sections treated with the control vehicle 20% PG are included in 
the Appendix (page. 255-256). 
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Figure 5.3 Photomicrographs of Sk-Mel-28 tumors stained with H&E for histopathological analysis after single intratumoral 
injection of 30 µg EBC-46 per tumor showing disintegration of tumor. 
A. H&E staining of Sk-Mel-28 tumor treated with 30 µg of EBC-46 for 2 hr 
B. H&E staining of Sk-Mel-28 tumor treated with 30 µg of EBC-46 for 4 hr 
C. H&E staining of Sk-Mel-28 tumor treated with 30 µg of EBC-46 for 7 days 
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for histological 
analysis. Stained tissue sections were scanned and imaged using the Aperio ScanScope XT at 20X magnification. Photographs of tumor 
sections treated with the control vehicle 20% PG are included in the Appendix (page.250-251). 
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Figure 5.4 Photomicrographs of Sk-Mel-28 tumors stained with H&E for histopathological analysis after treatment with 30 µg 
EBC-46 per tumor showing decrease in blood supply. 
A. H&E staining of Sk-Mel-28 tumor treated with 30 µg of EBC-46 for 4 hr 
B. H&E staining of Sk-Mel-28 tumor treated with 30 µg of EBC-46 for 8 hr.  
C. H&E staining of Sk-Mel-28 tumor treated with 30 µg of EBC-46 for 24 hr 
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for histological 
analysis and stained with H&E. Stained tissue sections were scanned and imaged using the Aperio ScanScope XT at 20X magnification. 
Photographs of tumor sections treated with the control vehicle 20% PG are included in the Appendix (page. 250-251). There was loss of blood 
supply within the tumor between 4 hr – 8 hr – 24 hr. This figure also indicated areas of haemmorhage around the periphery and within the 
tumor between 4 – 8 hr after treatment with EBC-46. 
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Figure 5.5 Photographs of Sk-Mel-28 tumors stained with CD-31 for detection of endothelial cells after treatment with 30 µg EBC-46 
per tumor  
A. Sk-Mel-28 tumor sections stained with CD-31 show presence of endothelial cells at 4 hr following treatment with EBC-46. 
B. Sk-Mel-28 tumor sections show a gradual decline in presences of endothelial cells by 8 hr after treatment with EBC-46 as 
seen by a reduction in the dark brown pigmented cells characteristic of CD-31/PECAM1 Ab staining indicating a loss of 
blood supply to the tumor. 
C. Sk-Mel-28 tumor sections staining with CD-31 demonstrated haemorrhaging and the development of necrosis within the 
tumor at 48 hr following treatment with EBC-46. 
D. By day 7 after treatment with EBC-46, no endothelial cells were found present within the tumor with the resultant onset of 
necrosis. 
Sk-Mel-28 tumors were treated with 30 µg EBC-46 or 20% PG vehicle control for various times. Tumors were processed for 
immunohistological analysis and stained with CD-31/PECAM1 for identification for endothelial cells which stain with a brown colouration. 
Stained tissue sections were scanned and imaged using the Aperio ScanScope XT at 20X magnification. Photographs of tumor sections treated 
with the control vehicle 20% PG are included in the Appendix (page.257-258). There is apparent decrease in the number of endothelial cells 
seen by the reduction of brown pigmentation with time.  
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observed from 4 hr post-treatment and beyond (Figure 5.5). Image C (Figure 5.5) also indicated 
areas of hemorrhage and necrosis within the tumor at 48 hr following treatment with 30 µg of EBC-
46. 
5.2.2 Neutrophil Requirement for the Efficacy of EBC-46 
From immunohistochemical analysis it was apparent that the main leukocyte involved in the 
inflammatory response was the neutrophil. However, it was not clear whether EBC-46 required 
neutrophils or another immune response for its cytotoxic effect on cancer cells, or whether it caused 
a direct cytotoxic effect on the cells and neutrophils were a secondary response to the tissue 
necrosis.  
The aim of this study was to deplete the peripheral neutrophils in mice with a neutralizing antibody 
to determine if the efficacy of subsequent intralesional treatments of EBC-46 would be affected. 
Mice were administered the neutrophil-neutralizing monoclonal antibody anti-Ly-6G or the control 
IgG2 via intraperitoneal (IP) injection. Two days after the initial antibody treatment, re-administered 
the anti-Ly-6G antibody or control IgG2 via IP injection. Sk-mel-28 tumors in BALB/c Foxn1
nu 
mice were treated with 20% PG or 30 µg EBC-46. Two days after treatment with EBC-46, the mice 
received a third treatment with the anti-Ly-6G antibody or the control IgG2 via IP injection. The 
mice were monitored regularly at intervals of 2 days during the first week of treatment, expanding 
the time interval to 4 days in the consecutive weeks until tumors were ablated or mice were culled 
as a result of tumor burden. From the start of the treatment with the antibodies up to day 10, blood 
smears were prepared to establish a leukocyte count.  
There was an obvious clinical difference between the EBC-46 and EBC-46 + Ly-6G groups at the 
site of EBC-46 injection. The Ly-6G + EBC-46 mice did not show any visible signs of 
inflammation, however there was tumor regression in 2 mice out of the 5 mice in the group. By day 
27, 3 mice in this group had relapsed at a total of 4 sites (Figure 5.6; A.). 
In contrast, the mice treated with EBC-46 or EBC-46 + IgG2 resulted in cure as expected, except for 
1 mouse in the EBC-46 + IgG2 group that had a recurrence at one site which was due to an 
intramuscular growth of the tumor (Figure 5.6; A.). In other words, the group depleted of 
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Figure 5.6; A   Effect of neutrophil depletion in BALB/c Foxn1nu mice on EBC-46 treatment of Sk-Mel-28 tumors. 
Figure 5.6; B        Neutrophil counts in mice given anti-Ly-6G and control (IgG2) antibodies 
Tumor growth in mice given anti-Ly-6G antibody, isotype control antibody or no antibody. Sk-Mel-28 cells were injected subcutaneously (10 
tumors/group, 2 tumors/mouse, 5 mice/group). When tumors were grown to approximately 100 mm3, mice were injected with the anti-Ly-6G 
antibody (clone 1A8; 100 µg i.p, on days -2, 0 and 2) with isotype control antibody (IgG2a, clone 2A3; 100 µg i.p, on days -2, 0 and 2) or with 
nothing. The tumor volumes represent the mean volume of individual tumors. 
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neutrophils had a greater number of persisting tumors or a faster recurrence rate. The lack of a 
visible inflammatory reaction at the site of treatment among the EBC-46 + Ly-6G mice was less 
obvious by day 10, most likely as the neutrophil levels had begun to return to normal levels (Figure 
5.6; B.) The neutrophil counts were determined for each group. In mice treated with the vehicle, 
EBC-46 or with the control Ab (PG / EBC- 46 + IgG2), the neutrophil count as a percentage of total 
white cells was unchanged (Figure 5.6, B) throughout the experiment. In contrast, the percentage of 
neutrophils dropped dramatically from ~60% to ~10% following treatment with the neutrophil 
neutralizing Ab Ly-6G in both the vehicle-treated and EBC-46 – treated groups. 
5.2.3 Induction of cytokines following EBC-46 treatment in vivo 
Production of cytokines was also assessed in vivo using blood from mice where tumors were treated 
with EBC-46, to obtain the systemic host response, and from supernatants of the treated tumors to 
ascertain the local response. A series of three cytokine bead assays each on mouse serum and tumor 
supernatants was performed demonstrating similar results: minimal expression levels, below an 
accepted detection cut off (< 10 pg/ml),except for MCP-1 and IL-6 in mouse blood and IL-1β and 
IL-8 in the tumor supernatants. The results have been summarized in Figure 5.7 
Overall, the level of cytokines induced by EBC-46 that could be detected in mice were low and 
varied, possibly because the process of hemorrhagic necrosis cut off circulating lymphocytes from 
exposure to significant concentrations of the drug.  The question of cytokine induction in 
lymphocytes was therefore addressed with the use of human PBMCs in culture.  
5.2.4 Induction of cytokines by EBC-46 in human peripheral blood lymphocytes (PBMCs) in 
vitro 
Cultured human lymphocytes were used as a substitute for mouse lymphocytes in vivo, to determine 
whether the rapid inflammation induced by EBC-46 could have been associated with the production 
of proinflammatory cytokines. A cytokine bead array was used to assess the expression of cytokines 
IL-12p70, TNF α, IL-10, IL-6, IL-1β and IL-8 by PBMCs treated with EBC-46 in vitro. In an 
additional arm of the experiment, PBMCs were co-cultured with tumor cells or human endothelial 
cells (HUVEC) in an attempt to simulate at least part of the in vivo context.  These cytokines are 
mainly produced by macrophages, dendritic cells and other immune cells. 
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Figure 5.7; A  Cytokine expression levels in serum of BALB/c Foxn1nu mice. 
BALB/c Foxn1nu mice growing Sk-Mel-28 tumors were treated with 30 µg of EC-46 via intralesional injection. Whole blood was 
collected at different times from the mice (2 mice per treatment per time-point) and serum was separated to be analysed for the production 
of cytokines. A BD Biosciences Cytokine Bead Assay Mouse Inflammation kit was used to perform the assay testing a panel of six 
cytokines, namely IL-12p70, TNF-α, IFN-γ, MCP-1, IL-10 and IL-6. The assay was performed following instructions as per the manual 
provided testing each sample in duplicate. A BD FACS Array was used to measure the absorbance and results were analysed using the 
FCAP Array software. The assay was repeated twice and the results of both were averaged and plotted using the GraphPad Prism 
software.  
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Figure 5.7; B  Cytokine expression levels from xenografts of human SK-Mel-28 tumor supernatants  
BALB/c Foxn1nu mice growing Sk-Mel-28 tumors were treated with 30 µg of EC-46 via intralesional injection. Tumors were harvested at 
different times after treatment (2 tumors per treatment per time-point). Cells from the tumors were scrapped out and used in ex vivo studies 
while the supernatant was utilized to assess the expression levels of cytokines as a result of EBC-46 activity. A BD Biosciences Cytokine 
Bead Assay Mouse Inflammation kit was used to perform the assay testing a panel of six cytokines, namely IL-12p70, TNF-α, IFN-γ, 
MCP-1, IL-10 and IL-6. The assay was performed following instructions as per the manual provided testing each sample in duplicate. A 
BD FACS Array was used to measure the absorbance and results were analysed using the FCAP Array software. This assay was repeated 
twice and the results of both were averaged and plotted using the GraphPad Prism software. 
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Tumor cells were co-cultured with PBMC’s and treated with 100 ng/ml of EBC-46 for 24 hr before 
harvesting cells and assaying for cytokine production. In Table.5.3, it is clear that there is high 
expression of TNF, IL-6 and IL-8.  LPS was used as a pro-inflammatory positive control. 
Lipopolysaccharides (LPS) are large molecules consisting of a lipid ad a polysaccharide joined by a 
covalent bond. They act as endotoxins and elicit strong immune responses and for this reason were 
used in this assay as an alternative immunostimulant to tumor cells. The results show that LPS 
significantly increased the expression of cytokines by PBMCs, not only of the human TNFs, but 
also IL-10, IL-6, IL-1β and IL-8.  A further increase was noted upon the addition of EBC-46. Co-
culture of the tumor cells Sk-Mel-28 and MCF7 with PBMCs induced a weaker response compared 
to LPS, but all the same result in a high expression of IL-6 and IL-8. Relative to the expression of 
cytokines in the presence of tumor cells, high levels of human TNF, IL-6, IL-1β and IL-8 were 
noted upon treatment of the co-cultures with EBC-46.  
Treatment of NFF’s in a PBMC environment resulted in higher expression of TNF α, IL-6 and IL-8. 
EBC-46 appeared to have an agonistic effect on cytokine production. Cytokine assays were also 
performed on B16 and HUVEC’s in vitro, giving a similar cytokine expression profile as the tumor 
cells. Production of cytokines were also assessed in vivo using blood from mice treated with EBC-
46 for tumors to obtain a host response and from tumor supernatants of the treated tumors to obtain 
a tumor response. However, the expression levels were minimal below an accepted detection cut off 
(< 10 pg/ml), except for MCP-1 and IL-6 in the mouse blood and IL-1β and IL-8 in the tumor 
supernatants.  
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Table 5.1  Induction of cytokines upon treatment of tumor cells co-cultured with PBMC cells with EBC-46 in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 IL-12p70 Human TNF IL-10 IL-6 IL-1β IL-8 
PBMC 3.01   ±  0.25 11.96   ±   3.92 2.97   ±   0.38 15.80  ±   5.63 5.58    ±   0.94 911.14   ±   246.95 
PBMC + LPS 5.23   ±  2.81 10704.55  ±  80.97 1176.12 ±   22.33 28726.45  ±  259.68 5446.69  ±   99.03 8267.26   ±   268.56 
PBMC + EBC-46 2.45   ±  0.26 4532.06  ±   110.51 3.43  ±   0.42 52.36  ±  3.79 141.96  ±  11.28 20059.96   ±   363.94 
PBMC + LPS +EBC- 46 3.02   ±  0.55 34731.41 ±  1223.1 18.79  ±   1.77 9502.47  ±  162.60 12319.31 ±  158.10 13258.83   ±   1325.43 
SK-MEL-8 2.66   ±  0.30 0.00 2.04  ±  0.22 0.00 6.97    ±   0.99 5400.96   ±   154.27 
SK-MEL-28 + PBMC 2.89   ±  0.24 0.00 1.97  ±  0.66 34.28  ±  4.61 12.00   ±    1.78 4540.29   ±   377.61 
SK-MEL-28 + EBC-46 2.22  ±  0.54 0.00 2.04  ±  0.22 0.00 9.41   ±   2.21 9465.25   ±   609.79 
SK-MEL-28 + PBMC + 
EBC-46 
2.55   ±  0.58 5339.38  ±  2642.25 8.15  ±  0.69 1189.09  ±  989.02 1179.90  ±  877.05 12976.93  ±   2351.48 
MCF7 2.62  ±  0.83 0.00 1.76   ±  0.47 11.94  ±  0.91 3.97   ±   1.19 4.94   ±   0.45 
MCF7 + PBMC 2.75  ±  0.63 17.80  ±  35.60 29.06  ±  7.83 165.95  ±  48.94 8.07  ±  1.43 1019.10   ±   309.13 
MCF7 + EBC-46 2.65  ±  0.38 0.00 1.56   ±  0.66 279.79  ±  40.04 3.59  ±  0.95 384.28   ±   28.99 
MCF7 + PBMC + 46 3.24  ±  1.90 1342.96  ±  156.71 20.23 ±  1.74 2985.46  ±  270.99 141.09  ±  19.77 13858.07   ±   514.39 
NFF 3.76  ±  0.96 95.64   ±  92.46 3.25   ±  0.66 3965.72   ±  375.37 5.49   ±   1.81 445.30   ±   64.50 
NFF + PBMC 4.01  ±  0.91 128.71  ±  98.99 8.12   ±  1.76 15685.93  ±  5251.62 7.08   ±   2.10 5588.36   ±   2600.88 
NFF + PBMC + EBC-46 3.56  ±  2.61 2190.87  ±  241.47 4.37   ±  2.08 23611.91  ±  3957.21 61.34   ±   7.47 18725.17   ±   72.31 
Tumor cells (~3x105 cells/well) and  NFF’s (~5x104 cells/well) were separately co-cultured with PBMC’s (~3x105 cells/well) and treated with 100 
ng/ml of EBC-46 for 24hr. The supernatants were analysed in quadruplicate. (mean ± standard deviation). 
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5.3 Discussion: 
To understand the mechanism of action of EBC-46 injected directly into tumors and to further 
investigate the inflammatory response observed in Chapter Four, immunohistochemical analysis 
and subsequent cytokine assays were performed. Using histopathology it was possible to visually 
assess not only the effect of EBC-46 on tumor cellular architecture but also confirm the increased 
presence of neutrophils and macrophages within the tumor following treatment with 30 µg of EBC-
46. The requirement of neutrophils for efficacy of EBC-46 was tested by ablating neutrophils in 
mice prior to treatment of tumors with EBC-46 using an anti-neutrophil neutralizing antibody. A 
modest depletion of efficacy was found, but considerably less than for topical efficacy of PEP005. 
Following intratumoral delivery of EBC-46 there was an increase in endothelial permeability 
leading to the extravasation of macrophages and neutrophils and a disruption of the tumor 
vasculature which together were associated with necrosis of cancer cells. Moreover, the timeline of 
these cellular changes within the tumor microenvironment coincided with results observed in the 
previous Chapter: development of an inflammatory reaction to EBC-46; the loss of clonogenic 
survival by 4 hr following treatment, determined by ex vivo assay. 
The infiltration of neutrophils and macrophages into the tumor by 4 hr after treatment, the 
disintegration of the tumor mass beginning at the early time-points between 2-4 hr following 
treatment with EBC-46, the vascular damage and obstruction of blood supply to the tumor between 
4-8 hr would explain  the extensive necrosis seen by day 7 following treatment. The overall action 
of EBC-46 thus leads to destruction of the tumor microenvironment through hemorrhagic necrosis.  
The immunological profile of tumors and the host upon treatment with EBC-46 was further 
investigated with cytokine assays. Cytokine expression levels from tumors treated in vivo and from 
mouse serum were minimal except for IL-1β, IL-8, IL-6 and MCP-1. This was possibly due to the 
vascular damage and loss of blood supply. As an alternative approach, PBMC cells were co-
cultured with tumor cells and treated in vitro, although at a much lower concentration of EBC-46 
than the 600 µg/ml injected dose. In part support of the in vivo results obtained in mice from the 
cytokine bead assays, in vitro treatment of human PBMCs revealed an increase in the numbers of 
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pro-inflammatory cytokines and chemokines that regulate expression of immune cells such as 
neutrophils and macrophages. 
The elevated expression of IL-6, IL-8, IL-1β, TNF-α correlated with the immunohistochemical 
observations of the increased presence of neutrophils and macrophages. These are important 
cytokines involved in the immune activity triggered by EBC-46. IL-8 is a chemokine also known as 
neutrophil chemotactic factor where it induces chemotaxis in target cells, primarily neutrophils, 
causing them to migrate toward the site of infection. Similarly, IL-6 and IL-1β are also important 
mediators of inflammatory responses. TNF α is involved in systemic inflammation and is produced 
chiefly by activated macrophages (M1). Its primary role is the regulation of immune cells and is 
able to induce apoptotic cell death, inflammation and inhibit tumorigenesis in addition to other 
functions. IL-10 on the other hand, is an anti-inflammatory cytokine and is involved in the 
regulation of the JAK-STAT signaling pathway. Also known as a cytokine synthesis inhibitory 
factor, is it capable of inhibiting synthesis of pro-inflammatory cytokines such as IFN γ, IL-2, TNF 
α produced by cells such as macrophages and regulatory T cells. IL-12 is an interleukin produced 
by dendritic cells and macrophages in response to antigenic stimulation. It is stimulates the growth 
and function of T cells by stimulating the production of IFN γ and TNF α.  
The importance of neutrophils for the anticancer activity of EBC-46 was investigated by using Anti-
Ly-6G antibody, a neutrophil neutralizing agent. An overall of 4 recurrences were observed in mice 
receiving the anti-Ly-6G antibody compared to a single recurrence in the mice treated with the 
isotype control IgG2 antibody. However, this study was not statistically significant, in part due to 
the larger volume of the recurring tumors in mice treated with the isotype antibody control and with 
the normalization of the depleted neutrophil count. One study reported that following the anti-Ly-
6G antibody administration, the peripheral neutrophil counts return to pretreatment level by day 5 
(Tateda et al., 2001). Hence, while it does appear that neutrophils are responsible at least in part for 
the anti-cancer efficacy of EBC-46, further studies using serial injections of the anti-Ly-6G 
antibody every 2 days to maintain the depletion of neutrophils could be carried out. Another factor 
to consider may be a larger experimental size with an increased number of mice.  
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6.1  Introduction 
In the earlier Chapters it was established that EBC-46 is a PKC activator that translocates PKC 
isoforms containing a C1 domain and subsequently activates ERK1/2 of the MAPK signaling 
pathway. Compared to the prototype PKC activator TPA, EBC-46 was found to be less cytotoxic on 
tumor cells in vitro. However, treatment of xenografts with EBC-46 resulted in cure of tumors in 
mice while tumors treated with TPA relapsed at all of the respective treatment sites. Either as an 
initial response or a secondary phenomenon to treatment with EBC-46, an inflammatory reaction 
developed within 4 hr of exposure to the drug which indicated the involvement of the host immune 
system in the efficacy of EBC-46 action on tumors in vivo. This was confirmed through 
immunohistochemical analysis of tumor tissue staining for neutrophils and macrophages, which 
showed infiltration of immune cells into the tumor site within 4 hr of EBC-46 treatment, declining 
in numbers by 24 hr. In addition, histological staining of tumors with CD-31 showed reduction in 
the number of endothelial cells from 8 hr after treatment with EBC-46 leading to the gradual onset 
of necrosis. Cytokine expression was shown to be greatly increased from 4 - 24 hr following 
treatment of tumor cells with EBC-46 in vitro when co-cultured with PBMCs. Hence, this indicated 
that 4-8 hr of treatment with EBC-46 was a significant time-frame where the effects of the 
compound reached its peak.  
To determine the molecular pathways involved, human and murine-specific microarray analysis 
was performed of gene expressions of tumor and host respectively in response to treatment with 
EBC-46 and TPA. It was possible that the differences in gene expression following treatment with 
EBC-46 compared with TPA would help explain why TPA was less effective than EBC-46 in vivo. 
 
6.2  Results 
cRNA microarray analysis was performed to determine the likely molecular pathways involved in 
the activity of EBC-46 and TPA on tumors and the host. To determine the changes resulting from 
activity of the diterpene esters, the treated RNA samples were compared to samples treated with the 
control vehicle 20% propylene glycol (PG). 
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BALB/c Foxn1nu mice with two Sk-Mel-28 tumors per mouse were treated with EBC-46 or TPA at 
30 µg per tumor site following which tumors were harvested at 1 hr, 2 hr, 4 hr, 8 hr, 24 hr or 48 hr. 
Total RNA was extracted from these tumors by homogenization in RLT buffer containing β-
mercaptoethanol, followed by extraction and purification using the Qiagen Plus RNeasy Kit (see 
Chapter Two; Materials and Methods; Section 2.8.1). The amount of total RNA extracted and 
purified was measured using the NanoDrop instrument followed by an assessment of the integrity of 
the RNA extracted. Samples were loaded and run through a denaturing agarose gel and stained with 
ethidium bromide (EtBr) alongside a 1kb DNA marker. 
Ideally total intact RNA run on a denaturing agarose gel will have sharp clear bands of 28S and 
18S, where the 28S rRNA band should be approximately twice as intense as the 18S rRNA band. 
The ratio of absorbance at 260 nm and 280 nm was used to assess the purity of RNA where a ratio 
between 1.8 -2.0 is accepted as “pure” RNA. Ratios outside of this range may indicate presence of 
protein, genomic DNA or other contaminants (NanoDrop Protocols). 
Among the RNA samples extracted from treated Sk-Mel-28 tumors and run on a 1% denaturing 
agarose gel, intact total RNA resulted in two clear bands 28S and 18S in samples from tumors 
treated with EBC-46 and TPA from 1 hr to 8 hr. However, by 24 hr after treatment, partial 
degradation of total RNA was observed. Extracted RNA was found to be completely degraded by 
48 hr following treatment. In contrast, intact total RNA was successfully extracted from tumors 
treated with vehicle alone (20% PG). Note the ratios highlighted in red which are relevant to RNA 
after 24 and 48 hr of exposure to EBC-46 (Table 6.1 and Figure 6.1). Repetitions of treatments and 
extractions to obtain intact total RNA post 8 hr of treatment with the diterpene esters resulted in the 
same observation of partial degradation by 24 hr- (Table 6.2). 
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Table 6.1 Concentration of RNA extracted from Sk-Mel-28 tumors after treatment 
with 30 µg EBC-46 per tumor or the vehicle control 20% PG. 
Sample ID ng/ul A260 nm A280 nm 260/280 Constant 
Sk-Mel-28  - untreated 315.84 7.896 3.906 2.02 40 
Sk-Mel-28  - 1 hr 20%PG 857.02 21.425 10.436 2.05 40 
Sk-Mel-28  - 1 hr EBC-46 627.29 15.682 7.574 2.07 40 
Sk-Mel-28  - 2 hr 20%PG 665 16.625 8.088 2.06 40 
Sk-Mel-28  - 2 hr EBC-46 904.4 22.61 10.919 2.07 40 
Sk-Mel-28  - 4 hr 20%PG 646.33 16.158 7.8 2.07 40 
Sk-Mel-28  - 4 hr EBC-46 897.44 22.436 10.933 2.05 40 
Sk-Mel-28  - 8 hr 20%PG 947.16 23.679 11.423 2.07 40 
Sk-Mel-28  - 8 hr EBC-46 607.9 15.197 7.36 2.06 40 
Sk-Mel-28  - 24 hr 20%PG 230.28 5.757 2.843 2.03 40 
Sk-Mel-28  - 24 hr EBC-46 193.36 4.834 2.029 2.38 40 
Sk-Mel-28  - 48 hr 20%PG 1112.23 27.806 13.565 2.05 40 
Sk-Mel-28  - 48 hr EBC-46 117.4 2.935 1.748 1.68 40 
Abbreviations: A260 nm – absorbance at 260 nm; A280 nm – absorbance at 280 nm. 
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Figure 6.1 RNA extracted from Sk-Mel-8 tumors treated with EBC-46 at 30µg per 
tumor and compared to 20% PG at different times following treatment.  
Integrity of RNA from Sk-Mel-28 tumors was assessed by agarose gel electrophoresis where ~ 
2 µl of RNA sample with formamide loading buffer was loaded into wells of agarose gel 
alongside 1 kb marker and run at 80 V for 45 min to separate the bands for visualization on 
UV gel doc. RNA was partially degraded in lanes 12 and 14 where Sk-Mel-28 tumors were 
treated with EBC-46 for 24 hr and 48 hr respectively.  
Table 6.2 Concentration of RNA extracted from Sk-Mel-28 tumors after treatment 
with 30 µg EBC-46 per tumor for 24 hr and 48 hr. 
Sample ID ng/ul A260 nm A280 nm 260/280 Constant 
Sk-Mel-28  
 24hr  EBC-46 398.68 9.967 4.912 2.03 40 
Sk-Mel-28  
 48hr  EBC-46 394.59 9.865 4.029 2.45 40 
Abbreviations: A260 nm – absorbance at 260 nm; A280 nm – absorbance at 280 nm. 
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A time-course analysis was performed to investigate the changes in gene expression after treatment 
of Sk-Mel-28 tumors on the host and tumor with TPA or EBC-46, using microarrays. The tumors 
were treated with a final dose of 30 µg of TPA or EBC-46 per tumor for 0.5 hr, 1 hr, 2 hr, 4 hr, and 
8 hr prior to extraction of total RNA. To determine the changes brought about by the diterpene 
esters, the samples were compared to treatments with the vehicle control 20% PG at the same times 
as mentioned above. Total RNA was extracted from tumors (Sk-Mel-28, human metastatic 
melanoma grown in BALB/c Foxn1nu mice) and profiled using Illumina Human HT-12 v4 chips to 
assess the effects on the tumor, or Mouse Ref8 v2.0 BeadChips to assess the effects on the host. The 
chips carry 50-mer oligonucleotides representing cDNA of the whole of the expressed mouse or 
human genome, with 30- or 15-fold redundancy respectively. Total RNA was reverse transcribed to 
cDNA, which was then transcribed in turn to produce biotin-labelled cRNA.  
cRNA microarray analysis was performed using the Illumina Whole-Genome Gene Expression 
Direct Hybridization Assay. The expression data read by the iScan System were decoded using 
GenomeStudio software (Illumina) before being exported to Agilent Technologies’ GeneSpring GX 
v12.5 where they were normalized across the genome by quantile normalization across all probes 
on the Bead Array and filtered to ensure that the gene lists were robust. The fold change was 
calculated as an average expression across replicates treated with the drug and divided by the 
expression of the vehicle only at different treatment times; e.g. expression at 4 hr of treatment with 
EBC-46 was divided by the expression resulting from treatment with the vehicle 20% PG alone to 
calculate the fold change. The statistical differences were then calculated as pair-wise analysis 
where expression of treated samples at each time-point was compared to the control; e.g. expression 
at 4 hr of treatment with EBC-46 was compared to vehicle control 20% PG. Hence, t-test was 
appropriate. Further, human PBMC cells were treated in vitro with 30 ng/ml of TPA or EBC-46 for 
4 hr, 24 hr and 96 hr, to additionally assess the effects of the compounds on cells of the immune 
system. 
6.2.1  Tumor response to activity of diterpene esters EBC-46 and TPA in vivo 
Microarrays were performed for three individual experimental groups of RNA extracted from Sk-
Mel-28 tumors treated in BALB/c Foxn1nu mice with 30 µg of EBC-46 or TPA in parallel with the 
vehicle control 20% PG. The resulting raw data generated were combined in GeneSpring GX v12.5  
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Figure 6.2  Venn diagrams comparing the changes in gene expression effected by 
diterpene ester EBC-46 at a final dose of 30 µg per tumor and vehicle control 20% PG, 
showing genes ( ) up-  or ( ) down-regulated with p ≤ 0.05 
RNA extracted from Sk-Mel-28 tumors treated with 30 µg EBC-46 per tumor or vehicle control 
20% PG were analysed on Illumina HumanHT-12 v4 BeadChips to assess the response of the 
tumor to treatment with the diterpene ester EBC-46 at 1 hr, 2 hr, 4 hr and 8 hr after treatment. 
The gene lists were compared using Venn diagrams in GeneSpring GX v12.5 to understand the 
changes induced by EBC-46. 
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Figure 6.3  Venn diagrams comparing of the changes in gene expression effected by 
diterpene ester TPA at a final dose of 30 µg per tumor and vehicle control PG, showing 
genes that are ( ) up-  or ( ) down-regulated with p ≤ 0.05 
RNA extracted from Sk-Mel-28 tumors treated with 30 µg TPA per tumor or vehicle control 
20% PG were analysed on Illumina HumanHT-12 v4 BeadChips to assess the response of the 
tumor to treatment with the diterpene ester TPA at 4 hr and 8 hr after treatment. The gene lists 
were compared using Venn diagrams in GeneSpring GX v12.5 to understand the changes 
induced by TPA. 
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Table 6.3 Top twenty genes significantly UP-regulated following 4 hr treatment by 30 µg EBC-46 (compared to vehicle control 20% 
PG) in Sk-Mel-28 tumors as detected on Illumina HumanHT-12 v4 BeadChips. 
ProbeID p 
Value 
Regulation FC 
(abs) 
Symbol Definition 
580161 0.001 up 13.249 SNORD3C Homo sapiens small nucleolar RNA, C/D box 3C (SNORD3C), small nucleolar RNA. 
2510164 0.003 up 12.796 SNORD3A Homo sapiens small nucleolar RNA, C/D box 3A (SNORD3A), small nucleolar RNA. 
380685 0.003 up 12.718 SNORD3D Homo sapiens small nucleolar RNA, C/D box 3D (SNORD3D), small nucleolar RNA. 
2570220 0.001 up 3.907 RN5S9 Homo sapiens RNA, 5S ribosomal 9 (RN5S9), ribosomal RNA. 
2450020 0.009 up 2.878 SNORD56 Homo sapiens small nucleolar RNA, C/D box 56 (SNORD56), small nuclear RNA. 
3850189 0.021 up 1.968 RNU4-2 Homo sapiens RNA, U4 small nuclear 2 (RNU4-2), small nuclear RNA. 
4200379 0.029 up 1.934 RNU11 Homo sapiens RNA, U11 small nuclear (RNU11), small nuclear RNA. 
240594 0.043 up 1.870 ANXA3 Homo sapiens annexin A3 (ANXA3), mRNA. 
3990463 0.008 up 1.770 RNU4-1 Homo sapiens RNA, U4 small nuclear 1 (RNU4-1), small nuclear RNA. 
7560041 0.035 up 1.705 AXUD1 Homo sapiens AXIN1 up-regulated 1 (AXUD1), mRNA. 
2600747 0.043 up 1.681 IFIT2 Homo sapiens interferon-induced protein with tetratricopeptide repeats 2 (IFIT2), mRNA. 
2190184 0.041 up 1.665 PRSS23 Homo sapiens protease, serine, 23 (PRSS23), mRNA. 
4220255 0.017 up 1.649 VTRNA1-1 Homo sapiens vault RNA 1-1 (VTRNA1-1), non-coding RNA. 
5700725 0.048 up 1.644 EPSTI1 Homo sapiens epithelial stromal interaction 1 (breast) (EPSTI1), transcript variant 2, mRNA. 
2340072 0.021 up 1.613 PARP12 Homo sapiens poly (ADP-ribose) polymerase family, member 12 (PARP12), mRNA. 
1240142 0.003 up 1.609 SAMD9 Homo sapiens sterile alpha motif domain containing 9 (SAMD9), mRNA. 
990176 0.048 up 1.597 RN7SK Homo sapiens RNA, 7SK small nuclear (RN7SK), non-coding RNA. 
7400743 0.012 up 1.588 KIAA1618 Homo sapiens KIAA1618 (KIAA1618), mRNA. 
2120079 0.002 up 1.570 EIF2AK2 Homo sapiens eukaryotic translation initiation factor 2-alpha kinase 2 (EIF2AK2), mRNA. 
5720040 0.008 up 1.550 EYA1 Homo sapiens eyes absent homolog 1 (Drosophila) (EYA1), transcript variant 1, mRNA. 
FC; fold change in expression compared with controls 
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Table 6.4 Top twenty genes significantly DOWN-regulated following 4 hr treatment by 30 µg EBC-46 (compared to vehicle control 
20% PG) in Sk-Mel-28 tumors as detected on Illumina HumanHT-12 v4 BeadChips. 
ProbeID p 
Value 
Regulation FC 
(abs) 
Symbol Definition 
7150296 0.044 down 2.232 LOC100130562 PREDICTED: Homo sapiens hypothetical protein LOC100130562, transcript variant 1 
(LOC100130562), mRNA. 
5900564 0.002 down 2.112 SLC16A6 Homo sapiens solute carrier family 16, member 6 (monocarboxylic acid transporter 7) 
(SLC16A6), mRNA. 
6330730 0.007 down 1.774 SNAI2 Homo sapiens snail homolog 2 (Drosophila) (SNAI2), mRNA. 
50255 0.018 down 1.682 SNAI2 Homo sapiens snail homolog 2 (Drosophila) (SNAI2), mRNA. 
780762 0.035 down 1.591 CSNK1D Homo sapiens casein kinase 1, delta (CSNK1D), transcript variant 1, mRNA. 
770743 0.029 down 1.565 MIR1978 Homo sapiens microRNA 1978 (MIR1978), microRNA. 
5270520 0.001 down 1.560 FAIM3 Homo sapiens Fas apoptotic inhibitory molecule 3 (FAIM3), mRNA. 
4590020 0.020 down 1.520 YOD1 Homo sapiens YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) (YOD1), mRNA. 
520468 0.041 down 1.517 LOC402175 PREDICTED: Homo sapiens misc_RNA (LOC402175), miscRNA. 
1430138 0.016 down 1.504 MAFF Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) (MAFF), 
transcript variant 1, mRNA. 
4390300 0.025 down 1.491 TOB1 Homo sapiens transducer of ERBB2, 1 (TOB1), mRNA. 
4150278 0.002 down 1.477 DUSP14 Homo sapiens dual specificity phosphatase 14 (DUSP14), mRNA. 
2750280 0.044 down 1.471 CDK5R1 Homo sapiens cyclin-dependent kinase 5, regulatory subunit 1 (p35) (CDK5R1), mRNA. 
1240228 0.026 down 1.467 PAG1 Homo sapiens phosphoprotein associated with glycosphingolipid microdomains 1 (PAG1), 
mRNA. 
360242 0.020 down 1.455 LOC440459 PREDICTED: Homo sapiens similar to solute carrier family 16, member 6 (LOC440459), 
miscRNA. 
1430598 0.000 down 1.444 FBXO32 Homo sapiens F-box protein 32 (FBXO32), transcript variant 1, mRNA. 
6860162 0.036 down 1.432 LOC441019 PREDICTED: Homo sapiens hypothetical LOC441019 (LOC441019), mRNA. 
4890358 0.049 down 1.426 LOC100131866 PREDICTED: Homo sapiens misc_RNA (LOC100131866), miscRNA. 
460193 0.001 down 1.420 MAD2L1BP Homo sapiens MAD2L1 binding protein (MAD2L1BP), transcript variant 2, mRNA. 
6290598 0.007 down 1.418 TMEM138 Homo sapiens transmembrane protein 138 (TMEM138), mRNA. 
FC; fold change in expression compared with controls 
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Table 6.5 Top twenty genes significantly UP-regulated following 8 hr treatment by 30 µg EBC-46 (compared to vehicle control 20% 
PG) in Sk-Mel-28 tumors as detected on Illumina HumanHT-12 v4 BeadChips. 
ProbeID p Value Regulation FC (abs) Symbol Definition 
2510164 0.031 up 25.916 SNORD3A Homo sapiens small nucleolar RNA, C/D box 3A (SNORD3A), small nucleolar RNA. 
380685 0.032 up 23.662 SNORD3D Homo sapiens small nucleolar RNA, C/D box 3D (SNORD3D), small nucleolar RNA. 
580161 0.036 up 21.770 SNORD3C Homo sapiens small nucleolar RNA, C/D box 3C (SNORD3C), small nucleolar RNA. 
2360091 0.040 up 3.913 RNU1G2 Homo sapiens RNA, U1G2 small nuclear (RNU1G2), small nuclear RNA. 
5670152 0.047 up 3.697 RNU1-3 Homo sapiens RNA, U1 small nuclear 3 (RNU1-3), small nuclear RNA. 
2570220 0.012 up 3.441 RN5S9 Homo sapiens RNA, 5S ribosomal 9 (RN5S9), ribosomal RNA. 
3780767 0.000 up 2.907 LOC10013256
4 
PREDICTED: Homo sapiens hypothetical protein LOC100132564 (LOC100132564), 
mRNA. 
6860377 0.008 up 2.382 DUSP1 Homo sapiens dual specificity phosphatase 1 (DUSP1), mRNA. 
4220255 0.022 up 1.959 VTRNA1-1 Homo sapiens vault RNA 1-1 (VTRNA1-1), non-coding RNA. 
990176 0.027 up 1.921 RN7SK Homo sapiens RNA, 7SK small nuclear (RN7SK), non-coding RNA. 
4280017 0.033 up 1.913 FOS Homo sapiens v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS), mRNA. 
3990463 0.036 up 1.723 RNU4-1 Homo sapiens RNA, U4 small nuclear 1 (RNU4-1), small nuclear RNA. 
6400364 0.031 up 1.711 NR4A2 Homo sapiens nuclear receptor subfamily 4, group A, member 2 (NR4A2), transcript 
variant 1, mRNA. 
2260309 0.031 up 1.659 RPPH1 Homo sapiens ribonuclease P RNA component H1 (RPPH1), RNase P RNA. 
4210044 0.039 up 1.519 SNORD46 Homo sapiens small nucleolar RNA, C/D box 46 (SNORD46), small nucleolar RNA. 
6520129 0.027 up 1.514 ZNF148 Homo sapiens zinc finger protein 148 (ZNF148), mRNA. 
50608 0.019 up 1.470 MTP18 Homo sapiens mitochondrial protein 18 kDa (MTP18), nuclear gene encoding 
mitochondrial protein, transcript variant 2, mRNA. 
1510228 0.042 up 1.462 SNORD12C Homo sapiens small nucleolar RNA, C/D box 12C (SNORD12C), small nucleolar RNA. 
650639 0.013 up 1.424 NR4A2 Homo sapiens nuclear receptor subfamily 4, group A, member 2 (NR4A2), transcript 
variant 1, mRNA. 
6450424 0.006 up 1.422 NME3 Homo sapiens non-metastatic cells 3, protein expressed in (NME3), mRNA. 
FC; fold change in expression compared with controls  
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Table 6.6 Top twenty genes significantly DOWN-regulated following 8 hr treatment by 30 µg EBC-46 (compared to vehicle control 
20% PG) in Sk-Mel-28 tumors as detected on Illumina HumanHT-12 v4 BeadChips.  
ProbeID p 
Value 
Regulation FC 
(abs) 
Symbol Definition 
630128 0.040 down 2.442 LOC286444 PREDICTED: Homo sapiens misc_RNA (LOC286444), miscRNA. 
7040008 0.039 down 1.961 CD74 Homo sapiens CD74 molecule, major histocompatibility complex, class II invariant 
chain (CD74), transcript variant 2, mRNA. 
4590576 0.029 down 1.955 LOC286444 PREDICTED: Homo sapiens misc_RNA (LOC286444), miscRNA. 
4560047 0.018 down 1.955 CD74 Homo sapiens CD74 molecule, major histocompatibility complex, class II invariant 
chain (CD74), transcript variant 1, mRNA. 
770743 0.026 down 1.862 MIR1978 Homo sapiens microRNA 1978 (MIR1978), microRNA. 
2000673 0.036 down 1.846 GAGE12C Homo sapiens G antigen 12C (GAGE12C), mRNA. 
7560047 0.040 down 1.827 CIRBP Homo sapiens cold inducible RNA binding protein (CIRBP), mRNA. 
990672 0.029 down 1.803 VPS18 Homo sapiens vacuolar protein sorting 18 homolog (S. cerevisiae) (VPS18), mRNA. 
6660601 0.032 down 1.798 HMOX1 Homo sapiens heme oxygenase (decycling) 1 (HMOX1), mRNA. 
3610544 0.039 down 1.727 GAGE2B Homo sapiens G antigen 2B (GAGE2B), mRNA. 
2350553 0.018 down 1.654 LOC645037 Homo sapiens similar to GAGE-2 protein (G antigen 2) (LOC645037), mRNA. 
2470161 0.019 down 1.654 PLEKHF1 Homo sapiens pleckstrin homology domain containing, family F (with FYVE 
domain) member 1 (PLEKHF1), mRNA. 
780762 0.029 down 1.627 CSNK1D Homo sapiens casein kinase 1, delta (CSNK1D), transcript variant 1, mRNA. 
2450725 0.028 down 1.618 SLC3A2 Homo sapiens solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 2 (SLC3A2), transcript variant 6, mRNA. 
3520044 0.004 down 1.591 LOC10013386
6 
PREDICTED: Homo sapiens similar to phosphodiesterase 4D interacting protein 
(myomegalin) (LOC100133866), mRNA. 
50220 0.024 down 1.574 GAGE4 Homo sapiens G antigen 4 (GAGE4), mRNA. 
4590670 0.021 down 1.562 LOC646294 PREDICTED: Homo sapiens misc_RNA (LOC646294), miscRNA. 
1240440 0.003 down 1.522 TXNIP Homo sapiens thioredoxin interacting protein (TXNIP), mRNA. 
1990079 0.031 down 1.520 FBXO32 Homo sapiens F-box protein 32 (FBXO32), transcript variant 2, mRNA. 
2120703 0.032 down 1.520 LOC645173 PREDICTED: Homo sapiens misc_RNA (LOC645173), miscRNA. 
FC; fold change in expression compared with controls  
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and the statistical significance in gene expression was determined using P values calculated from 
the unpaired Student’s T test where p ≤ 0.05 was considered significant. Once the gene lists were 
generated, Venn diagrams were utilized to compare differential gene expression effected by TPA or 
EBC-46 specifically.  
The treatments with EBC-46 (at 1 hr, 2 hr, 4 hr and 8 hr) or TPA (at 4 hr and 8 hr) were 
independently compared to the vehicle control 20% PG at each of the mentioned time-points 
(Figures. 6.2 and 6.3 respectively) to find differentially expressed genes only regulated by the 
compound of interest and not altered by the vehicle control (20% PG) treatment. The top 20 genes 
from these lists are shown for treatment time 4 hr and 8 hr in Tables 6.3 – 6.6 showing differential 
gene expression (up- and down-regulated genes) following treatment with EBC-46 only, after 
comparison with the vehicle control 20% PG. Gene expression lists were generated after analysis of 
expression upon treatment with EBC-46 at 1 hr and 2 hr after comparison with 20% PG at the 
different treatment times. These lists showing top 20 differentialy regulated genes have been 
included in the Appendix (p.259-262) Genes that were consistently up-regulated by EBC-46 at 1 hr, 
2 hr, 4 hr and 8 hr following intratumoral treatment were SNORD3A, SNORD3C and SNORD3D 
(Tables 6.3 and 6.5) SNORD3A is also known as RNU3, U3; SNORD3C as U3-3 and SNORD3D 
as U3-4. The top 20 genes differentially expressed by TPA only, after comparison with the vehicle 
control 20% PG at 4 hr and 8 hr after treatment are included in the Appendix (p.263-266).  
In Chapter Four, treatments of tumors with EBC-46 or TPA resulted in a significant difference 
between the efficacies of the two compounds. While TPA was the more potent cytotoxic agent in 
culture, it failed to cure tumors in mice compared to the positive response obtained with EBC-46. 
Bearing this in mind, the subsequent microarray analysis investigated the genes differentially 
expressed by EBC-46 in comparison to TPA. As observed in previous time-course experiments, 
the most significant time-frame for optimal activity of EBC-46 was between 4 hr – 8 hr after 
treatment. Hence the gene expression changes effected by EBC-46 (after comparison with the 
vehicle control 20% PG) and TPA (after comparison with the vehicle control 20% PG) were further 
compared against each other at 4 hr and 8 hr using Venn diagrams (Figure 6.4), to determine the 
changes in gene expression in SK-Mel-28 tumors due to treatment with 30 µg of EBC-46 or TPA. 
The gene  
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Figure 6.4  Comparison using Venn diagrams of differential gene expression upon 
treatment with diterpene esters EBC-46 or TPA after removal of 20% PG effects at a final 
dose of 30 µg per tumor at 4 h and 8 h where p value was calculated ≤ 0.05 showing genes 
that were ( ) up-  or ( ) down-regulated. 
RNA extracted from Sk-Mel-28 tumors treated with 30 µg EBC-46 or TPA per tumor were 
analysed on Illumina HumanHT-12 v4 BeadChips to evaluate the response of the tumor to 
treatment with the diterpene ester EBC-46 in comparison to TPA after removal of 20% PG 
effects at 4 hr and 8 hr after treatment and determine the difference in gene expression between 
the two compounds. 
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Table 6.7 Top twenty genes significantly UP-regulated following 4 hr treatment by 30 µg EBC-46 (after comparison with TPA) in Sk-Mel-28 tumors 
as detected on Illumina HumanHT-12 v4 BeadChips. 
 
ProbeID p  Value Regulation FC (abs) Symbol Definition 
380685 0.003 up 101.003 SNORD3D Homo sapiens small nucleolar RNA, C/D box 3D (SNORD3D), small nucleolar RNA. 
2510164 0.003 up 93.659 SNORD3A Homo sapiens small nucleolar RNA, C/D box 3A (SNORD3A), small nucleolar RNA. 
580161 0.004 up 55.830 SNORD3C Homo sapiens small nucleolar RNA, C/D box 3C (SNORD3C), small nucleolar RNA. 
2570220 0.005 up 5.518 RN5S9 Homo sapiens RNA, 5S ribosomal 9 (RN5S9), ribosomal RNA. 
6620170 0.044 up 3.765 HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
2260349 0.014 up 2.994 MIR1974 Homo sapiens microRNA 1974 (MIR1974), microRNA. 
3780767 0.003 up 2.364 LOC100132564 PREDICTED: Homo sapiens hypothetical protein LOC100132564 (LOC100132564), 
mRNA. 
5670753 0.045 up 2.075 RNU1F1 Homo sapiens RNA, U1F1 small nuclear (RNU1F1), small nuclear RNA. 
4640689 0.021 up 1.978 EIF4A2 Homo sapiens eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2), mRNA. 
4150519 0.003 up 1.960 FAM108C1 Homo sapiens family with sequence similarity 108, member C1 (FAM108C1), mRNA. 
6580368 0.035 up 1.804 LOC387753 PREDICTED: Homo sapiens similar to 60S ribosomal protein L21, transcript variant 1 
(LOC387753), mRNA. 
610019 0.026 up 1.729 POLR3F Homo sapiens polymerase (RNA) III (DNA directed) polypeptide F, 39 kDa (POLR3F), 
mRNA. 
1240142 0.017 up 1.716 SAMD9 Homo sapiens sterile alpha motif domain containing 9 (SAMD9), mRNA. 
5960181 0.019 up 1.715 ASNS Homo sapiens asparagine synthetase (ASNS), transcript variant 1, mRNA. 
4220437 0.024 up 1.671 UCN2 Homo sapiens urocortin 2 (UCN2), mRNA. 
1090500 0.022 up 1.664 LOC645166 PREDICTED: Homo sapiens similar to lymphocyte-specific protein 1 (LOC645166), 
mRNA. 
6220600 0.028 up 1.664 LOC113386 Homo sapiens similar to envelope protein (LOC113386), mRNA. 
FC; fold change in expression compared with TPA 
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FC; fold change in expression compared with TPA 
Table 6.8 Top twenty genes significantly DOWN-regulated following 4 hr treatment by 30 µg EBC-46 (after comparison with TPA) in Sk-
Mel-28 tumors as detected on Illumina HumanHT-12 v4 BeadChips. 
ProbeID p  Value Regulation  FC (abs) Symbol Definition 
630128 0.046 down 3.544 LOC286444 PREDICTED: Homo sapiens misc_RNA (LOC286444), miscRNA. 
3390463 0.049 down 2.165 KU-MEL-3 Homo sapiens KU-MEL-3 protein (KU-MEL-3), mRNA. 
510731 0.047 down 2.104 RRM2 Homo sapiens ribonucleotide reductase M2 polypeptide (RRM2), mRNA. 
150544 0.031 down 2.016 PSMC4 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4), transcript 
variant 1, mRNA. 
5360646 0.034 down 1.997 PSMC4 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4), transcript 
variant 1, mRNA. 
6180440 0.036 down 1.984 PSMC4 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4), transcript 
variant 1, mRNA. 
1740543 0.046 down 1.926 JAK1 Homo sapiens Janus kinase 1 (JAK1), mRNA. 
6650482 0.014 down 1.919 EPHA4 Homo sapiens EPH receptor A4 (EPHA4), mRNA. 
2570553 0.041 down 1.788 LOC652615 PREDICTED: Homo sapiens similar to Anaphase promoting complex subunit 1 (APC1) 
(Cyclosome subunit 1) (Protein Tsg24) (Mitotic checkpoint regulator) (LOC652615), mRNA. 
5560561 0.031 down 1.786 TNS3 Homo sapiens tensin 3 (TNS3), mRNA. 
6550754 0.030 down 1.755 EVL Homo sapiens Enah/Vasp-like (EVL), mRNA. 
1410408 0.023 down 1.750 ARID5B Homo sapiens AT rich interactive domain 5B (MRF1-like) (ARID5B), mRNA. 
1410333 0.024 down 1.740 LOC643668 PREDICTED: Homo sapiens similar to peptidase (prosome, macropain) 26S subunit, ATPase 
1 (LOC643668), mRNA. 
780762 0.042 down 1.725 CSNK1D Homo sapiens casein kinase 1, delta (CSNK1D), transcript variant 1, mRNA. 
2750719 0.027 down 1.709 DDX21 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 (DDX21), mRNA. 
6580605 0.034 down 1.683 LOC646294 PREDICTED: Homo sapiens misc_RNA (LOC646294), miscRNA. 
4590670 0.034 down 1.666 LOC646294 PREDICTED: Homo sapiens misc_RNA (LOC646294), miscRNA. 
6660768 0.029 down 1.662 IRF2BP2 Homo sapiens interferon regulatory factor 2 binding protein 2 (IRF2BP2), transcript variant 1, 
mRNA. 
2480468 0.048 down 1.636 RANBP10 Homo sapiens RAN binding protein 10 (RANBP10), mRNA. 
6110736 0.045 down 1.629 IRS2 Homo sapiens insulin receptor substrate 2 (IRS2), mRNA. 
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Table 6.9 Top twenty genes significantly UP-regulated following 8 hr treatment by 30 µg EBC-46 (after comparison with TPA) in Sk-Mel-
28 tumors as detected on Illumina HumanHT-12 v4 BeadChips. 
ProbeID p  Value Regulation  FC (abs)  Symbol Definition 
580161 0.010 up 56.909 SNORD3C Homo sapiens small nucleolar RNA, C/D box 3C (SNORD3C), small nucleolar RNA. 
2970482 0.028 up 5.344 RNU1-5 Homo sapiens RNA, U1 small nuclear 5 (RNU1-5), small nuclear RNA. 
5670152 0.025 up 5.256 RNU1-3 Homo sapiens RNA, U1 small nuclear 3 (RNU1-3), small nuclear RNA. 
2360091 0.024 up 4.835 RNU1G2 Homo sapiens RNA, U1G2 small nuclear (RNU1G2), small nuclear RNA. 
2570220 0.006 up 4.332 RN5S9 Homo sapiens RNA, 5S ribosomal 9 (RN5S9), ribosomal RNA. 
2260349 0.016 up 3.777 MIR1974 Homo sapiens microRNA 1974 (MIR1974), microRNA. 
7330681 0.045 up 3.452 RNU1A3 Homo sapiens RNA, U1A3 small nuclear (RNU1A3), small nuclear RNA. 
70167 0.045 up 3.348 LY96 Homo sapiens lymphocyte antigen 96 (LY96), mRNA. 
4780504 0.025 up 3.011 RNU6-15 Homo sapiens RNA, U6 small nuclear 15 (RNU6-15), small nuclear RNA. 
7560041 0.047 up 2.919 AXUD1 Homo sapiens AXIN1 up-regulated 1 (AXUD1), mRNA. 
3610279 0.037 up 2.874 RNU6-1 Homo sapiens RNA, U6 small nuclear 1 (RNU6-1), small nuclear RNA. 
6040731 0.034 up 2.487 TYRP1 Homo sapiens tyrosinase-related protein 1 (TYRP1), mRNA. 
3780767 0.001 up 2.432 LOC100132564 PREDICTED: Homo sapiens hypothetical protein LOC100132564 (LOC100132564), 
mRNA. 
4010452 0.048 up 2.184 SLC38A6 Homo sapiens solute carrier family 38, member 6 (SLC38A6), mRNA. 
4640689 0.040 up 2.138 EIF4A2 Homo sapiens eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2), mRNA. 
7050451 0.035 up 2.080 LOC100134504 PREDICTED: Homo sapiens hypothetical protein LOC100134504 (LOC100134504), 
mRNA. 
460386 0.018 up 2.021 PTMA Homo sapiens prothymosin, alpha (PTMA), transcript variant 1, mRNA. 
2510338 0.044 up 1.985 GGH Homo sapiens gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl 
hydrolase) (GGH), mRNA. 
6370091 0.032 up 1.982 ATP6V1G1 Homo sapiens ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 
(ATP6V1G1), mRNA. 
4640743 0.032 up 1.971 CNN3 Homo sapiens calponin 3, acidic (CNN3), mRNA. 
FC; fold change in expression compared with TPA 
 
Chapter Six 
_________________________________________________________________________________________________________________________ 
 
_________________________________________________________________________________________________________________________ 
 
Page | 187  
Table 6.10 Top twenty genes significantly DOWN-regulated following 8 hr treatment by 30 µg EBC-46 (after comparison with TPA) in Sk-
Mel-28 tumors as detected on Illumina HumanHT-12 v4 BeadChips. 
ProbeID p  
Value 
Regulation FC 
(abs) 
Symbol Definition 
630128 0.014 down 3.646 LOC286444 PREDICTED: Homo sapiens misc_RNA (LOC286444), miscRNA. 
1740673 0.045 down 3.594 LOC399942 PREDICTED: Homo sapiens similar to Tubulin alpha-2 chain (Alpha-tubulin 2), transcript variant 5 
(LOC399942), mRNA. 
5310634 0.031 down 3.213 FASN Homo sapiens fatty acid synthase (FASN), mRNA. 
7150296 0.040 down 2.821 LOC100130562 PREDICTED: Homo sapiens hypothetical protein LOC100130562, transcript variant 1 (LOC100130562), 
mRNA. 
4590576 0.011 down 2.760 LOC286444 PREDICTED: Homo sapiens misc_RNA (LOC286444), miscRNA. 
2000025 0.030 down 2.607 LOC648024 PREDICTED: Homo sapiens similar to eukaryotic translation initiation factor 4A, isoform 1 (LOC648024), 
mRNA. 
6980376 0.001 down 2.510 LOC388681 PREDICTED: Homo sapiens similar to phosphodiesterase 4D interacting protein isoform 1 (LOC388681), 
mRNA. 
7560047 0.034 down 2.328 CIRBP Homo sapiens cold inducible RNA binding protein (CIRBP), mRNA. 
6180440 0.015 down 2.321 PSMC4 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4), transcript variant 1, 
mRNA. 
1740543 0.021 down 2.234 JAK1 Homo sapiens Janus kinase 1 (JAK1), mRNA. 
1410408 0.020 down 2.160 ARID5B Homo sapiens AT rich interactive domain 5B (MRF1-like) (ARID5B), mRNA. 
5550220 0.034 down 2.129 NOP56 Homo sapiens NOP56 ribonucleoprotein homolog (yeast) (NOP56), transcript variant 1, mRNA. 
630167 0.026 down 2.123 SDCBP Homo sapiens syndecan binding protein (syntenin) (SDCBP), transcript variant 2, mRNA. 
2640088 0.041 down 2.115 ALDOA Homo sapiens aldolase A, fructose-bisphosphate (ALDOA), transcript variant 2, mRNA. 
2360414 0.040 down 2.097 PI4KAP1 Homo sapiens phosphatidylinositol 4-kinase, catalytic, alpha pseudogene 1 (PI4KAP1), non-coding RNA. 
770079 0.035 down 2.095 ATP2A2 Homo sapiens ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 (ATP2A2), transcript variant 1, 
mRNA. 
150544 0.039 down 2.077 PSMC4 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4), transcript variant 1, 
mRNA. 
5810189 0.049 down 2.046 ATP2A2 Homo sapiens ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 (ATP2A2), transcript variant 1, 
mRNA. 
6550754 0.025 down 2.031 EVL Homo sapiens Enah/Vasp-like (EVL), mRNA. 
4590670 0.010 down 1.998 LOC646294 PREDICTED: Homo sapiens misc_RNA (LOC646294), miscRNA. 
FC; fold change in expression compared with TPA 
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lists generated from the Venn diagrams were then assessed to determine the differential gene 
expression brought about by EBC-46 alone (without the effect of the vehicle control or TPA) and 
the top 20 genes differentially regulated by EBC-46 alone, at 4 hr and 8 hr are listed in Tables 6.7 – 
6.10). Once more, the SNORD3A, SNORD3C and SNORD3D genes were found to be up-regulated 
by more than 2-fold following treatment with EBC-46 alone at 4 hr and 8 hr. snoRNAs are small 
nucleolar RNAs involved in post-translational modifications. 
6.2.2  Host response to activity of diterpene esters EBC-46 and TPA in vivo 
RNA extracted from SK-Mel-28 treated and control tumors were analyzed using HumanHT-12 v4 
BeadChips to determine the tumor response in Section 6.2.1. The same amplified RNA samples 
were hybridized to Illumina MouseRef-8 v2.0 BeadChips to investigate the response of the host and 
infiltrating cells to the activity of EBC-46 in comparison to TPA at 0.5 hr, 1 hr, 2 hr, 4 hr and 8 hr. 
The MouseRef-8 v2.0 BeadChip targets at least 25,600 well-annotated RefSeq transcripts and over 
19,100 unique genes. The data generated were combined in GeneSpring and were subjected to 
quality control by filtering probe sets based on the detection score calculated by GenomeStudio 
where p ≤ 0.05 was considered significant. The next filtering step involved identifying those genes 
that were at least 2-fold differentially regulated. Treatments with the diterpene esters EBC-46 or 
TPA were independently compared to treatments with the vehicle control 20% PG. The lists of 
genes differentially regulated by EBC-46 (versus 20% PG) and TPA (versus 20% PG) were then 
compared against each other using Venn diagram to identify the differences between the two 
treatments, namely TPA and EBC-46 at the various time-points (Figure 6.5) on the host BALB/c 
Foxn1nu mice. 
There was a vast difference in the number of genes differentially regulated by EBC-46 or TPA 
specifically, in the host. The subsequent gene lists obtained were analyzed where the top 20 genes 
differentially regulated more than 2-fold by EBC-46 or TPA were selected and are included in the 
Appendix (p.267-285). The majority of the genes of interest included those associated with an 
immune response. The purpose of analyzing treated tumor RNA on mouse array chips was to 
understand the effect of the diterpene ester EBC-46 on the host at a molecular level and correlate 
the findings with the previous observations. Genes expressed by the activity of EBC-46 did not  
 Chapter Six 
________________________________________________________________________________ 
 
 
 
________________________________________________________________________________ 
 
Page | 189  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Figure 6.5  Differences in the host responses to treatment with EBC-46 and TPA where 
genes at least 2-fold ( ) up- or ( ) down-regulated were compared using Venn diagrams. 
RNA extracted from Sk-Mel-28 tumors treated with 30 µg EBC-46 or TPA per tumor were 
analysed on MouseRef-8 v2.0 Illumina BeadChips to evaluate the response of the host to 
treatment with the diterpene ester EBC-46 in comparison to TPA at 30 min, 1 hr, 2 hr, 4 hr and 
8 hr after treatment and determine the difference in gene expression between the two 
compounds. 
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show any significant changes in gene expression in the early time-points of 30 min to 2 hr following 
treatment. However, between 4-8 hr following treatment there was increased expression of genes 
regulating chemokines and inflammatory molecules where genes were significantly up-regulated ≥ 
2-fold. The top 20 genes differentially regulated by the host upon treatment with EBC-46 alone at 4 
hr and 8 hr are included in Tables catalogued in the Appendix (p.272-275). The genes of interest 
which were significantly up-or down- regulated included Cxcl1, Defb6, Ly6g6c Gja1, Ccl4 and 
Ifi27. These results confirm the observations made in the previous Chapters with regards to the 
inflammatory reaction and the time- frame during which activity of EBC-46 is at its peak. In 
contrast, TPA does not induce expression of any of the genes involved in regulation of immune 
responses except for Jun-B at 30 min after treatment and Infγ at 2 hr after treatment. However, the 
expression of these genes was not constant. A significantly up-regulated gene after 8 hr of treatment 
with TPA was Ncf1, encoding the cytosolic neutrophil factor-1 protein. The top 20 genes 
differentially regulated by the host in response to treatment with TPA alone at 4 hr and 8 hr are 
included in the Appendix (p.282-285). 
 
6.2.3 Transcriptional response of PBMCs to EBC-46 and TPA in vitro 
The concentration of EBC-46 and TPA injected into tumors (600 µg/ml) was clearly toxic to tumor 
and murine cells, and little information about gene expression changes could therefore be expected 
from lymphocytes at non-toxic concentrations at the limits of drug diffusion areas where 
lymphocyte activation might play a role in efficacy. Microarray experiments were therefore 
conducted on human PBMCs readily available from human blood. Cultures were treated with TPA 
or EBC-46 at 30 ng/ml each for 4 hr, 24 hr and 96 hr. As a control, untreated PBMCs were used. 
Total RNA was extracted and amplified to produce biotinylated cRNAs that were used in the 
microarray assay. Data was normalized across the human genome using Human BeadChips from 
Illumino, in GeneSpring GX v12.5 by quantile normalization and put through filtering steps to 
ensure a strong data set and decrease the number of uninformative entities. Genes at least 2 – fold 
up- and down-regulated were determined by dividing the average expression of the treatments with 
the expression of the vehicle control. Diterpene ester-treated PBMCs were independently compared 
to the untreated PBMCs and gene lists were generated following which Venn diagrams  
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Figure 6.6 Comparison of the cellular response of human PBMCs treated with EBC-
46 or TPA at 30 ng/ml each where genes at least 2 – fold ( ) up-  or ( ) down-regulated 
were determined. 
RNA extracted from human PBMCs and treated in vitro with 30 ng/ml of EBC-46 or TPA 
were analysed on HumanHT-12 v4 Illumina BeadChips to investigate the immune response to 
activity of the diterpene ester EBC-46 in comparison to TPA at 4 hr, 24 hr and 96 hr after 
treatment and determine the difference in gene expression between the two compounds. 
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were used to determine the changes in gene expression between treatments with TPA and EBC-46 
at the different time-points (Figure 6.6). 
More gene changes common to both treatments, namely EBC-46 and TPA occurred than those 
specific to either diterpene ester activity (Figure 6.6). The gene lists of the top 20 differentially 
regulated genes in response to treatment with EBC-46 or TPA alone are included in the Appendix 
(p.286-297). .  
Treatment with EBC-46 on PBMCs in vitro resulted in an increased expression of pro-inflammatory 
mediators. Genes of interest included IL28RA, IL1F5, CSF1, IL12RB1, MMP19 and TNFRSF12A. 
Among the genes differentially regulated by TPA were heat shock proteins and TNF receptors 
CD40, IFiT3 (see Appendix). 
6.2.4 Functional pathway and upstream regulator analysis of gene expression data  
The data obtained in GeneSpring GX v12.5 following stringent methods of filtering for significant 
data, were subsequently uploaded to Ingenuity Pathway Analysis software (IPA Ingenuity Systems, 
Redwood City, CA, USA; www.ingenuity.com). To identify biological functions/diseases that were 
significant to the data sets, functional analyses were performed. 
As seen in Tables 6.11 – 6.14, there is no overlap of pathways involved upon treatment of the two 
compounds. The effects of TPA and EBC-46 individually on tumors were very different from each 
other. EBC-46 has proved to be efficacious on tumors in vivo compared to TPA. Hence, studying 
the pathways activated by EBC-46 at 4 h and 8 h after treatment showed significant up-regulation of 
pathways involved in inflammation: interferon pathways, IL-1, JAK/STAT pathways all of which 
clearly indicate the involvement of the immune system in the activity of EBC-46 on tumors. The 
top 20 canonical pathways identified following treatment for 4 hr and 8 hr with 30 µg of EBC-46 
(Tables 6.11 and 6.12) and TPA (Tables 6.13 and 6.14) are listed. 
The IPA Upstream Regulator Analysis was used to predict which upstream regulators were 
activated or inhibited to explain the pattern of significantly up- or down-regulated gene expression. 
A Z-activation score was statistically calculated at ≥ 2.0 to evaluate the known targets of upstream 
regulators and the predicted direction of change in gene expression by comparing the target’s actual  
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Table 6.11  List of top twenty Canonical Pathways identified following Ingenuity 
Pathway Analysis of the Sk-Mel-28 tumors in response to 30 µg of EBC-46 
after 4 hr of treatment. 
Ingenuity Canonical Pathways  -log(p-value) Ratio 
LPS/IL-1 Mediated Inhibition of RXR Function 2.72E+00 7.76E-02 
TNFR2 Signaling 2.20E+00 1.47E-01 
Lactose Degradation III 1.98E+00 2.86E-01 
Interferon Signaling 1.95E+00 1.39E-01 
Induction of Apoptosis by HIV1 1.88E+00 1.04E-01 
Activation of IRF by Cytosolic Pattern Recognition 
Receptors 1.84E+00 9.46E-02 
TNFR1 Signaling 1.82E+00 1.11E-01 
Role of JAK1, JAK2 and TYK2 in Interferon Signaling 1.74E+00 1.43E-01 
Dermatan Sulfate Biosynthesis (Late Stages) 1.51E+00 1.04E-01 
Retinoic acid Mediated Apoptosis Signaling 1.42E+00 8.22E-02 
Chondroitin Sulfate Biosynthesis (Late Stages) 1.40E+00 9.09E-02 
 Thiamin Salvage III 1.37E+00 2.00E-01 
4-hydroxybenzoate Biosynthesis 1.37E+00 5.00E-02 
4-hydroxyphenylpyruvate Biosynthesis 1.37E+00 2.00E-01 
D-myo-inositol (1,3,4)-trisphosphate Biosynthesis 1.33E+00 1.20E-01 
TWEAK Signaling 1.28E+00 1.03E-01 
  Heparan Sulfate Biosynthesis (Late Stages) 1.26E+00 8.06E-02 
Agrin Interactions at Neuromuscular Junction 1.16E+00 8.57E-02 
Chondroitin Sulfate Biosynthesis 1.14E+00 6.94E-02 
Neuregulin Signaling 1.13E+00 6.73E-02 
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Table 6.12 List of top twenty Canonical Pathways identified following Ingenuity 
Pathway Analysis of the Sk-Mel-28 tumors in response to 30 µg of EBC-
46 after 8 hr of treatment. 
Ingenuity Canonical Pathways  -log(p-value) Ratio 
Polyamine Regulation in Colon Cancer 3.05E+00 1.67E-01 
Fatty Acid β-oxidation III (Unsaturated, Odd Number) 2.43E+00 4.00E-01 
Antigen Presentation Pathway 2.07E+00 1.19E-01 
Factors Promoting Cardiogenesis in Vertebrates 1.92E+00 8.16E-02 
Pyrimidine Deoxyribonucleotides De Novo 
Biosynthesis I 1.92E+00 8.82E-02 
Mechanisms of Viral Exit from Host Cells 1.88E+00 1.11E-01 
UDP-N-acetyl-D-galactosamine Biosynthesis I 1.45E+00 3.33E-01 
Histidine Degradation VI 1.41E+00 1.00E-01 
Role of CHK Proteins in Cell Cycle Checkpoint Control 1.34E+00 8.47E-02 
Thyroid Cancer Signaling 1.28E+00 9.09E-02 
Sulfate Activation for Sulfonation 1.16E+00 1.25E-01 
CTLA4 Signaling in Cytotoxic T Lymphocytes 1.15E+00 6.25E-02 
Acute Phase Response Signaling 1.13E+00 5.52E-02 
TGF-β Signaling 1.13E+00 6.67E-02 
Intrinsic Prothrombin Activation Pathway 1.12E+00 8.11E-02 
Choline Biosynthesis III 1.12E+00 9.09E-02 
GABA Receptor Signaling 1.10E+00 7.14E-02 
Fatty Acid β-oxidation I 1.08E+00 6.67E-02 
Ethanol Degradation II 1.05E+00 6.98E-02 
Telomere Extension by Telomerase 1.01E+00 1.11E-01 
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Table 6.13 List of top twenty Canonical Pathways identified following Ingenuity 
Pathway Analysis of the Sk-Mel-28 tumors in response to 30 µg of 
TPA after 4 hr of treatment. 
Ingenuity Canonical Pathways  -log(p-value) Ratio 
LXR/RXR Activation 2.06E+00 3.60E-02 
Role of CHK Proteins in Cell Cycle Checkpoint Control 1.71E+00 5.08E-02 
Flavin Biosynthesis IV (Mammalian) 1.68E+00 1.25E-01 
Glycerol-3-phosphate Shuttle 1.68E+00 1.11E-01 
Mitotic Roles of Polo-Like Kinase 1.57E+00 4.05E-02 
Thyroid Hormone Metabolism II (via Conjugation and/or 
Degradation) 1.53E+00 3.77E-02 
Acute Phase Response Signaling 1.52E+00 2.76E-02 
Thyronamine and Iodothyronamine Metabolism 1.51E+00 7.69E-02 
Methionine Salvage II (Mammalian) 1.51E+00 1.11E-01 
Thyroid Hormone Metabolism I (via Deiodination) 1.51E+00 7.69E-02 
Triacylglycerol Biosynthesis 1.34E+00 4.35E-02 
AMPK Signaling 1.33E+00 2.22E-02 
Cardiac β-adrenergic Signaling 1.31E+00 2.53E-02 
Glycerol Degradation I 1.29E+00 8.33E-02 
Citrulline-Nitric Oxide Cycle 1.29E+00 6.25E-02 
Cell Cycle Regulation by BTG Family Proteins 1.29E+00 5.13E-02 
tRNA Splicing 1.29E+00 4.35E-02 
Antigen Presentation Pathway 1.27E+00 4.76E-02 
MIF Regulation of Innate Immunity 1.19E+00 3.85E-02 
Tryptophan Degradation to 2-amino-3-carboxymuconate 
Semialdehyde 1.15E+00 5.56E-02 
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Table 6.14 List of top twenty Canonical Pathways identified following Ingenuity 
Pathway Analysis of the Sk-Mel-28 tumors in response to 30 µg of TPA 
after 8 h of treatment. 
Ingenuity Canonical Pathways  -log(p-value) Ratio 
Signaling by Rho Family GTPases 2.53E+00 8.78E-02 
IL-8 Signaling 2.32E+00 8.44E-02 
RhoGDI Signaling 2.26E+00 8.96E-02 
Ephrin A Signaling 1.86E+00 1.30E-01 
2-ketoglutarate Dehydrogenase Complex 1.79E+00 2.22E-01 
Ephrin B Signaling 1.78E+00 1.10E-01 
GADD45 Signaling 1.77E+00 1.67E-01 
DNA damage-induced 14-3-3σ Signaling 1.77E+00 1.82E-01 
Germ Cell-Sertoli Cell Junction Signaling 1.71E+00 8.88E-02 
G Beta Gamma Signaling 1.70E+00 8.26E-02 
IL-1 Signaling 1.61E+00 9.17E-02 
Lymphotoxin β Receptor Signaling 1.60E+00 1.13E-01 
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 1.57E+00 1.22E-01 
Agrin Interactions at Neuromuscular Junction 1.56E+00 1.14E-01 
Regulation of Actin-based Motility by Rho 1.49E+00 9.89E-02 
TCA Cycle II (Eukaryotic) 1.48E+00 9.76E-02 
Actin Cytoskeleton Signaling 1.45E+00 7.44E-02 
Ceramide Degradation 1.42E+00 1.43E-01 
IL-17A Signaling in Fibroblasts 1.41E+00 1.25E-01 
Paxillin Signaling 1.41E+00 8.55E-02 
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direction of change in the dataset to expectations derived from the literature (Chen et al., 2013). 
Similarly, functional analysis of the top 20 pathways involved and the upstream regulator analysis 
of gene expression relative to the host response to EBC-46 or TPA, as well as the specific cellular 
response of human PBMCs to the effect of either diterpene esters have been included in the 
Appendix (298-301). Analysis of the canonical pathways regulated by EBC-46 or TPA did not 
result in any significant correlation between the differentially expressed genes to the canonical 
pathways at any of the time points which may indicate a rapidly changing gene expression. 
 
6.3 Discussion 
The results in the previous Chapters established that treatment of tumors in vivo with 30 µg of EBC-
46 delivered as 50 µl of 600 µg/ml led to tumor ablation with the induction of a host innate immune 
response. In this Chapter the molecular pathways involved for the phenotypic changes induced by 
treatment with EBC-46 were investigated in comparison to TPA using changes in gene expression 
specific for either mouse or human sequences. As expected for the rapid tumor ablation described in 
earlier Chapters, RNA yield dropped rapidly after treatment and transcriptional responses were 
likely to be changing rapidly and skewed towards the remaining survivors at the particular time 
point assayed. Nevertheless some useful pointers emerged from the analysis and could be followed 
up. In an attempt to model lymphocyte responses to non-toxic levels of drug, transcriptional 
changes were also followed in human PBMCs treated in culture; this also enabled some of the 
cytokine responses to be compared with the cytokines released as protein (Chapter Five). 
 
Human tumor genes differentially regulated in response to treatment with EBC-46 
The one group of genes that was strikingly up-regulated (>10X) at all early time points by EBC-46 
but not by TPA: small nucleolar RNAs (snoRNAs). SNORD3A is also known as RNU3, U3; 
SNORD3C as U3-3 and SNORD3D as U3-4. SnoRNAs are a class of small RNA molecules that 
primarily guide post-transcriptional modifications of cellular RNAs. Post-transcriptional 
modification in eukaryotic cells is a process by which precursor messenger RNA (pre-mRNA) is 
converted to mature messenger RNA (mRNA) by splicing of the introns which are non-coding 
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sections of the primary transcript RNA. There are two classes of snoRNAs, the C/D box snoRNAs, 
which are associated with methylation and the H/ACA box snoRNAs which are involved in 
pseudouridylation. snoRNAs are non-coding RNAs which are transcribed by RNA Pol II, which in 
turn are required for the maturation of pre-RNAs (Kiss, 2002). There is evidence in the literature 
that protein kinase C phosphorylates RNA Pol II through a reaction which is calcium and 
phospholipid dependent. Phosphorylation by PKC was shown to increase the downstream rate of 
RNA synthesis. This suggested a mechanism by which gene expression can be regulated by PKC 
(Chuang et al., 1987), in this situation associated with necrosis. 
Genes differentially regulated by the host in response to treatment with EBC-46 but not by TPA 
The murine host response to EBC-46, supplemented in part by the human PBMC response in vitro, 
demonstrated an increased involvement of the host innate immune system with significant 
expression of cytokines and other pro-inflammatory molecules. An evaluation of the gene lists 
obtained from the microarray analysis (Appendix) showed differential gene expression of the 
following genes of interest: 
Cxcl1: Cytokine belonging to the chemokine family and was previously called GRO1 oncogene, 
Neutrophil-activating protein 3 (NAP-3). This gene is expressed in macrophages, neutrophils and 
epithelial cells (Becker et al., 1994, Iida and Grotendorst, 1990) and has neutrophil chemoattractant 
activity (Moser et al., 1990, Schumacher et al., 1992). 
Gja1: encodes the Gap junction alpha-1 protein. The encoded protein interacts with MAPK7/ERK5 
of the MAPK pathway family which is essential for endothelial cell function (Roberts et al., 2009, 
Roberts et al., 2010). It is interesting to note that the immunohistochemical results from Chapter 
Four show that endothelial cells are reduced in number following EBC-46 treatment, as indicated 
by CD-31 staining. 
Defb6: Beta defensins are mammalian defensins which are antimicrobial peptides involved in the 
resistance of epithelial surfaces to microbial migration. Beta defensin genes are responsible for the 
production of antimicrobial peptides found in leukocytes such as neutrophils, macrophages and NK-
cells and are also found in epithelial cells (Ganz, 2003).  
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Ly6g6c: The Ly6g6c gene belongs to a cluster of leukocyte antigen-6 (LY6) gene located in major 
histocompatibility complex (MHC) class III region on chromosome 6. It is also known as G6c, 
C6orf24, NG24. Most of the LY6 proteins are attached to the cell surface by a 
glycosylphosphatidylinositol (GPI) anchor which is directly involved in signaling transduction 
(Mallya et al., 2002). 
Ccl4: also known as Macrophage inflammatory protein-1β (MIP-1β) is a chemoattractant for NK-
cells, monocytes and other immune cells (Bystry et al., 2001). It interacts with CCL3/MIP-1α 
which is involved in the recruitment and activation of granulocytes (Wolpe et al., 1988). 
Ncf1: The Neutrophil cytosolic factor 1 protein encoded by Ncf1 is a 47 kDa cytosolic subunit of 
neutrophil NADPH oxidase and is also called p47. The phosphorylated form of p47 plays a role in 
the respiratory burst of neutrophils (el Benna et al., 1994, El Benna et al., 1996). 
Ifi27: Interferon, alpha-inducible protein 27 is involved in epithelial proliferation and is a marker 
for cancer (Suomela et al., 2004). 
 
Genes differentially regulated in human PBMCs in vitro by treatment with EBC-46 but not by TPA 
Treatment of human PBMCs in vitro with 30 ng/ml of EBC-46 resulted in up-regulation within 4 hr 
of cytokines and other molecules involved in immune regulation such as IL28RA, IL1F5, MMP19, 
MAPKAP1 and CSF1 increased by 24 hr though none of these genes were consistently expressed at 
all time-points. Among genes encoding cytokines, some of the other genes of interest from those 
catalogued in the Appendix. 
MMP19: Matrix metalloproteinase-19 is a matrix metalloproteinase gene which is involved in the 
breakdown of the extracellular matrix. MMPs are known to be involved in the release of apoptotic 
ligands, cleavage of cell surface receptors and cytokine/chemokine activation/inhibition. Apart from 
cell proliferation, migration and apoptosis, they are also considered to play a role in immune 
defense mechanisms. 
MAPKAP1: is a mitogen-activated protein kinase which encodes a protein similar to the yeast SIN1 
protein which is a stress-activated protein kinase. 
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CSF1: Macrophage colony stimulating factor-1 is a cytokine which influences the proliferation, 
differentiation and survival of monocytes and macrophages (Stanley et al., 1997). 
The expression of some potentially relevant cytokines is shown in Table 6.15, a stronger and/or 
more prolonged response being found for several cytokines induced by EBC-46 compared with 
TPA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.15 Expression levels of Cytokines in PBMC microarray data upon treatment 
with 30 ng/ml TPA or EBC-46 at varying times, relative to controls 
 Treatment (hr) 
 4 24 96 
 
IL-1alpha 
   
46 1+ 15 1 
TPA 1 6 1 
    
IL-1beta    
46 1 26 1 
TPA 2.6 15 0.25 
    
IL6    
46 1 33 1 
TPA 1 29 1 
    
IL-8    
46 1 18 1 
TPA 2.4 19 0.4 
    
IL-9    
46 1 1 3.7 
TPA 1 1 1 
+  Ratios >0.5 and <2.0 were assigned the control value of 1. 
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Conclusion 
From the experimental data in Chapter Four, it was clear that EBC-46 was efficacious in treating 
tumors in mice compared to TPA. This may be due to the strong host inflammatory response upon 
intratumoral delivery of the drug as shown in Chapter Five. The results from the expression 
profiling of the tumor and the host response after treatment of human tumor Sk-Mel-28 xenografts 
in BALB/c Foxn1nu mice with EBC-46 in this chapter, may further support the results of the 
previous chapters. These results indicate that EBC-46 may induce recruitment of the host immune 
response in curing tumors in mice. Analysis of the expression profiles following treatment  revealed 
an up-regulation of pro-inflammatory markers, as predicted by the structure of EBC-46, and also 
showed an up-regulation of some cytokines which were validated by protein assays as shown in 
Chapter Five (Sections 5.2.3 and 5.2.4 on p.155 & 158-163). The profiles were then further 
examined by pathway analysis. However, functional analysis of gene expression patterns using IPA 
did not give any clear indication of any strongly regulated canonical pathway following EBC-46 
treatment; nor was there much of an overlap between the time points. The same was also 
demonstrated by the Venn diagram analysis, where differential gene expression in PBMCs treated 
with EBC-46 or TPA did not result in significant pathways regulated by EBC-46 treatment. 
Interestingly, EBC-46 treatment resulted in constant up-regulation of snoRNAs (small nucleolar 
RNAs) in Sk-Mel-28 tumors throughout the treatment period. snoRNAs are non-protein-coding 
RNAs whose main function is to guide site-specific rRNA modifications. Several functions have 
been tentatively attributed to transcripts of snoRNAs such as being regulators of stress responses 
including oxidative and metabolic stress (Cohen et al., 2013, Michel et al., 2011). However, these 
are mostly uncharacterized genes, hence there was no connection found between the EBC-46 – 
differentially regulated genes in tumors and the canonical pathways obtained through the Ingenuity 
Pathway Analysis (IPA) software. The mechanism of action of EBC-46 is hypothesized to involve 
the expression of SNORD3 because oxidative and ER stress are known to result in cell death 
(Aoshiba and Nagai, 2003, Choi et al., 2009, Han et al., 2013). To validate the microarray results in 
Section 6.2.1, expression levels of SNORD3 could be examined in control and treated tumors by 
real-time PCR. To further understand the pathways involved in the antitumor activity of EBC-46 
and the correlation with snoRNA regulation, over-expression of SNORD3 would need to be induced 
to determine its involvement on tumor growth inhibition in relation to EBC-46. 
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In summary the results provide a novel insight into the gene expression profile induced by EBC-46 
in comparison to TPA, notably in the context of in vivo treatment where profiling of the tumor site 
with mouse and human-specific arrays allowed tumor and host responses to be distinguished from 
each other.. The gene expression changes brought about in the tumor and the host as well as the 
specific cellular response of human PBMCs from treatment with the diterpene ester EBC-46 in 
comparison to TPA were determined. There was consistent up-regulation of snoRNAs in the tumor, 
which facilitate post-translational modifications occurring with EBC-46 from the earliest time after 
intratumoral injection up to 8 hr but not with TPA. In addition, the host response to treatment with 
EBC-46 indicated activation of some components of the host immune system, with potential for 
enhancing the antitumor activity of EBC-46 in mice. These observations of the host response to 
EBC-46 (Table 6.15) were consistent with the gene expression profile of human PBMCs (primarily 
B- and T-cells) suggesting the ability of EBC-46 to up-regulate proinflammatory cytokines that can 
recruit and activate neutrophils and macrophages to the site of infection. The results therefore 
provided molecular leads for understanding EBC-46 action in the complex tumour-host situation, as 
well as for probing the lack of efficacy of the more potent PMA. 
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7.1  Protein kinase C (PKC) as a therapeutic target for cancer. 
Protein kinase C has attracted considerable research attention since its discovery. PKC is a 
serine-threonine protein kinase C family activated by calcium and phospholipids which 
include twelve isoforms sub-classified into 4 classes; classical, novel, atypical and distant. 
The protein kinase C isoforms are physiologically activated by 1,2-diacylglycerol (DAG) by 
binding to the C1 domain of the enzyme. Activated PKCs are involved in a number of 
cellular functions such as cell proliferation, cell cycle progression, differentiation, 
cytoskeletal remodelling and apoptosis (Dekker et al., 1995, Olson et al., 1993). 
Previously, PKC inhibitors have been used to treat cancers. Some common PKC inhibitors 
used in cancer therapy are PKC412, Go6976, LY317615, UCN-01/02 (Masur et al., 2001, 
Seynaeve et al., 1993a). These compounds have been shown to either decrease invasion of 
tumor cells or inhibit angiogenesis. PKC inhibitors PKC412 and UCN-01 have been tested in 
Phase I-III studies in human clinical trials. However, as they bind strongly to plasma proteins, 
there was limited bioavailability thus resulting in poor clinical effects. As a result, and with 
the knowledge that PKCs have many and different functions within the cell, research interest 
has widened to include PKC activators such as phorbol ester TPA, Bryostatin-1 and PEP005 
(ingenol-3-angelate). 
The affinity of PKCs to bind with phorbol esters and be subsequently activated proved to be 
of significance in understanding the intracellular signal transduction systems (Blumberg, 
1988). Phorbol esters initially became the object of research interest as a result of their 
potency as skin tumor promoters (Fisher and Morgan, 1994, Boutwell, 1974). Phorbol esters 
are PKC activators which compete with DAG for the C1 binding domain of PKC isoforms. 
Recently PKC activators have received attention as more favourable anti-cancer agents to 
PKC inhibitors. The prototypic PKC activator  TPA (12-O-tetradecanoylphorbol-13-acetate) 
has been established to induce cytotoxic effects on cancer cells (Hofmann, 2001). TPA has 
also been trialed systemically on humans for the treatment of myeloid leukaemia with 
positive results showing complete or partial remission of cancer cells and also resulted in an 
increase of depressed count of white blood cells and neutrophils in chemotherapeutic patients 
(Han et al., 1998 (ii), Han et al., 1998 (i)). Previously in this laboratory another PKC 
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activator had been studied. PEP005 (ingenol 3-angelate; Ing3A), derived from Euphorbia 
peplus sap, was shown to cure mice of subcutaneous tumors with the induction of a host 
inflammatory reaction following topical application of this drug (Challacombe et al., 2006). 
PEP005 had also shown efficacy for melanoma models in pre-clinical studies with the 
disruption of the mitochondria and plasma membrane leading to primary necrosis (Ogbourne 
et al., 2004). A 2010 Phase III trial of PEP005 in gel formulation successfully reached a 
primary clinical endpoint of complete clearance of actinic keratosis in non-head locations 
(Pharma, 2010). Depending on the tumor type, PKC may be a good target for inhibition or 
activation.  
 
7.2  The cytotoxic profile of EBC-46 on tumor cell lines in vitro 
QBiotics, a sister concern of EcoBiotics Pty Ltd, located in North Queensland, Australia 
recently discovered another compound of the same class as TPA and PEP005, named EBC-
46 (12-tigloyl/angeloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-
tigliaen-3-one). Upon discovery it has been clinically tested on larger animals such as dogs, 
cats and horses resulting in more than 80% successful treatment of the various solid tumors. 
Elucidation of the structure of EBC-46, revealed similarities to the prototype PKC activator 
TPA, where both compounds shared a similar polycyclic backbone (Figure 3.1). We initially 
aimed to establish the bioactivity profile of the compound EBC-46 and determine its PKC 
activating ability. Preliminary studies on the effect of EBC-46 on melanoma cells in vitro 
demonstrated the bipolar transformation of MM96L melanoma cells upon treatment with the 
compound. This morphological change is an indication of PKC activity.  
The evidence provided in Chapter Three confirmed PKC as a target for EBC-46 as it 
demonstrated that EBC-46 translocated PKC isoforms with a C1 domain, namely the 
classical and novel PKCs, as effectively as TPA. Translocation of PKC isoforms, particularly 
–, was detected from the cytosol to the plasma membrane or other subcellular organelles 
such as the Golgi apparatus or mitochondria. An important difference between TPA and 
EBC-46 was the selective translocation of PKC isozymes. While TPA led to efficient 
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translocation of -α, -β1, -β2, -γ and –θ isoforms expressed in HeLa cells; EBC-46 
demonstrated more specificity for PKC-β, while PKC-α and –γ were less efficiently 
translocated possibly to nuclear/perinuclear regions. The differences in the subcellular 
localization of PKC isoforms may result in differences in substrate specificity thereby 
determining the downstream biological responses. 
Activation of PKC isoforms and their subsequent involvement in the MAPK pathway was 
confirmed by western blot analysis on B16-F0 mouse melanoma and Sk-Mel-28 human 
metastatic melanoma when treated with 1 µg/ml of TPA or EBC-46 following pre-treatment 
with 5 µM BIS-1 (pan PKC inhibitor) for 1 hr. B16-F0 cells once again established the strong 
expression of PKC-α as seen previously (Oka and Kikkawa, 2005, Rosenbaum and Niles, 
1992) while human metastatic melanoma Sk-Mel-28 established the activation of PKC 
isoforms -α, -δ, -ε, -θ and -ι (Figure 3.4) where there was high expression of α and δ in intact 
cells that lowered in expression levels upon treatment with the diterpene esters. Results of 
Chapter Three indicated the involvement of PKC activity in cell signaling where pre-
treatment with the pan PKC inhibitor BIS-1 greatly lowered the activation of the MAPK 
pathway.  
As shown in Chapter Three, activation of neutrophils by EBC-46 provided a molecular basis 
for PKC-dependent activation of the innate immune system by very low doses of TPA or 
EBC-46. In intact cells phorbol esters lead to activation of NADPH oxidase enzyme, the 
prime catalyst for this process which is brought about by the protein phosphorylation and its 
translocation to the plasma membrane (Cox et al., 1985). EBC-46 was found to be equally 
potent in inducing the production of ROS as TPA, at an optimal dose of 100 ng/ml (Figure 
3.6) which was inhibited upon pre-treatment with BIS-1 thus confirming the role of PKC 
activation. 
The preliminary studies looking at the effect of EBC-46 on MM96L melanoma cells in vitro 
also indicated a cytotoxic effect of the compound on cancer cells. To further analyze this 
effect, tumor cells of human and mouse origin were subjected to treatment with EBC-46 and 
TPA where growth inhibition of melanoma cell lines was obtained at an IC50 of ≤ 30 µg/ml of 
both diterpene esters. Other cancer cell lines assayed were derived from lung and blood, were 
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more sensitive to treatment with either diterpene ester where the cytotoxic effect of EBC-46 
was achieved at ~ 10 ng/ml. Comparison of the diterpene esters showed that TPA was more 
potent than EBC-46 in vitro resulting in approximately 10-fold difference in cytotoxicity 
which may be attributed to the differences in cell type, growth rates, sensitivity to the drug 
and metastatic nature of the cells. Diterpene ester sensitivity appeared to be increased with 
over-expression of PKC isoforms in melanoma cell lines. However this observation is 
arguable as the control lacZ showed increased sensitivity to EBC-46. Despite the increased 
sensitivity of the lacZ controls to growth inhibition by EBC-46 or TPA, the additional 
increase in sensitivity in the two cell lines (Sk-Mel-28 and D04) shown in Figure 3.9 of 
Chapter Three where PKC isoforms α and δ were over-expressed, indicate that the 
compounds activate PKC. 
 
7.3  The efficacy of EBC-46 in mouse tumor models 
Preliminary work with this compound in vivo suggested the possibility of the involvement of 
the innate immune response upon activation of PKC. Chapter Three provided evidence for 
the same, demonstrating the ability of EBC-46 to activate neutrophils to produce reactive 
oxygen species (ROS) via a PKC-dependent process. The potential anti-tumor activity and 
efficacy of EBC-46 on pre-clinical tumor models in vivo including melanoma and non-
melanomas was determined.  
Mice were subcutaneously inoculated with tumor cells injected at two sites per mouse. A 
comparison between a single intralesional injection of 30 µg of EBC-46 and 30 µg of TPA 
resulted in EBC-46 being more potent in vivo with 75% cures of B16-F0 tumors in C57BL/6J 
mice while TPA failed to cure tumors in mice resulting in relapses at all treated sites (Figure 
4.1). Topical application of TPA compared to PEP005 in previous studies demonstrated a 
more efficient penetration of PEP005 through the dermis than TPA since PEP005 is a 
substrate for the epidermal multidrug transporter (ABCB1) (Li et al., 2010).An optimal dose 
for treatment of tumors approximately 100 mm3 in volume was determined by comparing two 
treatment groups 10 µg versus 30 µg of EBC-46 against the control vehicle 20% PG 
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treatment where 30 µg of BEC-46 effectively cured 75% of the tumors. The cure rate was 
calculated based on cure at each tumor site where the remaining 25% signifies the 5 relapsed 
tumor sites out of the 20 treated (Figure 4.3). 
Similarly, EBC-46 on human melanoma xenografts Sk-Mel-28 in BALB/c Foxn1nu mice 
resulted in approximately 88% cure with total loss of tumor cells after 24 hr of treatment. 
There was an inflammatory reaction observed immediately after injection, which was more 
prominent on the hairless nude mice (BALB/c Foxn1nu). This reaction lead to the 
development of an eschar by day 13 which detached by day 20 after treatment. Phorbol ester 
TPA is known to be a skin irritant and inflammatory agent that induces prompt remodelling 
of the vasculature, resulting in edema formation (Janoff et al., 1970). A similar outcome was 
noted upon topical application of PEP005 for treatment of a range of tumors where 
neutrophils were identified as the major infiltrate playing a central role in preventing relapse 
through a mechanism known as antibody-dependent cell-mediated cytotoxicity (ADCC) 
(Challacombe et al., 2006, Ogbourne et al., 2004). 
As demonstrated in Chapter Three, over-expression of PKC isoforms in B16-F0 tumor cells 
did not significantly increase their sensitivity to treatment with EBC-46 in vitro reflecting a 
similar result in vivo when 30 µg of EBC-46 was used to treat B16-F0 tumors over-
expressing PKC isoforms -α and –δ. The volume of tumor inoculum in relation to volume of 
diterpene ester injected into the tumor was also investigated as a possible determinant of anti-
tumor efficacy which demonstrated that the smaller inoculums of tumor cells (Figures 4.5; A 
& B and Figure 4.9) responded positively to treatment with a single intratumoral injection 50 
µl of 600 µg/ml of EBC-46, suggesting that a larger tumor volume may require a larger 
volume of the drug to cover the wider target area. 
Apart from melanoma tumor models the efficacy of EBC-46 was tested on non-melanoma 
tumors, namely MC38 which is a mouse colon cancer. Similar to results obtained with 
treatment of 30 µg of EBC-46 on B16-F0 and Sk-Mel-28 tumors, MC38 tumor cell 
responded positively to the activity of EBC-46 resulting in 80% of total ablation of tumor 
cells with only 2 recurrences. This was most likely due to the growth of tumor cells deep 
below the skin in the muscle which may have occurred at the time of inoculation. Hence, 
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EBC-46 showed efficacy in ablating different types of tumors based on species of origin and 
type of tumor. 
 
7.4 Is the efficacy of EBC-46 dependent on its pro-inflammatory properties? 
The first indication of the link between inflammation and cancer was observed by Rudolf 
Virchow in the 19th century. The in vivo efficacy studies in Chapter Four resulted in a 
marked inhibition of growth of tumor cells with a clinical outcome of initial inflammation, 
followed by eschar development and eventual healing. Despite the differences in tumor types 
and growth rates and morphology, there was similar significant regression of tumor growth 
following treatment with a single intralesional injection of 30 µg of EBC-46. The rapid 
inflammatory reaction was visible as early as 2 hr after injection and either as a primary 
response or through a secondary mechanism resulted in clearance of tumors by day 20. 
From the histological results in Chapter Five it became clear that the predominant infiltrating 
cells into the EBC-46 – treated tumor were the peripheral blood mononuclear cells (PBMCs) 
or neutrophils and macrophages. Apart from these cells there was sparse presence of other 
immune cells such as mast cells (data not shown). Generally neutrophils exist to defend the 
host from invading pathogens and also assist in wound healing. Neutrophils are the most 
abundant leukocytes in the blood stream though they have very short life, which lasts for a 
few hours but survive longer under inflammatory conditions. Their release of soluble 
chemotactic factors changes the tumor microenvironment thus guiding the recruitment of 
immune effector cells (Di Carlo et al., 2001). However, other studies have indicated that the 
presence of granulocytes can result in tumor promotion with the release of cytokines and 
other inflammatory mediators (Coussens and Werb, 2001).  
There was no substantial expression of cytokines in mouse serum or the supernatants of 
treated tumor because the vascular damage leading to hemorrhagic necrosis cut off the 
circulating lymphocytes from exposure to significant concentrations of the drug. The only 
cytokines expressed above the accepted detection limit of < 10 pg/ml were MCP-1 and IL-6. 
However an in vitro co-culture of tumor cells in the presence of PBMCs and treated with 100 
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ng/ml EBC-46 resulted in high expression of cytokines that increased with time. Cytokine 
expression was shown to be greatly increased from 4-24 hr following treatment of tumor cells 
with EBC-46 in vitro when co-cultured with PBMCs resulting in high expression of IL-1β, 
IL-8, IL-6 and TNF-α which correlated with the histological observation of increased 
neutrophils and macrophages.  
These results indicated the importance of neutrophils in the activity of EBC-46. However, it 
was not clear whether EBC-46 required neutrophils or another immune response for its 
cytotoxic response on cancer cells, or whether it resulted in the direct cytotoxic effect on the 
cells and neutrophils were a secondary response to the tissue necrosis. To understand the 
requirement of neutrophils in the efficacy of EBC-46, peripheral neutrophils were depleted 
with a neutralizing antibody. There was an obvious clinical difference among the control 
EBC-46 treated group and the EBC-46 – treatment group which received the antibody Ly-6G. 
The group depleted of neutrophils had a greater number of persisting tumors or a faster 
recurrence rate while those that received only EBC-46 were totally ablated of tumors by days 
5-6.  
 
7.5 Mechanism of action of EBC-46 in vitro 
The mechanism of action of EBC-46 raises the question whether the compound has a direct 
cytotoxic effect on the cells with a secondary immune response or induces an immune 
response which results in its cytotoxic effect on tumor cells. There is support for the first 
theory of a direct cytotoxic effect of EBC-46 on tumor cells in culture. Tumor cell lines 
treated in vitro with high doses of either TPA or EBC-46 resulted in rapid killing of cells 
from as quickly as 30 min after treatment. More so, this effect is most likely a PKC-
dependent process which was established with the use of BIS-1 (a pan-PKC inhibitor). 
Histological analysis of the EBC-46 – treated tumors showed a decrease in the presence of 
endothelial cells with prolonged exposure to the compound supporting the observation of lack 
of blood pockets with the tumor by 4 hr after treatment leading to hemorrhagic necrosis and 
eventual tumor destruction. The in vitro results from high dose killing of HUVEC cells (data 
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not shown) further supported the hypothesis of endothelial and tumor destruction resulting in 
rapid killing of tumor cells in vivo in the dose range of 600 µg/ml administered intratumoraly. 
It was hypothesized that the cytotoxic activity of EBC-46 caused the rupture of the plasma 
membrane with subsequent organelle destruction. High concentrations of EBC-46 or TPA 
both resulted in necrosis at early treatment times in culture. Necrotic death results from the 
disruption of plasma and nuclear membrane and was identified by the loss of cellular 
structure and shrinkage appearing as black debris in culture plates (Figure 3.8, Panel B and C 
of Chapter Three). This loss of plasma membrane integrity was seen by the uptake of 
propidium iodide which provided evidence of necrosis in vitro when tumor cell lines were 
treated with high doses of EBC-46 (100 µg/ml, 200 µg/ml and 300 µg/ml) and stained with 
propidium iodide (Figure 4.12 of Chapter Four). 
 
7.6  Mechanism of action of EBC-46 in vivo and significance of the host response 
In contrast, there is evidence to support the second theory of the mechanism of action of 
EBC-46 with the stimulation of the innate immune system resulting in a cytotoxic effect on 
tumor cells. Infiltration of neutrophils and macrophages into the tumor microenvironment can 
carry out a destructive effect. The recruited PBMCs produce several cytotoxic mediators, 
including reactive oxygen species (ROS), proteases and soluble mediators of cell killing such 
as IL-1β, TNF-α, IL-8, interferon (IFN), IL-6 and MCP-1(Di Carlo et al., 2001) (Chapter 
Five). Neutrophils can either directly kill tumor cells by recruiting defensins or their release 
of cytokines/chemokines can recruit other mediators. Defensins are reported to be the most 
abundant component of the primary granule present in PBMCs and are highly toxic against 
several types of tumors (Di Carlo et al., 2001). Neutrophils can also exert their effect on 
tumor cells via an antibody-dependent cell mediated cytotoxicity (ADCC) (Di Carlo et al., 
2001, Kindzelskii and Petty, 1999) and hemorrhagic necrosis (Westlin and Gimbrone, 1993).  
Neutrophils migrate out of the vascular system to the site of infection in response to 
inflammatory stimuli; phagocytose foreign material with the release of superoxide, and other 
oxygen radicals produced by the NADPH oxidase and release inflammatory cytokines ad 
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chemokines into the tissue. Migration and stimulation of neutrophils to the site of infection is 
mediated by PKC isoforms. Neutrophils are reported to express PKC-α, -β and –δ 
(Balasubramanian et al., 1998, Bertram and Ley, 2011, Devalia et al., 1992, Smallwood and 
Malawista, 1992). This further strengthens our findings in Chapters Three and Five which 
show the expression of PKCs-α, -δ and –β by EBC-46 and the host innate immune response 
to its activity, respectively. 
Under inflammatory conditions, neutrophils and macrophages roll along the endothelium 
aided by mediators such as L-selectins and bind to proteins such as PSGL-1, LFA-1, Mac-1 
and ICAM-1 present on endothelial cells leading to the adhesion and extravasation of the 
immune cells to the site of infection with the help of pro-inflammatory mediators such as 
TNF-α and IL-8 (reviewed by Bertram et al. 2011). Cytokine expression levels following 
exposure to EBC-46 in mouse serum and tumor supernatants were found to be enhanced for 
IL-6 and MCP-1 in serum and IL-1β and IL-8 in the tumor microenvironment. However, 
gene expression data did not reveal any significant changes in expression levels for these 
specific molecules except for an up-regulation of TNF receptor 12A in PBMCs treated in 
vitro by EBC-46. The most significant differentially expressed genes were small nucleolar 
RNAs (SNORD3A, SNORD3C and SNORD3D) which were consistently up-regulated by 
EBC-46. These genes are said to be involved in post-transcriptional modifications. However, 
they are largely uncharacterized; hence further functional pathway analysis did not reveal any 
involvement of significant pathways relative to these genes. 
 
7.7 Concluding remarks and Future directions 
The results presented in this thesis have demonstrated that the in vitro activity of EBC-46 and 
TPA are similar with TPA being more potent resulting in cytotoxicity of tumor cells at doses 
10-fold lower than EBC-46 on certain tumor cell types. However, the same was not true for 
its efficacy in ablating tumors in vivo where EBC-46 resulted in more than 80% cure in mice. 
Further analysis of other MAPK pathways such as p38MAPK, JNK, PTEN, should be carried 
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out upon treatment with EBC-46 as phorbol esters such as TPA and PEP005 have shown to 
activate these molecules too in addition to the ERK1/2.  
As hypothesized, it was found that EBC-46 stimulated the innate immune system of the host 
through PKC isoform activation. Depending on the PKC isoform activated, diterpene esters 
can cause either tumor cell death or differentiation (Chang and Lee, 2006). Activation of 
PKC-α and –δ in neutrophils and the expression of cytotoxic leukocytes results in neutrophil 
and macrophage recruitment. In addition the endothelial cell marker was found to gradually 
decrease 8 hr after treatment with EBC-46, consistent with H&E histological analysis 
indicating a reduction in blood supply to the tumor site. It could therefore be concluded that 
EBC-46 ruptures the surrounding blood capillaries leading to devascularization of the tumor 
microenvironment. However the exact molecular mechanism is not clear yet and requires 
further investigation. The inflammatory responses including the evident hemorrhaging are 
both significant outcomes to the treatment with EBC-46. Such pathways should be studied by 
testing EBC-46 in 3D cultures with or without the presences of hemorrhage pathway 
inhibitors. Electron microscopy of treated HUVECs, fibroblasts, skin and tumor cells should 
be performed to provide a better understanding of the morphological effects of EBC-46 on 
the tumor microenvironment and vasculature alongside the molecular analysis. 
The requirement for neutrophils by EBC-46 in localized antitumor activity has been validated 
in Figure 5.6 of Chapter Five where tumor-bearing mice ablated of neutrophils were treated 
with EBC-46 and resulted in tumor recurrences in all mice by day 27. On the negative side, 
activation of neutrophils by EBC-46 that is released into the circulation could make the drug 
cytotoxic to the animal and thus could preclude treatment of metastasis.  
Previously interaction of P-gp (P-glycoprotein 1, also known as MDR1 or ABCB1), with 
phorbol esters has been shown to result in disruption of the tumor vasculature. PEP005 
compared to TPA was shown to be a substrate for P-gp. Hence PEP005 was better 
transported past the skin barrier to the tumor unlike TPA and similarly in contrast to the 
activity of TPA, it inhibited the function of P-gp as demonstrated by Li et al. in 2010. A 
similar inflammatory response and haemorrhaging has been observed upon intratumoral 
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injections with EBC-46. To further understand the mechanism of action of EBC-46 it would 
be worth investigating the interaction of EBC-46 with P-gp. 
Bright field images of tumor cells treated with EBC-46 in comparison to TPA, showed a 
necrotic effect of EBC-46. Though definitive nuclear fragmentation was indistinguishable, 
the disruption of the cell membrane and shrinkage was clearly evident in Figure 3.8, Panel B 
and C of Chapter Three. Comparable evidence of cell death is seen in the histological 
sections of treated tumors stained with hematoxylin & eosin in Figure 5.3, Chapter Five. 
Immunohistological analysis as well as in vitro cell death indicated by the uptake of 
propidium iodide determines the disruption of the plasma membrane. Though the 
photomicrographs of propidium iodide staining did not show definitive nuclear fragmentation 
(Figure 4.12, Chapter Four), the increased uptake of PI stain with increase in concentration 
was evidence of plasma and nuclear membrane disruption. Electron microscopy of cells 
treated with the diterpene ester EBC-46 would provide further insight into the morphological 
effect of the compound on tumor cells which can be further analyzed at a molecular level to 
determine the pathways leading up to cell death. Also the cytotoxic effect of EBC-46 on 
intracellular organelles such as mitochondria will be further studied through EM analysis of 
tumor samples.  
Altogether, EBC-46 was found to be an activator of PKC isoforms with a C1 binding domain, 
and is also efficacious in ablating tumors in mouse models of cancer. It displays a direct 
cytotoxic effect on tumor cells and stimulates the innate immune system resulting in tumor 
cell death by inflammation and hemorrhagic necrosis (Figure 7.1). 
Exploration of structure/activity relationships is usually desirable for fine tuning prototype 
drugs. Fontainea picrosperma, the plant from which EBC-46 is purified, produces a wide 
variety of related structures that have more or less hydrophobic C-12 and C-13 esters. These 
could be tested for efficacy in vivo because of potentially improved solubility, efficacy or 
long term stability. The complex phorbol skeleton has yet to be synthesized in toto. The 
ingenol ester PEP005 has recently been synthesized from a simple natural starting material, 
but required many steps and overall yield was very poor. Collaborating chemists have been 
able to vary the EBC-46 ester groups by partial synthesis, providing opportunities for more   
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Figure 7.1  Proposed Mechanism of Action of EBC-46 
Treatment with EBC-46, a PKC activator, results in rapid killing of tumor cells co-dependent on a host inflammatory response. 
 
 Chapter Seven 
________________________________________________________________________________ 
 
 
 
________________________________________________________________________________ 
 
Page | 217 
 
discoveries, but have found modification of the southern part of the molecule to be problematic. 
This is due to the 6-7 epoxy groups. The possibility of the epoxide reacting covalently with a highly 
reactive protein thiol should also be explored. 
A single formulation based on propylene glycol was used in this study because the excipient 
dissolved EBC-46 to the required level and because it is an accepted excipient for parenteral 
administration. The vehicle alone had little effect on mouse tumors but the high osmolarity of 
propylene glycol may contribute synergistically to local vascular damage. A range of alternative 
solubilizing agents are available for testing such as the cyclodextrins and even human albumen.  
Much was learnt during this project about the mechanism of action of EBC-46 but many questions 
remain unanswered, as well as for PEP005 discovered for topical treatment of tumor nearly 10 years 
ago. Such questions include why TPA is more effective than EBC-46 in vitro but less effective in 
vivo, the relative contributions of host versus tumor responses to efficacy, whether the proximal 
molecular target is a PKC isoform or some other C1 peptide bearing protein, and which of the 
various signaling pathways involving such molecules lead to the rapid destruction of tumors in vivo.  
With the realization that TPA activates non-kinase proteins, the effects of TPA treatment cannot be 
solely attributed to PKC regulation. To address this, EBC-46 was assessed in cytotoxicity 
experiments against cancer cells in vitro in the presence of a pan-PKC inhibitor, BIS-1 where cells 
pre-treated with BIS-1 failed to show the cytotoxic effect of EBC-46. Another study on the roles of 
activation and depletion of PKC isoforms in cell lines treated for 24 hr with TPA or PEP005 at 1 
µg/ml in the presence of BIS-1 showed similar results indicating the affinity of PEP005 for PKC 
isoforms (Cozzi et al., 2006). However, PEP005 was later shown to activate RasGRPs, which are 
Ras activators (Song et al., 2013). Hence, this would warrant further investigation into the 
downstream targets of EBC-46, other than PKC isoforms. 
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Table 1: Calculation chart titled “Monitoring of Tumor Bearing Mice” following 
clinical assessment criteris was used to measure the volume of tumors.  
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Figure 1:  Sk-Mel-28 tumor sections stained with H&E for histological analysis where 
tumors were treated with 20% PG vehicle control or 30 µg of EBC-46 
following treatment from 1 hr up to 7 days. 
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Figure 1 (contd.):  Sk-Mel-28 tumor sections stained with H&E for histological analysis 
where tumors treated with 20% PG vehicle control or 30 µg of EBC-
46 following treatment from 1 hr after  up to 7 days. 
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Figure 2:   Normal skin sections stained with MPO for neutrophils where skin treated with 20% PG 
vehicle control or 30 µg of EBC-46 following treatment from 1 hr after  up to 7 days 
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Figure 3:  Sk-Mel-28 tumor sections stained with MPO for neutrophils where tumors were treated 
with 20% PG vehicle control or 30 µg of EBC-46 following treatment from 1 hr after  up 
to 7 days. 
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Figure 3 (contd.):  Sk-Mel-28 tumor sections stained with MPO for neutrophils where tumors treated 
with 20% PG vehicle control or 30 µg of EBC-46 following treatment from 1 hr after  
up to 7 days. 
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Figure 4: Sk-Mel-28 tumor sections stained with F4/80 for macrophages where tumors treated with 
20% PG vehicle control or 30 µg of EBC-46 following treatment from 1 hr after  up to 7 
days 
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Figure 4 (contd.):  Sk-Mel-28 tumor sections stained with F4/80 for macrophages where tumors 
treated with 20% PG vehicle control or 30 µg of EBC-46 following treatment 
from 1 hr after  up to 7 days 
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Figure 5:   Sk-Mel-28 tumor sections stained with CD-31 for endothelial cells where tumors treated 
with 20% PG vehicle control or 30 µg of EBC-46 following treatment from 1 hr after 
treatment up to 7 days. 
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Figure 5 (contd.):  Sk-Mel-28 tumor sections stained with CD-31 for endothelial cells where tumors 
treated with 20% PG vehicle control or 30 µg of EBC-46 following treatment from 
1 hr after  up to 7 days. 
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Appendix Table 1: Top twenty genes significantly UP-regulated following 1 hr treatment by 30 µg EBC-46 (compared to vehicle control 
20% PG) in Sk-Mel-28 tumors as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID 
p 
Value 
Regulatio
n 
FC 
(abs) Symbol Definition 
2510164 0.009 up 14.037 SNORD3A Homo sapiens small nucleolar RNA, C/D box 3A (SNORD3A), small nucleolar RNA. 
580161 0.009 up 12.791 SNORD3C Homo sapiens small nucleolar RNA, C/D box 3C (SNORD3C), small nucleolar RNA. 
380685 0.010 up 11.884 SNORD3D Homo sapiens small nucleolar RNA, C/D box 3D (SNORD3D), small nucleolar RNA. 
2750475 0.029 up 1.701 D4S234E Homo sapiens DNA segment on chromosome 4 (unique) 234 expressed sequence (D4S234E), 
transcript variant 2, mRNA. 
6290142 0.047 up 1.669 LOC100008589 Homo sapiens 28S ribosomal RNA (LOC100008589), non-coding RNA. 
5310634 0.045 up 1.578 FASN Homo sapiens fatty acid synthase (FASN), mRNA. 
6840301 0.030 up 1.395 NT5DC2 Homo sapiens 5'-nucleotidase domain containing 2 (NT5DC2), mRNA. 
6280504 0.040 up 1.374 LOC100008589 Homo sapiens 28S ribosomal RNA (LOC100008589), non-coding RNA. 
840474 0.039 up 1.367 GSTZ1 Homo sapiens glutathione transferase zeta 1 (maleylacetoacetate isomerase) (GSTZ1), transcript 
variant 2, mRNA. 
3850722 0.040 up 1.365 TMEM185B Homo sapiens transmembrane protein 185B (pseudogene) (TMEM185B), non-coding RNA. 
4050056 0.045 up 1.341 TBC1D16 Homo sapiens TBC1 domain family, member 16 (TBC1D16), mRNA. 
3930356 0.028 up 1.319 SNX8 Homo sapiens sorting nexin 8 (SNX8), mRNA. 
3940458 0.010 up 1.319 CRYL1 Homo sapiens crystallin, lambda 1 (CRYL1), mRNA. 
4040605 0.010 up 1.310 PSEN2 Homo sapiens presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, mRNA. 
1030768 0.043 up 1.306 LDLRAP1 Homo sapiens low density lipoprotein receptor adaptor protein 1 (LDLRAP1), mRNA. 
4780364 0.012 up 1.305 C11orf1 Homo sapiens chromosome 11 open reading frame 1 (C11orf1), mRNA. 
7160161 0.029 up 1.305 S100A5 Homo sapiens S100 calcium binding protein A5 (S100A5), mRNA. 
4610215 0.042 up 1.299 CTNNBIP1 Homo sapiens catenin, beta interacting protein 1 (CTNNBIP1), transcript variant 1, mRNA. 
6590037 0.013 up 1.298 SLC20A2 Homo sapiens solute carrier family 20 (phosphate transporter), member 2 (SLC20A2), mRNA. 
2900221 0.022 up 1.297 LRRC18 Homo sapiens leucine rich repeat containing 18 (LRRC18), mRNA. 
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Appendix Table 2: Top twenty genes significantly DOWN-regulated following 1 hr treatment by 30 µg EBC-46 (compared to vehicle 
control 20% PG) in Sk-Mel-28 tumors as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID 
p 
Value Regulation 
FC 
(abs) Symbol Definition 
4490176 0.010 down 3.067 RGS1 Homo sapiens regulator of G-protein signaling 1 (RGS1), mRNA. 
7160239 0.038 down 2.896 FOSB Homo sapiens FBJ murine osteosarcoma viral oncogene homolog B (FOSB), mRNA. 
6400364 0.002 down 2.861 NR4A2 Homo sapiens nuclear receptor subfamily 4, group A, member 2 (NR4A2), transcript 
variant 1, mRNA. 
6510367 0.000 down 2.742 JUN Homo sapiens jun oncogene (JUN), mRNA. 
650639 0.001 down 2.583 NR4A2 Homo sapiens nuclear receptor subfamily 4, group A, member 2 (NR4A2), transcript 
variant 1, mRNA. 
3400019 0.010 down 2.576 RGS2 Homo sapiens regulator of G-protein signalling 2, 24kDa (RGS2), mRNA. 
6860377 0.035 down 2.364 DUSP1 Homo sapiens dual specificity phosphatase 1 (DUSP1), mRNA. 
3930605 0.034 down 2.323 CYR61 Homo sapiens cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA. 
4280017 0.009 down 2.036 FOS Homo sapiens v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS), mRNA. 
3440138 0.034 down 1.844 CLK1 Homo sapiens CDC-like kinase 1 (CLK1), mRNA. 
2900348 0.002 down 1.811 ZFP36 Homo sapiens zinc finger protein 36, C3H type, homolog (mouse) (ZFP36), mRNA. 
240682 0.015 down 1.788 ANKRD37 Homo sapiens ankyrin repeat domain 37 (ANKRD37), mRNA. 
5670465 0.011 down 1.775 ADM Homo sapiens adrenomedullin (ADM), mRNA. 
2810463 0.037 down 1.744 LOC729009 PREDICTED: Homo sapiens misc_RNA (LOC729009), miscRNA. 
7400653 0.000 down 1.684 PFKFB4 Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), mRNA. 
50309 0.050 down 1.679 DPYSL4 Homo sapiens dihydropyrimidinase-like 4 (DPYSL4), mRNA. 
4040097 0.046 down 1.605 KLF6 Homo sapiens Kruppel-like factor 6 (KLF6), transcript variant 2, mRNA. 
1690121 0.017 down 1.602 CLK1 Homo sapiens CDC-like kinase 1 (CLK1), mRNA. 
4730181 0.016 down 1.600 FTHL12 Homo sapiens ferritin, heavy polypeptide-like 12 (FTHL12) on chromosome 9. 
5720039 0.003 down 1.598 CXCL1 Homo sapiens chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, 
alpha) (CXCL1), mRNA. 
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Appendix Table 3: Top twenty genes significantly UP-regulated following 2 hr treatment by 30 µg EBC-46 (compared to vehicle 
control 20% PG) in Sk-Mel-28 tumors as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID p Value Regulation 
FC 
(abs) Symbol Definition 
580161 0.010 up 28.295 SNORD3C Homo sapiens small nucleolar RNA, C/D box 3C (SNORD3C), small nucleolar RNA. 
380685 0.018 up 24.886 SNORD3D Homo sapiens small nucleolar RNA, C/D box 3D (SNORD3D), small nucleolar RNA. 
2510164 0.019 up 24.431 SNORD3A Homo sapiens small nucleolar RNA, C/D box 3A (SNORD3A), small nucleolar RNA. 
3780767 0.002 up 4.210 LOC100132564 PREDICTED: Homo sapiens hypothetical protein LOC100132564 (LOC100132564), mRNA. 
3850168 0.036 up 2.059 LOC644936 Homo sapiens cytoplasmic beta-actin pseudogene (LOC644936), non-coding RNA. 
4390564 0.003 up 1.951 NUCKS1 Homo sapiens nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1), 
mRNA. 
3060377 0.026 up 1.779 MFAP4 Homo sapiens microfibrillar-associated protein 4 (MFAP4), mRNA. 
1850678 0.026 up 1.732 MCAM Homo sapiens melanoma cell adhesion molecule (MCAM), mRNA. 
2710286 0.043 up 1.716 LRP1 Homo sapiens low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) 
(LRP1), mRNA. 
7040019 0.045 up 1.710 PCSK2 Homo sapiens proprotein convertase subtilisin/kexin type 2 (PCSK2), mRNA. 
2470719 0.048 up 1.709 RTN3 Homo sapiens reticulon 3 (RTN3), transcript variant 1, mRNA. 
3930020 0.048 up 1.671 CTSF Homo sapiens cathepsin F (CTSF), mRNA. 
6940475 0.050 up 1.595 AKAP12 Homo sapiens A kinase (PRKA) anchor protein (gravin) 12 (AKAP12), transcript variant 1, 
mRNA. 
4230292 0.028 up 1.594 CD109 Homo sapiens CD109 molecule (CD109), mRNA. 
2000133 0.008 up 1.573 RNU12 Homo sapiens RNA, U12 small nuclear (RNU12) on chromosome X. 
2940110 0.043 up 1.558 UHRF1 Homo sapiens ubiquitin-like with PHD and ring finger domains 1 (UHRF1), transcript variant 
1, mRNA. 
5260594 0.017 up 1.547 AHNAK2 Homo sapiens AHNAK nucleoprotein 2 (AHNAK2), mRNA. 
60427 0.034 up 1.538 NUCB2 Homo sapiens nucleobindin 2 (NUCB2), mRNA. 
4050554 0.028 up 1.524 NMI Homo sapiens N-myc (and STAT) interactor (NMI), mRNA. 
3450521 0.031 up 1.521 ECM1 Homo sapiens extracellular matrix protein 1 (ECM1), transcript variant 2, mRNA. 
 Appendix 
_______________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________ 
 
Page | 264 
 
 
Appendix Table 4: Top twenty genes significantly DOWN-regulated following 2 hr treatment by 30 µg EBC-46 (compared to 
vehicle control 20% PG) in Sk-Mel-28 tumors as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID 
p 
Value Regulation 
FC 
(abs) Symbol Definition 
380327 0.019 down 2.002 LOC730820 PREDICTED: Homo sapiens similar to nuclear receptor binding factor 2 (LOC730820), mRNA. 
2370193 0.039 down 1.801 RPS15A Homo sapiens ribosomal protein S15a (RPS15A), transcript variant 2, mRNA. 
130717 0.036 down 1.787 ARPC1B Homo sapiens actin related protein 2/3 complex, subunit 1B, 41kDa (ARPC1B), mRNA. 
5360646 0.032 down 1.750 PSMC4 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4), transcript 
variant 1, mRNA. 
430309 0.048 down 1.740 C6orf66 Homo sapiens chromosome 6 open reading frame 66 (C6orf66), mRNA. 
7160239 0.045 down 1.725 FOSB Homo sapiens FBJ murine osteosarcoma viral oncogene homolog B (FOSB), mRNA. 
7040095 0.048 down 1.723 RPL17 Homo sapiens ribosomal protein L17 (RPL17), transcript variant 2, mRNA. 
460193 0.014 down 1.673 MAD2L1BP Homo sapiens MAD2L1 binding protein (MAD2L1BP), transcript variant 2, mRNA. 
1470349 0.034 down 1.616 RPLP0 Homo sapiens ribosomal protein, large, P0 (RPLP0), transcript variant 2, mRNA. 
130414 0.034 down 1.610 LOC730167 PREDICTED: Homo sapiens similar to protein tyrosine phosphatase 4a1, transcript variant 1 
(LOC730167), mRNA. 
5820133 0.034 down 1.607 AKIRIN1 Homo sapiens akirin 1 (AKIRIN1), mRNA. 
3460553 0.036 down 1.604 LOC440055 PREDICTED: Homo sapiens similar to ribosomal protein S12 (LOC440055), mRNA. 
3990497 0.002 down 1.588 SNORA61 Homo sapiens small nucleolar RNA, H/ACA box 61 (SNORA61), small nucleolar RNA. 
2680706 0.034 down 1.569 PGAM1 Homo sapiens phosphoglycerate mutase 1 (brain) (PGAM1), mRNA. 
5260717 0.038 down 1.569 SBDSP Homo sapiens Shwachman-Bodian-Diamond syndrome pseudogene (SBDSP) on chromosome 7. 
1230309 0.014 down 1.557 RPL26 Homo sapiens ribosomal protein L26 (RPL26), mRNA. 
6220671 0.015 down 1.548 PLAUR Homo sapiens plasminogen activator, urokinase receptor (PLAUR), transcript variant 2, mRNA. 
1850458 0.039 down 1.546 SLC25A26 Homo sapiens solute carrier family 25, member 26 (SLC25A26), transcript variant 1, mRNA. 
2120377 0.042 down 1.538 LOC100130561 PREDICTED: Homo sapiens similar to high-mobility group (nonhistone chromosomal) protein 
1-like 10, transcript variant 2 (LOC100130561), mRNA. 
3360608 0.049 down 1.533 RPS15A Homo sapiens ribosomal protein S15a (RPS15A), transcript variant 1, mRNA. 
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Appendix Table 5: Top twenty genes significantly UP-regulated following 4 hr treatment by 30 µg TPA (compared to vehicle control 20% 
PG) in Sk-Mel-28 tumors as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID 
p 
Value Regulation 
FC 
(abs) Symbol Definition 
4540475 0.042 up 2.072 FABP5L2 PREDICTED: Homo sapiens fatty acid binding protein 5-like 2 (FABP5L2), mRNA. 
580358 0.037 up 1.907 FABP5L2 PREDICTED: Homo sapiens fatty acid binding protein 5-like 2 (FABP5L2), mRNA. 
5270021 0.030 up 1.844 UBE2E2 Homo sapiens ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast) (UBE2E2), 
mRNA. 
2630044 0.002 up 1.390 NRIP3 Homo sapiens nuclear receptor interacting protein 3 (NRIP3), mRNA. 
6100301 0.040 up 1.367 CDC123 Homo sapiens cell division cycle 123 homolog (S. cerevisiae) (CDC123), mRNA. 
3870255 0.021 up 1.347 PPPDE1 Homo sapiens PPPDE peptidase domain containing 1 (PPPDE1), mRNA. 
6660709 0.016 up 1.338 TTC37 Homo sapiens tetratricopeptide repeat domain 37 (TTC37), mRNA. 
630682 0.016 up 1.328 LOC642956 PREDICTED: Homo sapiens hypothetical LOC642956 (LOC642956), mRNA. 
2060601 0.024 up 1.325 FABP5 Homo sapiens fatty acid binding protein 5 (psoriasis-associated) (FABP5), mRNA. 
3990324 0.046 up 1.323 TANC1 Homo sapiens tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 (TANC1), 
mRNA. 
1770133 0.011 up 1.299 LOC389599 PREDICTED: Homo sapiens similar to amyotrophic lateral sclerosis 2 (juvenile) 
chromosome region, candidate 2 (LOC389599), mRNA. 
6650079 0.032 up 1.289 C3orf14 Homo sapiens chromosome 3 open reading frame 14 (C3orf14), mRNA. 
6980255 0.018 up 1.287 LEPROT Homo sapiens leptin receptor overlapping transcript (LEPROT), mRNA. 
2190189 0.021 up 1.283 NOP58 Homo sapiens NOP58 ribonucleoprotein homolog (yeast) (NOP58), mRNA. 
6370538 0.022 up 1.276 WBSCR22 Homo sapiens Williams Beuren syndrome chromosome region 22 (WBSCR22), mRNA. 
4010020 0.049 up 1.219 ELF1 Homo sapiens E74-like factor 1 (ets domain transcription factor) (ELF1), mRNA. 
4860379 0.040 up 1.216 C5orf21 Homo sapiens chromosome 5 open reading frame 21 (C5orf21), mRNA. 
4590521 0.009 up 1.207 NDUFA1 Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa 
(NDUFA1), nuclear gene encoding mitochondrial protein, mRNA. 
1770021 0.038 up 1.193 LOC100130591 PREDICTED: Homo sapiens hypothetical protein LOC100130591 (LOC100130591), 
mRNA. 
6550240 0.021 up 1.187 C1orf114 Homo sapiens chromosome 1 open reading frame 114 (C1orf114), mRNA. 
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Appendix Table 6:   Top twenty genes significantly DOWN-regulated following 4 hr treatment by 30 µg TPA (compared to vehicle control 
20% PG) in Sk-Mel-28 tumors as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID p Value Regulation FC (abs) Symbol Definition 
7040008 0.047 down 1.776 CD74 Homo sapiens CD74 molecule, major histocompatibility complex, class II invariant chain 
(CD74), transcript variant 2, mRNA. 
4560047 0.049 down 1.720 CD74 Homo sapiens CD74 molecule, major histocompatibility complex, class II invariant chain 
(CD74), transcript variant 1, mRNA. 
7560041 0.033 down 1.667 AXUD1 Homo sapiens AXIN1 up-regulated 1 (AXUD1), mRNA. 
1190367 0.039 down 1.664 IER3 Homo sapiens immediate early response 3 (IER3), mRNA. 
5390161 0.009 down 1.632 DUSP5 Homo sapiens dual specificity phosphatase 5 (DUSP5), mRNA. 
1230767 0.040 down 1.568 IFITM2 Homo sapiens interferon induced transmembrane protein 2 (1-8D) (IFITM2), mRNA. 
5420564 0.023 down 1.471 NFIL3 Homo sapiens nuclear factor, interleukin 3 regulated (NFIL3), mRNA. 
5900725 0.010 down 1.431 PHLDA1 Homo sapiens pleckstrin homology-like domain, family A, member 1 (PHLDA1), mRNA. 
3190148 0.010 down 1.374 DDIT4 Homo sapiens DNA-damage-inducible transcript 4 (DDIT4), mRNA. 
1410079 0.043 down 1.342 CDC26 Homo sapiens cell division cycle 26 homolog (S. cerevisiae) (CDC26), mRNA. 
4920164 0.013 down 1.298 SIK1 Homo sapiens salt-inducible kinase 1 (SIK1), mRNA. 
1690678 0.038 down 1.298 SIK1 Homo sapiens salt-inducible kinase 1 (SIK1), mRNA. 
5960196 0.041 down 1.281 MOGAT1 Homo sapiens monoacylglycerol O-acyltransferase 1 (MOGAT1), mRNA. 
6590538 0.035 down 1.272 TF Homo sapiens transferrin (TF), mRNA. 
3400050 0.022 down 1.271 TBL3 Homo sapiens transducin (beta)-like 3 (TBL3), mRNA. 
510678 0.025 down 1.252 LOC643009 PREDICTED: Homo sapiens similar to gamma-glutamyltransferase 2, transcript variant 2 
(LOC643009), mRNA. 
2340598 0.011 down 1.242 ANKRD54 Homo sapiens ankyrin repeat domain 54 (ANKRD54), mRNA. 
10189 0.004 down 1.240 C19orf24 Homo sapiens chromosome 19 open reading frame 24 (C19orf24), mRNA. 
1580521 0.043 down 1.237 RNF167 Homo sapiens ring finger protein 167 (RNF167), mRNA. 
2760370 0.019 down 1.232 CALR Homo sapiens calreticulin (CALR), mRNA. 
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Appendix Table 7: Top twenty genes significantly UP-regulated following 8 hr treatment by 30 µg TPA (compared to vehicle control 20% 
PG) in Sk-Mel-28 tumors as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID p Value Regulation 
FC 
(abs) Symbol Definition 
3870338 0.012 up 2.106 IFI44L Homo sapiens interferon-induced protein 44-like (IFI44L), mRNA. 
7320372 0.021 up 1.755 EOMES Homo sapiens eomesodermin homolog (Xenopus laevis) (EOMES), mRNA. 
6860747 0.036 up 1.616 THNSL1 Homo sapiens threonine synthase-like 1 (S. cerevisiae) (THNSL1), mRNA. 
1440328 0.044 up 1.516 LOC100129848 PREDICTED: Homo sapiens hypothetical protein LOC100129848 (LOC100129848), mRNA. 
1010307 0.007 up 1.501 ACER2 Homo sapiens alkaline ceramidase 2 (ACER2), mRNA. 
2000148 0.020 up 1.490 IFIT1 Homo sapiens interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), transcript 
variant 2, mRNA. 
6860524 0.002 up 1.488 METTL3 Homo sapiens methyltransferase like 3 (METTL3), mRNA. 
4640750 0.009 up 1.482 HIBCH Homo sapiens 3-hydroxyisobutyryl-Coenzyme A hydrolase (HIBCH), nuclear gene encoding 
mitochondrial protein, transcript variant 2, mRNA. 
2230452 0.042 up 1.475 MRPL11 Homo sapiens mitochondrial ribosomal protein L11 (MRPL11), nuclear gene encoding 
mitochondrial protein, transcript variant 3, mRNA. 
3940411 0.033 up 1.473 MGC16169 Homo sapiens hypothetical protein MGC16169 (MGC16169), mRNA. 
1990630 0.031 up 1.456 TRIB3 Homo sapiens tribbles homolog 3 (Drosophila) (TRIB3), mRNA. 
6550288 0.038 up 1.441 KTELC1 Homo sapiens KTEL (Lys-Tyr-Glu-Leu) containing 1 (KTELC1), mRNA. 
5810273 0.002 up 1.438 C5orf53 Homo sapiens chromosome 5 open reading frame 53 (C5orf53), mRNA. 
2230201 0.049 up 1.436 TARBP1 Homo sapiens TAR (HIV-1) RNA binding protein 1 (TARBP1), mRNA. 
2260477 0.002 up 1.423 PTGS2 Homo sapiens prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and 
cyclooxygenase) (PTGS2), mRNA. 
5810681 0.018 up 1.422 ZMYM6 Homo sapiens zinc finger, MYM-type 6 (ZMYM6), mRNA. 
1850619 0.027 up 1.417 LOC645203 PREDICTED: Homo sapiens similar to transmembrane protein 14C (LOC645203), mRNA. 
2320707 0.003 up 1.415 RABL4 Homo sapiens RAB, member of RAS oncogene family-like 4 (RABL4), mRNA. 
2690435 0.020 up 1.409 IFIT1 Homo sapiens interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), transcript 
variant 2, mRNA. 
2480398 0.013 up 1.399 FAM27L Homo sapiens family with sequence similarity 27-like (FAM27L), mRNA. 
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Appendix Table 8: Top twenty genes significantly DOWN-regulated following 8 hr treatment by 30 µg TPA (compared to vehicle 
control 20% PG) in Sk-Mel-28 tumors as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID p Value Regulation FC (abs) Symbol Definition 
770743 0.043 down 1.800 MIR1978 Homo sapiens microRNA 1978 (MIR1978), microRNA. 
670025 0.036 down 1.711 CORO1C Homo sapiens coronin, actin binding protein, 1C (CORO1C), transcript variant 1, mRNA. 
6200402 0.044 down 1.702 MT1A Homo sapiens metallothionein 1A (MT1A), mRNA. 
3610215 0.007 down 1.624 LOC100131866 PREDICTED: Homo sapiens misc_RNA (LOC100131866), miscRNA. 
2470161 0.025 down 1.611 PLEKHF1 Homo sapiens pleckstrin homology domain containing, family F (with FYVE domain) 
member 1 (PLEKHF1), mRNA. 
5290161 0.010 down 1.597 C17orf91 Homo sapiens chromosome 17 open reading frame 91 (C17orf91), transcript variant 2, 
mRNA. 
3290037 0.013 down 1.592 DNAJC7 Homo sapiens DnaJ (Hsp40) homolog, subfamily C, member 7 (DNAJC7), mRNA. 
1070373 0.046 down 1.550 SNX30 Homo sapiens sorting nexin family member 30 (SNX30), mRNA. 
3170286 0.042 down 1.531 LOC647000 PREDICTED: Homo sapiens similar to tubulin, beta 5 (LOC647000), mRNA. 
2940398 0.009 down 1.528 CDCA2 Homo sapiens cell division cycle associated 2 (CDCA2), mRNA. 
6480332 0.006 down 1.503 C20orf117 Homo sapiens chromosome 20 open reading frame 117 (C20orf117), transcript variant 2, 
mRNA. 
770561 0.001 down 1.474 C20orf108 Homo sapiens chromosome 20 open reading frame 108 (C20orf108), mRNA. 
3520044 0.001 down 1.460 LOC100133866 PREDICTED: Homo sapiens similar to phosphodiesterase 4D interacting protein 
(myomegalin) (LOC100133866), mRNA. 
4150053 0.011 down 1.460 YBX1 Homo sapiens Y box binding protein 1 (YBX1), mRNA. 
6580039 0.011 down 1.453 PKM2 Homo sapiens pyruvate kinase, muscle (PKM2), transcript variant 1, mRNA. 
3370703 0.038 down 1.449 FEN1 Homo sapiens flap structure-specific endonuclease 1 (FEN1), mRNA. 
2470687 0.038 down 1.448 LOC645387 PREDICTED: Homo sapiens misc_RNA (LOC645387), miscRNA. 
360114 0.032 down 1.447 CTXN1 Homo sapiens cortexin 1 (CTXN1), mRNA. 
4290044 0.017 down 1.431 STRN4 Homo sapiens striatin, calmodulin binding protein 4 (STRN4), transcript variant 1, 
mRNA. 
2450202 0.028 down 1.427 KIF3C Homo sapiens kinesin family member 3C (KIF3C), mRNA. 
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Appendix Table 9: Top twenty genes significantly UP-regulated following 30 min treatment by EBC-46 (compared to TPA) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
5340064 15.849 up Pvalb Mus musculus parvalbumin (Pvalb), mRNA. 
4860577 9.893 up Actn3 Mus musculus actinin alpha 3 (Actn3), mRNA. 
4250750 9.760 up Pgam2 Mus musculus phosphoglycerate mutase 2 (Pgam2), mRNA. 
1190347 8.393 up Actn3 Mus musculus actinin alpha 3 (Actn3), mRNA. 
1850100 7.269 up Rpl3l Mus musculus ribosomal protein L3-like (Rpl3l), mRNA. 
1070397 7.047 up Mybpc2 Mus musculus myosin binding protein C, fast-type (Mybpc2), mRNA. 
4040435 6.581 up Chchd10 Mus musculus coiled-coil-helix-coiled-coil-helix domain containing 10 (Chchd10), mRNA. 
2260066 6.071 up Tnni2 Mus musculus troponin I, skeletal, fast 2 (Tnni2), mRNA. 
4290273 5.672 up Ampd1 Mus musculus adenosine monophosphate deaminase 1 (isoform M) (Ampd1), mRNA. XM_921992 
1240243 5.313 up Pfkm Mus musculus phosphofructokinase, muscle (Pfkm), mRNA. 
2470356 5.262 up Cox6a2 
Mus musculus cytochrome c oxidase, subunit VI a, polypeptide 2 (Cox6a2), nuclear gene encoding 
mitochondrial protein, mRNA. 
4860465 4.792 up Ttn Mus musculus titin (Ttn), transcript variant N2-B, mRNA. 
6060523 4.733 up Rtn2 Mus musculus reticulon 2 (Z-band associated protein) (Rtn2), transcript variant B, mRNA. 
4250148 4.660 up Tmod4 Mus musculus tropomodulin 4 (Tmod4), mRNA. 
5690092 4.342 up Ak1 Mus musculus adenylate kinase 1 (Ak1), mRNA. 
3190689 4.194 up Adssl1 Mus musculus adenylosuccinate synthetase like 1 (Adssl1), mRNA. 
1780411 4.030 up Des Mus musculus desmin (Des), mRNA. 
4810646 3.896 up Eef1a2 Mus musculus eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), mRNA. 
2850398 3.884 up Asb2 Mus musculus ankyrin repeat and SOCS box-containing 2 (Asb2), mRNA. 
1770468 3.830 up Adssl1 Mus musculus adenylosuccinate synthetase like 1 (Adssl1), mRNA. 
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Appendix Table 10: Top twenty genes significantly DOWN-regulated following 30 min treatment by EBC-46(compared to TPA) in mice 
as detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
4830543 5.431 down Ifi27 Mus musculus interferon, alpha-inducible protein 27 (Ifi27), mRNA. 
5360370 5.276 down OTTMUSG00000000971 
Mus musculus predicted gene, OTTMUSG00000000971 (OTTMUSG00000000971), 
mRNA. 
2480296 5.061 down LOC100048554 
PREDICTED: Mus musculus similar to monocyte chemoattractant protein-2 (MCP-2) 
(LOC100048554), mRNA. 
7510243 4.325 down C4b 
Mus musculus complement component 4B (Childo blood group) (C4b), mRNA. 
XM_921663 XM_921673 XM_921676 XM_921678 
7050538 4.015 down Ccl9 Mus musculus chemokine (C-C motif) ligand 9 (Ccl9), mRNA. 
4010082 3.722 down Ctgf Mus musculus connective tissue growth factor (Ctgf), mRNA. 
4200341 3.172 down Lbp Mus musculus lipopolysaccharide binding protein (Lbp), mRNA. 
3120465 3.132 down Cstb Mus musculus cystatin B (Cstb), mRNA. 
4070348 3.113 down Rpl3 Mus musculus ribosomal protein L3 (Rpl3), mRNA. 
830369 3.081 down Cyba Mus musculus cytochrome b-245, alpha polypeptide (Cyba), mRNA. 
2030465 3.057 down 1810064F22Rik Mus musculus RIKEN cDNA 1810064F22 gene (1810064F22Rik), mRNA. 
6770114 3.027 down Trem2 Mus musculus triggering receptor expressed on myeloid cells 2 (Trem2), mRNA. 
7330278 2.943 down Lgals1  
4210196 2.891 down Ednrb Mus musculus endothelin receptor type B (Ednrb), mRNA. 
6110204 2.851 down Ctsk Mus musculus cathepsin K (Ctsk), mRNA. 
1940370 2.841 down Tmsb4x Mus musculus thymosin, beta 4, X chromosome (Tmsb4x), mRNA. 
7380327 2.820 down Slc12a5 Mus musculus solute carrier family 12, member 5 (Slc12a5), mRNA. 
5080326 2.775 down S100a6 Mus musculus S100 calcium binding protein A6 (calcyclin) (S100a6), mRNA. 
2230544 2.723 down Col3a1 Mus musculus collagen, type III, alpha 1 (Col3a1), mRNA. 
3180543 2.714 down Sdpr Mus musculus serum deprivation response (Sdpr), mRNA. 
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Appendix Table 11: Top twenty genes significantly UP-regulated following 1 hr treatment by EBC-46 (compared to TPA) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
5360228 11.583 up Lor Mus musculus loricrin (Lor), mRNA. 
2070593 7.035 up Krt10 Mus musculus keratin 10 (Krt10), mRNA. 
830333 7.009 up Krtdap Mus musculus keratinocyte differentiation associated protein (Krtdap), mRNA. XM_923930 XM_923934 
3940682 5.266 up Dmkn Mus musculus dermokine (Dmkn), transcript variant 2, mRNA. 
50521 5.023 up Dmkn Mus musculus dermokine (Dmkn), transcript variant 2, mRNA. 
5270408 4.927 up Lce1m Mus musculus late cornified envelope 1M (Lce1m), mRNA. 
1260358 4.775 up Lce1b Mus musculus late cornified envelope 1B (Lce1b), mRNA. 
5550184 3.326 up Calm4 Mus musculus calmodulin 4 (Calm4), mRNA. 
5720450 3.323 up Lce1d Mus musculus late cornified envelope 1D (Lce1d), mRNA. 
4780048 3.016 up Lce1a2 Mus musculus late cornified envelope 1A2 (Lce1a2), mRNA. 
1740424 2.966 up Elovl4 Mus musculus elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 4 (Elovl4), mRNA. 
6420356 2.907 up Lce1c Mus musculus late cornified envelope 1C (Lce1c), mRNA. 
7150326 2.810 up Krt5 Mus musculus keratin 5 (Krt5), mRNA. 
6650730 2.722 up Lce1a1 Mus musculus late cornified envelope 1A1 (Lce1a1), mRNA. 
2510064 2.668 up Col17a1 Mus musculus collagen, type XVII, alpha 1 (Col17a1), mRNA. 
5670554 2.667 up Crct1 Mus musculus cysteine-rich C-terminal 1 (Crct1), mRNA. 
5260392 2.612 up Asprv1 Mus musculus aspartic peptidase, retroviral-like 1 (Asprv1), mRNA. 
4120463 2.520 up Flg2 Mus musculus filaggrin family member 2 (Flg2), mRNA. 
4480615 2.479 up Sbsn Mus musculus suprabasin (Sbsn), transcript variant 1, mRNA. 
6200446 2.439 up Klk8 Mus musculus kallikrein related-peptidase 8 (Klk8), mRNA. 
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Appendix Table 12: Top twenty genes significantly DOWN-regulated following 1 hr treatment by EBC-46 (compared to TPA) in mice 
as detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
5340064 6.695 down Pvalb Mus musculus parvalbumin (Pvalb), mRNA. 
5490528 5.882 down Myh2  
3420110 5.692 down Tnnc2 Mus musculus troponin C2, fast (Tnnc2), mRNA. 
130349 5.472 down Mylpf Mus musculus myosin light chain, phosphorylatable, fast skeletal muscle (Mylpf), mRNA. 
110707 4.476 down Tnnt3 Mus musculus troponin T3, skeletal, fast (Tnnt3), mRNA. 
1070397 4.080 down Mybpc2 Mus musculus myosin binding protein C, fast-type (Mybpc2), mRNA. 
2510053 3.743 down Ckm Mus musculus creatine kinase, muscle (Ckm), mRNA. 
4040386 3.570 down Hspb6 Mus musculus heat shock protein, alpha-crystallin-related, B6 (Hspb6), mRNA. 
10639 3.404 down Fhl1 Mus musculus four and a half LIM domains 1 (Fhl1), transcript variant 2, mRNA. 
7150685 3.343 down Tcap Mus musculus titin-cap (Tcap), mRNA. 
5550309 3.183 down Fhl1 Mus musculus four and a half LIM domains 1 (Fhl1), transcript variant 1, mRNA. 
1050678 3.154 down Actn2 Mus musculus actinin alpha 2 (Actn2), mRNA. 
1070088 2.793 down Tpm2 Mus musculus tropomyosin 2, beta (Tpm2), mRNA. 
1470154 2.792 down Mb Mus musculus myoglobin (Mb), mRNA. 
4220474 2.765 down Myh4 Mus musculus myosin, heavy polypeptide 4, skeletal muscle (Myh4), mRNA. 
3990609 2.637 down Nrap Mus musculus nebulin-related anchoring protein (Nrap), transcript variant 1, mRNA. 
4250750 2.546 down Pgam2 Mus musculus phosphoglycerate mutase 2 (Pgam2), mRNA. 
1110687 2.385 down Ryr1 Mus musculus ryanodine receptor 1, skeletal muscle (Ryr1), mRNA. 
2470133 2.368 down Csrp3 Mus musculus cysteine and glycine-rich protein 3 (Csrp3), mRNA. 
2470356 2.349 down Cox6a2 
Mus musculus cytochrome c oxidase, subunit VI a, polypeptide 2 (Cox6a2), nuclear gene encoding 
mitochondrial protein, mRNA. 
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Appendix Table 13: Top twenty genes significantly UP-regulated following 2 hr treatment by EBC-46 (compared to TPA) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
1470619 5.574 up Krt14 Mus musculus keratin 14 (Krt14), mRNA. 
5360228 2.831 up Lor Mus musculus loricrin (Lor), mRNA. 
2070593 2.357 up Krt10 Mus musculus keratin 10 (Krt10), mRNA. 
3290240 2.096 up Gpr34 Mus musculus G protein-coupled receptor 34 (Gpr34), mRNA. 
2680072 2.085 up Doxl2 Mus musculus diamine oxidase-like protein 2 (Doxl2), mRNA. 
2510064 2.002 up Col17a1 Mus musculus collagen, type XVII, alpha 1 (Col17a1), mRNA. 
 
 
Appendix Table 14: Top twenty genes significantly DOWN-regulated following 2 hr treatment by EBC-46 (compared to TPA) in mice 
as detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
4760356 2.006 down Cat Mus musculus catalase (Cat), mRNA. 
830273 2.045 down Ccl11 Mus musculus small chemokine (C-C motif) ligand 11 (Ccl11), mRNA. 
5570435 2.269 down Mup2 Mus musculus major urinary protein 2 (Mup2), transcript variant 1, mRNA. 
160402 2.329 down Ogn Mus musculus osteoglycin (Ogn), mRNA. 
1740008 4.281 down Ptx3  
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Appendix Table 15: Top twenty genes significantly UP-regulated following 4 hr treatment by EBC-46 (compared to TPA) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
3610082 12.110 up Cxcl1 Mus musculus chemokine (C-X-C motif) ligand 1 (Cxcl1), mRNA. 
1710193 10.742 up Gja1 Mus musculus gap junction membrane channel protein alpha 1 (Gja1), mRNA. 
1780341 10.015 up Krt17 Mus musculus keratin 17 (Krt17), mRNA. 
1470619 9.664 up Krt14 Mus musculus keratin 14 (Krt14), mRNA. 
2070593 8.638 up Krt10 Mus musculus keratin 10 (Krt10), mRNA. 
1780475 6.977 up Defb6 Mus musculus defensin beta 6 (Defb6), mRNA. 
6620008 6.092 up Ly6g6c Mus musculus lymphocyte antigen 6 complex, locus G6C (Ly6g6c), mRNA. 
7040184 5.713 up Lgals7 Mus musculus lectin, galactose binding, soluble 7 (Lgals7), mRNA. 
3940138 4.989 up Lypd3 Mus musculus Ly6/Plaur domain containing 3 (Lypd3), mRNA. 
6620079 4.727 up Egr1 Mus musculus early growth response 1 (Egr1), mRNA. 
2490288 4.586 up LOC100047935 PREDICTED: Mus musculus similar to ribosomal protein L5 (LOC100047935), misc RNA. 
4830543 4.455 up Ifi27 Mus musculus interferon, alpha-inducible protein 27 (Ifi27), mRNA. 
4060504 4.214 up Rpl36a Mus musculus ribosomal protein L36a (Rpl36a), mRNA. 
460682 4.121 up 2200001I15Rik Mus musculus RIKEN cDNA 2200001I15 gene (2200001I15Rik), mRNA. 
1190082 4.002 up Eif3i Mus musculus eukaryotic translation initiation factor 3, subunit I (Eif3i), mRNA. 
6770754 3.856 up Trim29 Mus musculus tripartite motif protein 29 (Trim29), mRNA. 
5900504 3.810 up Rpl34 Mus musculus ribosomal protein L34 (Rpl34), transcript variant 1, mRNA. 
830333 3.806 up Krtdap 
Mus musculus keratinocyte differentiation associated protein (Krtdap), mRNA. XM_923930 
XM_923934 
4070348 3.659 up Rpl3 Mus musculus ribosomal protein L3 (Rpl3), mRNA. 
1850327 3.654 up 2900010M23Rik Mus musculus RIKEN cDNA 2900010M23 gene (2900010M23Rik), mRNA. 
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Appendix Table 16: Top twenty genes significantly DOWN-regulated following 4 hr treatment by EBC-46 (compared to TPA) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
2230681 11.187 down Arpc1a Mus musculus actin related protein 2/3 complex, subunit 1A (Arpc1a), mRNA. 
830240 8.816 down Lyz2 Mus musculus lysozyme 2 (Lyz2), mRNA. 
7400050 5.767 down Bckdk 
Mus musculus branched chain ketoacid dehydrogenase kinase (Bckdk), nuclear gene encoding mitochondrial 
protein, mRNA. 
3460356 5.008 down Pdia3 Mus musculus protein disulfide isomerase associated 3 (Pdia3), mRNA. 
1170398 4.653 down Med25 Mus musculus mediator of RNA polymerase II transcription, subunit 25 homolog (yeast) (Med25), mRNA. 
2940678 4.544 down Rtn4 Mus musculus reticulon 4 (Rtn4), transcript variant 1, mRNA. 
4220753 4.510 down Gnai2 Mus musculus guanine nucleotide binding protein, alpha inhibiting 2 (Gnai2), mRNA. 
2470195 4.498 down Pcbp1 Mus musculus poly(rC) binding protein 1 (Pcbp1), mRNA. 
2060435 4.382 down Sfrs5 Mus musculus splicing factor, arginine/serine-rich 5 (SRp40, HRS) (Sfrs5), transcript variant 2, mRNA. 
6250022 4.374 down Uba1 Mus musculus ubiquitin-like modifier activating enzyme 1 (Uba1), mRNA. 
4490482 4.344 down Sf1 Mus musculus splicing factor 1 (Sf1), mRNA. XM_979946 XM_979979 
4050121 4.304 down Rbpms Mus musculus RNA binding protein gene with multiple splicing (Rbpms), transcript variant 3, mRNA. 
6130692 4.296 down Hnrpm Mus musculus heterogeneous nuclear ribonucleoprotein M (Hnrpm), mRNA. 
1260482 4.259 down Sparc Mus musculus secreted acidic cysteine rich glycoprotein (Sparc), mRNA. 
3450072 4.234 down Zmym3 Mus musculus zinc finger, MYM-type 3 (Zmym3), mRNA. 
1570373 4.141 down Csnk1e Mus musculus casein kinase 1, epsilon (Csnk1e), mRNA. 
6580376 4.048 down Zfhx3 Mus musculus zinc finger homeobox 3 (Zfhx3), mRNA. 
1450246 4.017 down Trpc4ap 
Mus musculus transient receptor potential cation channel, subfamily C, member 4 associated protein 
(Trpc4ap), mRNA. 
510341 3.995 down Rnf10 Mus musculus ring finger protein 10 (Rnf10), mRNA. 
4760129 3.965 down Camta2 Mus musculus calmodulin binding transcription activator 2 (Camta2), mRNA. 
 
 
 Appendix 
_______________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________ 
 
Page | 276 
 
 
Appendix Table 17: Top twenty genes significantly UP-regulated following 8 hr treatment by EBC-46 (compared to TPA) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs) Regulation  Symbol Definition 
3610082 20.710 up Cxcl1 Mus musculus chemokine (C-X-C motif) ligand 1 (Cxcl1), mRNA. 
2510053 14.251 up Ckm Mus musculus creatine kinase, muscle (Ckm), mRNA. 
4220474 10.225 up Myh4 Mus musculus myosin, heavy polypeptide 4, skeletal muscle (Myh4), mRNA. 
3360270 9.740 up Cox7a1 Mus musculus cytochrome c oxidase, subunit VIIa 1 (Cox7a1), mRNA. 
3440615 9.616 up Dscr1  
1230767 7.854 up Thbd Mus musculus thrombomodulin (Thbd), mRNA. 
150544 7.030 up Ankrd1 Mus musculus ankyrin repeat domain 1 (cardiac muscle) (Ankrd1), mRNA. 
6180202 6.003 up LOC100044702 PREDICTED: Mus musculus similar to LPS-induced CXC chemokine (LOC100044702), mRNA. 
6940184 5.886 up Ccl4 Mus musculus chemokine (C-C motif) ligand 4 (Ccl4), mRNA. 
4120131 5.807 up Pdk4 Mus musculus pyruvate dehydrogenase kinase, isoenzyme 4 (Pdk4), mRNA. 
4220575 5.571 up Dysfip1 Mus musculus dysferlin interacting protein 1 (Dysfip1), mRNA. 
1780598 5.210 up Ttn  
4860577 5.187 up Actn3 Mus musculus actinin alpha 3 (Actn3), mRNA. 
4860465 5.049 up Ttn Mus musculus titin (Ttn), transcript variant N2-B, mRNA. 
4900438 4.978 up Ppp1r3c Mus musculus protein phosphatase 1, regulatory (inhibitor) subunit 3C (Ppp1r3c), mRNA. 
870601 4.951 up Myoz1 Mus musculus myozenin 1 (Myoz1), mRNA. 
1850100 4.921 up Rpl3l Mus musculus ribosomal protein L3-like (Rpl3l), mRNA. 
4290273 4.881 up Ampd1 Mus musculus adenosine monophosphate deaminase 1 (isoform M) (Ampd1), mRNA. XM_921992 
1190347 4.595 up Actn3 Mus musculus actinin alpha 3 (Actn3), mRNA. 
610671 4.464 up Ampd1 Mus musculus adenosine monophosphate deaminase 1 (isoform M) (Ampd1), mRNA. XM_921992 
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Appendix Table 18: Top twenty genes significantly DOWN-regulated following 8 hr treatment by EBC-46 (compared to TPA) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
6280026 2.480 down H2-K1 Mus musculus histocompatibility 2, K1, K region (H2-K1), mRNA. 
5270408 2.253 down Lce1m Mus musculus late cornified envelope 1M (Lce1m), mRNA. 
1050215 2.201 down Smpd1 Mus musculus sphingomyelin phosphodiesterase 1, acid lysosomal (Smpd1), mRNA. 
7650035 2.084 down Serpinb12 Mus musculus serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 12 (Serpinb12), mRNA. 
6510653 2.083 down Ap2a1 Mus musculus adaptor protein complex AP-2, alpha 1 subunit (Ap2a1), transcript variant 2, mRNA. 
3460379 2.042 down Arhgef2 Mus musculus rho/rac guanine nucleotide exchange factor (GEF) 2 (Arhgef2), mRNA. 
2570747 2.041 down Ube2k Mus musculus ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) (Ube2k), mRNA. 
1820215 2.032 down BC039093  
 
 
 
 
 Appendix 
_______________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________ 
 
Page | 278 
 
 
Appendix Table 19: Top twenty genes significantly UP-regulated following 30 min treatment by TPA (compared to EBC-46) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
460576 6.545 up Fstl1 Mus musculus follistatin-like 1 (Fstl1), mRNA. 
2100402 6.345 up Bgn Mus musculus biglycan (Bgn), mRNA. 
6220026 6.112 up Zfp36 Mus musculus zinc finger protein 36 (Zfp36), mRNA. 
4570368 5.328 up Errfi1 Mus musculus ERBB receptor feedback inhibitor 1 (Errfi1), mRNA. 
7160603 5.121 up Sepp1 Mus musculus selenoprotein P, plasma, 1 (Sepp1), transcript variant 1, mRNA. 
5960497 4.385 up Tgfbr2 
Mus musculus transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, 
mRNA. 
1400053 4.356 up LOC100047583 PREDICTED: Mus musculus similar to apolipoprotein D (LOC100047583), mRNA. 
270324 4.300 up Tnc Mus musculus tenascin C (Tnc), mRNA. 
7210041 4.223 up Col6a1 Mus musculus procollagen, type VI, alpha 1 (Col6a1), mRNA. 
3170280 4.220 up Col6a1 Mus musculus procollagen, type VI, alpha 1 (Col6a1), mRNA. 
610414 4.177 up Ctsa Mus musculus cathepsin A (Ctsa), transcript variant 2, mRNA. 
4150386 3.947 up Col5a1 Mus musculus procollagen, type V, alpha 1 (Col5a1), mRNA. 
6180544 3.870 up Mmp3 Mus musculus matrix metallopeptidase 3 (Mmp3), mRNA. 
580332 3.561 up C1qb Mus musculus complement component 1, q subcomponent, beta polypeptide (C1qb), mRNA. 
1740112 3.515 up Loxl1 Mus musculus lysyl oxidase-like 1 (Loxl1), mRNA. 
6620079 3.510 up Egr1 Mus musculus early growth response 1 (Egr1), mRNA. 
3120014 3.429 up Junb Mus musculus Jun-B oncogene (Junb), mRNA. 
4010292 3.393 up Nid1 Mus musculus nidogen 1 (Nid1), mRNA. 
6270600 3.385 up Osm Mus musculus oncostatin M (Osm), mRNA. 
3520066 3.313 up Mmp14 Mus musculus matrix metallopeptidase 14 (membrane-inserted) (Mmp14), mRNA. 
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Appendix Table 20: Top twenty genes significantly DOWN-regulated following 30 min treatment by TPA (compared to EBC-46) in mice 
as detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
770086 3.070 down Uqcr Mus musculus ubiquinol-cytochrome c reductase (6.4kD) subunit (Uqcr), mRNA. 
7210156 3.007 down Ndufb8 Mus musculus NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 (Ndufb8), mRNA. 
10598 3.006 down Cxcl9 Mus musculus chemokine (C-X-C motif) ligand 9 (Cxcl9), mRNA. 
5550543 2.741 down 2010107E04Rik Mus musculus RIKEN cDNA 2010107E04 gene (2010107E04Rik), mRNA. 
610392 2.703 down Chchd1 Mus musculus coiled-coil-helix-coiled-coil-helix domain containing 1 (Chchd1), mRNA. 
3140110 2.616 down LOC100044779 PREDICTED: Mus musculus similar to prothymosin alpha (LOC100044779), misc RNA. 
4120768 2.566 down Dnaja1 Mus musculus DnaJ (Hsp40) homolog, subfamily A, member 1 (Dnaja1), mRNA. 
5910475 2.488 down Ndufs6 Mus musculus NADH dehydrogenase (ubiquinone) Fe-S protein 6 (Ndufs6), mRNA. 
610746 2.470 down Gjb6 Mus musculus gap junction protein, beta 6 (Gjb6), transcript variant 2, mRNA. 
870382 2.361 down 1110020P15Rik Mus musculus RIKEN cDNA 1110020P15 gene (1110020P15Rik), mRNA. 
5290475 2.346 down 1110020P15Rik Mus musculus RIKEN cDNA 1110020P15 gene (1110020P15Rik), mRNA. 
1410068 2.339 down LOC100048301 
PREDICTED: Mus musculus similar to RNA Polymerase II subunit 14.5 kD (LOC100048301), 
mRNA. 
290672 2.339 down Pfn2 Mus musculus profilin 2 (Pfn2), mRNA. 
1500707 2.338 down Gcnt1 Mus musculus glucosaminyl (N-acetyl) transferase 1, core 2 (Gcnt1), mRNA. 
830600 2.312 down Nags Mus musculus N-acetylglutamate synthase (Nags), transcript variant 2, mRNA. 
940612 2.307 down 4930579E17Rik  
4070538 2.305 down Timm8a1 
Mus musculus translocase of inner mitochondrial membrane 8 homolog a1 (yeast) (Timm8a1), 
mRNA. 
6650674 2.295 down Gulo Mus musculus gulonolactone (L-) oxidase (Gulo), mRNA. 
3130324 2.295 down 2610109H07Rik Mus musculus RIKEN cDNA 2610109H07 gene (2610109H07Rik), mRNA. 
4900646 2.286 down Tnni3k Mus musculus TNNI3 interacting kinase (Tnni3k), mRNA. 
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Appendix Table 21: Top twenty genes significantly UP-regulated following 1 hr treatment by TPA (compared to EBC-46) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
3890274 40.195 up Scd1 Mus musculus stearoyl-Coenzyme A desaturase 1 (Scd1), mRNA. 
5570435 19.943 up Mup2 Mus musculus major urinary protein 2 (Mup2), transcript variant 1, mRNA. 
3800706 12.354 up A030004J04Rik Mus musculus RIKEN cDNA A030004J04 gene (A030004J04Rik), mRNA. 
2490288 12.235 up LOC100047935 PREDICTED: Mus musculus similar to ribosomal protein L5 (LOC100047935), misc RNA. 
6940521 11.959 up LOC100040592 PREDICTED: Mus musculus similar to Hmgcs1 protein, transcript variant 1, mRNA. 
830632 11.782 up Fcgr4 Mus musculus Fc receptor, IgG, low affinity IV (Fcgr4), mRNA. 
2970612 9.306 up Rps21 Mus musculus ribosomal protein S21 (Rps21), mRNA. 
6270228 9.196 up S100a3 Mus musculus S100 calcium binding protein A3 (S100a3), mRNA. 
2710477 8.838 up Rps24 Mus musculus ribosomal protein S24 (Rps24), transcript variant 1, mRNA. 
5290475 8.458 up 1110020P15Rik Mus musculus RIKEN cDNA 1110020P15 gene (1110020P15Rik), mRNA. 
3060095 8.395 up Krt71 Mus musculus keratin 71 (Krt71), mRNA. 
1450333 8.383 up Clec7a Mus musculus C-type lectin domain family 7, member a (Clec7a), mRNA. 
2510707 8.360 up Rpl38 Mus musculus ribosomal protein L38 (Rpl38), transcript variant 1, mRNA. 
2480296 8.316 up LOC100048554 PREDICTED: Mus musculus similar to monocyte chemoattractant protein-2 (MCP-2) mRNA. 
4200100 7.984 up Dusp1 Mus musculus dual specificity phosphatase 1 (Dusp1), mRNA. 
2230730 6.934 up Gjb2 Mus musculus gap junction protein, beta 2 (Gjb2), mRNA. 
1980288 6.634 up Sumo1 Mus musculus SMT3 suppressor of mif two 3 homolog 1 (yeast) (Sumo1), mRNA. 
1070762 6.617 up Cox4i1  
2060561 6.573 up Npm3 Mus musculus nucleoplasmin 3 (Npm3), mRNA. 
2060326 6.571 up Lamp2  
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Appendix Table 22: Top twenty genes significantly DOWN-regulated following 1 hr treatment by TPA (compared to EBC-46) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
4780762 205.469 down Ubb Mus musculus ubiquitin B (Ubb), mRNA. 
2690315 166.960 down Rps14 Mus musculus ribosomal protein S14 (Rps14), mRNA. 
110092 141.548 down Gm1821 Mus musculus gene model 1821, (NCBI) (Gm1821), non-coding RNA. XM_899826 
6350128 123.934 down Rps12 Mus musculus ribosomal protein S12 (Rps12), mRNA. 
7570762 122.270 down EG668668 Mus musculus predicted gene, EG668668 (EG668668), mRNA. 
2000398 116.611 down Hba-a1 Mus musculus hemoglobin alpha, adult chain 1 (Hba-a1), mRNA. 
1170372 98.762 down Actb Mus musculus actin, beta (Actb), mRNA. 
540326 93.080 down Rplp1 Mus musculus ribosomal protein, large, P1 (Rplp1), mRNA. 
2260576 88.968 down Tuba1b Mus musculus tubulin, alpha 1B (Tuba1b), mRNA. 
6840433 73.512 down Npm1 Mus musculus nucleophosmin 1 (Npm1), mRNA. 
360437 73.104 down Maged2 Mus musculus melanoma antigen, family D, 2 (Maged2), mRNA. 
1030484 71.317 down Hnrpm Mus musculus heterogeneous nuclear ribonucleoprotein M (Hnrpm), mRNA. 
4900519 63.052 down Sgk1 Mus musculus serum/glucocorticoid regulated kinase 1 (Sgk1), mRNA. 
1580471 53.728 down Atp5g3 
Mus musculus ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), 
isoform 3 (Atp5g3), nuclear gene encoding mitochondrial protein, mRNA. 
4060056 52.536 down 
2310016E0
2Rik Mus musculus RIKEN cDNA 2310016E02 gene (2310016E02Rik), transcript variant 1, mRNA. 
3890626 51.641 down Eef1g Mus musculus eukaryotic translation elongation factor 1 gamma (Eef1g), mRNA. 
1070224 40.546 down Emp3 Mus musculus epithelial membrane protein 3 (Emp3), mRNA. 
2370593 40.367 down D4Ertd22e 
Mus musculus DNA segment, Chr 4, ERATO Doi 22, expressed (D4Ertd22e), transcript variant 1, 
mRNA. 
780093 33.011 down Cox6b1 Mus musculus cytochrome c oxidase, subunit VIb polypeptide 1 (Cox6b1), mRNA. 
4220670 31.871 down Pcbp2 Mus musculus poly(rC) binding protein 2 (Pcbp2), mRNA. 
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Appendix Table 23: Top twenty genes significantly UP-regulated following 2 hr treatment by TPA (compared to EBC-46) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs) Regulation  Symbol Definition 
2320491 226.756 up Tmem176a Mus musculus transmembrane protein 176A (Tmem176a), mRNA. 
4050427 200.327 up Tmem45a Mus musculus transmembrane protein 45a (Tmem45a), mRNA. 
4560372 173.990 up Tmem50b Mus musculus transmembrane protein 50B (Tmem50b), mRNA. 
7610411 147.482 up Frag1 Mus musculus FGF receptor activating protein 1 (Frag1), mRNA. 
3800161 130.603 up 1700063I17Rik Mus musculus RIKEN cDNA 1700063I17 gene (1700063I17Rik), mRNA. 
3390424 128.561 up Atg2a Mus musculus ATG2 autophagy related 2 homolog A (S. cerevisiae) (Atg2a), mRNA. 
4860132 110.497 up Rufy3 Mus musculus RUN and FYVE domain containing 3 (Rufy3), mRNA. 
1980202 96.246 up Ttc30b Mus musculus tetratricopeptide repeat domain 30B (Ttc30b), mRNA. XM_911984 XM_986297 
3990152 94.715 up Fsd1 Mus musculus fibronectin type 3 and SPRY domain-containing protein (Fsd1), mRNA. 
6860278 92.165 up Samhd1 Mus musculus SAM domain and HD domain, 1 (Samhd1), mRNA. 
7610736 91.208 up Zfp445 Mus musculus zinc finger protein 445 (Zfp445), mRNA. 
540156 88.253 up Chmp2a Mus musculus chromatin modifying protein 2A (Chmp2a), mRNA. 
3520382 82.188 up Upp2 Mus musculus uridine phosphorylase 2 (Upp2), mRNA. 
2710341 81.593 up Nsg2 Mus musculus neuron specific gene family member 2 (Nsg2), mRNA. 
3170136 78.898 up A430083B19Rik Mus musculus RIKEN cDNA A430083B19 gene (A430083B19Rik), mRNA. 
7050193 72.038 up Ly9  
3830390 70.808 up Grik5 Mus musculus glutamate receptor, ionotropic, kainate 5 (gamma 2) (Grik5), mRNA. 
4890056 63.200 up Wdr4 Mus musculus WD repeat domain 4 (Wdr4), mRNA. 
5050095 60.733 up 2310007F21Rik Mus musculus RIKEN cDNA 2310007F21 gene (2310007F21Rik), mRNA. 
6280477 59.576 up Ifng Mus musculus interferon gamma (Ifng), mRNA. 
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Appendix Table 24: Top twenty genes significantly DOWN-regulated following 2 hr treatment by TPA (compared to EBC-46) in mice 
as detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
6350128 251.199 down Rps12 Mus musculus ribosomal protein S12 (Rps12), mRNA. 
4780762 219.573 down Ubb Mus musculus ubiquitin B (Ubb), mRNA. 
2690315 191.865 down Rps14 Mus musculus ribosomal protein S14 (Rps14), mRNA. 
540326 163.775 down Rplp1 Mus musculus ribosomal protein, large, P1 (Rplp1), mRNA. 
110092 159.445 down Gm1821 Mus musculus gene model 1821, (NCBI) (Gm1821), non-coding RNA. XM_899826 
6420242 126.901 down 
LOC10004818
7 
PREDICTED: Mus musculus similar to ribosomal protein S27 (metallopanstimulin 1) 
(LOC100048187), mRNA. 
7200097 113.634 down 
LOC10003957
1 PREDICTED: Mus musculus similar to ribosomal protein L23a (LOC100039571), mRNA. 
7570762 106.215 down EG668668 Mus musculus predicted gene, EG668668 (EG668668), mRNA. 
2000398 97.573 down Hba-a1 Mus musculus hemoglobin alpha, adult chain 1 (Hba-a1), mRNA. 
1170372 91.060 down Actb Mus musculus actin, beta (Actb), mRNA. 
4060056 86.159 down 
2310016E02Ri
k 
Mus musculus RIKEN cDNA 2310016E02 gene (2310016E02Rik), transcript variant 1, 
mRNA. 
6280541 83.213 down Rps19 Mus musculus ribosomal protein S19 (Rps19), mRNA. 
3890626 76.798 down Eef1g Mus musculus eukaryotic translation elongation factor 1 gamma (Eef1g), mRNA. 
1580187 73.253 down Mat2a Mus musculus methionine adenosyltransferase II, alpha (Mat2a), mRNA. 
6840433 73.088 down Npm1 Mus musculus nucleophosmin 1 (Npm1), mRNA. 
360437 71.852 down Maged2 Mus musculus melanoma antigen, family D, 2 (Maged2), mRNA. 
2030575 70.792 down Ppia Mus musculus peptidylprolyl isomerase A (Ppia), mRNA. 
6520619 69.984 down 
LOC10004799
8 PREDICTED: Mus musculus similar to ribosomal protein L37a (LOC100047998), mRNA. 
5720609 66.005 down Lyz Mus musculus lysozyme (Lyz), mRNA. 
1580471 62.044 down Atp5g3 
Mus musculus ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 
9), isoform 3 (Atp5g3), nuclear gene encoding mitochondrial protein, mRNA. 
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Appendix Table 25: Top twenty genes significantly UP-regulated following 4 hr treatment by TPA (compared to EBC-46) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
3360608 8.740 up Cfd Mus musculus complement factor D (adipsin) (Cfd), mRNA. 
1050678 3.439 up Actn2 Mus musculus actinin alpha 2 (Actn2), mRNA. 
4040386 2.881 up Hspb6 Mus musculus heat shock protein, alpha-crystallin-related, B6 (Hspb6), mRNA. 
6100612 2.642 up Pde4dip 
Mus musculus phosphodiesterase 4D interacting protein (myomegalin) (Pde4dip), transcript 
variant 1, mRNA. 
3610296 2.554 up Krtap16-3 Mus musculus keratin associated protein 16-3 (Krtap16-3), mRNA. 
1780411 2.540 up Des Mus musculus desmin (Des), mRNA. 
2510561 2.457 up Myl4 Mus musculus myosin, light polypeptide 4 (Myl4), mRNA. 
6860228 2.386 up Myh1 Mus musculus myosin, heavy polypeptide 1, skeletal muscle, adult (Myh1), mRNA. 
7150685 2.361 up Tcap Mus musculus titin-cap (Tcap), mRNA. 
4810450 2.219 up Adipoq Mus musculus adiponectin, C1Q and collagen domain containing (Adipoq), mRNA. 
4220364 2.214 up Ryr1 Mus musculus ryanodine receptor 1, skeletal muscle (Ryr1), mRNA. 
3990609 2.137 up Nrap Mus musculus nebulin-related anchoring protein (Nrap), transcript variant 1, mRNA. 
5220279 2.094 up Mt1 Mus musculus metallothionein 1 (Mt1), mRNA. 
7510243 2.051 up C4b 
Mus musculus complement component 4B (Childo blood group) (C4b), mRNA. XM_921663 
XM_921673 XM_921676 XM_921678 
2470133 2.016 up Csrp3 Mus musculus cysteine and glycine-rich protein 3 (Csrp3), mRNA. 
6100403 2.016 up 
8030451F13Ri
k Mus musculus RIKEN cDNA 8030451F13 gene (8030451F13Rik), mRNA. 
4490358 2.013 up Bloc1s1 
Mus musculus biogenesis of lysosome-related organelles complex-1, subunit 1 (Bloc1s1), 
mRNA. 
3440615 2.012 up Dscr1  
3120259 2.001 up Rnf114 Mus musculus ring finger protein 114 (Rnf114), mRNA. 
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Appendix Table 26: Top twenty genes significantly DOWN-regulated following 4 hr treatment by TPA (compared to EBC-46) in mice 
as detected on MouseRef-8 v2.0 BeadChips. 
 
ProbeID FC (abs)  Regulation  Symbol Definition 
5050750 2.451 down Med15 Mus musculus mediator complex subunit 15 (Med15), transcript variant 1, mRNA. 
6180544 2.117 down Mmp3 Mus musculus matrix metallopeptidase 3 (Mmp3), mRNA. 
6580470 2.040 down Mapk3  
510368 2.010 down Fos Mus musculus FBJ osteosarcoma oncogene (Fos), mRNA. 
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Appendix Table 27: Top twenty genes significantly UP-regulated following 8 hr treatment by TPA (compared to EBC-46) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
6060379 198.425 up Cdc2a Mus musculus cell division cycle 2 homolog A (S. pombe) (Cdc2a), mRNA. 
7510736 177.471 up Prl7a1 Mus musculus prolactin family 7, subfamily a, member 1 (Prl7a1), mRNA. 
2680133 163.174 up BC057371 Mus musculus cDNA sequence BC057371 (BC057371), mRNA. 
3370246 139.275 up Tmem110 Mus musculus transmembrane protein 110 (Tmem110), mRNA. 
5860204 136.629 up Og9x  
3290754 131.347 up Jarid1c  
7400544 122.666 up Tspyl1 Mus musculus testis-specific protein, Y-encoded-like 1 (Tspyl1), mRNA. 
3310746 107.408 up Ercc2 
Mus musculus excision repair cross-complementing rodent repair deficiency, 
complementation group 2 (Ercc2), mRNA. 
5390113 105.452 up 
OTTMUSG000000
16790 
Mus musculus predicted gene, OTTMUSG00000016790 (OTTMUSG00000016790), 
mRNA. 
3400609 105.040 up Lcmt1 Mus musculus leucine carboxyl methyltransferase 1 (Lcmt1), mRNA. 
4670008 100.948 up Mbd1 Mus musculus methyl-CpG binding domain protein 1 (Mbd1), mRNA. 
4590615 90.688 up Ccdc9 Mus musculus coiled-coil domain containing 9 (Ccdc9), mRNA. 
3520300 87.946 up Ncf1 Mus musculus neutrophil cytosolic factor 1 (Ncf1), mRNA. 
2570538 82.011 up LOC100047653 
PREDICTED: Mus musculus hypothetical protein LOC100047653, transcript variant 2 
(LOC100047653), mRNA. 
1260301 67.610 up Spint2 
Mus musculus serine protease inhibitor, Kunitz type 2 (Spint2), transcript variant 1, 
mRNA. 
3310484 60.909 up Mterfd1 Mus musculus MTERF domain containing 1 (Mterfd1), mRNA. 
1010204 58.736 up Wwtr1 Mus musculus WW domain containing transcription regulator 1 (Wwtr1), mRNA. 
7210736 57.206 up Gipc1 Mus musculus GIPC PDZ domain containing family, member 1 (Gipc1), mRNA. 
3830167 55.629 up Trim60 Mus musculus tripartite motif-containing 60 (Trim60), mRNA. 
2630348 54.816 up Dnase1 Mus musculus deoxyribonuclease I (Dnase1), mRNA. 
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Appendix Table 28: Top twenty genes significantly DOWN-regulated following 8 hr treatment by TPA (compared to EBC-46) in mice as 
detected on MouseRef-8 v2.0 BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
6350128 225.202 down Rps12 Mus musculus ribosomal protein S12 (Rps12), mRNA. 
4780762 200.248 down Ubb Mus musculus ubiquitin B (Ubb), mRNA. 
540326 177.389 down Rplp1 Mus musculus ribosomal protein, large, P1 (Rplp1), mRNA. 
2690315 170.250 down Rps14 Mus musculus ribosomal protein S14 (Rps14), mRNA. 
110092 160.279 down Gm1821 Mus musculus gene model 1821, (NCBI) (Gm1821), non-coding RNA. XM_899826 
7570762 141.669 down EG668668 Mus musculus predicted gene, EG668668 (EG668668), mRNA. 
1170372 94.878 down Actb Mus musculus actin, beta (Actb), mRNA. 
2000398 93.457 down Hba-a1 Mus musculus hemoglobin alpha, adult chain 1 (Hba-a1), mRNA. 
2260576 88.299 down Tuba1b Mus musculus tubulin, alpha 1B (Tuba1b), mRNA. 
1580471 86.363 down Atp5g3 
Mus musculus ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 3 
(Atp5g3), nuclear gene encoding mitochondrial protein, mRNA. 
4060056 79.448 down 2310016E02Rik Mus musculus RIKEN cDNA 2310016E02 gene (2310016E02Rik), transcript variant 1, mRNA. 
6520619 77.653 down LOC100047998 PREDICTED: Mus musculus similar to ribosomal protein L37a (LOC100047998), mRNA. 
6420242 77.376 down LOC100048187 
PREDICTED: Mus musculus similar to ribosomal protein S27 (metallopanstimulin 1) (LOC100048187), 
mRNA. 
360437 77.314 down Maged2 Mus musculus melanoma antigen, family D, 2 (Maged2), mRNA. 
6840433 73.169 down Npm1 Mus musculus nucleophosmin 1 (Npm1), mRNA. 
780093 63.526 down Cox6b1 Mus musculus cytochrome c oxidase, subunit VIb polypeptide 1 (Cox6b1), mRNA. 
7050300 61.216 down Eif4a2 Mus musculus eukaryotic translation initiation factor 4A2 (Eif4a2), mRNA. 
1470470 59.576 down Serf2 Mus musculus small EDRK-rich factor 2 (Serf2), mRNA. 
1580280 57.107 down Fth1 Mus musculus ferritin heavy chain 1 (Fth1), mRNA. 
6940014 50.841 down Tmem147 Mus musculus transmembrane protein 147 (Tmem147), mRNA. 
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Appendix Table 29: Top twenty genes significantly UP-regulated in PBMCs following 4 hr treatment by 30 ng/ml of EBC-46 (compared 
to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
450762 2.388 up FCGR2A Homo sapiens Fc fragment of IgG, low affinity IIa, receptor (CD32) (FCGR2A), mRNA. 
2190349 2.036 up KCNJ15 Homo sapiens potassium inwardly-rectifying channel, subfamily J, member 15 (KCNJ15), transcript variant 3, 
mRNA. 
3520398 2.090 up IL28RA Homo sapiens interleukin 28 receptor, alpha (interferon, lambda receptor) (IL28RA), transcript variant 1, 
mRNA. 
990474 2.105 up TAF9 Homo sapiens TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa (TAF9), 
transcript variant 2, mRNA. 
130181 2.822 up ANKRD22 Homo sapiens ankyrin repeat domain 22 (ANKRD22), mRNA. 
5570398 4.240 up FCGR1C Homo sapiens Fc fragment of IgG, high affinity Ic, receptor (CD64) (FCGR1C), mRNA. 
5270132 2.053 up CBLB Homo sapiens Cas-Br-M (murine) ecotropic retroviral transforming sequence b (CBLB), mRNA. 
1510364 3.203 up GBP5 Homo sapiens guanylate binding protein 5 (GBP5), mRNA. 
7040537 2.389 up TAF9 Homo sapiens TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa (TAF9), 
transcript variant 3, mRNA. 
20010 2.106 up CARS Homo sapiens cysteinyl-tRNA synthetase (CARS), transcript variant 4, mRNA. 
430630 2.034 up HSPA9 Homo sapiens heat shock 70kDa protein 9 (mortalin) (HSPA9), nuclear gene encoding mitochondrial protein, 
mRNA. 
3400722 2.126 up C7orf57 Homo sapiens chromosome 7 open reading frame 57 (C7orf57), mRNA. 
3420253 2.017 up CSTF3 Homo sapiens cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kDa (CSTF3), transcript variant 2, 
mRNA. 
3440400 2.251 up TMCC3 Homo sapiens transmembrane and coiled-coil domain family 3 (TMCC3), mRNA. 
5700707 3.134 up SPRED1 Homo sapiens sprouty-related, EVH1 domain containing 1 (SPRED1), mRNA. 
1240528 2.511 up IL1F5 Homo sapiens interleukin 1 family, member 5 (delta) (IL1F5), transcript variant 2, mRNA. 
1030463 2.395 up PROK2 Homo sapiens prokineticin 2 (PROK2), mRNA. 
2970164 2.220 up EDNRB Homo sapiens endothelin receptor type B (EDNRB), transcript variant 1, mRNA. 
3440735 2.025 up C10orf141 Homo sapiens chromosome 10 open reading frame 141 (C10orf141), mRNA. 
5220093 2.001 up HAVCR2 Homo sapiens hepatitis A virus cellular receptor 2 (HAVCR2), mRNA. 
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Appendix Table 30: Top twenty genes significantly DOWN-regulated in PBMCs following 4 hr treatment by 30 ng/ml of EBC-46 
(compared to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
5560193 3.194 down BCAS4 Homo sapiens breast carcinoma amplified sequence 4 (BCAS4), transcript variant 1, mRNA. 
6620392 3.187 down LFNG Homo sapiens LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase (LFNG), transcript variant 1, 
mRNA. 
670711 3.140 down PLCL2 Homo sapiens phospholipase C-like 2 (PLCL2), mRNA. 
2450129 3.121 down FLOT2 Homo sapiens flotillin 2 (FLOT2), mRNA. 
3710647 3.030 down MXD4 Homo sapiens MAX dimerization protein 4 (MXD4), mRNA. 
3710685 2.941 down CARD9 Homo sapiens caspase recruitment domain family, member 9 (CARD9), mRNA. 
1470215 2.914 down MAP3K8 Homo sapiens mitogen-activated protein kinase kinase kinase 8 (MAP3K8), mRNA. 
3450201 2.836 down FAM65B Homo sapiens family with sequence similarity 65, member B (FAM65B), transcript variant 2, mRNA. 
6330471 2.793 down BLK Homo sapiens B lymphoid tyrosine kinase (BLK), mRNA. 
7200743 2.770 down SLAMF6 Homo sapiens SLAM family member 6 (SLAMF6), mRNA. 
1050672 2.712 down CKAP2 Homo sapiens cytoskeleton associated protein 2 (CKAP2), transcript variant 2, mRNA. 
5290239 2.707 down XRCC6BP1 Homo sapiens XRCC6 binding protein 1 (XRCC6BP1), mRNA. 
1170703 2.693 down RCSD1 Homo sapiens RCSD domain containing 1 (RCSD1), mRNA. 
1430717 2.669 down BTN3A3 Homo sapiens butyrophilin, subfamily 3, member A3 (BTN3A3), transcript variant 2, mRNA. 
3120292 2.668 down FAM117B Homo sapiens family with sequence similarity 117, member B (FAM117B), mRNA. 
940152 2.632 down MKNK2 Homo sapiens MAP kinase interacting serine/threonine kinase 2 (MKNK2), transcript variant 1, mRNA. 
4830458 2.630 down GMPPB Homo sapiens GDP-mannose pyrophosphorylase B (GMPPB), transcript variant 2, mRNA. 
6960215 2.627 down PITPNM1 Homo sapiens phosphatidylinositol transfer protein, membrane-associated 1 (PITPNM1), mRNA. 
2060411 2.605 down LOC652616 PREDICTED: Homo sapiens similar to neutrophil cytosolic factor 1 (LOC652616), mRNA. 
5900286 2.604 down ZFP90 Homo sapiens zinc finger protein 90 homolog (mouse) (ZFP90), mRNA. 
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Appendix Table 31: Top twenty genes significantly UP-regulated in PBMCs following 24 hr treatment by 30 ng/ml of EBC-46 
(compared to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
5960196 2.109 up MOGAT1 Homo sapiens monoacylglycerol O-acyltransferase 1 (MOGAT1), mRNA. 
520162 2.896 up HPSE Homo sapiens heparanase (HPSE), mRNA. 
450674 2.403 up C10orf128 PREDICTED: Homo sapiens chromosome 10 open reading frame 128, transcript variant 5 (C10orf128), 
mRNA. 
2710746 2.385 up BCAR1 Homo sapiens breast cancer anti-estrogen resistance 1 (BCAR1), mRNA. 
5080131 2.116 up MGST1 Homo sapiens microsomal glutathione S-transferase 1 (MGST1), transcript variant 1a, mRNA. 
5690202 2.389 up AKIRIN2 Homo sapiens akirin 2 (AKIRIN2), mRNA. 
3940754 2.468 up CD226 Homo sapiens CD226 molecule (CD226), mRNA. 
6330270 6.610 up GPC4 Homo sapiens glypican 4 (GPC4), mRNA. 
7650689 2.636 up  ij82b05.y1 Human insulinoma Homo sapiens cDNA clone IMAGE: 5777984 5, mRNA sequence 
4230672 2.077 up LOC653496 PREDICTED: Homo sapiens similar to hypothetical gene supported by AK123662 (LOC653496), mRNA. 
5720184 4.393 up KLF10 Homo sapiens Kruppel-like factor 10 (KLF10), transcript variant 1, mRNA. 
7150619 2.765 up CSF1 Homo sapiens colony stimulating factor 1 (macrophage) (CSF1), transcript variant 1, mRNA. 
510576 2.112 up BCOR Homo sapiens BCL6 co-repressor (BCOR), transcript variant 1, mRNA. 
60102 2.114 up MAPKAP1 Homo sapiens mitogen-activated protein kinase associated protein 1 (MAPKAP1), transcript variant 6, 
mRNA. 
6400370 2.057 up IL12RB1 Homo sapiens interleukin 12 receptor, beta 1 (IL12RB1), transcript variant 2, mRNA. 
5260546 3.225 up ADAM17 Homo sapiens ADAM metallopeptidase domain 17 (ADAM17), mRNA. 
3420253 2.288 up CSTF3 Homo sapiens cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kDa (CSTF3), transcript variant 2, 
mRNA. 
6450687 2.021 up EXOSC7 Homo sapiens exosome component 7 (EXOSC7), mRNA. 
7150551 2.742 up MMP19 Homo sapiens matrix metallopeptidase 19 (MMP19), transcript variant 2, mRNA. 
2970164 2.640 up EDNRB Homo sapiens endothelin receptor type B (EDNRB), transcript variant 1, mRNA. 
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Appendix Table 32: Top twenty genes significantly DOWN-regulated in PBMCs following 24 hr treatment by 30 ng/ml of EBC-46 
(compared to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
2640619 2.931 down ZNF91 Homo sapiens zinc finger protein 91 (ZNF91), mRNA. 
7200240 2.731 down ARHGAP4 Homo sapiens Rho GTPase activating protein 4 (ARHGAP4), mRNA. 
1500189 2.686 down CD81 Homo sapiens CD81 molecule (CD81), mRNA. 
1410603 2.649 down RAB3IP Homo sapiens RAB3A interacting protein (rabin3) (RAB3IP), transcript variant A, mRNA. 
6370576 2.639 down TREM2 Homo sapiens triggering receptor expressed on myeloid cells 2 (TREM2), mRNA. 
1940273 2.567 down SGSM2 Homo sapiens small G protein signaling modulator 2 (SGSM2), transcript variant 1, mRNA. 
6480095 2.543 down SNX27 Homo sapiens sorting nexin family member 27 (SNX27), mRNA. 
6220438 2.518 down RPS6KA5 Homo sapiens ribosomal protein S6 kinase, 90kDa, polypeptide 5 (RPS6KA5), transcript variant 1, 
mRNA. 
3290292 2.491 down LAP3 Homo sapiens leucine aminopeptidase 3 (LAP3), mRNA. 
940639 2.472 down ERP27 Homo sapiens endoplasmic reticulum protein 27 kDa (ERP27), mRNA. 
2710682 2.462 down NQO2 Homo sapiens NAD(P)H dehydrogenase, quinone 2 (NQO2), mRNA. 
3890689 2.418 down CD247 Homo sapiens CD247 molecule (CD247), transcript variant 1, mRNA. 
6960288 2.402 down  Homo sapiens cDNA FLJ36653 fis, clone UTERU2001176 
240025 2.400 down CNPY3 Homo sapiens canopy 3 homolog (zebrafish) (CNPY3), mRNA. 
4120367 2.386 down LPCAT2 Homo sapiens lysophosphatidylcholine acyltransferase 2 (LPCAT2), mRNA. 
1070097 2.368 down TPCN1 Homo sapiens two pore segment channel 1 (TPCN1), mRNA. 
5050537 2.367 down OPLAH Homo sapiens 5-oxoprolinase (ATP-hydrolysing) (OPLAH), mRNA. 
6660626 2.353 down BRD3 Homo sapiens bromodomain containing 3 (BRD3), mRNA. 
1980521 2.349 down SLC44A2 Homo sapiens solute carrier family 44, member 2 (SLC44A2), mRNA. 
130086 2.347 down CYB561 Homo sapiens cytochrome b-561 (CYB561), transcript variant 1, mRNA. 
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Appendix Table 33: Top twenty genes significantly UP-regulated in PBMCs following 96 hr treatment by 30 ng/ml of EBC-46 (compared 
to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
1190064 3.911 up UGT2B7 PREDICTED: Homo sapiens UDP glucuronosyltransferase 2 family, polypeptide B7 (UGT2B7), mRNA. 
5420450 2.519 up UGT2B7 PREDICTED: Homo sapiens UDP glucuronosyltransferase 2 family, polypeptide B7 (UGT2B7), mRNA. 
4010491 2.906 up CST6 PREDICTED: Homo sapiens cystatin E/M (CST6), mRNA. 
3520092 2.064 up BAX Homo sapiens BCL2-associated X protein (BAX), transcript variant sigma, mRNA. 
2510253 2.301 up C10orf35 Homo sapiens chromosome 10 open reading frame 35 (C10orf35), mRNA. 
130717 2.466 up ARPC1B Homo sapiens actin related protein 2/3 complex, subunit 1B, 41kDa (ARPC1B), mRNA. 
510114 3.844 up CCNB1IP1 Homo sapiens cyclin B1 interacting protein 1 (CCNB1IP1), transcript variant 3, mRNA. 
6980167 2.340 up C21orf121 Homo sapiens chromosome 21 open reading frame 121 (C21orf121), mRNA. 
6510377 3.268 up TNFRSF12A Homo sapiens tumor necrosis factor receptor superfamily, member 12A (TNFRSF12A), mRNA. 
7050064 4.389 up RAMP1 Homo sapiens receptor (G protein-coupled) activity modifying protein 1 (RAMP1), mRNA. 
5570139 3.435 up QPCT Homo sapiens glutaminyl-peptide cyclotransferase (QPCT), mRNA. 
7550348 2.150 up NUP188 Homo sapiens nucleoporin 188kDa (NUP188), mRNA. 
1990196 2.067 up DACT3 Homo sapiens dapper, antagonist of beta-catenin, homolog 3 (Xenopus laevis) (DACT3), mRNA. 
2710575 6.069 up CD69 Homo sapiens CD69 molecule (CD69), mRNA. 
5420474 2.025 up HSPBL2 Homo sapiens heat shock 27kDa protein-like 2 pseudogene (HSPBL2), non-coding RNA. 
5570520 3.053 up RRAD Homo sapiens Ras-related associated with diabetes (RRAD), mRNA. 
7200639 2.523 up RRAD Homo sapiens Ras-related associated with diabetes (RRAD), mRNA. 
2940075 2.103 up STRADB Homo sapiens STE20-related kinase adaptor beta (STRADB), mRNA. 
1990630 2.275 up TRIB3 Homo sapiens tribbles homolog 3 (Drosophila) (TRIB3), mRNA. 
1340039 2.072 up TFPI Homo sapiens tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) (TFPI), 
transcript variant 1, mRNA. 
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Appendix Table 34: Top twenty genes significantly DOWN-regulated in PBMCs following 96 hr treatment by 30 ng/ml of EBC-46 
(compared to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
6370369 210.764 down CD14 Homo sapiens CD14 molecule (CD14), transcript variant 2, mRNA. 
4010296 171.783 down RNASE1 Homo sapiens ribonuclease, RNase A family, 1 (pancreatic) (RNASE1), transcript variant 1, mRNA. 
6660398 88.364 down FCN1 Homo sapiens ficolin (collagen/fibrinogen domain containing) 1 (FCN1), mRNA. 
1090307 58.509 down RNASE1 Homo sapiens ribonuclease, RNase A family, 1 (pancreatic) (RNASE1), transcript variant 3, mRNA. 
2260129 51.553 down MS4A6A Homo sapiens membrane-spanning 4-domains, subfamily A, member 6A (MS4A6A), transcript 
variant 2, mRNA. 
2060121 49.915 down FUCA1 Homo sapiens fucosidase, alpha-L- 1, tissue (FUCA1), mRNA. 
5310402 42.935 down FPR3 Homo sapiens formyl peptide receptor 3 (FPR3), mRNA. 
4560129 34.977 down LGMN Homo sapiens legumain (LGMN), transcript variant 2, mRNA. 
2470184 25.810 down ADAMDEC1 Homo sapiens ADAM-like, decysin 1 (ADAMDEC1), mRNA. 
6270553 23.977 down CXCL10 Homo sapiens chemokine (C-X-C motif) ligand 10 (CXCL10), mRNA. 
7560138 23.377 down PMP22 Homo sapiens peripheral myelin protein 22 (PMP22), transcript variant 2, mRNA. 
3180039 19.224 down RGL1 Homo sapiens ral guanine nucleotide dissociation stimulator-like 1 (RGL1), mRNA. 
6060484 17.002 down MARCKS Homo sapiens myristoylated alanine-rich protein kinase C substrate (MARCKS), mRNA. 
1690056 13.284 down LYZ Homo sapiens lysozyme (renal amyloidosis) (LYZ), mRNA. 
1510538 12.917 down EPB41L3 Homo sapiens erythrocyte membrane protein band 4.1-like 3 (EPB41L3), mRNA. 
3990433 11.953 down ADAP2 Homo sapiens ArfGAP with dual PH domains 2 (ADAP2), mRNA. 
2190717 11.363 down IL18BP Homo sapiens interleukin 18 binding protein (IL18BP), transcript variant A, mRNA. 
2750685 10.402 down LOC392437 PREDICTED: Homo sapiens misc_RNA (LOC392437), miscRNA. 
6450543 9.526 down CST3 Homo sapiens cystatin C (CST3), mRNA. 
3390594 8.779 down KLRD1 Homo sapiens killer cell lectin-like receptor subfamily D, member 1 (KLRD1), transcript variant 1, 
mRNA. 
 
 Appendix 
_______________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________ 
 
Page | 294 
 
 
Appendix Table 35: Top twenty genes significantly UP-regulated in PBMCs following 4 hr treatment by 30 ng/ml of TPA (compared to 
untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
6420520 2.547 up CD40 Homo sapiens CD40 molecule, TNF receptor superfamily member 5 (CD40), transcript variant 1, mRNA. 
5130397 2.235 up  602617110F1 NIH_MGC_79 Homo sapiens cDNA clone IMAGE:4730811 5, mRNA sequence 
6290187 2.382 up RCE1 Homo sapiens RCE1 homolog, prenyl protein peptidase (S. cerevisiae) (RCE1), transcript variant 2, 
mRNA. 
6180445 2.466 up LOC389286 Homo sapiens similar to FKSG62 (LOC389286), mRNA. 
3800551 2.088 up MICAL1 Homo sapiens microtubule associated monoxygenase, calponin and LIM domain containing 1 (MICAL1), 
mRNA. 
7150176 2.328 up MAT2A Homo sapiens methionine adenosyltransferase II, alpha (MAT2A), mRNA. 
1570273 2.045 up NEDD4L Homo sapiens neural precursor cell expressed, developmentally down-regulated 4-like (NEDD4L), 
mRNA. 
670136 2.022 up FLJ38717 Homo sapiens FLJ38717 protein (FLJ38717), mRNA. 
3800482 2.802 up MGC61598 PREDICTED: Homo sapiens similar to ankyrin-repeat protein Nrarp (MGC61598), mRNA. 
4250537 2.071 up DNAJB4 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 4 (DNAJB4), mRNA. 
5420528 2.131 up DNAJB4 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 4 (DNAJB4), mRNA. 
2650349 2.539 up C19orf48 Homo sapiens chromosome 19 open reading frame 48 (C19orf48), mRNA. 
2850630 2.260 up C19orf48 Homo sapiens chromosome 19 open reading frame 48 (C19orf48), mRNA. 
7380368 2.010 up WDR74 PREDICTED: Homo sapiens WD repeat domain 74 (WDR74), mRNA. 
2190537 2.090 up WDR74 PREDICTED: Homo sapiens WD repeat domain 74 (WDR74), mRNA. 
2650020 2.008 up PWWP2B Homo sapiens PWWP domain containing 2B (PWWP2B), transcript variant 1, mRNA. 
4590519 2.406 up LOC100130332 PREDICTED: Homo sapiens similar to PRO2474 (LOC100130332), mRNA. 
3440692 2.057 up CHMP7 Homo sapiens CHMP family, member 7 (CHMP7), mRNA. 
2370092 2.019 up STXBP6 Homo sapiens syntaxin binding protein 6 (amisyn) (STXBP6), mRNA. 
2060608 2.951 up  FNPARC07 FNP Homo sapiens cDNA, mRNA sequence 
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Appendix Table 36: Top twenty genes significantly DOWN-regulated in PBMCs following 4 hr treatment by 30 ng/ml of TPA (compared 
to untreated PBMCs)as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC 
(abs)  
Regulation  Symbol Definition 
1430280 7.064 down CEBPA Homo sapiens CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA), mRNA. 
50286 5.132 down EEPD1 Homo sapiens endonuclease/exonuclease/phosphatase family domain containing 1 (EEPD1), mRNA. 
4040162 5.000 down MEF2C Homo sapiens myocyte enhancer factor 2C (MEF2C), mRNA. 
1440064 4.211 down  Homo sapiens cDNA FLJ44441 fis, clone UTERU2020242 
1940021 4.098 down GRN Homo sapiens granulin (GRN), mRNA. 
6420750 4.012 down TLR2 Homo sapiens toll-like receptor 2 (TLR2), mRNA. 
3390438 4.000 down PLA2G7 Homo sapiens phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7), 
mRNA. 
2120053 3.953 down CYP1B1 Homo sapiens cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1), mRNA. 
580358 3.895 down FABP5L2 PREDICTED: Homo sapiens fatty acid binding protein 5-like 2 (FABP5L2), mRNA. 
4200343 3.881 down CYFIP1 Homo sapiens cytoplasmic FMR1 interacting protein 1 (CYFIP1), transcript variant 2, mRNA. 
6860482 3.865 down HERC6 Homo sapiens hect domain and RLD 6 (HERC6), transcript variant 1, mRNA. 
6380484 3.848 down SERPINA1 Homo sapiens serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 (SERPINA1), 
transcript variant 3, mRNA. 
520408 3.704 down IFIT3 Homo sapiens interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), mRNA. 
1240152 3.695 down CFD Homo sapiens complement factor D (adipsin) (CFD), mRNA. 
4610672 3.597 down FLJ14213 Homo sapiens protor-2 (FLJ14213), mRNA. 
1260228 3.579 down CLEC5A Homo sapiens C-type lectin domain family 5, member A (CLEC5A), mRNA. 
1190739 3.520 down ITPRIPL2 Homo sapiens inositol 1,4,5-triphosphate receptor interacting protein-like 2 (ITPRIPL2), mRNA. 
6840184 3.512 down GRN Homo sapiens granulin (GRN), mRNA. 
6400465 3.471 down PTPN6 Homo sapiens protein tyrosine phosphatase, non-receptor type 6 (PTPN6), transcript variant 2, mRNA. 
6060468 3.468 down S100A8 Homo sapiens S100 calcium binding protein A8 (S100A8), mRNA. 
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Appendix Table 37: Top twenty genes significantly UP-regulated in PBMCs following 24 hr treatment by 30 ng/ml of TPA (compared to 
untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
4230136 2.156 up TCP1 Homo sapiens t-complex 1 (TCP1), transcript variant 1, mRNA. 
6650692 2.223 up ISOC2 Homo sapiens isochorismatase domain containing 2 (ISOC2), mRNA. 
540717 2.210 up LONP1 Homo sapiens lon peptidase 1, mitochondrial (LONP1), nuclear gene encoding mitochondrial protein, 
mRNA. 
3800577 2.200 up LOC642661 PREDICTED: Homo sapiens misc_RNA (LOC642661), miscRNA. 
160537 2.148 up FVT1 Homo sapiens follicular lymphoma variant translocation 1 (FVT1), mRNA. 
3930132 2.203 up TUBA3D Homo sapiens tubulin, alpha 3d (TUBA3D), mRNA. 
5270296 2.161 up TFB2M Homo sapiens transcription factor B2, mitochondrial (TFB2M), nuclear gene encoding mitochondrial 
protein, mRNA. 
4060722 2.249 up PHB2 Homo sapiens prohibitin 2 (PHB2), transcript variant 2, mRNA. 
4830301 2.209 up KAT2A Homo sapiens K(lysine) acetyltransferase 2A (KAT2A), mRNA. 
6450372 2.059 up PDHA1 Homo sapiens pyruvate dehydrogenase (lipoamide) alpha 1 (PDHA1), mRNA. 
2760332 2.016 up SCARNA10 Homo sapiens small Cajal body-specific RNA 10 (SCARNA10), guide RNA. 
7150176 2.051 up MAT2A Homo sapiens methionine adenosyltransferase II, alpha (MAT2A), mRNA. 
6650176 2.204 up TRMT11 Homo sapiens tRNA methyltransferase 11 homolog (S. cerevisiae) (TRMT11), mRNA. 
1010630 2.318 up NOP2 Homo sapiens NOP2 nucleolar protein homolog (yeast) (NOP2), transcript variant 1, mRNA. 
6960538 2.275 up NOP2 Homo sapiens NOP2 nucleolar protein homolog (yeast) (NOP2), transcript variant 1, mRNA. 
4480341 2.741 up DHCR24 Homo sapiens 24-dehydrocholesterol reductase (DHCR24), mRNA. 
5310300 2.464 up SFRS13A Homo sapiens splicing factor, arginine/serine-rich 13A (SFRS13A), transcript variant 2, mRNA. 
630709 2.548 up ELOF1 Homo sapiens elongation factor 1 homolog (S. cerevisiae) (ELOF1), mRNA. 
2650349 2.767 up C19orf48 Homo sapiens chromosome 19 open reading frame 48 (C19orf48), mRNA. 
2850630 2.540 up C19orf48 Homo sapiens chromosome 19 open reading frame 48 (C19orf48), mRNA. 
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Appendix Table 38: Top twenty genes significantly DOWN-regulated in PBMCs following 24 hr treatment by 30 ng/ml of TPA (compared 
to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
3310538 7.616 down CD36 Homo sapiens CD36 molecule (thrombospondin receptor) (CD36), transcript variant 3, mRNA. 
2140136 6.465 down EMR2 Homo sapiens egf-like module containing, mucin-like, hormone receptor-like 2 (EMR2), transcript variant 2, 
mRNA. 
1010592 5.565 down CD36 Homo sapiens CD36 molecule (thrombospondin receptor) (CD36), transcript variant 1, mRNA. 
3290639 5.162 down RAB7B Homo sapiens RAB7B, member RAS oncogene family (RAB7B), mRNA. 
6040324 4.072 down SDCBP Homo sapiens syndecan binding protein (syntenin) (SDCBP), transcript variant 2, mRNA. 
1190739 3.851 down ITPRIPL2 Homo sapiens inositol 1,4,5-triphosphate receptor interacting protein-like 2 (ITPRIPL2), mRNA. 
6450092 3.803 down C5AR1 Homo sapiens complement component 5a receptor 1 (C5AR1), mRNA. 
3140364 3.636 down PTPN12 Homo sapiens protein tyrosine phosphatase, non-receptor type 12 (PTPN12), mRNA. 
7210170 3.512 down DSE Homo sapiens dermatan sulfate epimerase (DSE), transcript variant 1, mRNA. 
2030687 3.484 down C3orf59 Homo sapiens chromosome 3 open reading frame 59 (C3orf59), mRNA. 
5490240 3.428 down MAP1LC3A Homo sapiens microtubule-associated protein 1 light chain 3 alpha (MAP1LC3A), transcript variant 2, mRNA. 
3800463 3.274 down SLC29A3 Homo sapiens solute carrier family 29 (nucleoside transporters), member 3 (SLC29A3), mRNA. 
2480544 3.273 down KCNMB1 Homo sapiens potassium large conductance calcium-activated channel, subfamily M, beta member 1 (KCNMB1), 
mRNA. 
7040142 3.257 down KYNU Homo sapiens kynureninase (L-kynurenine hydrolase) (KYNU), transcript variant 2, mRNA. 
7210253 3.125 down LOC730415 PREDICTED: Homo sapiens hypothetical LOC730415, transcript variant 2 (LOC730415), mRNA. 
1030333 3.108 down CCL2 Homo sapiens chemokine (C-C motif) ligand 2 (CCL2), mRNA. 
510079 3.072 down HLA-DRB4 Homo sapiens major histocompatibility complex, class II, DR beta 4 (HLA-DRB4), mRNA. 
3460685 3.041 down KYNU Homo sapiens kynureninase (L-kynurenine hydrolase) (KYNU), transcript variant 1, mRNA. 
1400520 3.036 down CNTNAP2 Homo sapiens contactin associated protein-like 2 (CNTNAP2), mRNA. 
5900564 3.018 down SLC16A6 Homo sapiens solute carrier family 16, member 6 (monocarboxylic acid transporter 7) (SLC16A6), mRNA. 
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Appendix Table 39: Top twenty genes significantly UP-regulated in PBMCs following 96 hr treatment by 30 ng/ml of TPA 
(compared to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips. 
ProbeID FC (abs)  Regulation  Symbol Definition 
6650692 2.698 up ISOC2 Homo sapiens isochorismatase domain containing 2 (ISOC2), mRNA. 
4730168 2.556 up SARS2 Homo sapiens seryl-tRNA synthetase 2, mitochondrial (SARS2), nuclear gene encoding mitochondrial 
protein, mRNA. 
3420433 2.003 up SHMT1 Homo sapiens serine hydroxymethyltransferase 1 (soluble) (SHMT1), transcript variant 1, mRNA. 
2690528 2.126 up SHMT1 Homo sapiens serine hydroxymethyltransferase 1 (soluble) (SHMT1), transcript variant 1, mRNA. 
4060722 2.271 up PHB2 Homo sapiens prohibitin 2 (PHB2), transcript variant 2, mRNA. 
1660270 2.765 up MTHFD
1 
Homo sapiens methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthetase (MTHFD1), mRNA. 
1110440 2.394 up WDR77 Homo sapiens WD repeat domain 77 (WDR77), mRNA. 
2760332 2.036 up SCARN
A10 
Homo sapiens small Cajal body-specific RNA 10 (SCARNA10), guide RNA. 
3290291 2.235 up SLBP Homo sapiens stem-loop binding protein (SLBP), mRNA. 
2900692 3.323 up GSG2 Homo sapiens germ cell associated 2 (haspin) (GSG2), mRNA. 
610537 3.726 up C21orf42 Homo sapiens chromosome 21 open reading frame 42 (C21orf42), mRNA. 
7330338 2.411 up DEPDC1
B 
Homo sapiens DEP domain containing 1B (DEPDC1B), mRNA. 
1230730 2.005 up SLC30A
5 
Homo sapiens solute carrier family 30 (zinc transporter), member 5 (SLC30A5), transcript variant 1, mRNA. 
4810750 2.153 up BEND4 Homo sapiens BEN domain containing 4 (BEND4), mRNA. 
430100 2.098 up XRCC6 Homo sapiens X-ray repair complementing defective repair in Chinese hamster cells 6 (XRCC6), mRNA. 
6960538 2.106 up NOP2 Homo sapiens NOP2 nucleolar protein homolog (yeast) (NOP2), transcript variant 1, mRNA. 
1690392 2.543 up HIST1H2
BH 
Homo sapiens histone cluster 1, H2bh (HIST1H2BH), mRNA. 
4290259 2.251 up CCDC51 Homo sapiens coiled-coil domain containing 51 (CCDC51), mRNA. 
2650494 2.412 up SMC2 Homo sapiens structural maintenance of chromosomes 2 (SMC2), transcript variant 1, mRNA. 
6400647 2.053 up EHD4 Homo sapiens EH-domain containing 4 (EHD4), mRNA. 
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Appendix Table 40: Top twenty genes significantly DOWN-regulated in PBMCs following 96 hr treatment by 30 ng/ml of TPA 
(compared to untreated PBMCs) as detected on HumanHT-12 v4 Illumina BeadChips 
ProbeID FC (abs)  Regulation  Symbol Definition 
7550358 5.134 down NELL2 Homo sapiens NEL-like 2 (chicken) (NELL2), mRNA. 
3850246 4.900 down HOPX Homo sapiens HOP homeobox (HOPX), transcript variant 3, mRNA. 
2370438 4.606 down A2M Homo sapiens alpha-2-macroglobulin (A2M), mRNA. 
4280017 4.375 down FOS Homo sapiens v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS), mRNA. 
840685 4.302 down IL1B Homo sapiens interleukin 1, beta (IL1B), mRNA. 
2480092 4.165 down CCL22 Homo sapiens chemokine (C-C motif) ligand 22 (CCL22), mRNA. 
1990037 4.146 down CHI3L1 Homo sapiens chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), mRNA. 
4390450 4.109 down SGK Homo sapiens serum/glucocorticoid regulated kinase (SGK), mRNA. 
3930537 3.930 down  Human T-cell receptor (V beta 4.1-variant, J beta 2.1, C beta 2) mRNA 
1410209 3.855 down SGK1 Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA. 
1710070 3.786 down ITGAM Homo sapiens integrin, alpha M (complement component 3 receptor 3 subunit) (ITGAM), transcript variant 2, 
mRNA. 
1260086 3.748 down ID2 Homo sapiens inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2), mRNA. 
160242 3.625 down C13orf15 Homo sapiens chromosome 13 open reading frame 15 (C13orf15), mRNA. 
2030324 3.466 down SGK1 Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA. 
2640192 3.449 down BNIP3L Homo sapiens BCL2/adenovirus E1B 19kDa interacting protein 3-like (BNIP3L), mRNA. 
4490500 3.351 down ITGAX Homo sapiens integrin, alpha X (complement component 3 receptor 4 subunit) (ITGAX), mRNA. 
2140382 3.287 down PASK Homo sapiens PAS domain containing serine/threonine kinase (PASK), mRNA. 
4040653 3.276 down LOC728855 Homo sapiens hypothetical LOC728855 (LOC728855), non-coding RNA. 
1170671 3.244 down CD3D Homo sapiens CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA. 
1710279 3.200 down GZMM Homo sapiens granzyme M (lymphocyte met-ase 1) (GZMM), mRNA. 
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Appendix Table 41:   Upstream Regulator Analysis by IPA of Sk-Mel-28 tumor treated with EBC-46 (versus 20% PG) at 4 hr 
 
Upstream Regulator Molecule Type Predicted Activation State Activation z-score p-value of overlap 
miR-4717-3p (miRNAs w/seed CACAUGG) mature microRNA Inhibited -6.536 4.35E-04 
bexarotene chemical drug   -0.653 4.35E-04 
TGM2 enzyme Activated 2.988 4.87E-04 
miR-664-3p (and other miRNAs w/seed AUUCAUU) mature microRNA Inhibited -4.587 6.75E-04 
miR-4679 (miRNAs w/seed CUGUGAU) mature microRNA Inhibited -5.88 7.20E-04 
IFNA2 cytokine Activated 3.032 1.48E-03 
miR-4704-5p (miRNAs w/seed ACACUAG) mature microRNA Inhibited -5.089 1.66E-03 
miR-4501 (and other miRNAs w/seed AUGUGAC) mature microRNA Inhibited -5.632 1.74E-03 
15-LOX group     1.86E-03 
miR-4733-5p (miRNAs w/seed AUCCCAA) mature microRNA Inhibited -5.97 1.91E-03 
PAX8 transcription regulator Activated 2.164 2.12E-03 
NCAM1 other   1.067 2.45E-03 
HOXB9 transcription regulator     3.22E-03 
FADD other Activated 2.121 3.39E-03 
IFNB1 cytokine Activated 2.374 3.68E-03 
miR-654-3p (and other miRNAs w/seed AUGUCUG) mature microRNA Inhibited -5.384 3.70E-03 
miR-1193 (miRNAs w/seed GGAUGGU) mature microRNA Inhibited -5.897 4.00E-03 
miR-640 (miRNAs w/seed UGAUCCA) mature microRNA Inhibited -5.402 4.10E-03 
KRAS enzyme   0.544 4.57E-03 
miR-582-3p (miRNAs w/seed AACUGGU) mature microRNA Inhibited -5.862 4.65E-03 
miR-4717-3p (miRNAs w/seed CACAUGG) mature microRNA Inhibited -6.536 4.35E-04 
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Appendix Table 42:         Upstream Regulator Analysis by IPA of Sk-Mel-28 tumor treated with EBC-46 (versus 20% PG) at 8 hr 
 
Upstream Regulator Molecule Type Predicted Activation State Activation z-score p-value of overlap 
spermidine chemical - endogenous mammalian   1 3.35E-05 
Gsk3 group   0.579 7.44E-05 
miR-4277 (miRNAs w/seed CAGUUCU) mature microRNA Inhibited -5.874 7.79E-05 
ETS1 transcription regulator Activated 2.598 1.05E-04 
TNFSF14 cytokine   1.077 1.16E-04 
CSF1 cytokine Activated 3.236 1.63E-04 
HDAC3 transcription regulator     2.03E-04 
palmitic acid chemical - endogenous mammalian   1.674 2.97E-04 
green tea polyphenol chemical drug   0.625 3.51E-04 
miR-3651 (miRNAs w/seed AUAGCCC) mature microRNA Inhibited -5.392 4.01E-04 
GSK3B kinase   -1.485 4.22E-04 
11,12-epoxyeicosatrienoic acid chemical - endogenous mammalian   0.2 5.19E-04 
PDGF BB complex Activated 3.588 5.67E-04 
PRKAR2B kinase   -0.577 5.89E-04 
prostaglandin E2 chemical - endogenous mammalian   0.965 6.21E-04 
bezafibrate chemical drug   1.601 6.29E-04 
exenatide biologic drug     6.62E-04 
miR-1267 (miRNAs w/seed CUGUUGA) mature microRNA Inhibited -5.018 7.14E-04 
genistein chemical drug   -0.011 7.47E-04 
elastase group     7.90E-04 
spermidine chemical - endogenous mammalian   1 3.35E-05 
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Appendix Table 43:        Upstream Regulator Analysis by IPA of Sk-Mel-28 tumor treated with TPA (versus 20% PG) at 4 hr 
 
Upstream Regulator Molecule Type 
Predicted Activation 
State 
Activation z-
score 
p-value of 
overlap 
BSCL2 other     2.46E-05 
DAZ2 translation regulator     3.21E-04 
EIF2S1 translation regulator     3.71E-04 
glucosamine 
chemical - endogenous 
mammalian   -1 5.73E-04 
Immunoglobulin complex   0.053 1.01E-03 
IL5 cytokine Activated 2.938 1.06E-03 
miR-3688-3p (and other miRNAs w/seed AUGGAAA) mature microRNA Inhibited -3.552 1.17E-03 
1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-
octadecylcarbonate chemical - kinase inhibitor     2.18E-03 
estradiol valerate chemical drug     2.18E-03 
RLN1 other     2.18E-03 
CEBPB transcription regulator   1.937 2.67E-03 
miR-3925-3p (miRNAs w/seed CUCCAGU) mature microRNA Inhibited -3.921 2.74E-03 
IL1B cytokine Activated 2.75 2.86E-03 
OSMR transmembrane receptor     2.89E-03 
SU6656 chemical toxicant     3.32E-03 
beta-estradiol 
chemical - endogenous 
mammalian   0.606 4.91E-03 
IRAK4 kinase     5.22E-03 
NPPC other     5.56E-03 
ST3-Hel2A-2 chemical reagent     5.56E-03 
dexmedetomidine chemical drug     5.56E-03 
BSCL2 other     2.46E-05 
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Appendix Table 44:         Upstream Regulator Analysis by IPA of Sk-Mel-28 tumor treated with TPA (versus 20% PG) at 8 hr 
 
Upstream Regulator Molecule Type 
Predicted Activation 
State 
Activation z-
score 
p-value of 
overlap 
miR-4709-5p (miRNAs w/seed CAACAGU) mature microRNA Inhibited -6.574 6.74E-05 
miR-516a-3p (and other miRNAs w/seed GCUUCCU) mature microRNA Inhibited -7.648 4.62E-04 
miR-421-3p (and other miRNAs w/seed UCAACAG) mature microRNA Inhibited -7.973 6.13E-04 
miR-4519 (miRNAs w/seed AGCAGUG) mature microRNA Inhibited -6.915 7.54E-04 
sildenafil chemical drug   -1.237 8.14E-04 
miR-4293 (miRNAs w/seed AGCCUGA) mature microRNA Inhibited -6.998 8.49E-04 
galactose 
chemical - endogenous 
mammalian   1.067 1.09E-03 
TWIST1 transcription regulator   0.896 1.69E-03 
GnRH analog biologic drug   0.977 1.70E-03 
KRAS enzyme   -0.273 1.98E-03 
miR-1294 (miRNAs w/seed GUGAGGU) mature microRNA Inhibited -6.785 2.28E-03 
naproxen chemical drug     2.33E-03 
ANGPTL3 growth factor     2.58E-03 
CRYAA other     2.58E-03 
dicumarol chemical drug     2.58E-03 
bumetanide chemical drug     2.58E-03 
acacetin 
chemical - endogenous non-
mammalian     2.58E-03 
miR-5095 (and other miRNAs w/seed UACAGGC) mature microRNA Inhibited -8.937 2.74E-03 
miR-1976 (and other miRNAs w/seed CUCCUGC) mature microRNA Inhibited -9.334 2.75E-03 
miR-4755-3p (miRNAs w/seed GCCAGGC) mature microRNA Inhibited -11.433 2.76E-03 
miR-4709-5p (miRNAs w/seed CAACAGU) mature microRNA Inhibited -6.574 6.74E-05 
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